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OVERVIEW 
 
 The sequencing of the first draft of the human genome in 2003 was met with great enthusiasm 
from scientists and the general public alike. Heralding a new age of biomedical discovery, the Human 
Genome Project has brought forth significant advances in genomic technologies, scientific 
breakthroughs, and has the potential to improve health outcomes and reduce healthcare disparities in 
myriad ways. Though technological advancements like large-scale genotyping arrays, next-generation 
sequencing, and whole exome and whole genome sequencing have produced considerable data, from 
its conception, the Human Genome Project was designed to also consider the ethical, legal, and social 
implications of this new era in genetics.  It is at the intersection of modern genomics and ELSI where 
this thesis occurs.  
 Personalized, or precision, medicine can be thought of as the ability to identify the correct 
medical or lifestyle intervention at the optimal time for each individual. Chapter I provides an 
overview of personalized medicine: how it is currently implemented and ways in which it differs from 
current clinical practice. Cancer diagnosis and treatment, and pharmacogenomics are used as examples 
of how personalized medicine can lead to improved health outcomes while highlighting the challenges 
that are faced in extending this approach to more common, complex diseases. Women and individuals 
from diverse populations, historically underrepresented in clinical research, are at risk of widening 
health disparities unless additional emphasis is placed upon these individuals for future research—
putting the “personalization” in personalized medicine. I conclude Chapter I with an overview of the 
types of statistical models and study designs currently used in genetic studies.  
 I present the first of three case studies in Chapter II. Women’s health, long overlooked by the 
clinical research enterprise, is now fully recognized as an important facet to understanding the nuances 
of disease. The timing of the reproductive lifespan, in particular, dictates fertility and influences disease 
risk. After an overview of the female reproductive lifespan, I consider what genetic variants are 
associated with age at menarche and age at natural menopause in African American women from two 
population-based epidemiologic studies: the Atherosclerosis Risk in Communities (ARIC) and the 
Women’s Health Initiative (WHI). Most large scale or genome-wide association studies have been 
performed in European-descent populations; this association study was the first to examine these traits 
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in an African American cohort and provided us an opportunity to compare results to prior 
publications. 
 In Chapter III, I document the creation of an algorithm to extract ages of reproductive 
milestones from electronic medical records (EMRs). These data have significant research utility 
independently and as covariates in genome-wide association studies for a variety of diseases and have 
the potential to inform clinical care. After the Health Information Technology for Economic and 
Clinical Health (HITECH) Act of 2009, secondary uses of EMRs for research have become more 
common and include selecting cohorts for clinical and research studies and reporting health statistics 
on aggregated data for disease monitoring. However, these data are not consistently documented and 
are often missing due to a lack of standardized data fields, requiring data-mining techniques for 
extraction. I present the development process for a data-mining technique to extract the ages at 
reproductive milestones from the Vanderbilt University Medical Center (VUMC) Synthetic Derivative, 
a de-identified version of the VUMC EMR for research purposes, and the performance of this 
algorithm. I also consider potential uses of the algorithm for personalized medicine and in future 
genetic studies. 
 I present the second case study in Chapter IV. Endometrial cancer, the most common 
gynecologic cancer, affects more than 50,000 women in the United States yearly and is responsible for 
8,590 estimated annual deaths. Despite the prevalence of endometrial cancer, few genetic association 
studies have been performed and the etiology of this complex disease is not fully understood. I begin 
Chapter IV with an overview of the known molecular mechanisms, environmental risk factors, and 
genetic associations attributed to endometrial cancer. I hypothesized variants previously associated 
with other cancers may also play a role in the development of endometrial cancer in a small cohort 
from VUMC.  Using a candidate-gene association study approach, I present the results from our small 
sample and that of the larger meta-analysis in the Population Architecture using Genomics and 
Environment (PAGE) Study to which our results were contributed for meta-analysis. 
 The last case study is presented in Chapter V, where I used a genome-wide association study 
(GWAS) to identify genetic variants associated with serum thyroid stimulating hormone (TSH) levels 
in both African American and European descent individuals from the Electronic Medical Records and 
Genomics (eMERGE) Network. The eMERGE Network is a collaboration of nine medical centers with 
EMRs linked to biobanks and a coordinating center, which allows investigation of genotype-phenotype 
associations in larger sample sizes than each individual site can provide. With different EMRs utilized 
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at each eMERGE member site, phenotype harmonization and data extraction are important 
considerations for genetic studies in this consortium. TSH levels are measured to diagnose thyroid 
diseases, such as hypo- and hyperthyroidism and women are disproportionately affected by these 
disorders. To identify genetic variants associated with the distribution of TSH levels, I performed a 
GWAS in euthyroid (non-thyroid disease) subjects from the eMERGE Network. I present the results of 
this analysis for both European descent and African Americans and compare our results to previously 
published GWAS for this and other related traits. Given that environmental factors, such as BMI, 
influence TSH factors, I describe an interaction analysis between BMI and single nucleotide 
polymorphisms (SNPs). Lastly, I examine what role population differentiation plays as a possible 
reason for the disease burden faced by European descent and African American individuals. 
 In Chapter VI, I consider the ethical, legal, and social implications of personalized medicine and 
the analytic evidence supporting its use in the clinical setting for common, complex diseases. The 
methods currently used to obtain the necessary analytic evidence to recommend genetic testing in this 
context are both time- and resource-intensive. I propose a rapid structured review model using a 
hypothetical genetic test for hypothyroidism risk to address this issue and demonstrate how this 
method can be used to identify gaps in evidence at academic medical centers with limited resources. 
Finally, I examine in greater detail the ethical, legal and social impacts on both the health care system 
and the general public that personalized medicine for common, complex diseases will have.  
 This thesis encompasses several phenotypes that play a role in women’s health and highlight 
the challenges faced in generalizing research findings to diverse populations. Personalized medicine 
has the potential to reduce health disparities and improve health outcomes, but faces significant 
barriers. In Chapter VII, I look ahead and discuss how this might occur, from genetic study design, to 
the role of research findings in clinical care.  
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CHAPTER I 
INTRODUCTION 
 
I. INTRODUCTION 
Personalized medicine 
 Personalized, or precision, medicine has generally come to mean the use of genetic data to 
inform clinical care for individual patients, including decision-making for prevention, diagnosis, and 
treatment (National Human Genome Research Institute2014b). Personalized medicine (PM) gained 
traction and increased societal awareness after sequencing of the first draft of the human genome was 
completed: researchers and physicians were motivated to utilize the new wealth of genetic information 
in the clinical setting to improve health outcomes. New businesses based on bringing genetic testing 
directly to the masses fought for consumers and against regulation.  In the clinical setting, PM is used 
to determine which chemotherapy a tumor is susceptible to (Kim et al.2013), guide medication choice 
and drug dosage (Scott et al.2013), and diagnose unknown genetic disorders (Yang et al.2013). Despite 
direct-to-consumer marketing suggesting your genome can accurately predict risk for developing 
hundreds of complex diseases and traits at the present time, expansion to the clinical setting of PM for 
common, complex disease risk prediction and management of care is essentially nonexistent.   
 Cancer is the poster child for successful integration of PM in the clinical setting. BRCA1/2 
testing is routine in breast cancer diagnosis and is used to determine lifetime risk of developing breast 
and/or ovarian cancer in affected individuals and their family members (Peshkin et al.2002). 
Characterizing breast tumors as estrogen receptor positive/negative or overexpressing human 
epidermal growth-factor receptor 2 (HER2) results in targeted chemotherapies and improved clinical 
outcomes (Slamon et al.2001). Similarly, non-small-cell lung cancer patients now benefit from the 
identification of gene expression signatures that are sensitive to synthetic indolotriazine (Kim et 
al.2013) and from dosing recommendations for fluoropyrimidines based on DYPD genotypes (Caudle 
et al.2013).   Numerous cancer and medical centers now advertise the use of a patient’s tumor genome 
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to guide chemotherapy decisions for some types of cancer (The University of Arizona Cancer 
Center2014;Vanderbilt Ingram Cancer Center2014;University of California2014).     
 Personalized medicine is also being used to guide medication choice and drug dosage at several 
institutions (Rossolatos and Aitchison2014). Pharmacogenomics, the study of how the genome affects 
drug response, seeks to predict which patients will respond favorably, unfavorably, or not at all to a 
particular medication (National Library of Medicine2014). Though adverse drug events are rare, they 
are a significant cause of morbidity and mortality in the United States and over 200 drug labels carry 
warnings suggesting pharmacogenetic testing to guide therapy (Dodson2011).  The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) is a collaboration of investigators who are 
studying the role of genetics in pharmacology. CPIC publishes recommendations using a standardized 
format and grading system to evaluate the strength of the genotype-phenotype association (Caudle et 
al.2014). Nine studies, to date, on the use of genotypes to guide medication choice and dosage have 
been published by CPIC (Caudle et al.2014), including recommendations for codeine therapy based on 
CYP2D6 genotype (Crews et al.2014) and the anti-clotting agent clopidogrel based on CYP2C19 
genotypes (Scott et al.2013). These guidelines are being implemented in the clinical setting at 
institutions such as Vanderbilt University Medical Center (VUMC) and at St. Jude Children’s Research 
Hospital(Hoffman et al.2014). The VUMC Pharmacogenetic Resource for Enhanced Decisions in Care 
and Treatment (PREDICT) Program identifies patients at-risk for adverse events and prospectively 
genotyped them (Pulley et al.2012). Obtaining the genetic data prior to the clinical need allows for 
physicians to integrate the data into clinical care through decision support mechanisms implemented in 
the electronic health record.  
Current practice 
 The questions of when to screen a patient for a disorder, how to accurately identify those who 
are risk of disease, and when to provide prophylactic interventions (e.g., thyroid replacement hormone 
for subclinical hypothyroidism or statin therapy for hypercholesterolemia) to prevent disease or 
improve health outcomes are key points of PM research. The decision of whether to screen for a 
particular disease has primarily relied upon guidelines developed in 1968 by Wilson and Jungner 
(Table 1) (Wilson and Jungner 1968). These recommendations laid out ten criteria that a screening test 
should possess before a screening program is initiated, including that the condition should be an 
important health problem, that there should be a recognizable latent or early symptomatic stage, that a 
suitable test and treatment be available and are generally accepted by the public (Wilson and Jungner 
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1968). The Wilson and Jungner guidelines also require that the natural history of the condition, 
including development of the disease from latency to diagnosis be adequately understood and that the 
screening program be generally cost-effective compared to medical costs incurred by not screening 
(Wilson and Jungner 1968).  These criteria have been used to justify some public screening programs, 
(e.g., newborn screening for phenylketonuria (PKU)(Petros 2012)), and not others (screening for adult 
celiac disease(Evans, Hadjivassiliou, and Sanders 2011)). Advances in genomics have led some to 
consider if the Wilson-Jungner criteria should be updated in order to be more flexibly applied to 
genetic testing (Table 1) (Petros 2012;Andermann et al. 2008). These updated criteria may provide an 
initial guideline when determining which diseases a PM approach is appropriate. 
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Table 1. Screening criteria for disease. 
Wilson & Jungner 1968(Wilson and 
Jungner1968) 
Andermann et al. 2008(Andermann 
et al.2008) 
Petros 2012(Petros2012) 
The condition should be an important 
health problem. 
The screening should respond to a 
recognized need. 
The test may be multiplexed or overlaid 
onto an existing structure or system. 
There should be an accepted 
treatment for patients with 
recognized disease. 
The objectives of screening should be 
defined at the start of the program. 
The “diagnostic odyssey” for the 
patient/family may be reduced or 
eliminated. 
Facilities for diagnosis and treatment 
should be available. 
There should be a defined target 
population. 
Adverse outcome(s) are rare with a 
false-positive test. 
There should be a recognizable latent 
or early symptomatic stage. 
There should be scientific evidence of 
screening program effectiveness. 
Treatment costs may be covered by 
third parties (either private or public). 
There should be a suitable test or 
examination. 
 The program should integrate 
education, testing, clinical services 
and program management. 
Testing may be declined by 
parents/guardians. 
The test should be acceptable to the 
population. 
 There should be quality assurance, 
with mechanisms to minimize 
potential risks from screening. 
Adequate pretesting information or 
counseling is available to 
parents/guardians. 
The natural history of the condition, 
including development from latency 
to diagnosis, should be adequately 
understood. 
 The program should ensure 
informed choice, confidentiality, and 
respect for autonomy. 
Screening in the newborn period is 
critical for prompt diagnosis and 
treatment. 
There should be an agreed policy on 
whom to treat as patients. 
The program should promote equity 
and access to screening for the entire 
target population. 
Public health infrastructure is in place 
to support all phases of the testing, 
diagnosis, and interventions. 
The cost of case-finding (including 
diagnosis and treatment of diagnosed 
patients) should be economically 
balanced in relation to possible 
expenditure on medical care as a 
whole. 
The program evaluation should be 
planned from the start. 
If carriers are identified, genetic 
counseling is provided. 
Case-finding should be a continuing 
process and not a “once and for all” 
project. 
The overall benefits of screening 
should outweigh the harm. 
Treatment risks and the impact of a 
false-positive test are explained to 
parents/guardians. 
  The limitations of screening and risks of 
a false-negative test are explained to 
parents/guardians. 
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 Aspects of health “personalization” 
 Though the nomenclature may be recent, personalized clinical care has existed for hundreds of 
years (Murray 2012). Physicians routinely personalize clinical care based on sex, age, race/ethnicity, 
family history, and environmental exposures. For example, screening for colorectal cancer is age and 
family history dependent: the United States Preventative Services Task Force (USPSTF) recommends 
screening beginning at age 50 unless a family history or other risk factors cause a patient to be at higher 
risk of developing the disease (U.S.Preventative Services Task Force 2008). The pneumococcal 
vaccination is recommended for all children under age 5 years and adults with certain medical 
conditions, such as immunodeficiency, sickle cell disease, or chronic lung diseases (National Center for 
Immunization and Respiratory Diseases 2012). 
 For some diseases, family and health histories provide sufficient basis to accurately assign risk 
to an individual. Huntington’s disease, an autosomal dominant genetic disorder caused by a triplet 
repeat expansion in the HTT gene, provides an example of this. An individual with an affected parent 
has a 50% risk of inheriting the mutation and developing the disease. But for more common diseases, 
such as cancer or type 2 diabetes (T2D), that have both environmental and complex genetic factors and 
interactions, determining risk for an individual patient can be more challenging.   
 Sex and race/ethnicity have roles in disease risk, providing an opportunity for PM based, in 
part, upon those traits (Burchard et al. 2003). Women are disproportionately affected by numerous 
complex diseases, including autoimmune and reproductive disorders. There are notable differences in 
the incidences and severity of diseases between men and women, from Alzheimer’s disease (Irvine et 
al. 2012) to inflammatory arthritis (Barnabe et al. 2012), which may stem, in part, from hormone 
differences between men and women (Carter et al. 2012). Similarly, population-specific genetic 
differences have already been identified for ECG traits (Ramirez et al. 2011), and age-related macular 
degeneration (Klein et al. 2011). Given the underlying biological mechanisms for many complex 
diseases are not fully understood, these sex- and population-specific differences emphasize the benefit 
in a personalized medicine approach. 
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Current implementation 
EHR utilization 
 Personalized medicine often relies substantially on software systems that can identify at-risk 
patients across large patient populations and guide clinical decision-making. Electronic health/medical 
records (EHR/EMR) systems are a key factor in successful PM initiatives in medical centers. Through 
the HITECH Act, medical institutions benefit financially from meaningful uses of their EHR systems, 
such as monitoring communicable disease incidence and immunization statistics for national 
surveillance programs and recording patient data (e.g., demographic, medication allergy, smoking 
status), (Stevens et al. 2013; Blumenthal 2010; Blumenthal and Tavenner 2010; Blumenthal 2011; Jha et 
al. 2009; Kukafka et al. 2007). With bioinformatic and computational biology approaches, EHR systems 
can scan patient populations to find cohorts for clinical trials, identify patients delinquent in 
immunization schedules (Stevens et al. 2013), and target interventions to specific populations.  
 EHR utilization goes beyond the clinical space, however. Researchers also benefit from the 
ability to access EHRs to perform epidemiologic and genetic studies on patient populations to better 
understand how genetic variations contribute to health and disease. The Electronic Medical Records 
and Genomics (eMERGE) Network is an example of a group of medical centers where researchers 
access EHR data linked to biobanks in order to perform genetic studies (McCarty et al. 2011;Crawford 
et al. 2014). eMERGE has published numerous studies on a broad range of phenotypes, including 
hypothyroidism (Denny et al. 2011), low density lipoprotein (LDL) levels (Rasmussen-Torvik et al. 
2012), and cardiac conduction (Ritchie et al. 2013). However, this secondary use of clinical data by non-
clinical researchers leads to ethical, legal, and social issues (Clayton et al. 2010; Fullerton et al. 2012) 
that remain to be fully addressed.  
Decision support mechanisms 
 Identification of patients for an intervention is only one half of the PM implementation strategy. 
Moving from identification to intervention relies on decision support mechanisms. Decision support 
mechanisms may include computerized alerts, reminders to clinicians, generation of patient data 
reports, and automatic order set suggestions--approaches that integrate multiple pieces of healthcare 
data and may involve strategies to engage the patient in the healthcare decision making process 
(Downing et al. 2009). These may be built into the EHR system or exist as a secondary system 
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depending on the use. For example, at VUMC, prescriptions are ordered electronically, allowing for a 
decision support mechanism to alert a prescribing clinician when a medication that is contraindicated 
for a patient due to genetics or drug allergy has been ordered (Pulley et al. 2012). This alert can provide 
the relevant data for the clinician about the contraindication and suggest alternate medications or 
dosing strategies (Pulley et al. 2012). Monitoring patients with chronic health conditions, such as 
asthma or T2D, is a key attribute of the Kaiser Permanente health system (McCarthy, Mueller, and 
Wrenn 2009). This allows Kaiser to target information to their patients through multiple methods and 
interactions with healthcare providers; current smokers may receive information about smoking 
cessation programs and asthmatics may receive information about reducing the frequency of attacks 
(McCarthy, Mueller, and Wrenn 2009).  
 Despite the potential to improve health outcomes using decision support mechanisms, there are 
numerous challenges to implementing a decision support process. EHR systems may not have been 
designed for this type of use and require modification or replacement and a lack of interoperability 
between specialized EHR systems may impede clinical decision support (Blavin et al. 2013). Even when 
a decision support system is implemented at an institution, the decision to change orders based on an 
alert may not occur. Alert fatigue, a phenomenon where the physician becomes desensitized to decision 
support alerts and ignores the information, is a key problem (Ancker et al. 2014; McCoy et al. 2014). 
Additionally, ethical and legal concerns about clinical decision support systems have been noted by 
several (Berner 2002; Goodman 2007; Castillo and Kelemen 2013). The reliability and accuracy of the 
clinical decision support system needs to be verified and its limitations communicated to the end users 
(Castillo and Kelemen 2013). The challenges noted for clinical decision support systems and the use of 
EHRs should be addressed for successful implementation of personalized medicine. 
 
Current examples 
 Despite the abovementioned challenges, there are numerous examples of successful 
implementation of PM for pharmacogenetics and cancer treatment.   
Pharmacogenetics 
 One use of pharmacogenetics is to match drug therapy to the patient in which it will be 
effective. Cystic fibrosis, an autosomal recessive genetic disorder caused by mutations in CFTR, is 
associated with a reduced lifespan and pulmonary events such as mucus buildup, infection, 
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inflammation, bronchiecstasis and respiratory failure (Rowe, Miller, and Sorscher 2005). 
Approximately 1,900 variants in CFTR have been associated with the disease (Online Mendelian 
Inheritance in Man 2014) and the variants can be grouped into classes based on the mechanism of CFTR 
defect (Clancy et al. 2014). Current treatment of cystic fibrosis relies primarily on targeting the 
symptoms resulting from the CFTR mutations; however, there is interest in approaches that restore 
function to the mutant CFTR protein (Clancy and Jain 2012). Ivacaftor, is the first FDA-approved drug 
to target a specific CFTR defect: gating of CFTR at the plasma membrane (Van et al. 2009). The 
effectiveness of ivacaftor relies on CFTR expression on the cell surface and the ability of CFTR 
activation through normal intracellular signaling mechanisms (Eckford et al. 2012); therefore, only 
patients who are heterozygous or homozygous for the G551D-CFTR variant are recommended for 
ivacaftor therapy (Davies et al. 2013; Ramsey et al. 2011; Accurso et al. 2010).  
 Pharmacogenetics has also been used to identify which patients are at greater risk of adverse 
drug events. Codeine, an opioid analgesic, is activated by cytochrome p450 2D6 (CYP2D6). Variants in 
CYP2D6 have been associated with variations in drug efficacy and toxicity (Crews et al. 2014). 
Individuals with decreased codeine metabolism have demonstrated poor analgesic effects from codeine 
(Lotsch et al. 2009) and severe or life-threatening toxicity following normal doses have been observed 
in fast metabolizers (Gasche et al. 2004). As a standard starting dose can result in toxicity for ultrafast 
metabolizers, identifying these at-risk patients by their CYP2D6 genotypes may decrease potential 
adverse events through administration of alternate analgesics (Crews et al. 2014).  
Cancer treatment 
 Cancer medicine is the area where personalized medicine has arguably been the most 
successful. Substantially increased lifetime risk of breast and ovarian cancers has been associated with 
mutations in BRCA1 and BRCA2 (National Cancer Institute at the National Institutes of Health 2014a). 
Genetic testing for BRCA1/2 variants may enable carriers of deleterious mutations to seek 
chemoprevention, intensive cancer screening (Peshkin et al. 2002), or prophylactic surgery to reduce 
their risk of developing breast or ovarian cancers (U.S.Preventative Services Task Force 2013). Gene-
expression data has also contributed to the success of PM in cancer care. Increased expression of the 
human epidermal growth-factor receptor 2 (HER2) is present in approximately one quarter of breast 
cancers and is indicative of an aggressive subtype of disease with poor prognosis (Slamon et al. 
1987).Testing breast cancer tumors for increased HER2 expression allows oncologists to use 
 9 
 
trastuzumab antibody therapy in these patients, which has significantly improved health outcomes for 
this subset of breast cancer patients (Slamon et al. 2001).  
 Other cancers have also benefitted from personalized medicine approaches, including guiding 
treatment decisions and determining disease prognosis. Non-small cell lung carcinoma is a type of lung 
cancer where the tumor develops in the small alveoli of the lungs (National Cancer Institute at the 
National Institutes of Health 2014c). Prognosis and treatment depend upon whether the tumor has 
mutations in particular genes, such as the epidermal growth factor receptor (EGFR) or the anaplastic 
lymphoma kinase (ALK) gene. Specific ALK mutations are used to guide therapy with crizotinib, a 
tyrosine kinase inhibitors in lung cancer. Additionally, ALK overexpression has been associated with 
poor prognosis in colorectal cancer (Bavi et al. 2013).   
Common, complex diseases 
 Personalized medicine approaches, (i.e., patient-finding, treatment guiding, and intervention 
timing) have not been as successful for other non-cancer common, complex diseases. Though the public 
health burden from common diseases like cardiovascular disease, T2D, asthma, or autoimmune 
disorders is substantial, PM approaches have not generally been implemented on a population-level 
scale. Common disorders result from both genetic and environmental factors and complex interactions 
of those factors. The biologic mechanisms for these diseases are not fully understood, so identifying the 
optimal time and type of intervention for PM is difficult. Randomized clinical trials, considered to be 
the “gold standard” in evaluating an intervention, have been performed for pharmacogenetics and 
cancer treatments, but are rarely utilized for other common, complex diseases. The downstream 
consequence of this is a lack of evidence resulting in challenges to establishing policy for PM.  
 Despite these challenges, PM approaches have been used successfully for age-related macular 
degeneration. Age-related macular degeneration (AMD) is a phenotypically heterogeneous ocular 
disease characterized by central vision loss, from damage to the macula that presents with one of two 
subtypes: wet or dry (National Eye Institute at the National Institutes of Health 2013). Genetic (e.g., 
ARMS2/HTRA1, CFH) and environmental (e.g., cigarette smoking, elevated body mass index) factors 
contribute to disease development (Chakravarthy et al. 2013; Edwards et al. 2005; Haines et al. 2005; 
Klein et al. 2005; National Eye Institute at the National Institutes of Health 2013). A recent study has 
used a PM approach to classify neovascular AMD (nAMD) patients into subtypes for potential 
therapeutic interventions. Feehan et al. classified affected AMD patients into four discrete clusters 
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based on phenotypic and genotypic heterogeneity (Feehan et al. 2011). History of hypertension or of 
hypercholesterolemia were significant risk factors, as was the ARMS2/HTRA1 rs1049331 TT genotype 
(Feehan et al. 2011). Currently, injectable anti-VEGF therapies are used to treat nAMD; however, it has 
been proposed that these therapies are contraindicated in patients with cardiovascular risk factors 
(Enseleit, Michels, and Ruschitzka 2010). The ability to classify patients into these clusters, based on 
both environmental and genetic risk factors, may provide clinicians an opportunity to target 
pharmacologic treatments to specific patients and not others.  
 Response to AMD therapy based on genotype was investigated by Wang et al. (Wang et al. 
2012). Wang et al. identified an association between response to ranibizuman/bevacizumab therapy in 
nAMD patients and PLA2G12A rs2285714, though this association was not significant after Bonferroni 
correction for multiple testing (Wang et al. 2012). Interactions between genetic risk (CFH rs1061170 or 
ARMS2 rs10490924) and environment (dietary intake of antioxidants, zinc, and omega-3 fatty acids) 
were evaluated in a recent study (Wang et al. 2014a). Participants were grouped by number of risk 
alleles in CFH or ARMS2 and a regression analysis was performed to identify associations between 
genetic risk and the environmental variables. The authors found interactions between intake of 
antioxidants and fish consumption with decreased AMD risk, but only in participants with two or 
more risk alleles in CFH or ARMS2 (Wang et al. 2014a). This association highlights the potential 
opportunity for clinicians to identify at-risk patients who are most likely to benefit from specific 
interventions and demonstrates the use of PM for a common, complex disease.  
Personalization: Understanding Women’s Health 
 Tailoring clinical care to an individual can take many forms and may be based on several 
factors, including genetics, ethnicity, and sex. Known differences in disease prevalence and severity 
between men and women, and female-specific issues of reproduction and the reproductive lifespan, 
emphasize the need to perform disease research in women as well as men. 
Historic research inequality 
 Women comprise more than 50% of the US population (Bureau of the Census 2011; 
U.S.Department of Commerce 2014) and there are notable differences in the incidences and severity of 
diseases between men and women, from Alzheimer’s disease (Irvine et al. 2012) to inflammatory 
arthritis (Barnabe et al. 2012). Parity may affect disease manifestation or outcomes such as body mass 
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index (BMI) (Bobrow et al. 2013) and diabetes (Simons et al. 2012). The timing of the reproductive 
lifespan is associated with numerous disease traits; an earlier age at menarche and/or later age at 
menopause increases risk for several cancers, while an earlier age at menopause place women at 
increased risk for osteoporosis and cardiovascular disease, in addition to decreased fertility. It is 
unclear to what extent sex-specific genetic architecture and environmental factors (such as hormone 
fluctuations or behavior) contributes to observed disease prevalence or severity variation. Gene 
regulation differences and genotype-sex interactions have been suggested to play a role in sex-specific 
heritability for some diseases (Ober, Loisel, and Gilad 2008).  Nevertheless, only in the last few decades 
has the importance of women’s health and physiologic differences between males and females in the 
research setting come to the forefront of researchers and government agencies (Taylor 1994).  
Endometrial Cancer research 
 One example of a female-specific disease is endometrial cancer (EC). Endometrial cancer is the 
most common invasive gynecological cancer and has the fourth highest cancer incidence rate in the 
United States, with an estimated 52,630 new cases and 8,590 deaths in 2014 (National Cancer Institute at 
the National Institutes of Health 2014b). Worldwide, an estimated 287,000 new cases arise yearly, with 
twice the age-standardized incidence rate in developed countries as in developing countries (Jemal et 
al. 2011). Diagnosis of EC currently occurs after the patient is symptomatic. There is no standard 
screening test, making the development of biomarkers (including genetic risk scores) very important. 
Common forms of EC can be roughly categorized into three distinct subtypes: endometrioid, serous, 
and clear cell. Several rarer histological subtypes (e.g., mixed Müllerian, squamous cell carcinoma) also 
exist. Endometrioid cancer is estrogen dependent and is the most common of the subtypes; prognosis 
for endometrioid EC is often the best of the common subtypes and many of the cancers are diagnosed 
at early stages.  Serous and clear cell carcinoma are both estrogen-independent and are typically higher 
grade; outcomes for these cancers are worse than for endometrioid cancers, even when adjusted for 
stage (O'Hara and Bell 2012). EC risk increases with age, type 2 diabetes, obesity, hypertension, and 
gynecological disorders such as polycystic ovarian syndrome (PCOS), endometriosis, and uterine 
fibroids. Smoking, nulliparity, and hypertension are associated with increased risk of EC, while parity 
and oral contraceptive use have a protective effect against EC (Haidopoulos et al. 2010). 
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Genetic contributions to endometrial cancer 
 A family history of EC is a known risk factor for the disease and its heritability has been 
estimated at 52% (Schildkraut, Risch, and Thompson 1989).  Several studies performed in women with 
European ancestry have reported odds ratios (OR) ≈ 2.0 for EC for women with a family history of EC 
and/or colorectal cancers, however, results have been largely inconsistent (Lucenteforte et al. 2009).  It 
has been suggested that a family history of different cancers may predispose women to EC, an effect 
more pronounced in young women diagnosed at an early (<40 years) age (Lucenteforte et al. 2009). 
Lynch syndrome has been well documented to increase risk of several cancers, including EC, providing 
further evidence of a genetic contribution to EC through mutations in DNA mismatch repair genes 
(Wang et al. 2013; Gruber and Thompson 1996; Ma, Ledbetter, and Glenn 2013). HER-2/neu 
expression, also implicated in breast cancer, has been found to be associated with EC overall, cancer-
related, and disease-free survival (Kalogiannidis et al. 2014).  
 Several candidate gene association studies (CGAS) have been published for EC (Lee et al. 2010; 
Ashton et al. 2009b; Chen et al. 2012b; Xu et al. 2009a; Xu et al. 2009c). Given that endometrioid ECs are 
estrogen-dependent, one CGAS found ESR1 and ESR2 variants to be associated with increased EC risk, 
an effect which was increased in subjects with both polymorphisms (Ashton et al. 2009a). Variants in 
PGR, the progesterone receptor, have been associated with increased EC risk (Lee et al. 2010; O'Mara et 
al. 2011a); though a recent meta-analysis of eight studies found no significant association between the 
PGR +331G/A polymorphism and endometrial cancer risk (Pabalan et al. 2014). Polymorphisms in 
caspases, more broadly associated with the progression of cancer through the apoptotic pathway, were 
found to be associated with increased risk of EC in a cohort of Chinese women (Xu et al. 2009a). 
Obesity is a known risk for EC and is associated with adiponectin and leptin levels; it was 
hypothesized that obesity-related genes may play a role in EC risk (Chen et al. 2012b). Chen et al. 
identified variants in both LEP and ADIPOQ associated with reduced EC risk in their Chinese cohort 
(Chen et al. 2012b). In general, though several studies have identified variants associated with EC risk, 
these have typically been unreplicated or of mixed results, and represent a small fraction of genes 
involved in cancer initiation and progression pathways.   
 Four genome-wide association studies (GWAS) have been published for EC (Spurdle et al. 2011; 
Long et al. 2012; De, I et al. 2014; Kuhn et al. 2012). These studies have identified a single significant 
locus, HNF1B rs4430796, associated with EC after multiple testing corrections (p=7.1x10-10) (Spurdle et 
al. 2011; De, I et al. 2014). Three SNPs, all in LD in the first four exons of HNF1B, were associated with 
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endometrial cancer at p<10-07 in a European-descent population; one of these SNPs was tested in a 
Chinese cohort from Shanghai (Shanghai Endometrial Cancer Genetics Study), but failed to generalize 
to that population in a supplemental analysis (Spurdle et al. 2011). The second GWAS published for 
endometrial cancer performed a multiple-stage analysis, beginning with the Shanghai cohort from the 
first GWAS, and identified a variant near CAPN9 on chromosome 1 associated with EC, an effect that 
was more significant when the analysis was limited to endometrioid ECs (Long et al. 2012).  A 
replication study was performed in two studies from the PAGE Consortium; two SNPs, rs4430796 and 
rs7501939, identified in the Spurdle et al. GWAS for EC were tested for association with EC in 1,357 
incident cases of invasive EC in women of diverse ethnic ancestries from the Multiethnic Cohort Study 
(MEC) and the Women’s Health Initiative (WHI) (Setiawan et al. 2012). These SNPs were found to be 
protective against EC (both type I and type II tumors) in their overall study population and in women 
of European-descent, with similar trends found in the African American, Asian/Pacific Islander and 
Latina women (Setiawan et al. 2012). Despite the association between EC and HNF1B, no other variants 
have been associated with EC at genome-wide significance, suggesting common variants may not 
explain a significant amount of heritability for EC (Chen et al. 2014b). Therefore, an exome-wide 
association study (EXWAS) design was used to identify rare variants associated with EC in multiethnic 
participants from the Epidemiology of Endometrial Cancer Consortium (E2C2) (Chen et al. 2014b). No 
variants in the EXWAS reached genome-wide significance after Bonferroni adjustment for multiple 
tests, nor did a gene-based analysis identify significant associations with EC; however this study was 
small and powered only to detect ORs>2.53 for low frequency (MAF<0.02) variants (Chen et al. 2014b). 
The limited variants consistently identified through a relatively small number of genetic studies 
highlight the opportunities for additional studies to meaningfully contribute to the field.   
Timing of the Reproductive lifespan 
 Age at menarche (AM) and age at natural menopause (ANM) define the boundaries of the 
reproductive lifespan in women. Cross-sectional and longitudinal studies have shown a recent secular 
trend of earlier attainment of pubertal milestones (breast development, appearance of pubic hair, 
menarche) from the 1960s to present (Kaplowitz 2006; Herman-Giddens 2006).  This tendency is 
accelerated in girls of African American and Hispanic ancestry, a bias that remains after adjusting for 
socioeconomic variables and body mass index (BMI) (Wu, Mendola, and Buck 2002). Known 
environmental modifiers of age at menarche include exposure to organochlorine chemicals and 
polybrominated biphenyls (Wolff and Landrigan 2002; Blanck et al. 2000). Increased BMI is associated 
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with earlier AM (Biro, Khoury, and Morrison 2006) and later ANM (Palmer et al. 2003), while active 
smoking is associated with earlier ANM (Gold 2011). These and other known environmental factors 
explain only a small amount of individual variation in the timing of these reproductive measures. 
Menarche 
 The gonadotropin-releasing hormone (GnRH) can be considered the ‘master switch’ controlling 
the timing of puberty and release of hormones from the hypothalamus. Secretion of GnRH varies with 
age; in utero release of GnRH leads to pituitary release of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH). This hormonal cascade reaches a peak at about the same time the maximum 
number of oocytes is reached (DiVall and Radovick 2008). LH and FSH levels begin to decline as 
placental estrogen provides negative feedback on the hypothalamus-pituitary-gonadotropin (HPG) 
axis. After birth and the removal of placental estrogen, FSH and LH levels rise again, only to fall in the 
first two years of life to nearly undetectable levels.  From this point, the HGP axis enters what is known 
as the ‘juvenile pause,’ a state of relative quiet in the HPG axis (Nathan and Palmert 2005). 
 The process of puberty begins some time prior to menarche/initiation of menstruation.  
Kisspeptins, encoded by the KISS1 gene, stimulate pulsatile release of GnRH from the hypothalamus to 
the pituitary (Okamura et al. 2013); pituitary production of FSH and LH increases (Garcia-Galiano, 
Pinilla, and Tena-Sempere 2012; Matzuk and Lamb 2008). FSH leads to maturation of the follicles in the 
ovary and production of estradiol and anti-Mullerian hormone (AMH) (Burger et al. 2007; Hale et al. 
2007).  Estradiol is the strongest of three types of estrogens: estradiol, estrone, and estriol. Estradiol is 
the primary circulatory estrogen before the onset of menopause. In the pubertal girl, circulating 
estrogen leads to uterine and breast growth, and the lining of the uterus, the endometrium, becomes 
vascularized. AMH acts to inhibit overstimulation of follicles due to the increased levels of FSH. LH 
increases lead to ovulation and maintenance of the endometrium. In absence of pregnancy and 
hormone levels to sustain the vascularized tissue, the endometrium is sloughed off and menstruation 
occurs. It has been hypothesized that the first few anovulatory menses act to mature the HPG axis 
(Henriet, Gaide Chevronnay, and Marbaix 2012). Though ovulation may occur at the time of menarche, 
it is not common, and cyclic menstruation may occur in its absence (Zhang et al. 2008). As the HPG axis 
matures, menstrual cycles become regular and the cyclic rise and fall of the various hormones stabilizes 
into a regular pattern (Ruiz-Alonso, Blesa, and Simon 2012). 
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 In the clinical setting, female puberty can be subdivided into five stages based on breast 
(thelarche) and pubic hair (pubarche) development (Table 2) (Marshall and Tanner 1969; Tanner and 
Whitehouse 1976). Menarche, the initiation of the menstrual cycle, occurs typically at some time after 
Tanner stage 3 or 4, at which point breast and pubic hair development are continuing, but not mature 
(Tanner stage 5) (Marshall and Tanner 1969). In the Harpenden Growth Study, a longitudinal study of 
British girls from an institutional setting, the mean age at menarche was 13.47 years, with a standard 
deviation of 1.02 years (Marshall and Tanner 1969).   
Figure 1. Hormonal fluctuations during the menstrual cycle.  
Shown are the relative hormonal fluctuations that occur during a typical (non-disordered state) 28-day 
menstrual cycle. Colored boxes represent the three phases of the menstrual cycle as labeled above the 
figure. Abbreviations: luteinizing hormone (LH); follicle stimulating hormone (FSH). Adapted from 
Ruiz-Alonso et al. 2012. 
 16 
 
Table 2. Tanner stages of female puberty. 
Tanner Stage Breast Development Pubic Hair Development 
1 pre-adolescent; papilla elevation 
only 
pre-adolescent; no pubic hair 
2 breast bud stage; enlargement of 
breast and papilla as a small 
mound; enlargement of areola 
diameter 
sparse growth of long, slightly curled, 
and slightly pigmented hair; appears 
mainly on the labia 
3 continued enlargement of breast 
and areola 
darker, coarser, and more curled hair 
spread sparsely  
4 projection of papilla and areola to 
form a secondary mount above the 
level of the breast 
hair is adult in type but coverage is 
significantly less than in adults 
5 mature breast adult in quantity and type, spread to 
medial surface of the thighs but not 
above the base of the inverse triangle 
 
 Concern of a secular trend toward earlier attainment of the stages of pubertal development 
served as the impetus for several studies (Sun et al. 2005; Sun et al.2002). Using data collected from the 
National Health and Nutrition Examination Survey (NHANES) III (1988-1994), differences in timing of 
menarche and breast/pubic hair development were found between non-Hispanic blacks, Mexican-
Americans, and non-Hispanic whites (Chumlea et al. 2003; Sun et al. 2002). Comparing the sexual 
maturity data collected from the National Health Examination Survey (NHES) 1966, the Hispanic 
Health and Nutrition Examination Survey (HHANES) 1982-1984, and the NHANES III (1988-1994), no 
obvious secular trend for earlier attainment of breast or pubic hair development was found for non-
Hispanic blacks or non-Hispanic whites between NHES (1966) and NHANES III (1988-94) (Sun et al. 
2005). In Mexican-American girls, a greater proportion had attained Tanner stage 2 or higher in 
NHANES III than in HHANES; however, completion of pubertal development (Tanner stage 5) 
occurred later in NHANES III compared to HHANES (Sun et al. 2005). Age at menarche for all girls 
declined slightly in NHANES III (median: 12.43 years) compared to NHES (median: 12.77 years) (Sun 
et al. 2005). Non-Hispanic blacks reached menarche earliest of the three groups (median: 12.06 years), 
compared to non-Hispanic whites (median: 12.55 years) or Mexican-Americans (median: 12.25 years). 
The largest difference in age at menarche between NHES 1966 and NHANES III 1988-94 was observed 
in non-Hispanic blacks (difference: 0.46 years)(Sun et al. 2005). Despite the earlier age at menarche and 
breast development observed in NHANES III compared to earlier population surveys, the authors 
determined overall pubertal development had not substantially declined(Sun et al. 2005). Similarly, 
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data from NHANES (1999-2004) demonstrated a downward trend in age at menarche for all women 
and within each racial/ethnic category(McDowell, Brody, and Hughes 2007). 
 In the Copenhagen Puberty Study, using a cross-sectional population study design, 
investigators collected data for Tanner stages of puberty, weight and height, and hormone levels 
(estradiol, serum follicle-stimulating hormone (FSH), and luteinizing hormone (LH)) (Aksglaede et al. 
2009). The findings were similar to those found in the US study (Sun et al. 2005); the mean age at 
menarche declined from 13.42 years to 13.13 years and Tanner stage 2 (breast) declined from 10.88 
years to 9.86 years (Aksglaede et al. 2009). Increased gonadotropins were not associated with the 
observed earlier breast development; however, there was a small but significant decrease in estradiol 
levels among 8-10 year olds (Aksglaede et al. 2009). Notably, adjustment for BMI did not change the 
significance of the menarche or pubic hair development results (Aksglaede et al. 2009). These data, 
considered together, suggest that earlier breast development may occur as a result of estrogenic 
actions, rather than earlier activation of the HPG axis, and this is not associated with increasing 
incidence of childhood obesity (Aksglaede et al. 2009). 
 The Avon Longitudinal Study of Parents and Children (ALSPAC) evaluated the timing of 
puberty in a British cohort (Christensen et al. 2010b). This study used questionnaires mailed to the 
participants to obtain self-reported/parent-reported data on Tanner stages and age at menarche; 
drawings were provided to aid in the determination of Tanner stage (Christensen et al. 2010b). Several 
characteristics were assessed for association with Tanner stage of the child, including mother’s pre-
pregnancy BMI, mother’s age at delivery, mother’s age at menarche, mother’s level of education, social 
class, child’s birth weight, race, birth order, and BMI at time of questionnaire (Christensen et al. 2010b). 
The median age at menarche in ALSPAC was 12.9 years, though this was found to vary according to 
whether the participant began thelarche before pubarche, pubarche before thelarche, or entered 
thelarche and pubarche simultaneously (Christensen et al. 2010b). Unlike the Copenhagen cohort, 
increased BMI was associated with higher Tanner stages for breast and pubic hair development 
(Christensen et al. 2010b). 
 Though several studies have found a decrease in median age at menarche and earlier 
attainment of Tanner stages, the cause of this is not well understood. BMI is not consistently associated 
with earlier thelarche, pubarche, or menarche (Cousminer et al. 2014). Others have considered the 
influence of environmental factors such as exposure to chemicals that mimic estrogenic compounds 
(e.g., bisphenol A (BPA), phthalates) (Wolff and Landrigan 2002; Blanck et al. 2000). It is unclear if 
 18 
 
interactions between genetic variants and environmental factors play a role in the timing of puberty. 
Given the impact on future disease risk associated with timing of pubertal milestones, additional 
studies that examine both the genetic and environmental components of puberty are warranted.  
Menopause 
 The median age at which menopause occurs is 51 years, though unlike the relatively short 
timeframe for menarche, there is substantial variation (Cramer and Xu 1996; Gold 2011).  At the start of 
the menopausal transition, the follicular count continues to decrease and AMH levels are low (Burger 
et al. 2007; Harlow et al. 2012). Cycle length does not change initially. However, changes in the length 
of the cycle and FSH levels in the early follicular phase of the cycle increase as a woman approaches 
menopause.  As the menopausal transition progresses, variability is seen in the length of the cycle >7 
days from normal and is persistent across multiple cycles as the levels of FSH increase but are more 
variable (Harlow et al. 2012; Burger et al. 2007). As FSH levels continue to rise, estrogen levels further 
decline and missed menstruation (amenorrhea) occurs, though some women may experience normal 
cycles and normal or increased levels of estradiol up to age 55 (Harlow et al. 2012; Weiss et al. 2004; 
Santoro and Randolph, Jr. 2011). The Stages of the Reproductive Aging Workshop (STRAW) group 
have delineated the reproductive lifespan and menopausal transition into three main phases with 
seven stages based on frequency and variation of the menstrual cycle and supporting evidence from 
antral follicle counts and FSH and AMH levels (Table 3) (Harlow et al. 2012). The final menstrual 
period marks the boundary of the menopausal transition into post-menopause. At the end of the 
menopausal transition, the antral follicle count is very low, FSH levels continue to rise before 
stabilizing, and both estradiol and AMH levels are very low (Harlow et al. 2012). 
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Table 3. Stages of the Reproductive Lifespan 
 Reproductive  Menopausal Transition Postmenopause 
Stage -5 -4 -3b -3a -2 -1 +1a +1b +1c +2 
Menstrual Cycle variable to 
regular 
regular regular some 
changes to 
flow 
variable 
length 
amenorrhea 
≥60 days 
    
Endocrine Levels 
FSH   low variable variable, 
elevated 
elevated, 
>25 IU/L 
variable, 
elevated 
stabilizes  
AMH   low low low low low very low  
Inhibin B    low low low very low very low  
Antral Follicle Count   low low low low very low very low  
Shown are the stages of the reproductive lifespan, identified by the Stages of Reproductive Aging Workshop (STRAW). Menstrual Cycle, 
selected hormone levels and antral follicle counts are presented.  Stage (-5) begins with menarche. The postmenopausal period is divided 
into two main stages; stage (+1a) begins after a 12 month period of amenorrhea and defines that the final menstrual cycle has occurred. 
Shaded stage boxes indicate perimenopause. Abbreviations: follicle stimulating hormone (FSH), anti-Mullerian hormone (AMH). Adapted 
from Harlow et al. 2012. 
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Genetic contributions to timing of the female reproductive lifespan 
 The genetic component for the timing of menarche and natural menopause has been 
investigated in multiple twin, family, and large population studies, with heritability estimates of nearly 
50% for both AM and ANM (He and Murabito 2012). The associations between AM/ANM with disease 
underscore the importance of elucidating the mechanisms responsible for timing of these events and 
the genetic predisposition to timing which could affect future disease risk. 
 Genome-wide linkage analyses (GWLA) have been used to identify regions of the genome 
linked to AM and ANM—four for AM and two for ANM (Guo et al. 2006a; Anderson et al. 2008; 
Rothenbuhler et al. 2006; Murabito et al. 2005; Pan et al. 2008; van Asselt et al. 2004).  All of the GWLA 
were performed in European-descent populations (He and Murabito 2012).  There was little 
concordance in the results of the GWLA; only one region was identified in two separate GWLA for AM 
(22q13) (Pan et al. 2008; Guo et al. 2006a). Furthermore, these results have not been replicated in other 
studies, nor have the causal genes under the linkage peaks been identified.  Multiple candidate gene 
association studies have also been performed for AM and ANM, many of these in the last few years 
(reviewed in (He and Murabito 2012)).  While earlier candidate gene studies focused on estrogen 
biosynthesis pathways and yielded inconsistent findings, more recent studies have considered other 
biological pathways with some concordance. In a study evaluating biologic pathways for associations 
with AM and ANM, FSHB was associated with later onsets of menarche and menopause, and ESR2 
was associated with AM (He et al. 2010). In general, although linkage and candidate gene studies have 
identified several potential associations with AM and/or ANM, a lack of replication and inconsistency 
has resulted in few variants of accepted significance. 
 Genome-wide association studies (GWAS) have identified many novel loci associated with AM 
or ANM. Four GWAS published simultaneously for AM identified many of the same SNPs (He et al. 
2009a; Ong et al. 2009; Sulem et al. 2009; Perry et al. 2009). Variants in or near LIN28B (6q21) and 9q31.2 
reached genome-wide significance in these studies; however, they were responsible for less than 1.0% 
of the variation in AM (Perry et al. 2009; Ong et al. 2009).  The International ReproGen Consortium 
published a meta-analysis of 87,802 women with a replication cohort of 14,731 women, all of European 
ancestry. This meta-analysis confirmed the associations between LIN28B/6q21 and 9q31.2 with AM 
and identified 30 novel associations and ten suggestive associations with AM (Elks et al. 2010). Despite 
this increase in sample size, these 42 variants account for <10% of the observed variation in AM (Elks et 
al. 2010).  
 21 
 
 The findings from GWAS on ANM are similar to those for AM, with little concordance between 
studies. Studies have identified the same locus (19q13.42/BRSK1) at genome-wide significance (He et 
al. 2009a; Stolk et al. 2009). A recent meta-analysis from the ReproGen Consortium in 38,968 women 
with replication in 14,435 women, all of European ancestry, confirmed associations with four 
menopause loci and identified thirteen novel ANM associations in DNA repair and immune pathways 
(Stolk et al. 2012). Additionally, the WHI-SHARe (Women’s Health Initiative-SNP Health Association 
Resource) has generalized associations with eight menarche loci and two menopause loci to a cohort of 
Hispanic ancestry (Chen et al. 2012a). A pentanucleotide repeat polymorphism in SHBG was associated 
with an earlier age at menopause in a Greek study, though this effect was slight and the study size 
small (n=210) (Markatseli et al. 2014).  
 A lack of data for genetic variants associated with AM/ANM in non-European-descent 
populations has been highlighted as a known barrier to identifying loci associated with these traits in 
all race/ethnicities, and emphasizes the need to extend GWAS analyses to more diverse populations 
(Dvornyk and Waqar 2012). This disparity in research has recently been addressed in a GWAS meta-
analysis in African American women (n=6,510) from eleven studies across the US (Chen CT et al. 2014). 
Though no new associations with age at menopause were identified, the authors generalized to their 
participants six variants previously associated with ANM in European cohorts (Chen et al. 2014a).  
 A recent study has assessed the interaction between cigarette smoking and genetic variants on 
the timing of natural menopause in European-Americans (Butts et al. 2014). Smoking is a risk factor for 
natural menopause, decreasing the ANM by 1-2 years (Cramer et al. 1995; Gold et al. 2001; Sievert et al. 
2013). It has been hypothesized that smoking influences age at menopause through a mechanism that 
results in cytotoxicity to oocytes, leading to oocyte depletion to hastening time to menopause 
(Mattison, Nightingale, and Shiromizu 1983; Jurisicova et al. 2007; Matikainen et al. 2001) or though 
chemicals in cigarettes that lead to hypoestrogenism (Zhu and Conney 1998; Michnovicz et al. 1986). 
Candidate genes were selected for their association with timing of menopause or bioactivation of 
polyaromatic hydrocarbons that are in cigarettes (Butts et al. 2014). Significant associations of earlier 
age at menopause were found in carriers of CYP1B1*3 or CYP3A4*1B who were smokers, resulting in a 
more than two-fold increased risk of menopause than nonsmokers (Butts et al. 2014). However, this 
was a small study (n=410) and the findings only applied to the European-American participants 
(n=205), not the African Americans in their study, and the strata for each genotype and smoking status 
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were small (Butts et al. 2014). Nevertheless, these findings suggest interactions between genetic 
variants and environmental factors may play a role in the timing of menopause.  
Autoimmunity and Thyroid disease 
 Autoimmune disorders are a group of disorders characterized by a loss of immune tolerance to 
self antigens (Murphy, Travers, and Walport 2008). Autoimmune diseases can be generally organized 
into two groups: organ-specific and systemic; Graves’ disease and Hashimoto’s thyroiditis are 
examples of organ-specific autoimmune disorders (Murphy, Travers, and Walport 2008). For many 
autoimmune diseases, women are disproportionately affected (Lawrence et al. 1998; Weyand et al. 
1998) and there may be differences in disease incidence across racial/ethnic groups (Murphy, Travers, 
and Walport 2008; Cooper and Stroehla 2003; Okayasu et al. 1994). Though the human leukocyte 
antigen (HLA) region of chromosome six has been implicated in many autoimmune disorders 
(reviewed in (Gough and Simmonds 2007)), these diseases are not fully understood and represent an 
important area in women’s and minority health research. 
Epidemiology of autoimmune thyroid disease 
 The thyroid is a small, butterfly-shaped gland on the front and sides of the neck. As a part of the 
hypothalamus-pituitary-thyroid (HPT) axis, the thyroid helps to regulate many physiological 
processes, including metabolic processes and mitochondrial function (Bassett and Williams 2008; 
Costa-e-Sousa RH and Hollenberg 2012; Vidali et al. 2014). Thyroid disease is a broad term that 
encompasses several related, though clinically distinct, disorders including thyroid nodules and goiter, 
thyroid cancer, congenital hypothyroidism, hyperthyroidism, and hypothyroidism. Both 
hyperthyroidism and hypothyroidism may develop from autoimmune causes or from environmental 
factors, such as iodine insufficiency; in developed countries, where iodine is replete, autoimmune 
causes are the most common (Vanderpump 2011). Both hyperthyroidism and hypothyroidism are 
diagnosed by measuring the serum thyroid stimulating hormone (TSH), free thyroxine (free T4), and 
free tri-iodothyronine (free T3) levels (Vanderpump 2011;National Endocrine and Metabolic Diseases 
Information Service (NEMDIS), National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK), and National Institutes of Health 2014) (Table 4).  
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Table 4. Reference ranges and typical thyroid function test results. 
 TSH (mIU/L) free thyroxine 
(fT4)(ng/dL) 
free triiodothyronine 
(fT3) (pg/mL) 
Euthyroid (normal) 0.5-4.50 0.5-1.2 2.3-4.2 
Hypothyroid ↑ ↓ ↓ 
Hyperthyroid ↓ ↑ ↑ 
The reference range for TSH reflects the position of a joint conference of the American 
Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine 
Society (JAMA 2004; 291:228).  Arrows indicate direction of test value from the reference level in 
a typical thyroid diseased patient. Adapted from: (National Endocrine and Metabolic Diseases 
Information Service (NEMDIS), National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK), and National Institutes of Health 2014) 
 
 Hypothyroidism is most commonly caused by Hashimoto’s disease and is four times more 
common in women than in men; it is primarily seen in middle-aged women, though it may occur at 
any age in either sex (Vanderpump 2011; Hollowell et al. 2002). Symptoms of hypothyroidism include 
fatigue and/or muscle weakness, sensitivity to cold, constipation, unexplained weight gain, excessive 
or prolonged menstruation, and depression (Dubbs and Spangler 2014). Complications from 
hypothyroidism include development of a goiter, increased risk of heart disease (Bai et al. 2014), 
depression and other mental health issues, and myxedema; untreated myxedema is critical and may 
result in myxedemic coma or death (Dubbs and Spangler 2014). Pregnant women with untreated 
Hashimoto’s disease are at increased risk of adverse maternal and fetal outcomes including recurrent 
miscarriage and birth defects (Nathan and Sullivan 2014; Dosiou et al. 2012).   
Genetic contributions to the development of Hashimoto’s disease 
  The heritability of autoimmune hypothyroidism and thyroid hormones (TSH, T3, T4) has been 
assessed in several twin- and family-based studies with substantial variability (Brix et al. 2000; Panicker 
et al. 2008b; Samollow et al. 2004; Hansen et al. 2004; Meikle et al. 1988). Intra-individual variability has 
been shown to be roughly half that of inter-individual variability in these hormone levels for healthy 
individuals (Andersen et al. 2002). Nevertheless, these studies demonstrate a strong genetic component 
to thyroid hormone levels and corresponding disease state. Both candidate gene and genome-wide 
association studies have been used to identify genetic variants associated with hypothyroidism and 
corresponding thyroid hormone levels. Variants in PDE8B are associated with serum TSH levels 
(Arnaud-Lopez et al. 2008; Medici et al. 2011; Taylor et al. 2011); this gene encodes a cAMP-specific 
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protein expressed in thyroid tissue (Horvath et al. 2010). FOXE1, a thyroid transcription factor believed 
to be important in thyroid morphogenesis (Cuesta, Zaret, and Santisteban 2007), has been associated 
with hypothyroidism (Eriksson et al. 2012; Denny et al. 2011; Gudmundsson et al. 2009)  and may be 
weakly associated with serum TSH levels (Medici et al. 2011). Despite the strong autoimmune 
component to hypothyroidism, few variants in known autoimmune loci (e.g., HLA region, CTLA-4) 
have been found to be associated with the clinical disease (Eriksson et al. 2012). In summary, the 
known genetic variants associated with TSH levels or hypothyroidism account for little of the expected 
heritability, emphasizing the need for future studies to identify additional genetic risk factors. 
Personalization: Understanding Race/Ethnicity 
Historic research inequality 
 As women have historically been overlooked in clinical research, so too, have been populations 
of non-European ancestry. The NIH Revitalization Act of 1993 was put into place to require biomedical 
researchers include more women and minorities in their clinical research studies unless compelling 
reasons against their inclusion existed (National Institutes of Health 1993). This and other initiatives to 
include women and minorities has resulted in some success: a recent report by the Federal Food and 
Drug Administration (FDA) determined that sex composition of clinical trials in 2011 was reflective of 
the disease prevalence differences between men and women (Food and Drug Administration and 
U.S.Department of Health and Human Services 2013). However, more than a decade later, minority 
participation in clinical research is still lacking (Food and Drug Administration and U.S.Department of 
Health and Human Services 2013; Ford et al. 2005). For example, the African American participation in 
T2D clinical studies was less than 5%, despite the higher prevalence of T2D in African Americans and 
their overall percent of the US population (13.2%) (Food and Drug Administration and U.S.Department 
of Health and Human Services 2013; U.S.Department of Commerce 2014; Office of Minority Health and 
U.S.Department of Health and Human Services 2014a). This FDA report concluded that, for 2011 
clinical trials, non-white clinical trial study participants were underrepresented (Food and Drug 
Administration and U.S.Department of Health and Human Services 2013). 
  There are several barriers to participation in biomedical research by underrepresented groups 
from both the participant and the institutional perspectives. These include ineligibility per study 
design, cost, language differences, low literacy, and practical obstacles (e.g., number of visits required 
per study design) (Williams 2009). A lack of awareness and mistrust are challenges that result, in part, 
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from historic injustices to some groups (Armstrong et al. 1999; Gorelick et al. 1998). For example, the 
Tuskegee Syphilis Study, in which African American men with syphilis were untreated in order to 
study the natural progression of the disease, has had lingering effects on minority participation in 
biomedical research and clinical trials (Thomas and Quinn 1991; Freimuth et al. 2001; Gamble 1997; 
Tuskegee University Centers of Excellence Bioethics Center 2014). These challenges may be successfully 
overcome through use of social marketing, referrals from family or friends, and recruitment through 
healthcare providers (UyBico, Pavel, and Gross 2007). Use of EHRs to identify individuals who may 
qualify for participation in clinical research may improve minority participation. 
Clinical differences across diverse populations 
 Population-specific differences have already been identified for many diseases. For example, 
Native Hawaiians and Pacific Islanders are 30% more likely to have asthma than non-Hispanic whites, 
and from 2003-2005, African American children were 7 times more likely to die from asthma than non-
Hispanic white children (Asthma Disparities Working Group 2012). Type 2 diabetes disproportionately 
affects racial and ethnic minority groups; risk of diabetes compared to non-Hispanic whites is 18% 
higher in Asian Americans, 66% higher in Hispanics, and 77% higher in non-Hispanic blacks (Centers 
for Disease Control and Prevention and U.S.Department of Health and Human Services 2011). 
Complications from T2D, such as end stage renal disease and lower limb amputation are also more 
common in non-white individuals (Office of Minority Health and U.S.Department of Health and 
Human Services 2014b). Other population-specific differences have been identified for ECG traits 
(Ramirez et al. 2011), age-related macular degeneration (Klein et al. 2011), and heart disease (Office of 
Minority Health and U.S.Department of Health and Human Services 2014c). For reproductive traits, it 
is well-established that certain race/ethnicities differ in the median AM (Salsberry, Reagan, and Pajer 
2009), though the cause of those differences is not completely understood and is likely to arise from 
both genetic and environmental factors. Similarly, endometrial cancer rates differ between 
race/ethnicities, and these differences cannot be attributed solely to socioeconomic issues that impair 
access to care (1987). The incidence rate for cervical cancer is more than five times higher for 
Vietnamese women in the US than for white women (Agency for Healthcare Research and Quality 
2001). Given the public health burden of common, complex diseases, understanding the genetic, 
environmental, and socioeconomic factors that contribute to these disorders is imperative and 
necessitates studies in diverse populations.  
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Strategies for Building Statistical Models in Personalized Medicine 
 There are multiple approaches to designing a genetic study, each with a unique set of 
challenges and benefits. As the technology used to perform these studies changes, methods used to 
analyze the data must adapt to maximize the utility of the results. Many genetic studies follow the 
common disease/common variant hypothesis (CDCV), where common genetic variants confer the 
majority of disease susceptibility (Reich and Lander 2001). Because these risk alleles are common 
(typically defined as having a minor allele frequency >5%) and not subject to strong natural selections 
as are mutations, these risk alleles are likely ancient and shared across most populations. Each common 
variant is expected to confer a small effect towards disease risk; therefore, it is expected that common 
diseases will have multiple risk alleles and interactions with environmental factors. Genome-wide 
association studies, discussed below, were developed on the CDCV premise (Manolio et al. 2009). For 
most common disorders, current studies have failed to identify more than a small fraction of the 
genetic component using approaches based on CDCV, suggesting that rare variants with large effect 
sizes and/or complex interactions between genetic variants and environmental factors may play a 
substantial role in disease susceptibility (Manolio et al. 2009; Eichler et al. 2010; Cirulli and Goldstein 
2010). For women’s health, two main approaches have been used to identify the genetic variants 
associated with disease: candidate gene and genome-wide association studies.   
Candidate gene approach 
 Based on prior knowledge or biological plausibility, the candidate gene association study 
interrogates specific variants, genes, or regions for association with the disease or quantitative trait. 
Candidate gene association studies (CGAS) were the first type of association study performed and are 
still widely used. Benefits to this approach include lower costs than other methods, the hypothesis-
driven nature of the study, and limited number of tests performed. However, this design is not without 
drawbacks. If the correct variant/gene is not selected, no association with the phenotype will be 
found—a potential hazard due to genetic (both locus and allelic) heterogeneity. Candidate gene studies 
with small sample sizes have led to few of these studies replicating, though completely excluding a 
gene based on negative results is difficult. As in GWAS studies (see below), properly designed 
(appropriately powered) studies are essential when attempting to replicate a genotype-phenotype 
association. 
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 Despite the challenges inherent with CGAS, they have been successful in identifying genes 
associated with numerous phenotypes important in women’s health. Early CGAS evaluating the role of 
hormone biosynthesis pathways in the timing of the reproductive lifespan were largely unsuccessful; 
however, more recent studies have identified FSHB and ESR2 associations with timing of AM (He et al. 
2010). A CGAS was used to identify inflammatory pathway genes that were associated with 
endometrial cancer in the Shanghai Endometrial Cancer Genetics Study (Delahanty et al. 2013). CGAS 
may also be used to confirm results obtained from genome-wide association studies (GWAS) (see 
below); O’Mara et al. assessed five SNPs previously associated with endometrial cancer in GWAS, but 
failed to confirm these past associations(O'Mara et al. 2011b). In addition, CGAS may be used to 
prioritize studies hoping to generalize results from association studies in one population to another. 
With the majority of genetic studies performed in European-descent populations, extension of the 
findings to more diverse populations may suggest underlying biological disease mechanisms, while 
those that fail to associate may suggest population-specific disease risk or false positives. A recent 
CGAS assessed forty SNPs, previously identified in GWAS of European women, for association with 
breast cancer in Chinese women. rs9693444 was associated with overall breast cancer in this Chinese 
cohort (p=6.44x10-04), while others were associated with various breast cancer subtypes (Zhang et al. 
2014). Though there are significant challenges to the CGAS approach, it is a useful and relevant method 
to identify genotype-phenotype associations. 
Genome-wide association studies 
 Unlike candidate gene studies where an a priori hypothesis about a relationship between the 
genetic variant and phenotype exists, genome-wide association studies (GWAS) require no previous 
knowledge about such a relationship, relying instead on the CDCV hypothesis. In a GWAS, 
interrogation occurs across the genome, generally capturing common variants in European-descent 
populations; the exact number of variants tested varies by platform and assay. It is common for 
hundreds of thousands or millions of SNPs to be tested. Linkage disequilibrium, the non-random 
association of alleles, allows a fraction of the genome to be genotyped while inferring information 
about untyped variants. Though the GWAS approach offers researchers the ability to discover new 
genotype-phenotype associations, it comes with a high statistical price: correcting for multiple 
statistical tests. This statistical burden is often corrected for using the Bonferroni method, where the 
alpha value for a single hypothesis test is divided by the total number of tests performed. For GWAS, 
the rule of thumb is that a result is significant if the p-value <5x10-8 (0.05/1 million) (Dudbridge and 
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Gusnanto 2008). With newer GWAS chips capable of genotyping 5 million SNPs, this threshold may be 
inadequate; however, some have suggested the Bonferroni method is too stringent and other methods, 
such as false-discovery rates may be better (Zablocki et al. 2014; Pan 2013; Lin and Lee 2012; Wei 2012). 
This stringency arises from linkage disequilibrium; many of the SNPs tested in a GWAS are not 
independent, and the Bonferroni correction of these non-independent tests can result in a greater 
number of false negatives (missed true interactions) (De, Bush, and Moore 2014). In addition, GWAS 
chips primarily focus on common SNPs with allele frequencies greater than 0.05, limiting their ability 
to identify rare variants that are associated with a particular phenotype. The ability of genotyping chips 
to tag common variants also depends on the population under study (Hoffmann et al. 2011; Eberle et al. 
2007). Furthermore, most SNPs associated with a disease phenotype have small effect sizes, explaining 
only a small amount of the phenotypic variance. These small effect sizes may fail to be clinically 
meaningful and frustrate replication attempts, as increasingly larger sample sizes are required to 
replicate the initial discovery. For example, a recent meta-analysis performed in the GIANT consortium 
with more than 250,000 cases and controls identified novel variants associated with overweight with an 
OR=1.04 (Berndt et al. 2013); successful replication of these results will require many more thousands 
of individuals derived from the same population, not already used in one of the contributing studies, 
demonstrating the practical challenges of replicating results with very small effect sizes.  
 Despite these limitations, GWAS have been successful in identifying genetic variants associated 
with many women’s health traits and complex diseases and have led to additional hypotheses about 
the biological mechanisms responsible for disease. For example, a recent GWAS for systemic lupus 
erythematosus (SLE) identified novel HLA-region genes and replicated four genes previously 
associated with the autoimmune disorder (Armstrong et al. 2014). Numerous GWAS have been 
performed for breast cancer (briefly, (Low et al. 2013; Garcia-Closas et al. 2013; Michailidou et al. 2013)), 
endometriosis (Albertsen et al. 2013; Nyholt et al. 2012; Painter et al. 2011), and cervical cancer (Chen et 
al. 2013; Shi et al. 2013). Traits like gestational diabetes (Hayes et al. 2013) and fibroid tumors (Cha et al. 
2011) have also been assessed with GWAS. These studies represent only a few women’s health traits 
that have been investigated using GWAS. Though GWAS has not been successful in identifying causal 
variants with large effect sizes for most diseases/traits, the findings may point to underlying genetic 
architecture and biological mechanisms. 
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Interactions 
 Interactions, both gene-gene (GxG) and gene-environment (GxE), have been suggested as 
explanations for the “missing heritability” from GWAS studies (Zuk et al. 2012; Manolio et al. 2009). 
Interactions are challenging to identify in human genetic studies for a variety of reasons. Sample size 
requirements differ based on the study design (e.g., case-only vs. matched case-control), what type of 
interaction (GxG, GxE), and expected effect size of the interaction (Gauderman 2002a; Gauderman 
2002b). Testing for statistical interactions among all the genetic variants is computationally intensive 
and leads to sparse/no data for some interactions; limiting GxG testing to variants with significant 
associations with the phenotype improves the computational challenges, including corrections for 
multiple tests, but compromises the ability to identify interactions between variants without main 
effects. Testing for interactions may be done using data reduction methods (e.g., combinatorial 
partitioning (Nelson et al. 2001), restricted partitioning (Culverhouse 2007), multifactor dimensionality 
reduction (Ritchie et al. 2001)), extensions to regression analysis (e.g., classification and regression trees 
(CART) (Breiman, Friedman, and Olshen), multivariate adaptive regression splines (MARS) (Lin et al. 
2008)), and pattern recognition methods (e.g., neural networks (Turner, Dudek, and Ritchie 2010)). 
Prioritizing variants for GxG or GxE by biological plausibility reduces the number of statistical tests 
and computational burdens, yet restricts the potential to identify novel interactions that may be 
clinically meaningful.  
Gene-gene interactions 
 Despite the issues addressed above, GxG interactions have been identified for a variety of 
phenotypes. Gene-level interactions between SMAD3 and NEDD9 affecting lipid levels was found in 
the Atherosclerosis Risk in Communities (ARIC) study and replicated in an independent sample from 
the Multi-Ethnic Study of Atherosclerosis (MESA) (Ma, Clark, and Keinan 2013).  Samples with age-
related macular degeneration (Klein et al. 2005) were used to find variants in several genes interacting 
with CFH, a well-characterized AMD gene (Zhang, Long, and Ott 2014). Notably, the AMD results are 
not only biologically plausible, but the interaction between BBS9 and CFH replicates earlier studies 
performed using different methodology to detect the interactions (Chen et al. 2007; Wang et al. 2009).  
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Gene-environment interactions 
 Based on epidemiologic studies, environmental factors, which include such variables as body 
mass index (BMI), dietary intake, and carcinogen exposure, are known to play a role in the 
susceptibility of numerous disorders and complex traits (Cecchini et al. 2012; Turati et al. 2014; 
Steenland et al. 1996). How environmental exposures in conjunction with genetic variants contribute to 
the genetic architecture of complex diseases and traits is not fully understood. Examples of GxE 
interactions include exposure to farming with genetic variants on asthma risk (Ege et al. 2011; Ober and 
Vercelli 2011) and the effect of early childhood environment with genetic predisposition on mental 
health traits (Cicchetti and Rogosch 2012; Forsyth et al. 2013).  
 Despite some success, there is no systematic approach to identifying GxG or GxE and relatively 
few phenotypes have been adequately assessed for these potentially important interactions. The 
potential importance of GxG and GxE interactions should be considered in the context of personalized 
medicine. Individuals with significantly higher or lower disease risks based on GxG interactions may 
benefit from modified screening schedules; for example, in absence of a family history predisposing to 
colorectal cancer (CRC), someone with a GxG interaction that significantly increases their risk of 
developing CRC could benefit from more frequent colonoscopies. In addition, modifying exposures, 
such as alcohol intake, may reduce the risk of some diseases, like liver cancer. For individuals with 
increased genetic risk for a specific disease, understanding how environmental factors may interact 
with genetic factors may be a motivational tool to encourage healthy lifestyle choices.  
Summary 
 Personalized medicine offers the potential to improve health outcomes by tailoring clinical care, 
including preventative medicine, to the individual patient. Though PM for cancer treatment and 
pharmacogenetics have been successfully integrated into clinical care at some institutions, expansion to 
other common, complex diseases has yet to be realized. Importantly, PM initiatives may reduce the 
historic and continued health and research disparities faced by women and some populations as 
researchers seek to understand the genetic architecture of complex traits and translate these findings to 
clinical care, or may lead to increased health disparities if access to and coverage of genetic testing is 
not universal or if decision support rules are invalid for non-European descent individuals. This body 
of work presents three genetic studies with an emphasis on complex traits important through the 
 31 
 
course of a woman’s life, from menarche through menopause and beyond, and then considers what 
work remains to effectively use this information to improve health outcomes in the future.  
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CHAPTER II 
CASE STUDY: GENETICS OF THE FEMALE REPRODUCTIVE LIFESPAN1 
II. CASE STUDY: GENETICS OF THE FEMALE REPRODUCTIVE LIFESPAN 
Introduction 
As noted in Chapter 1, age at menarche and age at natural menopause are heritable traits that 
influence a variety of phenotypes along the female life course. In this study, we used data from the 
Metabochip genotyping array to characterize previously identified variants associated with menarche 
and menopause in African Americans in a combined cohort of African-American women from the 
Women’s Health Initiative (WHI) and Atherosclerosis Risk in Communities (ARIC) studies (Matise et 
al. 2011) as part of the Population Architecture using Genomics and Epidemiology (PAGE) Study 
(Buyske et al. 2012).  The Metabochip array is based on the Illumina iSelect platform and contains 
approximately 200,000 single nucleotide polymorphisms (SNPs) consisting of GWAS index variants 
and fine-mapping common and less common variants for GWAS-identified regions relevant to 
metabolic and cardiovascular traits (Voight et al. 2012; Buyske et al. 2012).  Using current GWAS and 
candidate gene literature as a guide, we attempted to generalize previously identified menarche and 
menopause SNPs and gene regions identified in European-descent populations to African Americans 
in the PAGE Study.   We then sought to identify novel SNPs associated with AM and/or ANM. 
Menarche 
Study population 
 Women participants from two cohorts of the PAGE Study (Matise et al. 2011), Atherosclerosis 
Risk in Communities Study (ARIC) and the Women’s Health Initiative (WHI), were included in these 
analyses. ARIC is a population-based prospective study of cardiovascular diseases and their causes in 
~16,000 men and women aged 45-64 at baseline (1989).  Participants were recruited in Forsyth County, 
N.C., Jackson, M.S., Minneapolis, M.N., and Washington County, M.D.  From this group, 2,070 women, 
                                                     
1 Adapted from: Spencer KL*, Malinowski J*, Carty CL, Franceschini N, et al. Genetic variation and reproductive 
timing: African American women from the Population Architecture using Genomics and Epidemiology (PAGE) 
Study. PLoS One. (2013). 8(2), e5528 PMID: 23424626 *these authors contributed equally to the work. 
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all of self-reported African American race/ethnicity and with information on reproductive timing, 
were selected for study.  The WHI is a long term national health study investigating the leading causes 
of mortality and frailty in post-menopausal women in the United States, including heart disease, breast 
and colorectal cancer, and osteoporotic fractures (1998).  A subset of 2,455 self-reported African 
American women selected based on consent to use DNA and availability of DNA, blood lipids, and 
glucose and insulin measurements were included in this study.  The appropriate institutional review 
board at each participating study site approved all procedures, and written informed consent was 
obtained from all participants. Age at menarche was defined as the age when menstrual periods started 
in years, with extreme values pooled in groups of 9 years or less and 17 years or older.   
Genotyping and statistical methods 
 Genotyping and quality control methods were the same for the age at menarche and the age at 
natural menopause analyses. Genotyping was performed on the Metabochip, a custom Illumina iSelect 
genotyping chip designed to genotype SNPs associated with metabolic traits and cardiovascular 
disease (Buyske et al. 2012; Voight et al. 2012). The array also includes 2,207 SNPs associated at 
genome-wide significance to any trait published in the NHGRI GWAS catalog as of August 1, 2009.  
For each of these GWAS-identified SNPs, an additional proxy SNP with r2>0.90 in the CEU HapMap II 
dataset, plus up to four additional SNPs with r2>0.5 in the YRI HapMapII dataset were also included on 
the array.  Lastly, SNPs selected to fine-map regions of interest related to metabolic traits, copy number 
variant-tagging SNPs, Major Histocompatibility Complex (MHC) SNPs, SNPs on the X and Y 
chromosomes, mitochondrial DNA SNPs, and “wildcard” SNPs were also targeted, for a total of 
approximately 200,000 SNPs.  Of these, 161,098 (81.9%) passed quality control filters for tests of Hardy-
Weinberg Equilibrium (>1x10-7) and genotyping efficiency (>95% call rate). There was no filter for 
minor allele frequency due to PAGE quality control protocol.  The design and performance of this 
genotyping chip in this African American sample has been described in detail elsewhere (Buyske et al. 
2012). All analyses were carried out in either METAL or the R software package, and data were plotted 
using LocusZoom (Pruim 2010; R Development Core Team 2012). Statistical power to detect an 
expected association was estimated in Quanto (Gauderman 2002a) assuming the observed sample size 
and coded allele frequency in this African American cohort and the genetic effect size previously 
reported in the literature. 
 All participants self-reported African American ancestry. To adjust for potential population 
stratification, we used the principal components method implemented in EIGENSTRAT  (Price et al. 
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2006). We excluded any ancestry outliers further than eight standard deviations away from the mean 
for the first ten principal components determined by EIGENSOFT. 
 For menarche, linear regression was performed assuming an additive genetic model to test for 
associations between individual SNPs and the outcomes of age at menarche in years. We examined two 
models for menarche: 1) a minimally adjusted model that accounted only for study sites and principal 
components, and 2) a fully adjusted model that included study site, year of birth, principal 
components, and body mass index at ascertainment, with the understanding that BMI at ascertainment 
may be a poor proxy for BMI at age of menarche. Age at menarche was self-reported many years later 
at time of examination, which has been shown to be fairly accurate (Must et al. 2002). 
 We studied one model for natural menopause using Cox’s proportional hazards for time-to-
event (natural menopause) analysis, which adjusted for study site, principal components, and year of 
birth. Women with a missing age at menopause, an age at menopause <40 years, or hysterectomy, 
oophorectomy, or hormone replacement therapy after age 40 but prior to menopause, were excluded 
from the study. Women who had menopause >60 years had their ANM set as censored at age 60. A 
fixed effects meta-analysis was then performed using METAL to obtain effect size and standard error 
(SE) estimates (Willer, Li, and Abecasis 2010).  
 We looked to generalize to our population of African American women genes, gene regions 
(400 kb upstream and downstream of a gene of interest), and SNPs described in previous GWAS and 
candidate gene studies associated with AM.  We tested all SNPs in the regions regardless of linkage 
disequilibrium (LD) with the index SNP, although we only considered a test of association generalized 
if the tested SNPs were identical to the index SNP or in strong LD with the index variant in HapMap 
CEU samples. For each candidate gene, we plotted results of single SNP tests of association using 
LocusZoom and examined regions 400kb upstream and downstream of the gene/gene region of 
interest. Tests of association were considered significant for generalization at a liberal threshold of 
p<0.05. For previously reported variants not genotyped in our study, we identified SNPs in LD with 
our directly genotyped SNPs (Johnson et al. 2008) and reported results from our minimally adjusted 
model (Model 1) for the proxy SNPs. 
 In addition to generalization, we sought to discover novel SNP-trait associations using the 
entire Metabochip. Significance in this discovery phase was defined as p<3.1x10-7, after Bonferroni 
correction (0.05/161,098). Because this threshold is highly conservative given the correlation among the 
 35 
 
SNPs on the Metabochip, we also defined an arbitrary suggestive significance level as p<1x10-4 in the 
discovery phase. 
Results 
 A total of 4,159 African American female participants met the study definitions for AM and 
both PAGE studies were represented roughly equally (Table 5). In ARIC, the mean age at menarche 
was 12.9 years, which was slightly greater than the mean age at menarche in WHI (12.6 years) (Table 5). 
Groups’ participants’ heights, weights, and body mass indices were comparable. In both ARIC and 
WHI, the majority of participants’ decade of birth was the 1930s (Table 5). 
 
Table 5. Population characteristics of African American women from the PAGE Study for age at 
menarche (AM) analysis.  
 Age at Menarche (AM) 
 Study Population 
 ARIC WHI 
Participants (n) 2078 2081 
Age at menarche, yrs 12.89 (1.76) 12.56 (1.64) 
Age at enrollment, yrs 53.36 (5.73) 61.01 (6.87) 
Body mass index, kg/m2 30.86 (6.63) 31.34 (6.83) 
Weight, lbs. 181.05 (39.68) 182.87 (41.26) 
Height, in. 64.24 (2.43) 64.00 (2.63) 
Decade of birth, #(%) 1910s - 26 (1.24) 
 1920s 504 (24.07) 414 (19.82) 
 1930s 1083 (51.72) 981 (46.96) 
 1940s 507 (24.21) 668 (31.98) 
Data presented as means (sd) unless otherwise noted. Abbreviations: 
Population Architecture using Genomics and Epidemiology (PAGE), 
Atherosclerosis Risk in Communities (ARIC), Women’s Health Initiative 
(WHI), years (yrs), standard deviation (sd). 
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Generalization to PAGE African Americans 
 To generalize previously-associated genetic variants in our African American population, we 
examined regions/genes previously associated with AM from either published candidate gene studies 
or GWAS: CYP19A1, CYP17, CYP1B1, FTO, LIN28B, 9q31.2 region, IGF1, TNFSF11, TNFRSF11A, and 
LHCGR (Guo et al. 2006b; Mitchell et al. 2008; Elks et al. 2010; Zhao et al. 2007; Perry et al. 2009; Ong et 
al. 2009; Lu et al. 2010; He et al. 2009a; He et al. 2010).  We also evaluated forty-two SNPs associated 
with AM identified in a recent meta-analysis by Elks et al. of >87,000 European-descent women from 
forty-nine studies (Elks et al. 2010).   
 Overall, 11/21 (52%) SNPs previously identified for AM from earlier studies and 15/42 (36%) 
from the Elks et al. meta-analysis were directly genotyped or in strong (r2>0.70) LD in the CEU panel of 
HapMap with those genotyped (Table 6 and Appendix A, respectively), and one generalized to this 
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Figure 2. Regional association plot for AM in African American women from 
PAGE Study.  
Locus Zoom plot for LIN28B region in age at menarche (AM) analysis. Vertical axis is –log10 of 
the p-value, the horitzontal axis is the chromosomal position. Each dot represents a SNP tested 
for association with AM in 4,159 African American women from the Population Architecture 
using Genomics and Epidemiology (PAGE) Study. Approximate linkage disequilibrium 
between the most significant SNP, rs408949, listed at the top of the plot, and the other SNPs in 
the plot is shown by the r2 legend. 
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African American cohort: rs9385399, in LD with previously reported rs1361108 (r2=1.00, p=0.01) 
(Appendix A).  A LocusZoom plot of the results of association tests and LD in this African American 
sample is given for LIN28B -- previously associated with AM (Figure 2) (He et al. 2009a; Ong et al. 2009; 
Sulem et al. 2009; Perry et al. 2009).  
Three SNPs in LIN28B were included on the Metabochip (rs314277, rs4946651, and rs7759938), 
and while the direction of genetic effect was consistent with previous reports, all failed to reach 
statistical significance in this sample (p>0.30) (Table 6).  Four additional SNPs in LD with these LIN28B 
SNPs were also not significant. At the 9q31 locus, rs7861820 and rs4452860, both located downstream of 
TMEM38B, had betas opposite to prior reports (Perry et al. 2009; He et al. 2009a). Neither SNP nor their 
proxy SNPs were significant at p<0.05. Similarly, SNPs in LD (rs1856142 and rs605765) with previously 
associated variants in and around FSHB were not significantly associated with AM in this African 
American sample, though rs605765 (β=-0.06) had the same direction of effect and comparable 
magnitude as rs1782507 (β=-0.07) (He et al. 2010). 
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Table 6. Comparison of GWAS-identified age at menarche (AM) variants in African American women from the Population Architecture 
using Genomics and Epidemiology (PAGE) Study.  
Prior GWAS in European descent women African American women from the PAGE Study 
SNP CHR Gene/Region Coded 
Allele 
Beta P-value Ref. Best Proxy SNP 
from present 
study 
r2 in 
HapMap 
CEU/YRI 
Coded 
Allele 
Model 1 Model 2 
Beta (SE) P-
value 
Beta (SE) P-
value 
rs314277 6 LIN28B A 0.16 2.7E-13 (He et al.2009a) rs314277 - A 0.03(0.04) 0.34 0.03(0.04) 0.36 
rs369065 6 LIN28B C 0.11 2.4E-11 (He et al.2009a) rs7759938 1.00/0.34 A -0.02(0.04) 0.61 -0.02(0.04) 0.55 
rs7759938 6 LIN28B C 0.09 7.0E-09 (Perry et al.2009) rs7759938 - A -0.02(0.04) 0.61 -0.02(0.04) 0.55 
rs314276 6 LIN28B C -0.22 1.5E-08 (Ong et al.2009) rs314274 1.00/0.73 A 0.05(0.04) 0.22 0.05(0.04) 0.24 
rs314280 6 LIN28B T 0.09 2.3E-08 (Sulem et al.2009;He 
et al.2009a) 
rs7759938 0.64/0.28 A -0.02(0.04) 0.61 -0.02(0.04) 0.55 
rs4946651 6 LIN28B A 0.09 3.1E-08 (He et al.2009a) rs4946651 - A 0.03(0.04) 0.55 0.03(0.04) 0.55 
rs314262 6 LIN28B C 0.08 9.7E-08 (He et al.2009a) rs7759938 0.60/0.29 A -0.02(0.04) 0.61 -0.02(0.04) 0.55 
rs7861820 9 9q31 C -0.09 3.4E-09 (He et al.2009a) rs7861820 - A -0.10(0.06) 0.10 -0.09(0.06) 0.12 
rs12684013 9 9q31 T -0.10 3.6E-08 (He et al.2009a) rs4452860 0.81/0.01 A -0.03(0.04) 0.43 -0.03(0.04) 0.42 
rs4452860 9 9q31 G -0.09 7.9E-08 (He et al.2009a) rs4452860 - A -0.03(0.04) 0.43 -0.03(0.04) 0.42 
rs7028916 9 9q31 A -0.09 9.7E-08 (He et al.2009a) rs4452860 0.98/0.85 A -0.03(0.04) 0.43 -0.03(0.04) 0.42 
rs2090409 9 9q31 A -0.10 1.7E-09 (Perry et al.2009) rs4452860 0.83/0.82 A -0.03(0.04) 0.43 -0.03(0.04) 0.42 
rs555621 11 FSHB C 0.06 0.001 (He et al.2010) rs1856142 0.43/0.71 A 0.03(0.04) 0.44 0.03(0.04) 0.36 
rs1782507 11 FSHB T -0.07 0.006 (He et al.2010) rs605765 0.83/0.87 A -0.06(0.04) 0.14 -0.06(0.04) 0.13 
rs4953616 2 LHCGR T -0.07 0.006 (He et al.2010) rs1589749 0.17/0.05 A 0.002(0.07) 0.97 -0.01(0.07) 0.87 
rs7579411 2 LHCGR T 0.06 0.01 (He et al.2010) rs1589749 0.17/0.05 A 0.002(0.07) 0.97 -0.01(0.07) 0.87 
rs4374421 2 LHCGR C 0.06 0.02 (He et al.2010) rs17326321 0.19/0.69 A -0.01(0.06) 0.86 -0.01(0.06) 0.84 
rs2470144 15 CYP19A1 G - 5.9E-06 (Guo et al.2006b) rs12148492 0.23/0.01 A -0.01(0.07) 0.91 -0.02(0.07) 0.73 
rs2445761 15 CYP19A1 G - 1.2E-06 (Guo et al.2006b) rs4774585 0.28/0.02 A 0.04(0.05) 0.47 0.03(0.05) 0.58 
rs9525641 13 TNFSF11/RANKL T - 0.04 (Lu et al.2010) rs931273 0.05/0.03 A 0.11(0.09) 0.24 0.11(0.09) 0.21 
rs3826620 18 TNFRSF11A/RANK A - 0.02 (Lu et al.2010) rs8092336 0.16/0.22 A 0.16(0.17) 0.33 0.17(0.17) 0.29 
rs6214 12 IGF1 G - 0.02 (Zhao et al.2007) rs6214 - A -0.01(0.04) 0.71 -0.02(0.04) 0.61 
Comparison of previously reported SNPs associated with AM in European descent women to 4,159 African American women from the PAGE 
Study in a minimally adjusted model for AM (Model 1) and a model adjusted for study site, year of birth, principal components, and body mass 
index (Model 2). Data are presented for the previously identified SNP. If the previously identified SNP was not directly genotyped in present 
study, data shown are for best proxy SNP based on linkage disequilibrium from the International HapMap Project CEU panel. 
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 We also examined SNPs associated with AM that were reported in a recent meta-analysis 
performed by Elks et al. for the ReproGen Consortium (Elks et al. 2010) (Appendix A). Of the forty-two 
SNPs associated with AM in Elks et al., we detected an association with rs9385399 (p=0.01), located 
downstream of CENPW, which is a perfect proxy (r2=1.00) for previously associated variant rs1361108, 
and the only SNP to generalize to our African American sample. We also identified an association with 
rs2947411 (p=0.02) with AM (Appendix A), though the directions of effect were opposite.  One 
additional SNP, rs4929923 (p=0.06), nearly reached the significance threshold and had a similar 
magnitude and direction of effect compared with the previous report. Overall, AM SNPs from 
previously published studies of European-descent women, including the Elks et al. meta-analysis, did 
not generalize to our PAGE African American population. 
Discovery 
 We tested all SNPs genotyped on the Metabochip for an association with AM adjusted for study 
site and principal components (Model 1) and adjusted for study site, year of birth, principal 
components, and body mass index (Model 2) (Appendix C). After accounting for multiple testing 
(p<3.1x10-7), no SNPs were significantly associated with AM in either model (Appendix C). The most 
significant SNP in both models was rs11604207 (Model 1:  p=1.59x10-6; Model 2: p=1.82x10-6), which is 
located upstream of RSF1, a gene encoding a chromatin remodeling protein implicated in ovarian and 
breast cancers (Maeda et al. 2011; Choi et al. 2009; Brown et al. 2008) (Appendix C). 
Menopause 
Study population 
 Age at natural menopause was defined as the age at which cessation of regular menstrual 
periods due to the body’s natural aging process occurred.  In ARIC, women were asked, “Was your 
menopause natural or the result of surgery or radiation?”  Only women who indicated natural 
menopause were included.  Women in WHI who underwent hysterectomy, oophorectomy, or hormone 
replacement therapy before the onset of natural menopause were excluded.  In both studies, women 
reporting age at natural menopause <40 years were excluded; women reporting age at natural 
menopause >60 years were censored at age 60. All women included in the present study were post-
menopausal.  
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Genotyping and statistical methods 
 Genotyping, quality control, and statistical methods are detailed above for age at menarche.  
Results 
 A total of 1,860 African American female participants met the study definitions for ANM and 
both PAGE studies were represented roughly equally (Table 7). In ARIC, the mean age at natural 
menopause was 48, which was slightly younger than the WHI group (Table 7). The body mass indices, 
heights, and weights of both groups were comparable. In ARIC and WHI, the majority of participants’ 
decade of birth was the 1930s (Table 7).  
 
Table 7. Population characteristics of African American women from the Population Architecture 
using Genomics and Epidemiology (PAGE) Study for age at natural menopause (ANM) analysis.  
Age at Natural Menopause (ANM) 
Study Population 
 ARIC WHI 
Participants (n) 994 866 
Age at menopause, yrs 47.97 (3.83) 50.84 (4.50) 
Age at enrollment, yrs 53.07 (5.75) 61.30 (6.78) 
Body mass index, kg/m2 31.29 (6.94) 30.95 (6.76) 
Weight, lbs. 183.78 (40.80) 181.05 (40.63) 
Height, in. 64.31 (2.38) 64.05 (2.75) 
Decade of 
birth, #(%) 
1910s - 12 (1.39) 
 1920s 221 (22.23) 183 (21.13) 
 1930s 522 (52.52) 414 (47.81) 
 1940s 251 (25.25) 257 (29.68) 
Data presented as means (sd) unless otherwise noted. Abbreviations: 
Atherosclerosis Risk in Communities (ARIC), Women’s Health 
Initiative (WHI), years (yrs), standard deviation (sd). 
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Generalization to PAGE African Americans 
As with AM, to generalize results to our African American population, we examined previously 
identified 400kb regions around genes associated with ANM from published candidate gene studies 
and GWAS (Table 8) (He et al. 2010; He et al. 2009a; He et al. 2007; Murray et al. 2011; Stolk et al. 2009; 
Meng et al. 2011a; Long et al. 2006; Voorhuis et al. 2011; Lu et al. 2010). We also examined twenty SNPs 
associated with ANM that were identified in a recent study by Stolk et al. (Stolk et al. 2012) (Appendix 
B).  
Overall, 14/23 (40%) SNPs previously identified for ANM via GWAS and 6/20 SNPs from the 
Stolk et al. meta-analysis were directly genotyped on the Metabochip or were in strong LD (r2>0.70) in 
CEU panel of HapMap. One twelfth (8%) of the tested SNPs in these regions/genes generalized to this 
African American sample: rs8113016 (Table 8).  rs8113016, located in an intron of 
TMEM150B/TMEM224 and downstream of BRSK1, is in LD with previously reported rs897798 (r2=0.72) 
and was associated with ANM in our sample (p=0.03). An intronic APOE variant, rs769450, was 
associated with ANM (p=0.03), though the nonsynonymous APOE rs7412 was not (p=0.55); these SNPs 
are not in LD with each other (r2=0.04). In BRSK1, no previously reported SNPs were genotyped in our 
study; however, directly genotyped intronic TMEM150B rs4806660 was in very strong LD with intronic 
BRSK1 rs1172822 (r2=0.98).  BRSK1 rs1168309, in strong LD with rs2384687 (r2=0.85) was not associated 
with ANM in this African American sample (p=0.59).  
 Three of the twenty SNPs recently identified by Stolk et al. as associated with ANM were 
directly genotyped on the Metabochip (Appendix B). Two of the three genotyped SNPs (rs2303369 and 
rs2153157) had the same directions of effect, though the magnitudes were smaller. Of the remaining 17 
SNPs not directly targeted by the Metabochip, three were in strong LD (HapMap CEU r2 ranging from 
0.86 to 0.91) with the SNPs identified by Stolk et al: rs1176133, rs4668368, and rs12593363.  For seven 
SNPs, no proxy SNP could be identified on the Metabochip (Appendix B). Of the twenty SNPs 
identified in the Stolk et al. meta-analysis and directly or indirectly represented on the Metabochip, 
none were associated with ANM in this African American sample (Appendix B).
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Table 8. Comparison of GWAS-identified age at natural menopause (ANM) variants in African American women in the Population 
Architecture using Genomics and Environment (PAGE) Study.  
Prior GWAS in European descent women African American women from the PAGE Study 
SNP Chr Gene/Region Coded 
Allele 
Beta P-
value 
Ref. Best Proxy SNP 
from present study 
r2 in HapMap 
CEU/YRI  
Coded 
Allele 
Beta 
(SE) 
P-
value 
rs16991615 20 MCM8 A 1.07 1.21E-21 (He et al.2009a;Murray et 
al.2011) 
rs16991615 - A -0.17(0.15) 0.25 
rs236114 20 MCM8 A 0.50 9.71E-11 (Stolk et al.2009) rs236114 - A 0.02(0.06) 0.69 
rs1172822 19 BRSK1 T -0.49 1.8E-19 (Stolk et al.2009;He et 
al.2009a) 
rs4806660 0.98/0.64 A 0.002(0.03) 0.97 
rs2384687 19 BRSK1 C -0.47 2.4E-18 (He et al.2009a) rs11668309 0.85/0.43 A 0.02(0.04) 0.59 
rs897798 19 BRSK1 G -0.40 1.1E-14 (He et al.2009a) rs8113016 0.72/0.02 A 0.12(0.05) 0.03 
rs1065778 15 CYP19A A - 0.05 (He et al.2007) rs10519297 0.90/0.32 A -0.01(0.05) 0.84 
rs2255192 15 CYP19A A - 0.04 (He et al.2007) rs10459592 0.32/0.02 A -0.02(0.04) 0.52 
rs621686 11 FSHB A 0.32 0.007 (He et al.2010) rs1856142 0.27/0.32 A 0.04(0.03) 0.29 
rs7951733 11 FSHB A -0.32 0.02 (He et al.2010) rs7951733 - A 0.11(0.13) 0.37 
rs769450 19 APOE A - 0.007 (He et al.2009b) rs769450 - A -0.07(0.03) 0.03 
rs7412 19 APOE - - 0.001 (Meng et al.2011b) rs7412 - A -0.03(0.05) 0.55 
rs1019731 12 IGF1 C -0.28 0.005 (He et al.2010) rs1019731 - A -0.03(0.11) 0.82 
rs9457827 17 IGF2R T 0.37 0.04 (He et al.2010) rs9457827 - A 0.04(0.04) 0.28 
rs4135280 3 PPARG T 0.54 0.005 (He et al.2010) rs4135280 - A -0.14(0.18) 0.42 
rs1256044 14 ESR2 G - 0.03 (He et al.2007) rs1268656 0.08/0.004 A -0.01(0.06) 0.88 
rs1256059 14 ESR2 A - 0.05 (He et al.2007) rs1268656 0.08/0.004 A -0.01(0.06) 0.88 
rs1056836 2 CYP1B1 G - 0.04 (Long et al.2006) rs10495874 0.04/0.03 A -0.03(0.05) 0.60 
rs346578 13 TNFSF11 A - 0.007 (Lu et al.2010) rs6561072 0.07/0.07 A 0.04(0.04) 0.22 
rs9525641 13 TNFSF11 T - 0.01 (Lu et al.2010) rs931273 0.05/0.03 A -0.02(0.08) 0.81 
rs8086340 18 TNFRSF11A G - 0.02 (Lu et al.2010) rs8094440 0.10/0.01 A 0.03(0.03) 0.38 
rs2002555 12 AMHR2 G 0.30 0.02 (Voorhuis et al.2011) rs7131938 0.59/0.54 A 0.01(0.04) 0.84 
rs2384687 19 TMEM224 C 0.38 1.39E-10 (Stolk et al.2009) rs11668309 0.85/0.43 A 0.02(0.04) 0.59 
rs897798 19 TMEM224 G 0.31 3.91E-08 (Stolk et al.2009) rs8113016 0.72/0.02 A 0.12(0.05) 0.03 
Comparison of previously reported SNPs associated with ANM in European and Chinese descent women to 1,860 African American women from the PAGE Study. Data presented are for the previously identified SNP. If the previously 
identified SNP was not directly genotyped in present study, data shown are for the best proxy SNP based on linkage disequilibrium calculated from the International HapMap Project CEU data. 
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Age at Natural Menopause: Discovery 
We tested all SNPs on the Metabochip for associations with ANM adjusted for study site and 
principal components. Three SNPs were significant after Bonferroni correction (p<3.1x10-7):  LDLR 
(rs189596789, p=4.98x10-8), KCNQ1 (rs79972789, p=1.90x10-7), and COL4A3BP (rs181686584, p=2.85x10-7) 
(Table 9).  The most significant association was with rs189596789, located approximately 10kb upstream 
of the low-density lipoprotein receptor (LDLR) gene, which has been associated with familial 
hypercholesterolemia (Diakou et al. 2011; De Castro-Oros et al. 2011).  
Several of the most significant SNPs for ANM were located in/near genes previously associated 
with obesity, type 2 diabetes (T2D), coronary artery disease and lipid metabolism, e.g., LDLR 
(rs189596789), NOS1AP (rs76078015), DGKB (rs74486449), LYPLAL1 (rs78696400), and CDKAL1 
(rs114158228) (Appendix D). We were unable to generalize the previously reported association between 
ANM and PPARG rs4135280 in this African American sample. 
 
 
Table 9. Significant SNP associations for ANM in African Americans from the PAGE Study. 
CHR SNP GENE GENE 
REGION 
CODED 
ALLELE 
CAF BETA SE P VALUE 
19 rs189596789 LDLR upstream A 0.006 1.09 0.20 4.98x10-8 
11 rs79972789 KCNQ1 intronic C 0.997 -1.76 0.34 1.90x10-7 
5 rs181686584 COL4A3BP intronic A 0.002 2.35 0.46 2.85x10-7 
Tests of association at p≤3.1x10-7 (Bonferroni correction) from individual SNP linear regressions 
adjusted for study site and principal components in 1,860 African American women from the 
PAGE study are shown. For each significant test of association, the chromosome, rs number, 
nearest gene, location, coded allele, beta, standard error, and p-value are given. Genes listed are 
nearest genes to SNP as measured from the transcription start site for upstream SNPs or the 
transcription stop site for downstream SNPs. Abbreviations: chromosome (CHR), single 
nucleotide polymorphism (SNP), coded allele frequency (CAF), standard error (SE). 
 
 
 Two genes were suggestively associated with both ANM and AM at a nominal significance 
threshold. PHACTR1 was suggestively associated with AM (rs73725617;Appendix C) and ANM 
(rs117124693;Appendix D). Though the direction of effects was similar for each SNP in PHACTR1, the 
SNPs are not in LD with each other. Likewise, SNPs in ARHGAP42, located at the 11q22.1 locus, were 
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suggestively associated with AM (rs11224447;Appendix C) and ANM (rs11224401; Appendix D), but 
are not in LD with each other, though the direction of effects was the same. 
 
Summary 
 Here we demonstrated the use of the Metabochip genotyping array to identify SNPs associated 
with AM and ANM in a sample of African American women.   Previous GWAS studies for AM and 
ANM have been performed in primarily European descent populations; generalization to diverse 
populations has largely been lacking (Dvornyk and Waqar 2012). Our study is the first, to our 
knowledge, to consider this trait in a large African American cohort. We were able to generalize only 
one previously identified variant for AM and two variants for ANM to our African American cohort 
[AM: rs1361108; ANM: rs897798 and rs9385399 (proxy for rs1361108)]. Overall, however, we were 
unable to generalize the majority of significant associations for previously identified SNPs associated 
with AM, including LIN28B or the 9q31 locus, or with ANM, including MCM8 or 
TMEM150b/TMEM224, which have recently been identified in several GWAS of European-descent 
women. Our inability to replicate earlier findings in our African American sample may have, in part, 
resulted from scant Metabochip coverage of these regions.  The emphasis of the Metabochip on genes 
involved in lipid metabolism and cardiovascular traits is evident comparing coverage in the FTO 
region (1053 SNPs) to the LIN28B region (28 SNPs).    
 In the discovery phase of our AM analysis, none of our results reached genome-wide 
significance.  However, the ANM analysis yielded three associations that were significant after 
multiple testing corrections. Broadly, we demonstrate the ability to potentially uncover new variants 
associated with age at natural menopause in our African American cohort using the Metabochip.       
 Several studies have shown relationships between a woman’s reproductive milestones (AM, 
ANM, parity) and menstrual characteristics and risk for breast cancer, endometrial cancer, and ovarian 
cancer (Milne et al. 2011; Opdahl et al. 2011; Narod 2011a; Narod 2011b; Jasen 2011) and chronic 
diseases such as diabetes, osteoporosis and cardiovascular disease (briefly (Dishi et al. 2011; Campbell 
Jenkins et al. 2011; Kallen and Pal 2011) ). Interestingly, a recent study that assessed breast cancer 
susceptibility loci for associations with timing of menarche, menopause and the reproductive lifespan 
found only two SNPs associated with ANM: CASP8 rs17468277 and 5p12 rs10941679; however, these 
results were not replicated in a validation cohort (Warren et al. 2014). The relationships between the 
timing of these reproductive events and their influences on complex diseases remain to be elucidated. 
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 The most significant result in the ANM analysis was a SNP located upstream of LDLR 
(rs189596789) which encodes a low density lipoprotein receptor implicated in familial cholesterolemia. 
KCNQ1 (rs79972789) also reached genome wide significance in our ANM analysis. Numerous variants 
in KCNQ1 have also been implicated in type 2 diabetes in several populations, though none were in 
linkage disequilibrium with rs79972789 (Cui et al. 2011; Saif-Ali et al. 2011a; Saif-Ali et al. 2011b; Rees et 
al. 2011; Yasuda et al. 2008; Unoki et al. 2008). Recently, Buber et al. evaluated the role of menopausal 
hormonal changes with cardiac events in women with mutations in KCNQ1 and congenital long-QT 
syndrome (LQTS) and determined the onset of menopause was associated with an increase in the risk 
of cardiac events in LQTS women (Buber et al. 2011). Though not significant, suggestive AM 
associations included LPL and CYP4F22, which are associated with type 2 diabetes and lipid 
metabolism (rs1372339, rs4922116, rs1273516), and TMEM18 (rs2947411), associated with obesity and 
body mass index (Jurvansuu and Goldman 2011; Speliotes et al. 2010). These ANM associations and 
suggestive AM associations with genes involved in cardiovascular function, lipid metabolism, and type 
2 diabetes concur with research showing later AM lowers obesity and diabetes risk while earlier ANM 
increases risk for cardiovascular disease, obesity and insulin resistance (Carr 2003; Salpeter et al. 2006).  
 Different pathways appear to be involved in the initiation and cessation of menses. Other 
GWAS and linkage studies performed in European descent or Asian populations for AM and ANM 
show little concordance with specific genes (reviewed in (Hartge 2009) (Perry et al. 2014).  Our analysis 
is consistent with this observation.  Only PHACTR1 and ARHGAP42 SNPs were suggestively 
significant in both our AM and ANM analyses. PHACTR1 is a phosphatase and actin regulator which 
has been implicated in coronary artery disease (Schunkert et al. 2011; Ripatti et al. 2010).  Its role in 
menarche and menopause is yet to be determined. ARHGAP42, a Rho GTPase activating protein, has 
not yet been evaluated for a role in menarche or menopause.  A GWAS identified intronic ARHGAP42 
rs633185 is associated with blood pressure (Ehret et al. 2011) , but this variant is not in strong LD with 
ARHGAP42 variants suggestively associated with either AM or ANM in this study.  A recent study by 
Lu et al., found SNPs in both TNFSF11 and TNFRSF11A significant for AM and ANM (Lu et al. 2010).  
SNPs genotyped on the Metabochip were in weak LD with the reported SNPs and failed to reach 
significance in this African American sample.  Given the role that both PHACTR1 and ARHGAP42 play 
in atherosclerosis, osteoporosis and the development of lactation glands in pregnancy, further 
investigation on the influence of these genes in AM and ANM is warranted  (Hofbauer and Schoppet 
2004; Boyce and Xing 2008).  
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The Metabochip was designed to be a cost-effective method of genotyping approximately 
200,000 metabolic and cardiovascular SNPs and SNPs in other useful regions of the genome, such as 
the HLA region and the X and Y chromosomes.  Overall, median SNP density on the Metabochip is 
approximately one SNP per 370 bases (Buyske et al. 2012). This coverage appears sufficient to replicate 
some loci associated with both cardiovascular or metabolic traits and AM/ANM. However, we found 
instances of previously identified genes for AM/ANM with little/no Metabochip coverage (CYP1B1, 
LIN28B, ESR2, and BRSK1) which may have impacted our results. Additionally, prior studies that 
identified SNPs associated with AM and ANM were performed primarily in European-descent cohorts. 
Though our study included over 4,000 African American women, we had limited power to identify 
significant associations in most previously identified loci, which may explain why we failed to detect 
the same associations identified in European-descent GWAS.  For specific tests of association, our 
power was impacted by sample size and by minor allele frequencies. For example, the allele frequency 
for rs7861820 in this African American cohort was 0.11 compared to a higher frequency observed in 
HapMap CEU (0.57; Table 10).  Interestingly, we were adequately powered (>98%) (Appendix E) to 
generalize the intronic LIN28B SNP, rs314277, with AM in our sample, yet failed to find an association 
with this SNP or with SNPs in strong LD with it (Table 6, Appendix A).  
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Table 10. Minor allele frequency comparisons of African American women in the Population 
Architecture using Genomics and Epidemiology (PAGE) Study to HapMap CEU Panel.  
 
SNP Gene/Region HapMap CEU AF 
(Allele) 
PAGE Study AF 
(Allele) 
rs314277 LIN28B 0.13 (A) 0.39 (A) 
rs7759938 LIN28B 0.64 (T) 0.46 (A) 
rs4946651 LIN28B 0.48 (A) 0.75 (A) 
rs7861820 9q31 0.57 (T) 0.11 (A) 
rs4452860 9q31 0.72 (A) 0.67 (A) 
rs16991615 MCM8 0.09 (A) 0.01 (A) 
rs236114 MCM8 0.21 (A) 0.09 (A) 
rs7951733 FSHB 0.95 (A) 0.99 (A) 
rs769450 APOE 0.38 (A) 0.38 (A) 
rs7412 APOE 0.09 (T) 0.10 (A) 
rs1019731 IGF1 0.14 (T) 0.02 (A) 
rs9457827 IGF2R 0.05 (T) 0.28 (A) 
rs4135280 PPARG 0.98 (T) 0.99 (A) 
Comparison of allele frequencies between PAGE Study African American women and 
HapMap CEU Panel. SNPs compared were previously associated with age at menarche or 
age at natural menopause and directly genotyped on the Metabochip. Abbreviation: 
single nucleotide polymorphism (SNP), allele frequency (AF). 
 
 
 
 Metabochip performance in non-European populations was recently evaluated in a pilot study 
in African American PAGE participants (Buyske et al. 2012). In this pilot study, Buyske et al. 
demonstrated that the majority (89%) of SNPs targeted by the Metabochip passed rigorous quality 
control with high call rates (Buyske et al. 2012).  Using lipid traits as an example, Buyske et al. 
demonstrated that Metabochip data can be used to replicate known GWAS-identified SNP-trait 
relationships (Buyske et al. 2012). Furthermore, the pilot study demonstrated that Metabochip data can 
be used to fine-map GWAS-identified regions to uncover potential novel index SNPs specific to African 
Americans in an established locus for that trait.  Fine-mapping data for AM/ANM was not included in 
the Metabochip content. While we were able to use the Metabochip to identify potentially novel SNP-
trait relationships for AM/ANM, additional fine-mapping efforts of other loci already implicated for 
these traits are needed. Furthermore, additional studies in general are warranted for diverse (non-
European descent) populations using Metabochip or other arrays designed for fine-mapping.   
Admixture in the African American population and its associated decreased LD compared to European 
Americans challenge identification of trait-associated SNPs. Targeted fine mapping, such as use of the 
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Metabochip, may be more appropriate in some circumstances than GWAS to evaluate specific SNPs 
and regions associated with particular traits.   
 A GWAS meta-analysis for age at menarche in African Americans was published shortly after 
publication of the PAGE study (Demerath et al. 2013). In a much larger cohort (n=18,089), Demerath et 
al. found only suggestive associations (p>5x10-8) between AM and FLRT2 and PIK3R1; conditional 
analyses identified RORA rs339978 and rs980000 as additional variants, independently associated with 
AM (Demerath et al. 2013). Additionally, they generalized to their cohort 25/42 (60%) variants 
previously associated in the Elks meta-analysis (Elks et al. 2010). This is higher than the 36% that we 
were able to generalize to the PAGE African American cohort (Appendix A), though the substantial 
increase in sample size for the Demerath et al. meta-analysis likely played a role.  
 Although the Metabochip was designed for genotyping of cardiovascular and metabolic SNPs, 
this study demonstrates the feasibility of utilizing such a targeted chip to identify SNP associations 
with age at menarche and age at natural menopause.  We identified potentially novel associations with 
AM/ANM at loci implicated in cardiovascular traits, obesity and cancer.  This may result from 
pleiotropic loci or may suggest that the AM/ANM timing mechanisms influence underlying disease 
process. With numerous genes implicated in both metabolic and cardiovascular phenotypes and both 
AM and ANM, further studies will allow us to consider how specific genes may influence the 
reproductive lifespan in women. 
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CHAPTER III 
ALGORITHMIC EXTRACTION OF FEMALE REPRODUCTIVE 
MILESTONES FROM ELECTRONIC MEDICAL RECORDS2 
III. ALGORITHMIC EXTRACTION OF FEMALE REPRODUCTIVE 
MILESTONES FROM ELECTRONIC MEDICAL RECORDS 
Introduction 
 As described in Chapter 1, the rich phenotypic data existing in EMR systems allows clinicians 
and researchers to identify potential cohorts, while EMRs that are linked to biobanks extend this 
framework to genotype-phenotype association studies. Traditional epidemiologic studies are costly 
and require significant amounts of time to complete; furthermore, these studies may not include 
sufficient numbers of individuals from diverse ancestries. The Epidemiologic Architecture for Genes 
Linked to Environment (EAGLE) Study seeks to address these limitations by enabling high-throughput 
identification and generalization of genotype-phenotype associations in diverse research populations. 
Accessing data from EMRs for use in research may prove to be a cost effective alternative to traditional 
ascertainment and data collection.  One challenge to research use of EMR-derived data is the lack of 
consistency in recording certain types of data in the EMR. Despite the obvious health implications, AM 
and AAM/ANM are not recorded consistently or in a standardized manner in the EMR. This presents 
a challenge for researchers and suggests algorithm development is a necessary first step in developing 
a resource for women’s health studies in diverse populations. 
 
BioVU 
 BioVU is the Vanderbilt University Medical Center (VUMC) biorepository linked to the EMR 
system. Beginning in 2007, discarded blood samples from routine clinical testing have the DNA 
extracted, stored, and linked to a de-identified version of the EMR termed the Synthetic Derivative 
                                                     
2 Adapted from: Malinowski J, Farber-Eger E, Crawford DC. Development of a data-mining algorithm to identify 
ages at reproductive milestones in electronic medical records. Pacific Symposium in Biocomputing. (2014) 19:376-87 
PMID: 24297563 
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(SD).  As of mid-2012, more than 150,000 samples have been collected for BioVU, including more than 
16,000 pediatric samples.  Patients are given the opportunity to opt-out of BioVU at any time. Once a 
sample has been accepted into the system, a unique ID is generated through a one-way hash 
mechanism and linked to that patient’s SD. The SD removes or de-identifies Health Insurance 
Portability and Accountability Act (HIPAA) information, such as names, geographical locations, and 
social security numbers, and replaces dates with dates that have been randomly shifted by up to six 
months. The date shifting is consistent within a single SD record. The SD enables researchers to 
examine genome-phenome associations and identify cohorts for research.  
Methods 
Study population 
 As part of the Population Architecture using Genomics and Epidemiology (PAGE) I Study, 
EAGLE genotyped all non-European descent patients in BioVU (EAGLE BioVU, n=15,863) on the 
Metabochip, a custom genotyping array with an emphasis on cardiovascular disease and metabolic 
traits (see Chapter II, Methods and (Voight et al. 2012) for full details on the design). Overall, 11,521 
African Americans, 1,714 Hispanics, 1,122 Asians and others were genotyped on the Metabochip in 
EAGLE.  For the AM study, all females age>6 in EAGLE BioVU as of January 31, 2013 were eligible for 
inclusion. For the AAM study, all females >18 years were eligible for inclusion; for the ANM study, 
only women ages≥41 were eligible for inclusion. All patients were of diverse race/ethnicity. 
Algorithm development 
 We developed a flow chart to visualize the inclusion/exclusion processes for the algorithms 
(Figure 3A-C).   AM and age at menopause or age at natural menopause (AAM/ANM) are not 
consistently recorded in the EMR system at VUMC; individuals may enter BioVU through numerous 
outpatient clinics with different data field requirements. The lack of a pre-specified field for AM and 
AAM/ANM in the EMR necessitated a combination of free text data mining using regular 
expressions/pattern matching, billing (ICD-9) codes, and procedure (CPT) codes to identify AM and 
AAM/ANM in the subsequently generated SD. All analysis for this study was performed using the SD. 
Age at menarche (AM) 
 Primary exclusion criteria for AM phenotype consisted of four components: age<7 years, male 
sex, ICD-9 codes for delayed puberty/sexual development (259.0) and precocious puberty/sexual 
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development (259.1), and keywords (Figure 3A). Inclusion of any of the preceding criteria in the SD 
resulted in exclusion for the AM study.  As part of the de-identification data scrubbing to convert a 
patient’s EMR to the SD, ages and dates may be masked and listed as “birth-12” or “in teens.” Dates 
and ages which are not masked were  date shifted by up to six months forward or backward from the 
actual date.  
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Figure 3. Flow chart for algorithm development for reproductive milestones. 
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 To identify a listed AM for an individual, we utilized pattern matching to seek instances with 
menarche keyword phrases (Figure 3A). Numbers and dates were allowed to be included as numerals 
only.  Instances where the AM was listed as a date used the subject’s birthdate to calculate the age (in 
years) at menarche.  In cases of ties, where more than one AM was identified and recorded an equal 
number of times in the SD, the AM was determined to be the one listed first in the SD. If the algorithm 
identified multiple versions of the AM (an exact age, an age calculated from a date, or a de-identified 
age), a hierarchy was used to determine the AM for the output, where an exact age or date was 
prioritized over de-identified age ranges.  Instances where multiple different ages were listed in the SD 
as AM defaulted to the age listed most frequently. We considered situations where the algorithm 
identified an exact AAM and a de-identified AAM range containing the exact AAM to be the same for 
purpose of calculating sensitivity, specificity, and positive predictive value (PPV), but different for the 
purpose of calculating accuracy. The resulting output file contained the subject’s unique research id 
(RUID), date of birth, and either an algorithm-generated AM or null value. 
Age at menopause (AAM) 
 For an algorithm to identify all post-menopausal women and their age at menopause (AAM), 
we initially excluded all males, set a minimum age of 18 years, and excluded patients with a Fragile X 
diagnosis (ICD-9 759.83) (Figure 3B).  Pattern matching was utilized to find keyword phrases similar to 
those used in the menarche algorithm, substituting “menopause” for “menarche” (Figure 3D).  
Furthermore, we included keywords pertaining to surgical procedures that induce cessation of 
menses/menopause (Figure 3D). We excluded instances where the word “possible” immediately 
preceded a keyword.  For instances where the SD had scrubbed the exact age, decade-specific results 
(e.g. “in 30s”, “in 50s”) were captured by our algorithm. CPT (Table 11) and ICD-9 (Table 12) codes 
were used to identify women with surgical menopause or menses-ceasing procedures. 
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Table 11. CPT codes for age at menopause (AAM) and age at natural menopause (ANM) algorithms. 
CPT code Procedure 
58150 Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or 
without removal of ovary(s) 
58152 Total abdominal hysterectomy (corpus and cervix), with or without removal of tube(s), with or 
without removal of ovary(s); with colpo-urethrocystopexy (eg, Marshall-Marchetti-Krantz, Burch) 
58180 Supracervical abdominal hysterectomy (subtotal hysterectomy), with or without removal of tube(s), 
with or without removal of ovary(s) 
58200 Total abdominal hysterectomy, including partial vaginectomy, with para-aortic and pelvic lymph 
node sampling, with or without removal of tube(s), with or without removal of ovary(s) 
58260 Vaginal hysterectomy, for uterus 250g or less 
58262 Vaginal hysterectomy, for uterus 250g or less, with removal of tube(s), and/or ovary(s) 
58263 Vaginal hysterectomy, for uterus 250g or less, with removal of tube(s), and/or ovary(s), with repair 
of enterocele 
58267 Vaginal hysterectomy, for uterus 250g or less, with colpo-urethrocystopexy (eg, Marshall-Marchetti-
Krantz type, Pereyra type) with or without endoscopic control 
58270 Vaginal hysterectomy, for uterus 250g or less, with repair of enterocele 
58275 Vaginal hysterectomy, with total or partial vaginectomy 
58280 Vaginal hysterectomy, with total or partial vaginectomy, with repair of enterocele 
58285 Vaginal hysterectomy, radical (schauta type operation) 
58290 Vaginal hysterectomy, for uterus greater than 250g 
58291 Vaginal hysterectomy, for uterus greater than 250g, with removal of tube(s), and/or ovary(s) 
58292 Vaginal hysterectomy, for uterus greater than 250g, with removal of tube(s), and/or ovary(s), with 
repair of enterocele 
58293 Vaginal hysterectomy, for uterus greater than 250g, with colpo-urethrocystopexy (eg, Marshall-
Marchetti-Krantz type, Pereyra type) with or without endoscopic control 
58294 Vaginal hysterectomy, for uterus greater than 250g, with repair of enterocele 
58353 Endometrial ablation, thermal, without hysteroscopic guidance 
58541 Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less 
58542 Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less, with removal of tube(s), 
and/or ovary(s) 
58543 Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g 
58544 Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g, with removal of 
tube(s), and/or ovary(s) 
58548 Laparoscopy, surgical, with radical hysterectomy, with bilateral total pelvic lymphadenectomy and 
para-aortic lymph node sampling (biopsy), with removal of tube(s) and ovary(s), if performed 
58550 Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less 
58552 Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less, with removal of tube(s) 
and ovary(s) 
58553 Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g 
58554 Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g, with removal of 
tube(s) and ovary(s) 
58563 Hysteroscopy, surgical, with endometrial ablation (eg endometrial resection, electrosurgical 
ablation, thermoablation) 
58570 Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less 
58571 Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less, with removal of tube(s) and 
ovary(s) 
58572 Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g 
58573 Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g, with removal of 
tube(s) and ovary(s) 
CPT codes used to identify menopausal women for the age at menopause (AAM) algorithm and to identify women 
to exclude in a time-dependent manner for the age at natural menopause (ANM) algorithm in EAGLE BioVU. 
Abbreviations: Current procedural terminology (CPT). 
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Table 12. ICD-9 codes for age at menopause (AAM) and age at natural menopause (ANM) 
algorithms. 
65.5 Bilateral oophorectomy 
65.51 Other removal of both ovaries at same operative episode 
65.52 Other removal of remaining ovary 
65.53 Laparoscopic removal of both ovaries at same operative episode 
65.54 Laparoscopic removal of remaining ovary 
65.6 Bilateral Salpingo-oophorectomy 
65.61 Other removal of both ovaries and tubes at same operative episode 
65.62 Other removal of remaining ovary and tube 
65.63 Laparoscopic removal of both ovaries and tubes at the same operative episode 
65.64 Laparoscopic removal of remaining ovary and tube 
68.23 Endometrial ablation 
68.3 Subtotal abdominal hysterectomy 
68.31 Laparoscopic supracervical hysterectomy 
68.39 Other and unspecified subtotal abdominal hysterectomy 
68.4 Total abdominal hysterectomy 
68.41 Laparoscopic total abdominal hysterectomy 
68.49 Other and unspecified total abdominal hysterectomy 
68.5 Vaginal hysterectomy 
68.51 Laparoscopically assisted vaginal hysterectomy (LAVH) 
68.59 Other and unspecified vaginal hysterectomy 
68.6 Radical abdominal hysterectomy 
68.61 Laparoscopic radical abdominal hysterectomy 
68.69 Other and unspecified radical abdominal hysterectomy 
68.7 Radical vaginal hysterectomy 
68.71 Laparoscopic radical vaginal hysterectomy (LRVH) 
68.79 Other and unspecified radical vaginal hysterectomy 
68.9 Other and unspecified hysterectomy 
ICD-9 codes used to identify menopausal women for the age at menopause (AAM) algorithm and to identify women 
to exclude in a time-dependent manner for the age at natural menopause (ANM) algorithm in EAGLE BioVU. 
Abbreviations: International Classification of Diseases, Ninth Revision (ICD-9). 
 
 After SD review of initial algorithms and subject matter knowledge, we implemented secondary 
exclusion criteria based on the algorithm-identified AAM and excluded subjects with a calculated 
AAM<18 or AAM>65 (Figure 3B). A hierarchy was used to determine the AAM for the output, with an 
exact age or date identified by keyword or pattern matching and ICD-9/CPT codes prioritized over de-
identified age ranges. In rare instances where the algorithm identified more than one AAM for a 
subject, the age recorded most frequently was determined to be the AAM for that patient. In cases of 
ties, where more than one AAM was identified and recorded an equal number of times in the SD, the 
AAM was determined to be the one listed first in the SD. We considered situations where the algorithm 
identified an exact AAM and a de-identified AAM range containing the exact AAM to be the same for 
purpose of calculating sensitivity, specificity, and PPV, but different for the purpose of calculating 
accuracy. The resulting output file contained the subject’s unique research id (RUID), date of birth, 
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race/ethnicity, either an algorithm-generated AAM or null value, the method by which the AAM was 
calculated (e.g., from ICD-9 code, keyword), and the date in the SD corresponding to the AAM 
identification. 
Age at natural menopause (ANM) 
 To discriminate age at natural menopause (ANM) from all instances of menopause (AAM), we 
extended the AAM algorithm to exclude women aged <41 years, men, and subjects with ICD-9 codes 
signifying premature ovarian failure/premature menopause (256.31), artificially induced menopause 
(627.4), ovarian failure (256.39), and Fragile X syndrome (759.83) (Figure 3C). We used pattern 
matching with the menopause keywords to identify an age at menopause (Figure 3D). We did not use 
ICD-9 codes, CPT codes, or keywords associated with procedures that induce menopause to identify 
subjects for the ANM cohort.  
 Medication delivery and prescriptions are captured by the EMR at VUMC and are included in 
the SD. To ascertain the temporal relationship between AAM and menopause-inducing/menses-
ceasing surgery or hormone replacement therapy (HRT) use, we first calculated the AAM with the 
alternate algorithm (Figure 3C). Surgery-inducing menopause, determined through CPT and/or ICD-9 
codes or keywords, and HRT were not exclusion criteria unless the first instance of surgery or HRT 
occurred prior to the extended algorithm-identified AAM. Keyword pattern matching was performed 
using surgical keywords (Figure 3D). We used a combination of brand-name and generic names for 
HRT identification (Figure 3D).  If AAM was identified and no keywords or CPT/ICD-9 codes were 
found to indicate artificially induced menopause, the subject was deemed to have undergone natural 
menopause. If surgery or HRT occurred after the algorithm-determined ANM, the subject was also 
considered to have undergone natural menopause. If the subject had either surgery or used HRT prior 
to menopause, they were excluded from the cohort and the resulting output was a null value. 
 We implemented secondary exclusion criteria (Figure 3C) based on the algorithm-identified age 
at menopause and excluded subjects with a calculated ANM<18 or ANM>65 based on subject matter 
knowledge and review of early versions of our algorithms. A hierarchy was used to determine the 
ANM for the output. If the algorithm determined more than one ANM for a subject, we used the same 
procedure as described above to determine the final ANM generated by our query. We again  
considered situations where the algorithm identified an exact ANM and a de-identified ANM range 
containing the exact ANM to be the same for purpose of calculating sensitivity, specificity, and PPV, 
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but different for the purpose of calculating accuracy. The resulting output file contained the subject’s 
unique research id (RUID), date of birth, race/ethnicity, either an algorithm-generated ANM or null 
value, the method by which the ANM was calculated (e.g., from exact date, de-identified age), and the 
date in the SD corresponding to the ANM identification. 
Manual review 
 To determine the sensitivity, specificity, PPV, and accuracy of the AM, AAM, and ANM 
algorithms, extensive manual chart review was performed by a single individual for consistency.  Each 
algorithm output contained three types of values: exact ages, de-identified ages, and null values. For 
each algorithm, a random number generator was used to randomize RUIDs within each of the three 
types of output and the subjects were then sorted in ascending value by the random number. The first 
50 subjects in the exact age and de-identified age categories and the first 100 subjects with a null value 
had their SD reviewed manually to determine the AM, AAM, or ANM. Sensitivity, specificity, PPV and 
accuracy were calculated by comparing the automated algorithm result to the manual review result for 
each subject. 
Results 
Population characteristics 
 A total of 10,051 females were genotyped on the Metabochip in BioVU in EAGLE for various 
studies. We identified an age for menarche (exact or de-identified) in 1,618 individuals. For the AAM 
algorithm, we identified an AAM (exact age or de-identified decade) for 1281 individuals. We 
identified 83 individuals with an ANM (exact or de-identified decade) (Table 13). The algorithm-
extracted mean AM in our population was 12.7 (+/- 2.1 ) yrs. The mean AAM in our population was 
44.6 (+/- 9.8) yrs. and the mean ANM was 49.7 (+/- 5.6) yrs. (Table 13). Approximately half of the 
algorithm extracted AM (54.7%) and ANM (47.0%) were exact ages, while the majority of AAM (92.5%) 
were exact ages (Table 13).  
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Table 13. Population characteristics for women with algorithm-identified age at menarche (AM), age 
at menopause (AAM), and age at natural menopause (ANM) from EAGLE BioVU.  
 AM AAM ANM 
N, total 1618 1281 83 
exact age (n) 885 1185 39 
de-identified age (n) 733 96 44 
Age at event, mean +/- sd (yrs)  12.7 (2.1) 44.6 (9.8) 49.7 (5.6) 
Age range at event (yrs) 8-20 18-65 40-65 
Race/ethnicity (n)     
African American 1232  1112  62  
Hispanic 120  45  4  
Asian 115  66  11  
Other 151  58  6  
Abbreviations: standard deviation (sd), years (yrs). 
 
AM algorithm performance 
 We manually reviewed 200 SD entries for the AM algorithm to determine sensitivity, specificity, 
PPV, and accuracy. Of the 100 subjects with an algorithm-specified AM, 94 were confirmed by manual 
review. For the 100 subjects without an AM captured by the algorithm, 99 were not found to have an 
identifiable AM upon manual review. The AM algorithm had a sensitivity and specificity of 99.0% and 
94.3%, respectively, and a PPV of 94.0% (Table 14).  We calculated the accuracy of the algorithm by 
comparing the results for the 94 subjects with both manually identified and algorithm identified AMs, 
requiring identical results for concordance. Of these 94 subjects, we found 87 where the AM matched in 
both manual and algorithm identification for an accuracy of 92.6% (Table 14). We observed instances 
where the algorithm calculated an exact AM (e.g., 8) and manual review found a de-identified AM 
(e.g., birth-12), or vice-versa. If we allow these to be concordant, accuracy increases to 94.7%. 
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Table 14. Performance of the age at menarche (AM), age at menopause (AAM), and age at natural 
menopause (ANM) algorithms in women from EAGLE BioVU.  
 Sensitivity Specificity Accuracy PPV 
AM (n=200) 99.0% 94.3% 92.6% 94.0% 
AAM (n=200) 94.4% 85.6% 52.4% 84.0% 
ANM (n=183) 89.8% 75.8% 75.5% 63.9% 
Abbreviations: positive predictive value (PPV). 
 
AAM algorithm performance 
 For the AAM algorithm, we manually reviewed 200 SD entries to determine sensitivity, 
specificity, PPV, and accuracy. Of the 100 subjects with an algorithm-identified AAM, we identified 82 
with AAM via manual review. Only five of the 100 subjects without an algorithm-identified AAM were 
found to have an identifiable AAM with manual review.  Overall, our algorithm was found to have 
94.4% sensitivity, 85.6% specificity, and a PPV of 84.0% (Table 14). We also calculated the accuracy of 
our AAM algorithm by comparing the algorithm-obtained AAM to the manual review-obtained AAM. 
We observed a 52.4% exact concordance within our 82 subjects with AAMs calculated from both 
manual review and the algorithm. If we allowed a de-identified age range encompassing an exact age 
to be considered concordant with the exact age obtained from the other method, our accuracy 
improved to 61.9%. 
ANM algorithm performance 
 The ANM algorithm identified 83 individuals with an ANM; therefore, we manually reviewed 
183 SD entries to determine the specificity, sensitivity, PPV, and accuracy of our ANM algorithm. Of 
the 100 individuals with no algorithm-identified ANM, manual review of the SD found 6 instances 
with an identifiable ANM (Table 14). Of the 83 individuals with an algorithm-specified ANM, manual 
review confirmed 53. Overall, the sensitivity and specificity of the ANM algorithm were 89.8% and 
75.8%, respectively, and the PPV was 63.9%. Of the 53 subjects with both algorithm- and manually-
identified ANM, 40 were an exact match, yielding an accuracy of 75.5%. We again observed instances 
where the algorithm yielded an exact age, but manual review of the SD obtained only a de-identified 
ANM range that encompassed the exact age, and vice-versa; if we considered these as concordant, our 
accuracy increased to 81.1%. 
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Summary 
Potential use in personalized medicine  
 Menarche and menopause are the bookends of the reproductive lifespan in women. The timing 
of these events may increase risk for various complex disorders and cancers, such as osteoporosis and 
breast cancer (Hartge 2009).  Precocious or delayed menarche may signal the occurrence of hormonal 
imbalance, inadequate nutrition or caloric intake, or pituitary diseases (Hartge 2009). The timing of 
menopause directly affects reproductive capabilities. In addition, premature menopause may result 
from hormonal imbalances, genetic disorders such as Fragile X Syndrome, metabolic disorders, or 
autoimmune diseases such as thyroid disease or rheumatoid arthritis (Okeke, Anyaehie, and 
Ezenyeaku 2013). Though the timing of menarche and menopause may increase risk for disease or 
indicate underlying pathologies, this information is not consistently included in electronic health 
records, leading to missed opportunities to inform clinical care and represents a challenge to clinicians 
and researchers alike. A clinical decision support mechanism to identify women who are at risk of 
developing certain diseases as a result of the timing of their reproductive milestones may be useful in 
clinical practice.  
Potential use for genetic studies of reproductive timing 
 Data-mining EMRs has been used to identify cohorts for research studies (Newton et al. 2013; 
Stratton-Loeffler et al. 2012; Brownstein et al. 2010; Warren et al. 2012), determine smoking status 
(Wiley et al. 2013), and predict disease, such as sepsis (Mani et al. 2014). Our development of 
algorithms to extract these important data is notable for the emphasis on diverse populations and 
attention to women’s health, both historically underrepresented in health outcomes research.  The 
menarche (AM) and menopause (AAM) algorithms have PPV>80% and high specificity and sensitivity, 
though accuracy of the AAM algorithm was just over 50%.  The age at natural menopause (ANM) 
algorithm had moderately high (>75%) sensitivity and specificity but the lowest PPV, at 63.9%. 
However, the accuracy of the ANM algorithm bested that of the AAM (75.5% vs. 52.4%, respectively). 
In addition, the algorithm-extracted ages at menarche, menopause, and natural menopause are 
consistent with published research, validating our methodology. 
 Several factors may have reduced the performance of our menopause algorithms. We observed 
many instances where the ages calculated by the algorithm and by manual review differed by one year. 
This may have been the result of the date-shifting done within each individual’s SD for de-
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identification purposes.  If the method for calculating the age differed between the methods, it is 
possible this could result in the observed one-year difference. When we allowed a +/- 1 year difference 
in the algorithm and manual identified AAM and ANM, the accuracy of our algorithms improved to 
70.2% and 90.6%, respectively. The timing of menopause is challenging to identify, as the menstrual 
cycle becomes more erratic as a woman moves through perimenopause into menopause. Months may 
lapse between cycles; hormone levels may change substantially.  In addition, the normal menopausal 
age range is quite large, taking place between the ages of 40 and 60. These factors challenge the 
accurate dating of the onset of menopause.  
 Furthermore, an algorithm designed to identify the age at menopause may not accurately 
reconcile multiple mentions in an EMR of menopause. Discerning between natural menopause and 
medically/surgically induced menopause is an additional challenge. Our extensive list of time-
dependent exclusions for HRT and surgical procedures was not exhaustive and may have led to the 
algorithm identifying an ANM where manual review identified HRT and/or a procedure artificially 
inducing menopause. Correctly identifying the temporal relationship between attainment of natural 
menopause and surgical procedures that result in menopause may perform inconsistently in the 
absence of these data in structured fields in an EMR. Addressing some of these issues by including 
structured fields for age at menarche, age at menopause, and type of menopause (natural/medical), 
and standardizing the reporting of these data could greatly improve the performance of our 
algorithms. 
 We have demonstrated the performance of algorithms designed to extract the age at menarche 
and age at menopause from the Synthetic Derivative, a de-identified version of the electronic medical 
record at Vanderbilt University Medical Center. Furthermore, we have developed an algorithm to 
discriminate naturally occurring menopause from artificially-induced menopause. Our method 
combining text-mining for regular expressions and pattern matching, and structured data derived from 
the EMR to obtain the age at menarche and the age at menopause is likely to be easily transferable to 
other institutions, given the simplicity of the approach. Overall, these algorithms provide an 
opportunity for researchers and clinicians to obtain these valuable, though inconsistently reported 
data. 
  
 62 
 
CHAPTER IV 
CASE STUDY: GENETIC VARIANTS ASSOCIATED WITH ENDOMETRIAL 
CANCER 
IV. CASE STUDY: GENETIC VARIANTS ASSOCIATED WITH 
ENDOMETRIAL CANCER 
Introduction 
 As discussed in Chapter I, endometrial cancer (EC) is the most common invasive gynecological 
cancer in the United States; an estimated 52,630 new cases arise yearly with approximately 8,590 deaths 
in 2014 (National Cancer Institute at the National Institutes of Health 2014b). EC typically occurs in 
post-menopausal women; the average age at diagnosis is 60 years (Jick, Walker, and Rothman 1980). 
Symptoms of EC include irregular or post-menopausal bleeding, pelvic pain, presence of a pelvic mass, 
and weight loss (National Cancer Institute at the National Institutes of Health 2014b). Known risk 
factors for Type I EC include hormone imbalances, greater than average number of menstrual cycles 
over the reproductive lifespan, early menarche, late age at menopause, nulliparity, tamoxifen use for 
breast cancer, estrogen-only hormone replacement therapy (HRT), obesity, and hypertension 
(Haidopoulos et al. 2010).  Risk factors for Type II ECs include long term use of tamoxifen, history of 
pelvic radiation, and hereditary conditions like childhood retinoblastoma and hereditary 
leiomyomatosis and renal cell carcinoma syndrome.  Prolonged exposure to estrogen-only therapy is 
associated with an increased risk of EC while progesterone plus estrogen has a protective effect (Jick, 
Walker, and Jick 1993a; Jick, Walker, and Jick 1993b). There are notable differences in EC incidence 
internationally, with European-Americans and US Hawaiian Japanese immigrants having the highest 
rates among twenty-two international cancer registries (Katanoda and Qiu 2006). Variation in EC 
incidence and survival across racial/ethnic groups has been observed in US cohorts (Setiawan et al. 
2007; Madison et al. 2004). In the Multiethnic Cohort Study, Setiawan et al. identified lower relative 
risks for EC in African Americans and Latinas compared to European Americans, while the risks in 
Native Hawaiians and Japanese Americans were similar (Setiawan et al. 2007).    
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 EC can be categorized into different subtypes by histology: endometrioid, serous, clear cell, and 
poorly differentiated (2007; Creasman et al. 2006; Creasman et al. 2004).  ECs that arise in the inner 
layer of the uterus (endometrium) are known as endometrial carcinomas. These comprise most ECs. 
ECs that arise in the muscle layer (myometrium) or connective tissues are called sarcomas. EC 
carcinomas that begin in the cells that form the glands of the endometrium are known as 
adenocarcinomas; of these, the most common form is endometrioid adenocarcinomas that comprise 
80% of ECs.  The endometrioid type of EC tends to be less aggressive than the more uncommon forms 
of EC (e.g. clear cell or serous) and are the type of EC that presents clinically most often (O'Hara and 
Bell 2012).  
 EC tumors can be further divided into three histological grades (1-3) based on the percentage of 
tissue forming glands. Grade 1 tumors have more than 95% of the cancerous tissue forming glands; 
grade 2 tumors have between 50-94%. Grade 3 tumors are more aggressive, may have metastasized at 
the time of diagnosis, and tend to have a poor outlook compared to grades 1 and 2 (O'Hara and Bell 
2012). EC tumors are also divided into two types based on estrogen dependence. Type I cancers are 
typically slow to spread and are not usually aggressive.  They appear to be estrogen-dependent and 
immunostaining has demonstrated that they do not stain for p53. Grades 1 and 2 endometrioid ECs are 
often Type I. Type II EC cancers are estrogen-independent and appear not to be related to endometrial 
hyperplasia; grade 3 endometrioid ECs (serous, clear cell, and poorly differentiated) are all Type II 
(Kitchener and Trimble 2009). Type II cancers physiologically do not resemble normal endometrium; 
these cancers tend to be more aggressive than Type I and are more likely to be high-grade serous and 
clear cell ECs (O'Hara and Bell 2012). Type II cancers immunostain for p53, supporting the hypothesis 
that Types I and II ECs have a different etiology (Kitchener and Trimble 2009). A small fraction (~4%) 
of uterine cancers are uterine carcinosarcoma, also known as malignant mixed mesodermal or 
malignant mixed Mullerian tumors.  These cancers contain features of both carcinomas and sarcoma, 
with similar natural history to Type II ECs.  Along with type and grade, EC tumors are also classified 
by their stage; these three classifications comprise the International Federation of Gynecology and 
Obstetrics (FIGO) score for tumors (Table 15) (Compton 2012). 
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Table 15. FIGO scoring for endometrial carcinoma tumors. 
Category FIGO Stage for EC 
carcinomas 
Description 
 
 
 
Tumor 
I, IA, IB tumor is confined to corpus uteri, tumor may invade >1/2 or more of 
myometrium 
II tumor invades stromal connective tissue of the cervix but doesn’t invade 
beyond uterus 
IIIA, IIIB tumor involves vagina  
IVA tumor invades bladder and/or bowel mucosa 
Lymph Node Involvement IIIC1, IIIC2 regional lymph node metastasis pelvic (IIIC1) or para-aortic (IIIC2) lymph 
nodes 
Metastasis IVB distant metastasis to lung, liver, bone or inguinal lymph nodes 
Description and FIGO scoring criteria for endometrial carcinoma tumors. Abbreviations: Federation of Gynecology and Obstetrics (FIGO). 
 
Molecular mechanisms 
 The molecular mechanisms responsible for development of EC are not well understood. Some 
forms of Type II EC have mutations in p53, a tumor suppressor gene, suggesting germline or somatic 
mutations play a role in development of Type II EC (Garg et al. 2010; Tashiro et al. 1997).  Other risk 
factors include Lynch syndrome and a first-degree relative with EC, though these risk factors are not 
entirely understood and account for a small percent of ECs.  
 Changes to the HPG axis that results in excess estrogen can lead to unregulated proliferation 
and vascularization of the endometrium, yielding an environment amenable to the development of 
Type I EC. A similar result can be found in women with intact uteri who take tamoxifen for breast 
cancer treatment. Though tamoxifen acts in an anti-estrogenic way in breast tissue, tamoxifen behaves 
like estrogen in the uterus, causing growth of the endometrium  (Lumachi et al. 2012). Ovarian tumors 
known as granulosa-theca tumors also lead to increased levels of estrogen and an increased risk for EC. 
Gynecological disorders, such as polycystic ovarian syndrome (PCOS) and endometriosis, with 
increased androgens and estrogens, also lead to an increased risk for EC, as the estrogens and 
androgens are accompanied by lower than normal levels of progesterone.  Diminished levels of 
progesterone lead to unopposed levels of estrogen, disrupting the homeostatic balance of the HPG axis. 
This is also consistent with evidence that the risk of Type I EC is twice as high in overweight women as 
in normal weight women, and three times as high in obese women (Everett et al. 2003), suggesting a 
dose-dependent effect of estrogen on Type I EC. In general, the more menstrual cycles a woman 
experiences and fewer instances of pregnancy, the greater her exposure to estrogens. This leads to the 
repeated proliferation and vascularization of the endometrium, supporting the known increased risk of 
EC due to early menarche, late menopause, and nulliparity. 
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Genetic associations 
 Heritability of EC has been estimated at 0.52 (Schildkraut, Risch, and Thompson 1989), but the 
unknown molecular mechanisms responsible for EC have made identifying the genetic risk factors 
challenging. As a result, numerous candidate gene studies have been performed for EC, primarily for 
genes involved in sex hormone biosynthesis (Figure 4). The strong relationship between estrogen and 
EC risk has been explored through candidate gene studies (Ashton et al. 2009a). Two estrogen receptor 
SNPs in ESR1 and four ESR2 SNPs were assessed in a case-control study of European-descent women 
from Australia (Ashton et al. 2009a). The authors observed SNPs in each estrogen receptor gene that 
were associated with increased EC risk after adjusting for risk factors: ESR1 rs2234693 and ESR2 
rs1255998 and rs944050 (Ashton et al. 2009a). Thirty-six variants involved in sex hormone metabolism, 
including CYP17, ESR1, and ESR2 were considered in a pathway-based case-control study of Polish 
women (Yang et al. 2010). Only AR, involved in the synthesis of androgen response elements (Figure 
4), was significantly associated in a gene-based analysis with EC risk in this population; however, SNP-
based analyses uncovered associations with multiple SNPs in genes: AKR1C2, AR, CYP11B1, HSD17B2, 
CYP19A1, CYP1A1/A2, SHBG, and SRD5A1, though these results were not corrected for multiple tests 
(Yang et al. 2010). The role of CYP17, a gene that encodes an enzyme in the estrogen biosynthesis 
pathway (Figure 4), was assessed in a recent meta-analysis in a multi-ethnic study (Xu et al. 2013). In 
this meta-analysis, rs743572(C) was significantly associated with EC using a recessive model in 
European-descent and East Asian populations, but not others (Xu et al. 2013). Given the differences in 
EC incidence across diverse populations, additional studies to evaluate the population-specific 
frequencies of CYP17 variants and their effect on EC risk may be warranted. 
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Figure 4. Sex hormone metabolic pathway. 
Shown are the genes (bold) involved in the biosynthesis of sex hormones and their products. Adapted from Yang HP et al. 2010 and Hyland PL et al. 2013. 
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 Other genes not involved in sex hormone metabolism have been considered for association with 
EC based on known risk factors and biologic mechanisms of disease. A proposal by Modugno et al. 
(Modugno et al. 2005) that inflammation may be a factor in the development of EC led Ashton et al. to 
investigate the role of NOD and TLR polymorphisms and EC in their Australian cohort (Ashton et al. 
2010). Haplotype analysis demonstrated TLR9 rs5743836(C) and rs187084(C) were protective for EC 
(Ashton et al. 2010), though these results have not yet been replicated in an independent cohort. 
 The strong positive association between obesity and endometrial cancer risk was further 
assessed by a candidate gene study for variants in adipokine and leptin genes (Chen et al. 2012b). 
Adipokines are hormones that play a role in energy regulation and insulin sensitivity  (Rasmussen-
Torvik et al. 2009) and have been shown to inhibit cell growth and angiogenesis and induce apoptosis 
(Korner et al. 2007; Dieudonne et al. 2006; Jarde et al. 2009); women with the highest levels of 
adiponectin were observed to have a 50% reduced risk of EC compared to women with the lowest 
levels, independent of BMI, in a nested case-control study in the European Prospective Investigation 
into Cancer and Nutrition (Cust et al. 2007). Leptins, conversely, promote cell proliferation and 
angiogenesis (Korner et al. 2007; Dieudonne et al. 2006; Jarde et al. 2009). In a case-control study of 
women from the Shanghai Endometrial Cancer Study and the Shanghai Breast Cancer Study, Chen et 
al. observed three SNPs in ADIPOQ (rs3774262, rs1063539, rs12629945) and one SNP in LEP (rs2071045) 
associated with EC risk (Chen et al. 2012b). In addition, women carrying two or more minor alleles for 
the ADIPOQ SNPs were found to have a 22% lower EC risk than women with no minor alleles (Chen et 
al. 2012b). Though promising, there are limitations to this study. Study subjects’ adiponectin and leptin 
levels were not measured, preventing the authors from assessing the relationship between the 
significant variants and hormone levels. Additionally, this study has not been validated in an 
independent cohort and the authors did not correct for multiple tests (e.g., Bonferroni correction). 
Furthermore, the generalizability of the study results to other (non-Chinese) populations with differing 
obesity levels is unknown. Despite these limitations, the results are suggestive of a role for adipokines 
in EC risk.  
 As with many other diseases and traits, GWAS have been performed for EC. The first GWAS 
for EC was published in 2011 by Spurdle et al. in European-descent women from Australia and the UK 
(Spurdle et al. 2011). The authors identified HNF1B rs4430796(G) associated with endometrioid EC 
(OR=0.84, p=7.1x10-10), an association that held in their independent validation cohort of European-
descent women (Spurdle et al. 2011). This locus has been previously associated with prostate cancer 
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(Elliott et al. 2010) and with increased risk for type 2 diabetes (Voight et al. 2010). Subsequent studies 
have attempted to replicate the association of EC with HNF1B variants, with mixed results (De, I et al. 
2014; Setiawan et al. 2012; Long et al. 2012). A recent exome-wide association study failed to identify 
any novel variants associated with EC in a multiethnic population from the Epidemiology of 
Endometrial Cancer Consortium (E2C2) (Chen et al. 2014b). Given the limited number of variants 
associated with EC, additional studies performed in diverse populations may improve our 
understanding of the molecular mechanisms responsible for EC and the genetic factors influencing 
population-specific disease burdens.   
Influence of the female reproductive lifespan 
 The length of the reproductive lifespan (age at menarche) and parity play a role in the risk for 
developing EC. An early age at menarche and/or later age at natural menopause are risks for EC, as 
the lifetime exposure to estrogen increases (Hartge 2009).   Similarly, nulliparous women are at higher 
risk than parous women. EC risk in women with ten or more deliveries was found to be substantially 
lower than a Finnish reference population (Hognas et al. 2014).  Whether this protective effect is dose-
dependent (number of deliveries) or occurs at a given threshold is unknown. Use of estrogen-only 
hormone replacement therapy (HRT) in post-menopausal women is also a significant risk factor for EC 
and other poor outcomes, though absolute risk for an individual patient may differ (Ali 2014; Manson 
2014; Harman 2014).  
 Influence of cancer-associated variants 
 There is evidence that some cancers may be associated with the same genetic variants, 
suggesting pleiotropic effects. For example, a meta-analysis of PAGE, Genetic Epidemiology of 
Colorectal Cancer (GECCO), and the Colon Cancer Family Registry (CCFR) identified associations with 
colorectal cancer in 8q24, a known cancer locus (Cheng et al. 2014). As noted above, HNF1B has been 
associated with both EC (Spurdle et al. 2011) and with prostate cancer (Elliott et al. 2010). Females with 
Lynch syndrome, a hereditary colorectal cancer syndrome caused by mutations in DNA mismatch 
repair genes, have a 40-60% lifetime risk of developing endometrial cancer (Sehgal et al. 2014). Whether 
additional variants, associated with other cancers, are also associated with EC remains unknown. 
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Methods  
Selection of genetic variants 
 Variants were selected based upon their association with other cancers and identified by PAGE 
I Study investigators from the NHGRI GWAS catalog as of January 2010, fine mapping literature, and 
review of recent cancer GWAS.  One hundred twenty-two (122) candidate SNPs plus 128 ancestry 
informative markers (AIMS) were genotyped using Sequenom and TaqMan assays (Appendix G).  
Study population 
 The Epidemiologic Architecture for Genes Linked to Environment (EAGLE) study, as part of 
the Population Architecture using Genomics and Epidemiology (PAGE) I Study, accessed DNA 
samples from BioVU, the Vanderbilt University Medical Center biorepository linked to de-identified 
medical records. A description of BioVU was presented in Chapter III. Women 18 years of age and 
older were eligible for this study. Endometrial cancer cases were required to have a tumor registry 
entry for endometrial (uterine) cancer with a primary site of C540 (Isthmus uteri), C549 (Corpus uteri), 
or C559 (Uterus NOS); women with lymphoma or leukemia primary histology (9590-9989) were 
excluded. Controls for this study were females from the eligible BioVU population, excluding women 
with any ICD-9-CM code for EC, a tumor registry entry, or cancer-associated terminology in their 
synthetic derivative record. 
Statistical methods 
 Quality control (QC) methods were performed based on the QC consensus pipeline from the 
PAGE Coordinating Center (Cheng et al. 2014). The principal components method implemented in 
EIGENSTRAT was used to adjust for potential population stratification (Price et al. 2006). Samples 
were excluded based on call rates (<90%), departure from Hardy-Weinberg equilibrium (p<0.001), and 
concordance of blinded replicates (≤98%). A total of 114 candidate SNPs passed the QC process and 
were assessed for association with EC. An additive genetic model was selected for logistic regression 
between each SNP and EC; the ‘risk’ allele was defined as the allele previously associated with 
increased cancer risk in prior publications. We considered a minimally adjusted model and a fully 
adjusted model that included age, principal components, and body mass index (BMI). We defined 
significance as p<4.39x10-4, which is Bonferroni corrected (0.05/114). 
 Unexpectedly, only 20/206 EC cases and 156/2227 controls (European descent) and 2/20 cases 
and 22/335 controls (African American) remained for analysis after QC. Approximately half of the 
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samples had BMI data, a critical covariate in the EC study. Therefore, we contributed our European-
descent samples’ data to a larger meta-analysis (Setiawan et al. 2014) from the PAGE Study (Matise et 
al. 2011) and the E2C2 (Olson et al. 2009). Log odds regression estimates were combined across study 
sites in a fixed-effect, inverse-variance weighted meta-analysis implemented in METAL (Willer, Li, and 
Abecasis 2010). Heterogeneity across studies was estimated based on Cochran’s Q statistic. For the 
meta-analysis, significance was defined as a Bonferroni-corrected p<2.35x10-4 (0.05/213) (Setiawan et 
al. 2014). 
Results 
 Presented are the single-site (EAGLE BioVU) results for the EC study. The controls were slightly 
older than the cases; BMI for the cases and controls was comparable (Table 16). No SNPs met the 
Bonferroni-corrected significance threshold of 4.39x10-4 (Appendix H). The most significant SNPs at 
p<0.05 are listed in Table 17. Full logistic regression results for the EAGLE BioVU study are presented 
in Appendix H. 
 
Table 16. Population characteristics for EAGLE BioVU endometrial cancer study. 
 Cases Controls 
Number of subjects (n) 20 156 
Mean age (yrs.) 88.1 89 
Mean BMI (kg/m2) 25.8 25.5 
 
 
Table 17. Significant results from EAGLE BioVU endometrial cancer analysis. 
CHR SNP GENE A1 NMISS OR SE P-value 
8 rs10086908 intergenic T 92 8.06 0.80 9.20x10-3 
2 rs1465618 THADA T 92 7.13 0.82 0.02 
12 rs10778826 PPFIA2 A 92 4.41 0.63 0.02 
8 rs6983267 CCAT2 G 92 0.26 0.59 0.02 
8 rs10505477 LOC101930033 A 92 0.26 0.59 0.02 
Data shown are significant SNP associations at p<0.05 for EAGLE BioVU endometrial 
cancer analysis. For each SNP, p-values, risk allele, odds ratio, number of cases and 
controls are given for a fully adjusted model that included age, principal components, 
and body mass index (BMI). Gene shown is the closest gene to the SNP. Abbreviations: 
chromosome (CHR), single nucleotide polymorphism (SNP), risk allele (A1), number of 
cases and controls used in each logistic regression (NMISS), odds ratio (OR), standard 
error (SE). 
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 The most significant associations from the EC logistic regression include SNPs previously 
implicated in prostate cancer and colorectal cancer. The most significant result from our analysis 
(p<0.05) was rs10086908, located in an intergenic region in chromosome 8q24. This locus has been 
identified in several studies to be associated with prostate cancer (Liu et al. 2011; Xu et al. 2009b; Liu et 
al. 2008; Robbins et al. 2007). THADA rs1465618 at 2p21 has been associated with prostate cancer in 
both Europeans (Eeles et al. 2009) and Chinese males (Zhao et al. 2014). rs6983267, in 8q24.21, a 
colorectal cancer susceptibility SNP has recently been associated with prostate cancer and tumor 
volume in European descent men (Reinhardt et al. 2013) and with prostate cancer in a Hispanic 
(Chilean) population (San Francisco et al. 2014). rs10505477, another colorectal cancer associated SNP is 
also located in the 8q24 region (Table 17). 
 Comparing our single-site results to those of the larger meta-analysis, we failed to find 
agreement between any of the most significant associations (p<0.05) observed in EAGLE BioVU (Table 
17) and the associations reported by the PAGE I Study meta-analysis (p<0.05) (Setiawan et al. 2014). 
The lack of agreement is expected given the smaller sample size and limited power of EAGLE BioVU 
(20 cases, 156 controls) compared with the overall PAGE I Study meta-analysis (3758 cases, 5966 
controls) (Setiawan et al. 2014). Despite this lack of similarity, in both the single-site and meta-analysis, 
the most significant results were also associated with prostate cancer, suggesting pleiotropic effects for 
these SNPs and perhaps a shared biological mechanism for the development of both cancers (Table 17, 
(Setiawan et al. 2014)). 
Summary 
 Pleiotropy, the association of a genetic locus with more than one distinct phenotype (Stearns 
2010; Solovieff et al. 2013), has been investigated for a few diseases, most recently with the PheWAS—
the phenome-wide association study (Pendergrass et al. 2011; Denny et al. 2010). The PheWAS design is 
similar to that of the GWAS; where a GWAS interrogates multiple SNPs for association with a single 
phenotype, the PheWAS interrogates multiple phenotypes with a single variant (Pendergrass et al. 
2011; Denny et al. 2010). This approach may uncover previously unknown genotype-phenotype 
associations and suggest underlying biological mechanisms that are shared across phenotypes. Though 
PheWAS is a new approach for assessing pleiotropy on a large scale, testing individual variants where 
prior studies have shown associations across multiple phenotypes remains a valid approach.  
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 Studies have identified multiple genetic variants that are associated with several cancer 
phenotypes. In a recent analysis, SNPs in the 5p15.33 region, were assessed for their association with 
six distinct cancers (Wang et al. 2014b). This region has been previously linked to ten different cancers, 
including bladder (Rothman et al. 2010), glioma (Shete et al. 2009), lung (Wang et al. 2008), ovarian 
(Beesley et al. 2011), melanoma (Rafnar et al. 2009), and prostate cancer (Kote-Jarai et al. 2011) and 
contains TERT, a gene coding for a subunit of telomerase reverse transcriptase (Kim et al. 1994) and 
CLPTM1L, a gene implicated in lung and pancreatic cancer (James et al. 2012; Jia et al. 2014). Wang et 
al. identified five SNPs in TERT and one in CLPTM1L with significant pleiotropic effects (Wang et al. 
2014b).  
 This study and the meta-analysis to which it contributed, considered how GWAS-identified 
variants from other cancer studies might be associated with EC. For example, HNF1B is associated with 
endometrial cancer (Spurdle et al. 2011) and prostate cancer (Elliott et al. 2010) and has been linked to 
increased risk for type 2 diabetes (Voight et al. 2010). Interestingly, we failed to find HNF1B variants 
associated with EC at a nominal (p<0.05) significance level in EAGLE BioVU (Appendix H). However, 
we did observe SNPs in the 8q24 region, previously associated with colorectal (Real et al. 2014) and 
prostate cancer (Robbins et al. 2007), to be nominally significant in our study (Table 17). Additionally, 
THADA rs1465618 was nominally significant in our study and has been previously associated with 
prostate cancer (Eeles et al. 2009). The mechanism by which the 8q24 intergenic region contributes to 
cancer susceptibility remains unknown. This locus appears to generalize to diverse populations--
African American (Han et al. 2014), European (Eeles et al. 2009), and Chinese males (Hui et al. 2014); its 
association with multiple cancer phenotypes further suggests a role as a part of a general cancer 
mechanism. 
 A significant limitation of this single-site study is the sample size.  Though we were adequately 
powered (power=0.80) to identify an odds ratio (OR) ≈ 2.25 with our pre-QC sample size of 206 cases 
and 2227 controls (European descent), once quality control procedures were completed, our sample 
size dropped to 20 cases. We would have needed to detect an OR>4.75 with an allele frequency ≥0.15 to 
have sufficient power with this reduced sample size (Appendix I).  Given that we were underpowered 
to detect associations of modest size, we contributed our data to a larger effort that combined studies 
from two consortia: PAGE and E2C2.  In addition, this study only assessed a relatively small number of 
SNPs that were previously associated with a variety of cancers, primarily through GWAS. It is likely 
that other SNPs, not considered in this analysis, may also demonstrate pleiotropic effects in multiple 
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cancer phenotypes. Future studies investigating this potential are needed. Furthermore, despite initial 
intentions of including African American samples in this analysis, the number of EAGLE BioVU cases 
was insufficient (n=2). The lack of EC minority cases makes generalizing results to a non-European 
population challenging; the larger meta-analysis also limited their results to European-descent women. 
Additional studies in more diverse populations should be performed to verify the associations 
identified here and in other studies. Despite these limitations, this single-site study identified 
nominally significant associations between prostate cancer SNPs and endometrial cancer, suggesting 
these variants may have pleiotropic effects across multiple cancer phenotypes.     
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CHAPTER V 
CASE STUDY: A GENOME-WIDE ASSOCIATION STUDY FOR SERUM 
THYROID STIMULATING HORMONE LEVELS3 
V. CASE STUDY: A GENOME-WIDE ASSOCIATION STUDY FOR SERUM 
THYROID STIMULATING HORMONE LEVELS 
Introduction 
 Hyperthyroidism and hypothyroidism are important endocrine diseases caused by over- or 
under-production of thyroid hormone, which is regulated by thyroid stimulating hormone (TSH) 
produced in the anterior pituitary gland. Hypothyroidism, the most common thyroid disease, can be 
caused by iodine insufficiency, autoimmunity, pregnancy, pituitary disease (leading to increased TSH 
production), or other conditions. Thyroid diseases occur more often in women than in men 
(Vanderpump 2011) and the risk of developing hypothyroidism increases with age (Laurberg et al. 
2005; Bagchi, Brown, and Parish 1990).  Diagnosis of thyroid diseases involves measuring TSH levels 
and circulating thyroxine (T4) and triiodothyronine (T3) in the blood; elevated TSH levels and 
depressed T4 levels signify clinical hypothyroidism (Laurberg et al. 2005; Means 1940) while elevated 
TSH levels and normal T4 levels indicate mild (subclinical) hypothyroidism (Hollowell et al. 2002). 
TSH is produced by a normally functioning pituitary gland in response to decreased thyroid hormone 
levels; as thyroid hormone levels decrease, TSH signals to the thyroid to produce additional thyroid 
hormone.  When the thyroid gland does not maintain sufficient production of thyroid hormone, serum 
TSH levels become elevated, and the individual develops hypothyroidism. Similarly, elevated thyroid 
hormone levels from primary hyperthyroidism result in decreased TSH levels.   
 Both genetic and environmental factors influence serum TSH levels.  Physical and emotional 
stress, poor nutrition, increased body mass index (BMI), current smoking, and pregnancy are all risk 
factors for elevated serum TSH levels (Brix et al. 2000; Jorde and Sundsfjord 2006; Nyrnes, Jorde, and 
Sundsfjord 2006).  Normal serum TSH levels range from 0.3 µIU/mL – 4.0 µIU/mL but are tightly 
                                                     
3 Adapted from: Malinowski JR, Denny JC, Bielinski SJ, Basford MA, Bradford Y, et al. Genetic variants associated 
with serum thyroid stimulating hormone (TSH) levels in European Americans and African Americans: an 
eMERGE Network analysis. PLoS One. In press. 
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regulated within an individual, suggesting a genetic ‘set point’ for individual thyroid hormone levels 
(Hollowell et al. 2002; Chiamolera and Wondisford 2009; Arnaud-Lopez et al. 2008). A cross-sectional 
population study demonstrated differences in mean TSH levels between race/ethnicities, with higher 
mean TSH levels in non-Hispanic whites than in Mexican Americans or non-Hispanic blacks 
(Hollowell et al. 2002). The etiology behind the observed differences in mean TSH levels across ethnic 
groups has not been elucidated, and it is unclear if those differences lead to lower prevalence of 
hypothyroidism in populations of diverse ancestry. A recent study identified differences in prevalence 
of thyroid cancer across racial/ethnic groups living in England (Finlayson et al. 2014), and TSH 
antibodies were demonstrably lower in non-Hispanic blacks compared to non-Hispanic whites or 
Mexican-Americans in the National Health and Nutrition Examination Survey (NHANES) III (Spencer 
et al. 2007); however, studies evaluating hypothyroidism or hyperthyroidism burden among different 
racial/ethnic groups have not been performed. Twin and family-based studies have suggested 
heritability estimates of 32%-67% for TSH, T4, and T3 levels (Panicker et al. 2008b; Panicker et al. 2008a; 
Panicker 2011). Several genetic association studies have been performed, including two meta-analyses 
of GWAS (Porcu et al. 2013; Rawal et al. 2012). These studies have identified common variants 
associated with serum TSH levels: rs2046045 (PDE8B), rs10917477 (CAPZB), rs10028213 (NR3C2), and 
rs3813582 (16q23) (Panicker et al. 2010; Porcu et al. 2013). Altogether, the known loci explain <5% of the 
variance in TSH levels (Rawal et al. 2012). However, these GWAS and meta-analyses have been 
performed in populations of European ancestry, and it is unclear if these findings generalize to other 
race/ethnicities.  
 In this study, we sought to identify variants associated with normal variability of serum TSH 
levels in euthyroid (thyroid disease free) European Americans and African Americans from the 
Electronic Medical Records and Genomics (eMERGE) Network. We looked to replicate in our study 
known associations between SNPs and serum TSH levels. We hypothesized variants associated with 
serum TSH levels might also be associated with thyroid disorders, such as hyperthyroidism (Grave’s 
disease), hypothyroidism (Hashimoto’s disease), and thyroid cancer. Given that increased BMI is a risk 
factor for elevated serum TSH levels, we also tested for evidence that TSH-associated SNPS are 
modified by BMI in this study of euthyroid European and African Americans from the eMERGE 
Network. 
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Methods 
 The eMERGE Network is a collaboration of institutions with biobanks linked to EMRs.  The 
data for these analyses included Phase I of the eMERGE Network whose members included Group 
Health Cooperative/University of Washington, Marshfield Clinic, Mayo Clinic, Northwestern 
University, Vanderbilt University and the eMERGE Administrative Coordinating Center (McCarty et 
al. 2011). 
Study population and phenotype 
 This study was performed in the eMERGE Network which includes approximately 17,000 
individuals who were genotyped for a variety of complex diseases (e.g. dementia, cataracts, peripheral 
arterial disease (PAD), type 2 diabetes) and medically relevant quantitative traits (e.g. cardiac 
conduction) (Denny et al. 2011). To qualify for euthyroid designation in this analysis, individuals were 
required to have at least one test of thyroid function (i.e., TSH and T3 or T4 if available) with no 
abnormal results, must not have any billing codes for hypothyroidism or history of myasthenia gravis 
in his/her EMR or evidence of thyroid replacement medication, and must have at least two past 
medical history sections (non-acute visits) and medication lists. For individuals with multiple TSH 
tests, the median TSH level was used in the analysis. Individuals were excluded if they had any cause 
of hypothyroidism or hyperthyroidism, any other thyroid diseases (e.g. Graves, thyroid cancer) as 
indicated by billing (ICD-9) codes, procedure (CPT) codes or text word diagnoses, or were on thyroid-
altering medication (e.g., lithium) (Denny et al. 2011). From this group, 6,086 European Americans and 
633 African Americans qualified as euthyroid, of which 4,501 European Americans and 351 African 
Americans had body mass index (BMI). The appropriate institutional review board at each 
participating study site approved all procedures. 
Genotyping 
 Genotyping was performed using the Illumina Human660W-Quadv1_A and the Illumina1M 
BeadChips for European Americans and African Americans, respectively, as previously described 
(Denny et al. 2011).  Of the SNPs on each array, 474,366 SNPs and 905,285 SNPs, respectively, passed 
quality control filters for tests of genotyping efficiency (>99% call rate), and minor allele frequency 
(>5%). Details of eMERGE quality control have been previously published (Turner et al. 2011; Zuvich et 
al. 2011). Briefly, datasets from each of the five participating eMERGE Phase I sites were combined at 
the eMERGE Coordinating Center. Sample relatedness was assessed by calculating pairwise kinship 
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estimates in PLINK with the –genome command; the sample with the lowest call rate of the related 
pairs (e.g., full sibling, avuncular, parent-offspring) was removed (Zuvich et al. 2011). Population 
stratification was examined using the principal components analysis implemented in EIGENSTRAT 
(Price et al. 2006). Hardy-Weinberg equilibrium (HWE) was evaluated after dividing the data into two 
main groups by ancestry, European and African; a HWE threshold of p<1x10-4 was implemented. Call 
rates and minor allele frequencies were examined for each study site individually to assess batch effects 
that could skew results (Zuvich et al. 2011).    
Statistical methods 
 Quality control and data analysis were performed using a combination of PLINK  (Purcell et al. 
2007; Purcell 2009), and R software, and data were plotted using R code obtained from the Getting 
Genetics Done website (Turner and Bush 2012; R Development Core Team 2012),  Stata (StataCorp 
2011) and Synthesis-View (Pendergrass et al. 2010).  Power calculations were performed using Quanto 
(Gauderman 2002a).  Linear regression was performed assuming an additive genetic model to test for 
associations between individual SNPs and log-transformed median serum TSH levels. Tests were 
performed stratified by race/ethnicity, unadjusted and adjusted for age, sex, BMI, and first principal 
component (PC1) calculated with EIGENSTRAT (Price et al. 2006). Additional tests of association were 
performed in European Americans stratified by BMI (normal: BMI 18.5-24.9; overweight: BMI≥25) and 
adjusted for age, sex, and PC1.  We also performed formal tests of interaction between SNPs associated 
with TSH levels as a significance threshold of p<1x10-4 and stratified BMI (normal versus overweight) 
stratified by race/ethnicity in adjusted (age, sex, PC1, and main effects) models. We considered a SNP-
BMI interaction significant at a threshold of p<0.05. Wilcoxon rank-sum tests were performed to 
compare median TSH levels at each genotype for normal vs. overweight BMI categories for each SNP. 
 In addition to GWAS discovery, we sought to replicate and generalize previously reported 
genetic associations for TSH levels.  We considered a SNP replicated in European Americans if the 
tested SNP was identical to the index SNP, or a proxy in strong linkage disequilibrium (LD) (r2>0.7) 
with the index SNP in 1000 Genomes CEU reference panel, and the direction of effect was consistent 
with the previous report after taking into account coding allele differences.  We considered a SNP 
generalized to African Americans if the tested SNP was identical to, or a proxy in strong LD with 
(r2>0.7), the index SNP in 1000 Genomes CEU reference panel, and the direction of effect was consistent 
with European Americans. For the replication/generalization analysis, significance was defined at a 
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threshold of p<0.05.  Power calculations were performed assuming the genetic effect sizes reported in 
the literature, the present study sample size, and the present study coded allele frequencies. 
Results 
 All eMERGE participating sites contributed data for European Americans and all sites except 
Marshfield Clinic contributed data for African Americans (Appendix J). Collectively, European 
Americans had higher mean TSH levels compared to the African Americans (1.90 μIU/mL vs. 1.45 
μIU/mL), had lower BMI (27.51 kg/m2 vs. 32.16 kg/m2), included more men (52.19% male vs. 25.07%), 
and were older (median decade of birth 1930s vs. 1950s) (Table 18). The higher mean TSH level in 
European Americans compared to African Americans is consistent with previous epidemiologic 
reports (Vanderpump 2011; Hollowell et al. 2002; Boucai and Surks 2009). The age, BMI, and sex ratio 
differences between the groups observed here most likely reflect ascertainment differences resulting 
from the characteristics of the source populations at each eMERGE site, rather than true differences at 
the overall population level. 
 
Table 18. Population characteristics in euthyroid individuals for serum TSH levels in the eMERGE 
Network. 
 European Americans 
(n=4,501) 
African Americans (n=351) 
Female (%) 47.81 74.93 
Body mass index, kg/m2 27.51 (5.55) 32.16 (8.43) 
Age at lab, years  65.50 (12.48) 50.59 (18.41) 
TSH levels, μIU/mL  1.90 (0.93) 1.45 (0.72) 
 
 
 
Decade of 
birth, # 
(%) 
1910s 608 (13.51) 30 (8.55) 
1920s 865 (19.22) 40(11.40) 
1930s 994 (22.08)  22 (6.27) 
1940s 1246 (27.68) 40 (11.40) 
1950s 612 (13.60) 71 (20.23) 
1960s 89 (1.98) 67 (19.09) 
1970s 48 (1.07) 42 (11.97) 
1980s 38 (0.84) 38 (10.83) 
1990s 1 (0.02) 1 (0.28) 
Data are presented as means (standard deviation) unless otherwise noted. Abbreviations: thyroid stimulating 
hormone (TSH), the Electronic Medical Records and Genomics (eMERGE). 
 
Discovery 
 We performed standard single SNP tests of association stratified by race/ethnicity and adjusted 
for sex, age (decade of birth), BMI, and PC1.  For European Americans, we identified six SNPs in 
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PDE8B on chromosome 5 as associated with TSH levels at genome-wide significance (p<5x10-8) (Table 
19, Figure 5).  Our most significant result, rs1382879, was a perfect proxy for previously-identified 
(Rawal et al. 2012) rs2046045 (r2=1.00) and was in moderate-to-high LD (r2>0.30) with the other 
significant PDE8B SNPs.  No novel genotype-phenotype associations were identified at genome-wide 
significance in this sample of European Americans.  However, an additional 111 SNPs were 
suggestively associated with serum TSH levels (p<1x10-4), including seven SNPs in PDE8B, ten SNPs 
near FOXE1, three SNPs in PDE10A, four SNPs in THBS4, and eight SNPs in NRG1 (Appendix K). The 
majority of these SNPs are located in noncoding regions of the genome (intronic, upstream, 
downstream); however, rs3745746 (CABP5, p=4.93x10-5) is a missense mutation, and rs1443434 (FOXE1, 
p=6.53x10-5) is located in the 3′ untranslated region. 
 
Table 19. Genome-wide significant SNP associations for serum TSH levels in eMERGE euthyroid 
European Americans. 
CHR SNP GENE GENE REGION CODED 
ALLELE 
BETA (SE) P-VALUE 
5 rs1382879 PDE8B intronic G 0.09 (0.01) 7.16x10-18 
5 rs2046045 PDE8B intronic C 0.09 (0.01) 1.85x10-17 
5 rs989758 PDE8B intronic T 0.08 (0.01) 1.33x10-14 
5 rs9687206 PDE8B intronic G 0.08 (0.01) 5.52x10-14 
5 rs12515498 PDE8B intronic C 0.07 (0.01) 3.27x10-10 
5 rs6885813 PDE8B intronic A 0.06 (0.01) 4.05x10-8 
Tests of association using linear regression for 474,366 SNPs assuming an additive genetic model and adjusted for 
age, sex, principal component (PC1), and body mass index were performed. Significance defined as p<5x10-8. 
Abbreviations: single nucleotide polymorphism (SNP), thyroid stimulating hormone (TSH), Electronic Medical 
Records and Genomics (eMERGE). 
  
 No SNPs were associated with TSH levels in African Americans at the genome-wide 
significance threshold of p<5.0x10-8 (Appendix L).  However, 87 SNPs reached a suggestive significance 
level (p<1x10-4); the most significant result was rs1409005 (POU4F1-AS1, p=5.02x10-7). Similar to the 
results in the European Americans, the majority of these SNPs were located in noncoding regions 
except for two missense mutations (COQ5 rs3742049, p=6.08x10-5; RBM20 rs942077, p=8.47x10-5) and 
one synonymous substitution (KLK1 rs1054713, p=4.16x10-5) (Appendix L).
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Data shown are p-values from single SNP tests of association with serum TSH levels in a model adjusted 
for age, sex, principal component (PC1), and body mass index in euthyroid European Americans in 
eMERGE Network (n=4,501). The y-axis represents the –log10 (p-value); horizontal lines represent 
Bonferroni corrected significance level (p<5x10-8)(top) and suggestive significance level (1x10-4)(bottom). 
Chromosomes are arranged on the x axis. Abbreviations: thyroid stimulating hormone (TSH), Electronic 
Medical Records and Genomics (eMERGE), single nucleotide polymorphism (SNP). 
Figure 5. Manhattan plot of tests of association with serum TSH levels in euthyroid 
European Americans in eMERGE Network. 
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Trans-population genetic associations 
 Given the smaller sample size of African Americans with serum TSH levels, the GWAS was 
underpowered to detect associations at genome-wide significance with expected small to moderate 
effect sizes.  Therefore, we evaluated the 31 most significant (p<1x10-5) associations from the European 
American dataset for evidence of generalization to the African American dataset at a liberal 
significance threshold of 0.05 (Figure 6). One SNP, rs813379, was not directly genotyped in African 
Americans. We observed two SNPs in PDE8B associated with serum TSH levels in European 
Americans (rs2046045: p=1.85x10-17 and rs12520862: p=7.48x10-6) that were also associated in African 
Americans (p=0.03 and 0.01, respectively) with consistent directions and magnitude of effect after 
accounting for the coded allele (Figure 6).  We also observed two SNPs upstream of IGFBP5 (rs1861628 
and rs13020935) associated both in European Americans (p=3.68x10-6 and 7.02x10-6, respectively) and 
African Americans (1.82x10-4 and 1.82x10-4, respectively).  These SNPs are in perfect LD in both 1000 
Genomes CEU and YRI reference panels (r2=1.00). Interestingly, while the direction of effect was 
consistent between the two populations, the magnitude of effect was larger in African Americans β= -
0.1492, SE=0.04; β=-0.1492, SE=0.04, respectively) compared with European Americans (β = -0.05, 
SE=0.01; β=-0.05, SE=0.01, respectively).  One additional variant, ABO rs657152, was significant in both 
European Americans (p=4.17x10-6, β=0.05) and African Americans (p=0.03, β=0.09). Overall, most 
genetic associations identified in European Americans for serum TSH levels were not significant 
(p<0.05) in African Americans (25/30; 83.3%); however, the majority of associations (21/30; 70.0%) had 
genetic effects in the same direction between the two populations (Figure 6). 
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Figure 6. Comparison of most significant associations identified in European Americans 
with African Americans from the eMERGE Network. 
Shown are p-values, coded allele frequencies, and betas for euthyroid European Americans (n=4,501) and 
African Americans (n=351) in the eMERGE Network for serum TSH level tests of association using 
SynthesisView. Data shown are comparisons between European Americans (blue markers) and African 
Americans (red markers) for p-values (data shown are –log10(p-value)), genetic effect magnitudes (beta), and 
coded allele frequencies (MAF) for the 31 most significant SNPs in European Americans. Red horizontal line on 
p-value track indicates p=0.05. SNPs are oriented across the top of the figure, arranged by chromosomal 
location. Large triangles represent p-values at or smaller than 5x10-8. Direction of the marker for p-values 
indicates direction of effect for each SNP. Abbreviations: Electronic Medical Records and Genomics (eMERGE), 
thyroid stimulating hormone (TSH), single nucleotide polymorphism (SNP). 
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Replication and Generalization 
 At least 24 SNPs have been associated with serum TSH levels in European descent populations 
in the literature (Rawal et al. 2012; Porcu et al. 2013; Taylor et al. 2011; Panicker et al. 2010). We 
considered a SNP replicated if the direction of effect was the same as previously reported and 
associated at a liberal threshold of p<0.05 with serum TSH levels. In European Americans, we 
replicated 22/25 (88%) SNPs previously associated with serum TSH levels (Table 20).  As previously 
mentioned, the most significant association with TSH levels in European Americans replicated the 
published reports for PDE8B SNPs rs2046045 and rs6885099 (Table 20).  Beyond PDE8B, we replicated 
two SNPs on chromosome 1 in CAPZB previously implicated as associated with serum TSH levels 
(Table 20). One SNP, rs12138950, was a perfect proxy for previously-reported CAPZB rs10917469 (1000 
Genomes CEU r2=1.00, β=-0.05, p=8.97x10-5) (Table 20). 
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Table 20. Comparison of prior associations with TSH levels to eMERGE European Americans. 
Locus Prior Association Current Study 
SNP Chr Gene/ 
Gene Region 
C
A 
CAF β 
(SE) 
P-value Ref. SNP/Best Proxy 
SNP 
r2 CA CAF β 
(SE) 
P-value 
rs10917469 1 CAPZB G 0.16 -0.16(0.03) 3.2x10-08 
(Panicker et al.2010) 
rs12138950 1.00 C 0.15 -0.05(0.01) 8.97x10-05 
rs10917477 1 CAPZB A 0.51 -0.06(0.01) 1.54x10-08 (Rawal et al.2012) rs6683419 0.73 G 0.48 0.04(0.01) 3.56x10-04 
rs10799824 1 CAPZB A 0.16 -0.11(0.01) 3.60x10-21 (Porcu et al.2013) rs12138950 0.95 C 0.15 -0.05(0.01) 8.97x10-05 
rs334699 1 NFIA A 0.05 -0.14(0.02) 5.40x10-12 (Porcu et al.2013) rs334708 0.79 C 0.08 -0.05(0.02) 7.20x10-03 
rs13015993 2 IGFBP5 A 0.74 0.08(0.01) 3.24x10-15 (Porcu et al.2013) rs1861628 1.00 T 0.27 -0.05(0.01) 3.68x10-06 
rs10028213 4 NR3C2 C 0.82 0.08(0.01) 2.88x10-10 (Rawal et al.2012) rs10519980 1.00 T 0.18 -0.04(0.01) 0.001 
rs10032216 4 NR3C2 T 0.78 0.09(0.01) 9.28x10-16 (Porcu et al.2013) rs17025017 1.00 A 0.19 -0.04(0.01) 2.38x10-03 
rs2046045 5 
PDE8B 
T 0.62 -0.12(0.01) 2.79x10-27 (Rawal et 
al.2012;Eriksson et 
al.2012;Medici et 
al.2011) 
rs2046045 -- C 0.40 0.09(0.01) 1.85 x10-17 
rs6885099 5 PDE8B A 0.59 -0.14(0.01) 1.95x10-56 (Porcu et al.2013) rs2046045 1.00 C 0.40 0.09(0.01) 1.85 x10-17 
rs4704397 5 PDE8B A 0.40* 0.21 1.64x10-10 (Taylor et al.2011) rs1382879 0.94 G 0.39 0.09(0.01) 7.16 x10-18 
rs753760 6 PDE10A C 0.69 0.10(0.01) 1.21x10-24 (Porcu et al.2013) rs2983514 0.93 G 0.33 -0.05(0.01) 1.36 x10-05 
rs9472138 6 VEGFA T 0.29 -0.08(0.01) 6.72x10-16 (Porcu et al.2013) rs9472138 -- T 0.28 -0.04(0.01) 6.41 x10-04 
rs11755845 6 VEGFA T 0.27 -0.07(0.01) 1.68x10-10 (Porcu et al.2013) rs11755845 -- T 0.24 -0.02(0.01) 0.04 
rs9497965 6 SASH1 T 0.42 0.05(0.01) 2.25 x10-08 (Porcu et al.2013) rs9377117 0.54 G 0.30 0.02(0.01) 0.12 
rs7825175 8 NRG1 A 0.21 -0.07(0.01) 2.94 x10-09 (Porcu et al.2013) rs2466067 0.21 C 0.31 -0.05(0.01) 8.41 x10-06 
rs657152 9 ABO A 0.34 0.06(0.01) 4.11 x10-10 (Porcu et al.2013) rs657152 -- T 0.38 0.05(0.01) 4.17 x10-06 
rs1571583 9 GLIS3 A 0.25 0.06(0.01) 2.55 x10-08 (Porcu et al.2013) rs1571583 -- T 0.25 0.03(0.01) 0.01 
rs17723470 11 PRDM11 T 0.28 -0.07(0.01) 8.83 x10-11 (Porcu et al.2013) rs7940871 0.89 T 0.29 -0.04(0.01) 1.42 x10-04 
rs1537424 14 MBIP T 0.61 -0.05(0.01) 1.17 x10-08 (Porcu et al.2013) rs1537424 -- G 0.43 0.03(0.01) 2.89 x10-03 
rs11624776 14 ITPK1 A 0.66 -0.06(0.01) 1.79 x10-09 (Porcu et al.2013) rs957362 0.31 C 0.22 0.02(0.01) 0.09 
rs10519227 15 FGF7 A 0.25 -0.07(0.01) 1.02 x10-11 (Porcu et al.2013) rs7168316 1.00 T 0.23 -0.05(0.01) 2.10 x10-05 
rs17776563 15 MIR1179 A 0.32 -0.06(0.01) 2.89 x10-10 (Porcu et al.2013) rs11073790 0.81 T 0.35 -0.01(0.01) 0.24 
rs3813582 16 LOC440389/
MAF 
T 0.67 0.08(0.01) 8.45 x10-18 (Rawal et al.2012;Porcu 
et al.2013) 
rs17767383 1.00 A 0.31 -0.04(0.01) 1.42 x10-04 
rs9915657 17 SOX9 T 0.54 -0.06(0.01) 7.53 x10-13 (Porcu et al.2013) rs9915657 -- C 0.46 0.03(0.01) 9.53 x10-04 
rs4804416 19 INSR T 0.57 -0.06(0.01) 3.16 x10-10 (Porcu et al.2013) rs4804416 -- G 0.44 0.03(0.01) 7.20 x10-04 
SNP rs number, chromosomal location, nearest gene/gene region, coded allele (CA), coded allele frequency (CAF), and association summary statistics (betas, standard 
errors, and p-values) are given for each previously reported association with the TSH levels in European Americans. CAF for rs4704397 is the mean CAF for the combined 
cohorts described in Taylor et al. For SNPs not directly genotyped in this study, the proxy in highest linkage disequilibrium in 1000 Genomes CEU reference panel was 
identified. Results of adjusted (age, sex, body mass index, and principal component 1) tests of association are given for each previously reported SNP or its proxy in this 
European American dataset (n=4,501). 
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 In African Americans, 5/24 (25%) SNPs previously associated with TSH levels in European-
descent populations generalized at a liberal significance threshold of p<0.05 and a consistent direction 
of effect (Appendix M). PDE8B rs2046045, a proxy for rs6885099 (1000 Genomes CEU r2=1.00, YRI 
r2=0.945), was associated with serum TSH levels in African Americans (β = -0.09, p=0.03) (Appendix 
M).  NFIA rs334713, a proxy for rs334699 (1000 Genomes CEU r2=1.00, YRI r2=0.774), was associated 
with serum TSH levels in eMERGE African Americans (p=1.50x10-3) with a similar effect size (β=-0.17) 
as previously-reported European-descent populations.  Notably, the coded allele frequency of this SNP 
was greater in African Americans (coded allele frequency = 0.17) compared with either eMERGE 
European Americans (rs334708 coded allele frequency=0.08)(Table 20) or the previously-reported 
European descent population (0.05) (Appendix M). Intronic ABO rs657152 was significant at p=0.03, 
and the magnitude and direction of effect were similar to previously published European American 
data (Appendix M). VEGFA rs11755845 was significant at p=0.01 (Appendix M) with an effect size 
nearly double that of the previously reported result in European Americans (Appendix M). SNP 
rs13020935 upstream of IGFBP5, a proxy for rs13015993 (r2=1.00), was significant at p=1.82x10-4 
(Appendix M). 
SNPs previously associated with thyroid disease 
 Next, we investigated SNPs that had previously been associated with a thyroid disease 
phenotype, specifically: hypothyroidism, thyroid cancer, and Graves disease (Eriksson et al. 2012; Chu 
et al. 2011; Gudmundsson et al. 2009), since variation in TSH levels may indicate thyroid disease.  Six 
SNPs in the FOXE1 region, including rs925489, generalized to euthyroid European American subjects 
(Appendix N). An additional SNP in FOXE1, rs965513, previously associated with hypothyroidism 
(Eriksson et al. 2012; Denny et al. 2011), generalized to serum TSH levels in European Americans 
(p=1.09x10-6, β=-0.05) (Appendix N).  FOXE1 rs1877432, previously associated with hypothyroidism, 
generalized to serum TSH levels in African Americans (p=9.73x10-3, β=0.11) (Appendix O). 
RHOH/CHRNA9 rs6832151, previously associated with Grave’s Disease, generalized to serum TSH 
levels in African Americans (p=0.01, β=-0.10) (Appendix O). None of the SNPs previously associated 
with thyroid cancer (Gudmundsson et al. 2009) were associated with serum TSH levels in either  
European Americans or African Americans at a liberal significance threshold of p<0.05 (Appendix N, 
Appendix O).  Broadly, we found little evidence of association with serum TSH levels for SNPs, apart 
from FOXE1, that have been associated with other thyroid-related phenotypes. 
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Interaction with BMI 
 Increased BMI is significantly associated with TSH levels and changes in BMI can be a symptom 
of thyroid disease, with hypothyroid persons gaining weight and hyperthyroid persons losing weight 
(Knudsen et al. 2005). We observed that the addition of BMI into the linear regression model yielded 
more significant p-values for the SNPs in PDE8B and others, and the results from the stratified analyses 
differed within each race/ethnicity (Appendix P, Appendix Q). Therefore, we performed formal tests 
of interaction between BMI and all SNPs (n=118) with p<1x10-4 from the age, sex, PC1, and BMI 
adjusted model in European Americans and considered evidence for an interaction at p<0.05.   Three 
SNPs met our significance threshold in European Americans for an interaction with BMI: NFIA 
rs10489909, NRG1 rs2466067 and rs4298457. An additional NRG1 SNP was just outside the p<0.05 
significance threshold for the interaction: rs10954859 (Table 21). The NRG1 SNPs are in moderate-to-
high LD with each other (r2>0.70). We compared median TSH levels by BMI category for each genotype 
by SNP and observed lower median TSH levels for individuals with the AA genotype for rs10489909 
who were of normal BMI than compared to individuals with overweight BMI (p<0.005) (Figure 7). We 
observed similar trends for rs2466067 (CC genotype), rs10954859 (GG genotype), and rs4298457 (GG 
genotype) (p<0.05) which suggests serum TSH levels may be attenuated based on BMI for these 
homozygous genotypes (Figure 7). 
 
Table 21. Body mass index as a modifier of serum TSH levels genetic associations. 
POPULATION SNP GENE/REGION MODIFIER BETA (SE 
SNPxBMI) 
P (SNPxBMI) 
European American rs10489909 NFIA BMI 0.01(0.004) 6.21E-03 
European American rs2466067 NRG1 BMI 0.004(0.002) 0.040 
European American rs4298457 NRG1 BMI 0.004(0.002) 0.047 
European American rs10954859 NRG1 BMI 0.004(0.002) 0.050 
African American rs6728613 MYT1L BMI -0.016(0.005) 2.28E-03 
African American rs4073401 MYT1L BMI -0.016(0.005) 2.28E-03 
African American rs10518306 LOC285419 BMI -0.026(0.011) 0.020 
African American rs6062344 TCEA2 BMI -0.010(0.005) 0.043 
African American rs6090040 TCEA2 BMI -0.009(0.005) 0.047 
Interaction analyses were performed using the SNPs with p<1x10-4 significance levels in the model adjusted for age, 
sex, principal component 1 (PC1), and body mass index (BMI) in European Americans (n=4,501) and African 
Americans (n=351) in eMERGE serum TSH levels study. The model was stratified by race/ethnicity and by 
normal/overweight BMI (normal: BMI 18-24.9; overweight: BMI 25+). We considered a SNPxBMI interaction 
significant at a threshold of p<0.05. Displayed are significant interaction results at p=0.05. 
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Figure 7. BMI as a modifier of serum TSH levels in eMERGE European Americans. 
Interaction analyses were performed using the SNPs with p<1x10-04 significance levels in the model adjusted for age, sex, PC1, 
and body mass index in European Americans (n=4,501). For each significant (p<0.05) interaction term, the model was then 
stratified by normal/overweight BMI (normal BMI =18-24.9; overweight BMI≥25). We considered a SNPxBMI interaction 
significant at a threshold of p<0.05. Shown are p-values from Wilcoxon rank-sum test comparing median TSH values between 
BMI categories at each genotype. 
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 We also performed tests of interaction in African Americans for BMI and the 87 most significant 
SNPs (p<1x10-4 from the age, sex, PC1, and BMI adjusted model). We observed five SNPs at the p<0.05 
significance threshold (Table 21, Appendix R). MYT1L rs6728613 and rs4073401 are in perfect LD with 
each other (r2=1.00) and were the most significant in this interaction analysis (p=2.28x10-3) (Table 21, 
Appendix R). While other interaction terms were significant in the African American sample, small 
sample sizes and low counts made comparisons across genotypes and BMI categories difficult to 
interpret (Appendix R). 
 
Summary 
 The eMERGE Network was established in 2007 to determine whether electronic medical records 
could be used to identify disease susceptibility in diverse patient populations for complex 
traits/diseases. At each study site, DNA linked to an EMR was genotyped for a GWAS for specific 
complex diseases (e.g., type II diabetes) and medically relevant quantitative traits (e.g., cardiac 
conduction). A recent eMERGE Network GWAS demonstrated that these study-specific genotype data 
can be “reused” for additional GWAS for binary outcomes (hypothyroidism) extracted from the EMR 
(Denny et al.2011). As an extension of this exercise, we performed a GWAS for an additional medically 
relevant quantitative trait: thyroid stimulating hormone (TSH) levels, in 4,501 European American and 
351 African American euthyroid individuals. 
 Several studies have shown associations between TSH levels and PDE8B (briefly: (Arnaud-
Lopez et al. 2008; Medici et al. 2011; Taylor et al. 2011)).  PDE8B is a phosphodiesterase gene that 
encodes a cAMP-specific protein expressed in thyroid tissue (Horvath et al. 2010).  PDE8B upregulates 
cAMP through interaction with the TSH receptor on thyroid cells (Arnaud-Lopez et al. 2008; Horvath et 
al. 2010). In this study, we have replicated the results recently obtained by several groups finding 
association of TSH levels and several SNPs in the PDE8B region in European Americans (Medici et al. 
2011; Taylor et al. 2011). Variants in PDE8B were the only SNPs in this analysis to reach genome-wide 
significance in European Americans after accounting for multiple testing. In African Americans, 
rs2046045 (in high/perfect LD with rs6885099 and rs4704397) was nominally significant.   
 The FOXE1 region was not as strongly associated with TSH levels as PDE8B in European 
Americans, a result similar to that obtained by Medici et al (Medici et al. 2011). FOXE1 encodes a 
thyroid transcription factor with a characteristic forkhead motif believed to be important in thyroid 
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morphogenesis (Cuesta, Zaret, and Santisteban 2007; De and Di 2004). Mutations in FOXE1 have been 
implicated in hypothyroidism (Eriksson et al. 2012; Gudmundsson et al. 2009; Denny et al. 2011)  and 
thyroid cancer (Tomaz et al. 2012; Landa et al. 2009).  No SNPs in FOXE1 reached genome-wide 
significance in this study, though several were associated at the 10-6 threshold in European Americans.   
 Given the relationship between TSH levels and specific clinical outcomes, we hypothesized that 
serum TSH levels would also be associated with SNPs previously associated with hypothyroidism, 
Grave’s Disease, or thyroid cancer by GWAS or candidate gene studies (Chu et al. 2011; Gudmundsson 
et al. 2009; Eriksson et al. 2012). Patients with these disorders exhibit abnormal TSH levels and there is 
a strong autoimmune component to the diseases.  No SNPs in previously identified gene regions 
(CTLA-4, TSHR, TTF1, HLA, and PTPN22) were significantly associated with TSH levels in either 
European Americans or African Americans from the eMERGE Network (Appendix N, Appendix O).  
 Obesity (BMI >30) has been implicated in higher TSH levels and change in an individual’s set 
point (Marzullo et al. 2010; De et al. 2007). We performed additional analyses adjusting for age, sex, 
PC1, and BMI in both the European American and African American cohorts and stratified analyses by 
BMI (normal versus overweight).  In the European Americans, adjusting for BMI did not appreciably 
modify the results, though the results in both PDE8B and FOXE1 were more highly significant 
(Appendix P).  These results led us to consider potential SNPxBMI interactions.  After performing tests 
of association for an interaction in the most significant results from the primary analysis, we identified 
two loci with SNPxBMI interactions in European Americans: NFIA and NRG1.  NFIA, a transcription 
factor, has not previously been associated with thyroid-related traits. NRG1 encodes neuregulin, a 
signaling protein recently identified in a study to be associated with thyroid cancer, potentially 
mediated by regulation of TSH levels (Gudmundsson et al. 2009). Neuregulin is expressed in papillary 
thyroid carcinomas and has been found to regulate cell proliferation in a rat thyroid cell model 
(Breuleux 2007).  Further studies on the role NRG1 may play in regulating TSH levels are warranted. In 
the African American subjects, significant interactions at a liberal threshold (p<0.05) were identified, 
but small sample sizes and low genotype counts per BMI category made comparisons across groups 
difficult.   
 We compared results from the African Americans to those of the European Americans in our 
study and observed several differences.  While several SNPs in PDE8B reached genome-wide 
significance in European Americans, none were significant in African Americans, and only two PDE8B 
variants identified in previous GWAS generalized to this population at a liberal significance threshold 
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of p<0.05. Of the 32 most significant SNPs in European Americans, 21 had the same direction of effect 
and similar effect sizes in African Americans.  
 A major limitation of this study is sample size.  Among both populations, we exclude 
individuals in eMERGE with an abnormal TSH level given this study sought to identify genetic 
determinants of the normal distribution for TSH levels. Despite excluding individuals with abnormal 
TSH values, the mean (standard deviation) observed here for European Americans [1.90 (0.93)] was 
well within the range of previous TSH level genetic association studies:  1.5 (0.80) to 2.7 (4.1) μIU/mL 
(Porcu et al. 2013). The addition of the few individuals with abnormal TSH levels would unlikely 
increase statistical power enough to detect additional genome-wide associations nor substantially 
impact the overall trait distribution. In comparison, the African American sample size was very small 
which impacted our ability to generalize previous findings to this population. In eMERGE African 
Americans, we were only adequately powered (>80%) for one test of association: PDE8B rs4704397.  
This SNP was not directly genotyped in the eMERGE African American dataset, but is in very high LD 
with genotyped rs2046045 in the 1000 Genomes CEU panel (r2=0.94), but not with the 1000 Genomes 
YRI panel (r2=0.49). The small sample size coupled with lower linkage disequilibrium resulted in 
underpowered tests of association for the African American dataset. 
 We also observed striking differences in minor allele frequencies (MAF) between European 
Americans and African Americans that may have impacted our ability to replicate and generalize 
previously associated variants. In European Americans, most of the minor allele frequencies were 
comparable to those in previously published studies (Appendix S), and we were adequately powered 
(80%) to replicate 18/25 SNPs previously associated with serum TSH levels at a liberal significance 
threshold of 0.05 (Appendix S). Of the 18 properly powered tests of association, all of these SNPs 
replicated in the eMERGE European American dataset. We further considered that population 
differentiation may have prevented us from generalizing known variants to the eMERGE African 
Americans. Between populations, differences in environmental pressures can lead to differential 
changes in allele frequencies. Calculating FST by both the Weir/Cockerham(Weir and Cockerham 1984) 
and Wright(Wright 1965) methods using PLATO((The Ritchie Lab 2013)), we found no evidence 
corroborating this hypothesis (Table 22). 
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Table 22. FST Calculations for European and African Americans in eMERGE TSH analysis. 
 FST 
Gene SNP Weir/Cockerham Wright 
PDE8B rs2046045 0.03 0.00 
CAPZB rs10799824 0.00 0.00 
VEGFA rs9472138 0.00 0.00 
VEGFA rs11755845 0.01 0.11 
NRG1 rs7825175 0.00 0.00 
ABO rs657152 0.00 0.00 
GLIS3 rs1571583 0.00 0.00 
PRDM11 rs17723470 0.00 0.00 
MBIP rs1537424 0.03 0.00 
ITPK1 rs11624776 0.00 0.00 
SOX9 rs9915657 0.00 0.00 
INSR rs4804416 0.01 0.00 
Shown are FST calculations, rounded to the nearest hundredth, for SNPs previously associated with serum TSH levels 
in European populations and the FST at each locus for eMERGE European Americans and African Americans. FST was 
calculated with PLATO software for both the Weir/Cockerham and Wright methods. Gene shown is the gene closest 
to the SNP presented.  
 
 This study further demonstrates the feasibility of using genotypes linked to EMRs to perform 
secondary analyses for quantitative traits in complex diseases in diverse populations (Crosslin et al. 
2013; Ding et al. 2012). We identified SNPs associated with serum TSH levels and replicated findings 
from earlier GWAS for TSH levels and thyroid-related traits to the eMERGE European American 
euthyroid population.  We further suggest BMI may modify genetic associations with serum TSH 
levels. Consistent with other reports, we found few associations with SNPs associated with serum TSH 
levels that have effects on other thyroid-related traits/diseases. Importantly, we identified suggestive 
associations with biologically plausible SNPs and generalized several SNPs from previous GWAS to 
the eMERGE African American euthyroid population, suggesting additional studies in diverse 
populations are warranted. 
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CHAPTER VI 
IMPLEMENTING PERSONALIZED MEDICINE: EVIDENCE AND ETHICS4,5 
VI. IMPLEMENTING PERSONALIZED MEDICINE: EVIDENCE AND 
ETHICS 
Introduction 
 Personalized medicine (PM), defined as individualization of clinical care based, in part, on the 
genomic background of an individual, (Cornetta and Brown 2013), has more generally come to mean 
the use of genetic/genomic data to inform clinical care (decision-making for prevention, diagnosis, and 
treatment) for individual patients (National Human Genome Research Institute 2014b). Genetics and 
genomics has been used to identify the etiology of unknown genetic conditions (Need et al. 2012) and 
additional variants responsible for known disorders (Lupski et al. 2010), determine a tumor’s 
susceptibility to chemotherapies (Tessari, Palmieri, and Di 2013), and guide dosage requirements for 
medication (Scott et al. 2013). Given the public health impact of complex diseases such as type 2 
diabetes (T2D), cardiovascular disease (CVD), and asthma, which have genetic and environmental 
components, leveraging PM to improve health outcomes in complex diseases offers much potential. 
PM may be used for complex disease to predict which individuals are at greatest risk for disease 
development based on their genetic composition and environmental exposures, allowing for pre-
symptomatic intervention, or to inform pharmacologic therapy choices once a disorder has manifested. 
However, there are numerous challenges to overcome for PM to be successful for common, complex 
diseases. The clinical validity, utility and added benefit attributable to including genetic and genomic 
information in clinical care for complex disorders has not been adequately assessed.  The impact on the 
health care system, including integration of these data into electronic medical records, data access, 
privacy, and physician decision support, remain important issues for multiple stakeholders. 
Addressing public understanding of genomics in the context of healthcare is necessary to avoid 
                                                     
4 Adapted from: Malinowski J & Clayton EW. From pharmacogenetics and cancer to common, complex diseases: 
are we ready for precision medicine? (In preparation). 
 
5 Adapted from: Malinowski J & Naylor H. A rapid evidence review for the inclusion of genetic data in clinical 
care for a common, complex disease. (In preparation). 
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genetic-based discrimination, genetic determinism, and conflation of genetic ancestry with complex 
social constructs of race/ethnicity. This chapter will describe the scientific, systemic, and social barriers 
to successful implementation of PM for complex disease in the clinical setting and consider how these 
challenges have been addressed for pharmacogenetics and cancer treatment.
 
Figure 8. Analytic framework for personalized medicine implementation for complex 
diseases. 
Analytic framework showing how personalized medicine might be used to screen asymptomatic individuals 
to identify at-risk individuals, allowing for early intervention to prevent disease, leading to improved health 
outcomes, but with risks from harms caused by both screening and the intervention. 
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Scientific issues 
 Challenges to implementation of PM for common, complex diseases in the clinical setting 
include a deficit of data on the analytic validity, clinical validity, and clinical utility of genetic tests for 
risk prediction of complex diseases. Genome-wide association studies (GWAS) have identified 
thousands of genetic variants associated with complex traits and common diseases but have not 
generally provided the data necessary to ascertain their benefit in a clinical setting. 
 
Analytic validity 
 Analytic validity refers to the ability of a genomic test to determine the presence or absence of a 
particular variant (Table 23) (National Cancer Institute at the National Institutes of Health 2012a). 
Accuracy and reliability are key measures of analytic validity. Accuracy refers to the ability of a test to 
measure a specific variant correctly; reliability refers to the ability of a test to yield the same answer 
when the test is repeated. Despite the importance of this information, little has been published in peer-
reviewed literature documenting the analytic validity of genetic tests (Sun et al. 2011). For example, a 
2007 review of the literature assessed genetic testing of cytochrome p450 polymorphisms in adults with 
depression to guide treatment decisions (Thakur et al. 2007).  This systematic review included 
MEDLINE and other databases, such as FDA documents, but found few of the studies compared their 
results to the “gold standard” of DNA sequencing or other methods such as polymerase chain reaction 
and restriction fragment length polymorphism or allele specific PCR (Thakur et al. 2007). Of the thirty-
seven studies which met their inclusion threshold, nine reports compared clinical genotyping of 
CYP2D6 SNPs to a reference standard, but only two studies compared to DNA sequencing (Thakur et 
al. 2007). This lack of data on the analytic validity of genetic tests has not since been adequately 
addressed.  
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Table 23. Glossary of selected terms. 
Analytic validity The ability of a laboratory test to accurately and reliably measure the 
property it is designed to measure(National Cancer Institute at the 
National Institutes of Health2012a). 
Clinical validity The accuracy with which a test predicts the presence or absence of a 
clinical condition or predisposition(National Cancer Institute at the 
National Institutes of Health2012c). 
Clinical utility The usefulness of the test and value of the information to clinical 
practice(National Cancer Institute at the National Institutes of 
Health2012b). 
Positive predictive value (PPV) The proportion of positive results of a given test that is truly 
positive(Gordis2009). 
Negative predictive value (NPV) The proportion of negative results of a given test that is truly 
negative(Gordis2009). 
Quality-adjusted life years (QALYs)  A measure of disease burden that takes into account quality of and 
length of time lived(Hyder and Morrow2006).  
Disability-adjusted life years (DALYs)  A measure of disease burden that is expressed by the length of time 
that is lost due to death or disability(Hyder and Morrow2006). 
Health-adjusted life expectancy (HALE)  A measure of life expectancy at birth given healthy and sick health 
states(Hyder and Morrow2006). 
Genotype The genetic constitution of an individual, collectively at all loci or at 
a single locus(Nussbaum, McInnes, and Willard2007). 
 
 The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working group 
was established in 2005 to extend the Analytic Validity, Clinical Validity, Clinical Utility, and Ethical, 
Legal, & Social Implications (ACCE) Project, a pilot study funded by the Centers for Disease Control 
and Prevention. The goal of EGAPP is to provide evidence-based evaluation of genomic data for use in 
clinical practice through a systematic review process, similar to the comprehensive evaluations 
completed by the US Preventative Services Task Force (USPSTF) for other clinical services (EGAPP 
Working Group 2014). The EGAPP evaluations methodically review the peer-reviewed literature and 
other sources (e.g., industry white pages, government documents) to identify the analytic and clinical 
validity of genetic tests and the clinical utility of these tests in a medical setting. The rigor of the 
literature and potential bias are also considered (Teutsch et al. 2009). A recent article outlining the 
challenges and successes of the Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) Working Group noted the dearth of publicly available data upon which to establish analytic 
validity (EGAPP Working Group 2014). With a lack of substantive data, the inherent trust in the 
 96 
 
analytic validity of genetic tests can lead to erroneous interpretations in the clinical setting, and may 
lead to negative patient outcomes (Baggerly and Coombes 2011). 
Clinical validity 
 Clinical validity refers to the accuracy with which a test predicts the presence or absence of a 
clinical condition/disorder (Table 23). For genetic tests, it is the predictive value of the genetic variant 
for the disorder: what is the probability that someone with a particular variant has the disorder? 
Several scientific factors determine the clinical validity of genetic information in personalized medicine 
initiatives. Genome-wide association studies (GWAS) have built upon earlier genetic studies, including 
linkage analysis and family studies, and uncovered thousands of loci associated with hundreds of 
phenotypes. Recently, these GWAS findings have been applied to determine risk for hundreds of 
complex traits and disorders by direct-to-consumer genetic testing companies, such as 23&Me. 
However, these associations may not be the causal variants responsible for expression of the phenotype 
or disease, nor may they identify the biologic mechanism responsible for increased disease risk 
(EGAPP Working Group 2014). This complicates building an accurate and complete risk model for the 
disease using GWAS findings. Additionally, complex diseases result from the interplay of genetics and 
environment. The relative contributions each makes to the development of disease is specific for each 
disorder and have yet to be fully elucidated, affecting the clinical validity by varying the predictive 
ability of the genetic information (Table 23).  Genetic heterogeneity, where multiple variants may cause 
a disorder, and incomplete penetrance, where there is variation in the expressivity of the disease, 
further undermine the predictive abilities of genetic tests. Furthermore, intervention in the context of 
personalized medicine takes place at the individual level, while most genotype-phenotype associations 
arise from population studies. This changes the role of genetics from deterministic to probablistic, 
leading to a measure of uncertainty in the relationship between the genetic information and disease 
risk. 
 Positive predictive values (PPV), the area under the receiver-operating characteristic curve 
(AUC), and clinical validity (Table 23) are important, and to-date, mostly missing pieces of data, 
essential to demonstrate the utility of genetic information in implementation of personalized medicine 
in the clinical setting. The PPV and other metrics such as the sensitivity, specificity, and negative 
predictive value (NPV) can be calculated using a 2x2 table (Table 24). For example, the sensitivity of a 
test is measured by the ratio of true positives and all those who are disease positive (a/a+c); the 
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specificity is the ratio of true negatives and all those who test negative (d/b+d) (Table 24). The PPV is 
the ratio of individuals with the genetic variant who have the disorder and the total number of 
individuals who test positive (including those without the disease) (a/a+b). Consider two scenarios: in 
the first, the disorder is rare with a 0.5% population prevalence (Appendix T); and in the second, the 
disorder is more common, with a population prevalence of 8.3%, similar to the prevalence in the 
general public of type 2 diabetes (T2D)(Centers for Disease Control and Prevention 2012) (Appendix 
U).  If we assume the tests we perform have high sensitivity and specificity (99% each), the PPV of the 
test will depend on the population prevalence of the disorder. In the first example, the low population 
prevalence results in a PPV = 0.33, while the increased prevalence in the second example results in a 
higher PPV = 0.92.  This strategy for calculating the PPV of a test for a particular disorder works well 
when the test provides a dichotomous outcome. For some disorders, such as Huntington’s disease, a 
genetic test can yield a true positive or negative outcome and calculating the PPV of a test for the 
disorder can be done using a 2x2 table. A PCR-based assay for Huntington’s disease has a PPV of close 
to 1.00 for CAG repeats ≥40 (Saft, Leavitt, and Epplen 2014).   
 
Table 24. Calculating specificity, sensitivity, positive and negative predictive values for genetic tests 
using a 2x2 table. 
Variant Disease (+) (-) Total 
 (+) True Positives 
(a) 
False 
Positives (b) 
a+b 
(-) False 
Negatives (c) 
True 
Negatives (d) 
c+d 
Total a+c b+d a+b+c+d 
PPV=a/(a+b)   NPV=d/(c+d) 
Abbreviations: positive predictive value (PPV), negative 
predictive value (NPV). 
 
 
 For complex diseases, such as T2D or cardiovascular disease (CVD), as lifetime risk and/or 
population prevalence increases, the upper limit on the predictive capacity of genetic data may 
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decrease (Dreyfuss et al. 2012). This is unsurprising considering the other factors that come into play 
with common, complex diseases: the relative contribution of the environment to the disorder, genetic 
heterogeneity, incomplete penetrance, complex inheritance patterns, gene-environment interactions, 
and variable expressivity. Therefore, calculating the PPV of a genetic test for a common, complex 
disorder using the traditional 2x2 tables may not be the most appropriate method (Janssens et al.2006). 
The area under the receiver operator characteristic (ROC) curve (AUC) yields the accuracy of a 
continuous test to discriminate those who will develop the disease from those who will not and may be 
used for genetic tests as a measure of clinical validity (Wray et al. 2010).  The measure of a test that 
perfectly discriminates between those who will develop disease and those who will not will have an 
AUC = 1.00, while a test that performs no better than random chance will have an AUC = 0.50 (Figure 
9) (Wray et al. 2010). Calculating the maximum AUC to determine the clinical validity of a given 
genetic test for a common, complex disorder requires the genomic architecture of a disease be 
understood and the genetic variance completely explained by the variants tested. Complex genomic 
architecture that is unaccounted for will decrease the AUC (Wray et al. 2010).  For any two disorders 
with the same population prevalence, the AUC will be higher (and the genetic test more predictive of 
disease status) for the disease with the greater genetic contribution relative to the environmental 
component (Wray et al. 2010). Similarly, for any two disorders with the same heritability measurement, 
the AUC will be higher for the disease with the lower population prevalence (Wray et al. 2010).  Thus 
far, the variance explained by genetic associations identified through GWAS is small for common 
diseases with complex genetic architecture and often undetermined environmental component. 
Therefore, the effective AUC is likely to be much lower than the maximum AUC for any genetic test for 
common, complex disorders.  
 This suggests a potential trade-off in the benefit of genetic testing for complex disease in a 
clinical setting. Screening all patients who come to a clinic or medical center for a complex disease with 
moderate-to-high prevalence and complex genetic and environmental architecture will reduce the 
predictive value of an individual genetic test. In the context of PM used to predict disease risk, 
institution-wide screening would result in many false positives and the value of the genetic 
information would differ based on the prevalence of the disease considered. Evaluating only patients 
who have already been identified as ‘at risk’ is not ideal, either. This method would lead to decreased 
negative predictive value (NPV, Table 23) as initial risk scores fail to capture 100% of the at-risk 
population. Additionally, this method would reduce some of the potential benefit ascribed to PM: 
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namely, that PM could allow you to identify at-risk individuals prior to the development of risk 
factors/symptoms. 
Clinical utility: interventions and patient behavior 
 The clinical utility of a test broadly refers to the ability of the test (screening or diagnostic) to 
inform clinical decision making, generally in comparison to the current test or case management 
(Grosse and Khoury 2006; Bossuyt et al. 2012).  For genetic tests used as a screening mechanism to 
identify at-risk individuals for common diseases, there must be recognized interventions available to 
ameliorate disease risk. These interventions may be clinical in nature, such as more frequent lab tests, 
or behavioral, such as smoking cessation. When the genetic test is used as a diagnostic tool, such as in 
cancer treatments or pharmacogenomics, the intervention is the alternate treatment. For both screening 
and diagnostic genetic tests, comparing the outcome from the standard treatment absent the genetic 
Figure 9. Receiver-operator characteristic curve of hypothetical genetic tests for complex 
diseases. 
Area under the receiver-operator characteristic (ROC) curve (AUC) to determine accuracy of genetic tests. Blue 
line (bottom) represents an uninformative genetic test with AUC=0.50. Red line (top) represents an informative 
genetic test with AUC=0.869. 
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information to the course with the information is essential. A lack of clearly stated, measurable health 
outcomes makes determining the utility of personalized medicine challenging (Botkin et al. 2010). 
Borrowing from epidemiology and public health research, health-adjusted life expectancy (HALE), 
quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) (Table 23) may be of use 
to researchers addressing personalized medicine outcomes in large populations. Additional 
quantitative outcomes may include: cost-effectiveness analyses, time to diagnosis of disease from onset 
of symptoms, number of tests needed to diagnose disease, clinical measurements (e.g., lab values, 
BMI), symptom severity, and dose of medication required to maintain appropriate lab values. 
Qualitative data may also contribute meaningfully to health outcomes research in personalized 
medicine. These may include psychosocial measures such as lifestyle changes and patient/clinician 
perspectives. These valuable measurements will provide the foundation for clinical utility research in 
PM; though thousands of genetic variants have been associated with hundreds of clinical traits and 
diseases, few of them have been evaluated in this context. Electronic health records may facilitate this 
research by aiding risk model algorithm development, prescription information, and the ability to 
follow patients over the course of many years. Determining the clinical utility of genetic variants for 
complex diseases could be accomplished through EGAPP, evidence-based practice centers, or 
translational scientists. The EGAPP working group has repeatedly determined there is insufficient 
evidence to recommend genetic testing to improve health outcomes for several diseases; however, they 
have completed fewer than a dozen studies thus far, and it may be premature to draw broad 
conclusions from their work (EGAPP Working Group 2014). 
  Cost-utility analysis (CUA) is one type of cost-effectiveness study that integrates economic 
costs with health outcomes using QALYs (Phillips et al. 2014). A recent analysis of fifty-nine published 
CUAs for PM tests found gene expression profile tests for breast cancer to be the most common 
(Phillips et al. 2014). The majority of tests evaluated by Phillips et al. provided improved health 
outcomes; however, this was countered by increased costs (Phillips et al. 2014). Less than 25% of the 
CUAs evaluated demonstrated cost-savings and 8% had increased costs while failing to demonstrate 
improvements in outcomes (Phillips et al. 2014). An additional challenge to accurately assessing the 
costs associated with PM programs is that many economic evidence studies rely on statistical modeling 
with hypothetical cohorts (Lieberthal 2013). A recent review by Lieberthal found most literature on the 
economics of genomic testing for women with breast cancer relied on modeling with hypothetical 
cohorts for their analyses (Lieberthal 2013). Cost-effectiveness studies in pharmacogenomics also use 
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hypothetical cohorts and statistical modeling (Pink et al. 2014; Paulden et al. 2013; You et al. 2012).  
Utilizing clinical trials data to generate the cost-effectiveness data needed of genetic tests would 
provide an accurate representation of the costs in real-world scenarios; however, the overall dearth of 
comparative effectiveness research or clinical utility data for genetic tests performed for risk prediction 
of common, complex diseases is likely to remain a major barrier to necessary cost-effectiveness studies 
for PM (Lieberthal 2013; Garber and Tunis 2009). 
 Despite the lack of data demonstrating clinical utility for inclusion of genetic information in 
clinical care, several studies have evaluated research participants’ lifestyle changes and opinions about 
the personal utility of genetic information for complex disease risk. Little behavioral change has been 
observed in a survey of young adults given hypothetical risk scenarios for CVD, T2D, and stroke 
(Vassy et al. 2013). High-risk genetic results were associated with increased likelihood that individuals 
would alter their diet and exercise behavior; however, this response was mitigated by poor nutrition 
and physical activity at baseline (Vassy et al. 2013).  Several studies have examined the impact of 
genetic information of on smoking cessation (Lerman et al. 1997; Audrain et al. 1997; McBride et al. 
2002; Ito et al. 2006; Carpenter et al. 2007). Lerman et al. found initial differences in perceived risk of 
lung cancer and benefits to smoking cessation in smoking participants given risk information about 
genetic susceptibility to lung cancer compared to participants not given genetic risk information; 
however, these differences were no longer observed at the two-month follow-up (Lerman et al. 1997). 
Long-term follow-up in this cohort failed to identify significant differences in actual smoking cessation 
between the groups, though subjects who had been given their genetic susceptibility were more likely 
to have attempted quitting (Audrain et al. 1997). More recent studies continue to support a lack of 
significant changes in long-term smoking behavior attributable to the participant’s knowledge of 
genetic susceptibility to smoking-associated disease (McBride et al. 2002; Carpenter et al. 2007; Ito et al. 
2006). 
 A 2011 study by Roberts et al. examined the perceived clinical utility of APOE testing for risk of 
Alzheimer’s disease among the Risk Evaluation and Education for Alzheimer’s disease (REVEAL) 
Study participants (Roberts, Christensen, and Green 2011). Roberts et al. chose Alzheimer’s disease as a 
model for other common, complex disorders, because of similarities in the low predictive value of 
genetic risk factors identified via GWAS, increased population prevalence of risk alleles compared to 
rare Mendelian variants, and the availability (at that time) of direct-to-consumer genetic testing which 
provided a risk assessment for the disorder (Roberts, Christensen, and Green 2011). The authors 
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identified several purposes driving study participation, including the opportunity to consider long 
term care insurance, the impact on personal affairs, and the ability to prepare oneself and family 
emotionally for disease development (Roberts, Christensen, and Green 2011). Despite the lack of 
medical interventions to reduce Alzheimer’s disease risk, participants believed the genetic information 
to be valuable (Roberts, Christensen, and Green 2011).  
 Colorectal cancer is a complex disease with both genetic and environmental risk factors, such as 
lack of physical activity, low vegetable and fruit intake, obese and overweight BMI, and alcohol or 
tobacco use(Centers for Disease Control and Prevention 2014). Graves et al. evaluated response to 
genetic SNP testing for CRC risk in male and female primary care patients (Graves et al. 2013).  
Participants received genetic counseling pre- and post-test; post-test materials included lifetime risk 
assessments based on their genetic test results, family history, and other risk factors.  Subjects were 
assessed for their emotional distress, comprehension of lifetime risk estimates, lifestyle changes, 
disclosure of results to family, and contact with physicians or colorectal cancer screenings (Graves et al. 
2013).  This study found no distress among participants after learning of their genetic test results and 
limited (28% of study participants) disclosure of the results to physicians (Graves et al. 2013).  
Participants reported increased physical activity and healthy eating post-test (Graves et al. 2013), 
though self-report of exercise, diet, and traits like BMI may be subject to bias (Wen and Kowaleski-
Jones 2012; Warren et al. 2010).  
 Others have observed an increase in risk-reducing behaviors following DNA based risk 
information (Watson et al. 2004; Johnson et al. 2002; Botkin et al. 2003; Schwartz et al. 2002). REVEAL 
study participants with APOE ε4 alleles who are at increased risk for developing Alzheimer’s disease 
were more likely to have indicated lifestyle changes specific to Alzheimer’s disease prevention (e.g., 
diet, exercise) than those without the ε4 alleles (Chao et al. 2008; Vernarelli et al. 2010).  These data and 
others (Bloss et al. 2013; Bunnik, Janssens, and Schermer 2014)  suggest individuals may obtain 
personal utility from learning of their genetic risk for complex disease. Bunnick et al. described the 
personal utility of genetic testing to include reproductive and lifestyle planning and psychological 
benefit of “knowing” genetic risk (Bunnik, Schermer, and Janssens 2011).  A follow up study in the 
Scripps Genomic Health Initiative group found that participants generally felt no long term distress 
related to their genetic testing and believed the test to be of high personal utility, though there was little 
change for those at risk in fat intake or exercise compared to pre-test levels (Bloss et al. 2013).  
 A 2006 paper that modifies Leventhal’s common-sense model (CSM) of self-regulation of health 
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and illness (Leventhal et al. 1997) may provide a basis for the lack of consistent, observable risk-
reducing behaviors when individuals are given genetic risk information (Marteau and Weinman 2006). 
This self-regulation theory suggests individuals cope with information about health threats based on 
their pre-existing beliefs and how the new information fits within their belief structure. Extending this 
framework to a personalized medicine context, patients may decide to act in a clinically meaningful 
way when provided genetic risk information based on their perception of the health risk, their 
perception of the likely effectiveness of the suggested behavior change, and their confidence in their 
ability to perform the behavior (De Wit and Stroebe 2004). The physician and patient perception of the 
health threat may differ, particularly when the connection between the risk-reducing behavior and the 
health threat are abstract (Marteau and Weinman 2006). If patients perceive death from cancer to be a 
greater and more significant threat than death from cardiovascular disease, they may be more willing 
to modify their behavior to reduce the perceived threat of cancer. This may partly explain the 
discrepancy among study outcomes. 
 With complex diseases, the lack of consistent, observable risk-reducing behaviors following 
genetic testing may also stem from a general inability to integrate multiple pieces of information 
(French et al. 2002; French et al. 2000). Patients may be less likely to believe that a DNA test can 
accurately predict disease risk for common diseases with genetic and environmental contributions 
and/or complex genetic architecture (e.g., genetic heterogeneity, variable expressivity) (Michie et al. 
2003; Michie et al. 2002). The weight a patient assigns to the genetic and environmental contribution to 
disease risk may also play a role in whether or not the patient engages in risk reducing behavior after 
learning of their genetic risk.  If a patient perceives that the genetic component to disease risk 
outweighs the environmental or modifiable contribution, they may be less likely to engage in risk-
reducing behaviors; the CSM suggests this is due to an imbalance between perceived cause of health 
threat and the related coping procedure (Marteau and Weinman 2006).  
 For some individuals, belief that both genetics and the environment contributed to the 
development of familial adenomatous polyposis (FAP) made them less likely to believe a genetic test 
could accurately predict their risk of FAP (Michie et al. 2002). Comparing individuals who expected to 
undergo colonoscopy screening for FAP with those who did not plan to, genetic tests were less likely to 
be perceived as extremely accurate in those who planned to have bowel screenings and those 
individuals were more likely to attribute the cause of FAP to behavioral factors (Michie et al. 2002). 
Though both environmental and genetic factors contribute to psychiatric disorders, the stigma 
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associated with mental illness often prevents affected individuals from seeking professional treatment 
(Corrigan 2004). The Genes, Disease, and Stigma (GDS) Study and the MacArthur Mental Health 
Module of the 1996 General Social Survey were analyzed to identify potential associations between 
participants’ beliefs about the role of genetics in mental illness etiology and the perceived effectiveness 
of treatment  for depression and schizophrenia (Phelan, Yang, and Cruz-Rojas 2006). Individuals 
attributing genetic factors to the cause of the illness were more likely to recommend prescription 
medication or psychiatric hospitalization for treatment than those who did not believe the illness was 
caused by genetic factors (Phelan, Yang, and Cruz-Rojas 2006). Perceived effectiveness in treatment did 
not differ between depression and schizophrenia; however, in the GDS study, attributing genetic 
factors to the disorder significantly reduced belief in the effectiveness of the treatment (Phelan, Yang, 
and Cruz-Rojas 2006).  
 In families with familial hypercholesterolemia, individuals with genetic mutations who 
received routine clinical diagnosis and genetic testing trended toward stronger belief in the efficacy of 
cholesterol lowering medication and decreased belief that diet could reduce cholesterol levels (Marteau 
et al. 2004). However, a recent study evaluating participant trust in genetic risk assessment for T2D 
reported high levels of trust in the information (Mills, Barry, and Haga 2014). Mills et al. used surveys 
to assess participant understanding of genetic tests for risk prediction of T2D and attitudes about risk, 
test results, and method of result delivery (online through testing company website or in person via 
genetic counselor) (Mills, Barry, and Haga 2014).  The majority of participants perceived the benefit of 
genetic testing for T2D risk to be learning about healthy behaviors that could reduce risk for 
developing T2D to be very or somewhat important (98.8%) (Mills, Barry, and Haga 2014).  Accurate 
portrayal of the clinical validity and utility of genetic tests will likely improve patient perceptions in the 
context of assigning disease risk based on genotypes; patient attitudes toward the efficacy of lifestyle-
based interventions to minimize disease risk may be more challenging to change. To obtain improved 
health outcomes with PM for common, complex diseases, it will be necessary to use a multifaceted 
approach that broadens patients’ understanding of complex disease composition, provides concrete 
examples of disease risk, offers interventions that are acceptable to patients, and educates patients so 
their perceptions of disease risk and the benefit of risk-reducing behaviors more closely align to 
physician perspectives.   
Added value of genomic information with existing risk models 
 For complex diseases like CVD or T2D, physicians can use established risk models based on a 
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combination of variables (e.g., family history, anthropomorphic traits such as body mass index, and lab 
values) to predict the likelihood of developing the disorder in a future time period. For PM to be 
widely implemented, clinicians need to demonstrate that adding genomic information to a risk model 
improves the model’s ability to distinguish those who will remain unaffected from those who will 
become affected, or provides incentive to those who are genetically at risk of developing the disease to 
make behavioral changes to minimize risk. T2D has an estimated prevalence of 9.3% and is responsible 
for an estimated $174 billion in direct and indirect costs in the United States (Sheehy, Coursin, and 
Gabbay 2009). Risk prediction for T2D is not generally a part of routine clinical practice; however, 
lifestyle interventions have been shown to reduce the development of T2D in high risk individuals 
(Knowler et al. 2002; Teufel and Ritenbaugh 1998) and the development of complications (Sheehy, 
Coursin, and Gabbay 2009), supporting the utility of identifying at-risk individuals prior to the 
development of disease. For healthy individuals, the Cambridge and Framingham risk score 
algorithms predict risk of developing T2D based on routinely collected clinical data and information, 
such as parental history of T2D, sex, and body mass index (BMI) (Rahman et al. 2008; Wilson et al. 
2007). In a study by Talmud et al., using the prospective Whitehall II cohort, adding the known genetic 
associations with T2D to the Framingham and Cambridge risk scores did not significantly improve the 
predictive ability of those models (Talmud et al. 2010). Notably, the predictive ability of the genetic 
information alone yielded an AUC of 0.54, far below that of the Framingham risk model (AUC=0.78) or 
Cambridge risk model (AUC=0.72) (Talmud et al. 2010). These data suggest including genetic data in 
clinical practice for T2D yields limited benefit for the prediction of disease development (Clayton 2009).    
 Cardiovascular disease is another complex disease with significant morbidity, mortality, and 
associated economic costs.  The Framingham Risk Score (FRS) is a well-known model that includes 
variables such as age, sex, BMI, smoking status, and cholesterol levels to predict the 10 year risk of 
developing cardiovascular disease (D'Agostino, Sr. et al. 2008). Similar to the findings in the Talmud et 
al. paper for T2D, adding genetic variants to the FRS model has not consistently improved 
discrimination in several studies (Brautbar et al. 2012; Hughes et al. 2012; Talmud et al. 2008). These 
studies indicate that using genetic variants, which have previously been associated with disease in 
GWAS, to predict complex disease risk, does not generally prove as predictive as established risk 
scores based on easily obtainable clinical data. Furthermore, including the genetic component to these 
risk scores does not significantly improve the predictive ability of the risk score (Mihaescu et al. 2011; 
Wray et al. 2013). Though the added benefit of genetics in a risk model will likely differ substantially 
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across complex diseases, it is clear that for some, there is little evidence to suggest that this information 
is currently clinically useful.   
 A new study being performed in adult US Air Force primary care patients seeks to determine if 
health coaching with dissemination of genetic information leads to improved health outcomes for T2D 
and coronary heart disease (Vorderstrasse et al. 2013).  This study employs the modified CSM (Marteau 
and Weinman 2006) and considers patient response to genetic information using a variety of clinical 
measures (e.g., BMI, lipid profile) and surveys (Vorderstrasse et al. 2013).  Additional studies similar to 
Vorderstrasse et al., leveraging study techniques employed by social scientists and behavioral 
psychologists in addition to clinical measurements, would improve the ability of genetic researchers to 
calculate the added value of genetic information in current disease management. 
 
Evidence review for inclusion of genetic data in clinical care for hypothyroidism 
 A recent review by the EGAPP working group noted the challenge in implementing thorough 
reviews with limited resources and time, and the scant evidence for analytic validity, clinical validity, 
and clinical utility (EGAPP Working Group 2014). To address the lack of clinical validity and utility 
data, we investigated if a rapid evidence review could be performed in an academic setting to identify 
analytic evidence that inclusion of genetic data associated with common, complex diseases in clinical 
care improved health outcomes. Our goal was to establish a first-pass method to evaluate the evidence 
base for including genetic data in the clinical setting, which could be used to identify gaps in 
knowledge or to justify more comprehensive evidence reviews (Ganann, Ciliska, and Thomas 2010; 
Watt et al. 2008).  
 Until recently, consumers could bypass medical professionals and obtain their genetic data for 
carrier status and disease risk through direct-to-consumer (DTC) genetic testing providers, e.g., 23&Me. 
These DTC companies provided consumers’ estimated risks of developing more than one hundred 
disorders (e.g., T2D, CVD, hypothyroidism) and traits (e.g., male pattern baldness, response to the drug 
clopidogrel) (23&Me 2014a) with a goal of empowering their customers to use genetic data to improve 
their lives (23&Me 2014b). However, few variants identified through genome-wide association studies 
(GWAS) have been demonstrated to be actionable clinically as part of a screening mechanism. 
Candidate gene studies similarly lack accepted, clinically actionable results, though there are 
exceptions: pre-symptomatic risk assessment using genetic/genomic testing performed for breast 
cancer (BRCA1/2) (Robson and Offit 2007), screening for Lynch syndrome hereditary colon cancer in 
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family members of those recently diagnosed with the disease (MLH1, MSH2, MSH6, PMS2) (2009), and 
long QT interval (KCNQ1, KCNH2, SCN5A) (Napolitano et al. 2005). Well-documented obstacles to 
expanded implementation of PM are the unknown risks and benefits in the clinical setting, lack of 
clinical validity and utility data (Teutsch et al. 2009; Palomaki et al. 2009b; Palomaki et al. 2009a; 
Palomaki et al. 2010; Palomaki et al. 2013),  and the challenge of incorporating multiple causes (genetic, 
environmental, behavioral) in a risk prediction model (Wray et al. 2013). 
 For this study, we selected a common, complex disease, hypothyroidism and related 
quantitative trait, serum thyroid stimulating hormone (TSH) levels, both with numerous genetic 
associations identified through GWAS (see Chapter I). Diagnosis of hypothyroidism involves 
measuring TSH levels in the blood; elevated TSH levels may indicate hypothyroidism. TSH levels vary 
across individuals, with higher mean TSH levels observed in non-Hispanic whites than in Mexican 
Americans or non-Hispanic blacks (Hollowell et al. 2002); however, within an individual, TSH levels 
are tightly regulated (Hollowell et al. 2002; Arnaud-Lopez et al. 2008; Chiamolera and Wondisford 
2009). Environmental and genetic factors influence TSH levels and risk for hypothyroidism. Increased 
body mass index (BMI), smoking, pregnancy, and physical and emotional stress are all risk factors for 
elevated TSH levels (Brix et al. 2000; Jorde and Sundsfjord 2006; Nyrnes, Jorde, and Sundsfjord 2006). 
Several genes have been implicated in hypothyroidism (FOXE1, PTPN22, VAV3, and the HLA region) 
(Eriksson et al. 2012; Denny et al. 2011) and serum TSH levels (PDE8B, CAPZB, NR3C2) (Panicker et al. 
2010; Rawal et al. 2012; Porcu et al. 2013; Malinowski et al. 2014(in press)). Symptoms for 
hypothyroidism are generally nonspecific and include fatigue, sensitivity to cold, unexplained weight 
gain, and depression (Dubbs and Spangler 2014). Left untreated, hypothyroidism may lead to goiters 
which can affect appearance and breathing/swallowing, heart problems, depression, peripheral 
neuropathy, infertility, and myxedema (Dubbs and Spangler 2014). Untreated hypothyroidism during 
pregnancy may lead to adverse maternal and fetal outcomes, including recurrent miscarriage and birth 
defects, and though screening high-risk pregnant women is advocated, universal screening is 
controversial (Nathan and Sullivan 2014; Dosiou et al. 2012). 
 
Methods 
 We began our review by identifying a clinical scenario to guide the process. The clinical 
scenario focuses on women of childbearing age (18-55) in the general (not high-risk) population being 
offered a genetic test to assess their risk for developing hypothyroidism. These women would be 
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asymptomatic, or be unrecognized as having symptoms, of hypothyroidism and therefore, be unlikely 
to have their TSH levels checked during a routine clinic visit. The proposed clinical utility for testing is 
to improve health outcomes in women of childbearing age by identifying those who are at risk for 
developing the disease.  Identification of at-risk individuals based on genetic information could lead to 
1) regular TSH level testing, potentially minimizing the lag time between development of symptoms 
and a diagnosis of hypothyroidism and treatment; 2) knowledge of health behaviors, such as smoking, 
some medication use, and maintaining a healthy BMI, that can be changed to reduce the risk of 
developing hypothyroidism; 3) reduction of miscarriages and/or birth defects caused by 
undiagnosed/untreated hypothyroidism prior to conception and during the prenatal period. This 
review addressed the overarching question: “Does the genotyping of variants previously associated 
with hypothyroidism in adult, asymptomatic women of reproductive age (18-55), lead to improved 
health outcomes?” 
 The ACCE framework used by the CDC EGAPP (Teutsch et al. 2009) working group was used 
as a reference to perform this rapid review. The disease hypothyroidism was selected as an example of 
a common, complex disease with numerous genetic associations identified through genome-wide 
association studies (GWAS) that might be a candidate for personalized medicine initiatives in a clinical 
setting. The variants selected for this were those used by a direct to consumer genetic testing company 
to provide their customers risk of developing hypothyroidism (Table 25). The general stages of a 
systematic evidence review were followed. In collaboration with an information scientist in knowledge 
management at the Vanderbilt University Medical Center (VUMC) Eskind Biomedical Library (EBL), 
an overarching research question was developed based on similar questions from previous evidence 
reviews, generally following the PICOTS (population, intervention, comparator, outcome, timing, 
setting) method. Key questions were formulated to identify the analytic validity, clinical validity, and 
clinical utility of genetic tests for those variants. Additional questions were created to identify evidence 
of improved health outcomes tied to the genetic tests and relevant ethical, legal, or social issues (ELSI) 
associated with genetic testing for hypothyroidism. A comprehensive PubMed search for citations was 
developed incorporating Medical Subject Heading (MeSH) terminology and search results exported for 
abstract and full text reviews. Citations were included in this rapid review if they were included in the 
PubMed search results as of August 2013 and were written available in English. 
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Table 25. Variants selected for inclusion in rapid evidence review. 
Variant Gene GWAS Study OR P-value 
rs7850258 FOXE1 Denny,J.C., 2011 0.74(A) 3.96x10-9 
rs2476601 PTPN22 Eriksson,N., 2012 1.36(A) 3.9x10-13 
rs3184504 SH2B3 Eriksson,N., 2012 0.84(C) 2.6x10-12 
rs4915077 VAV3 Eriksson,N., 2012 1.30(C) 7.5x10-10 
rs2517532 HLA region Eriksson,N., 2012 0.86(A) 1.3x10-8 
Shown are single nucleotide polymorphisms selected for inclusion in a rapid 
evidence review of genetic data for hypothyroidism in a personalized medicine 
program in a clinical, but asymptomatic and low-risk, population. Variants were 
previously used by 23&Me to report risk for developing hypothyroidism to their 
clients. Listed are the SNP rs number, nearest gene to the SNP, GWAS study first 
author and year of publication, odds ratio (OR) and allele, and p-value.  
 
 Study data were collected and managed using REDCap electronic data capture tools hosted at 
Vanderbilt University Medical Center (Harris et al. 2009). REDCap (Research Electronic Data Capture) 
is a “secure, web-based application designed to support data capture for research studies, providing 1) 
an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export 
procedures; 3) automated export procedures for seamless data downloads to common statistical 
packages; and 4) procedures for importing data from external sources” (Harris et al. 2009). An abstract 
review was performed independently by two reviewers. After the first 50 search results were reviewed, 
concordance was evaluated between reviewers to identify key questions that could be misinterpreted 
and discrepancies were resolved by discussion. Concordance was again evaluated at the halfway point 
of the abstract review. Citations without abstracts or instances where the reviewers selected “cannot 
determine” answers for any of the key questions were automatically passed through to the full text 
review.  A full text review was performed on the citations for which full text articles were available to 
the two reviewers either in print, or electronically. Concordance was evaluated after the first 50 articles 
had been reviewed to assure interpretation of the questions was consistent. A third reviewer was 
available for the full text review for discordant reviews. Branching logic was used in REDCap for full 
text review questions; the first non-affirmative answer for a question provided by the reviewer 
prompted questions pertaining to the next key question. The survey was ended when no further 
affirmative answers were provided by the reviewer (Figure 10). Data from the full text review was 
exported from REDCap (Harris et al. 2009) to Stata (Boston and Sumner 2003). 
 Studies were excluded from final analysis on the basis of several factors: inclusion of pediatric 
samples in the study without stratification or statistically adjusting for age, inclusion of male samples 
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in the study without stratification or statistical adjustment for age, failure to include race/ethnicity 
information about the sample, small sample size (n<10), or inclusion of thyroid cancer samples in the 
study without stratification. Additional exclusion criteria included failure to provide effect sizes/odds 
ratios, positive predictive values (PPV) or area under the receiver-operator characteristics curve (AUC) 
for the genetic variant. Studies that did not address the key questions in any way were also removed 
from analysis. 
Results 
 This rapid review was started in August 2013 and completed in March 2014. Specific variants 
were selected for evaluation as they had been used previously by a direct to consumer genetic testing 
company to report risk of developing hypothyroidism (23&Me 2014a). A total of 631 citations were 
obtained from the search query and their abstracts were reviewed using a REDCap database 
specifically set up for this project; 346 articles were moved forward to full text review (54.9%). No 
articles were accepted after full text review for further analysis (Table 26). Twenty-five articles were 
unavailable through open-access publications, EBL electronic subscription, or in-print at EBL (7.2%) 
(Table 26).  One article was eliminated due to inclusion of samples with thyroid cancer and three were 
removed due to low sample size (n<10) (Table 26). The majority of articles were excluded due to the 
study’s focus not providing information corresponding to one of our key questions (65.0%) (Table 26). 
Fourteen of the articles fully reviewed provided odds ratios but not positive predictive values or AUC 
for the genetic variant (4.0%) (Table 27). No articles addressed the ethical, legal, or social issues (ELSI) 
of genetic testing for hypothyroidism risk in asymptomatic women of childbearing age (18-55). We 
found no evidence that genetic testing of five SNPs improved health outcomes for this clinical 
population.
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Figure 10. Flowchart for rapid evidence review. 
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Table 26. Number of studies excluded in full text review. 
Reason for removal Count (n) 
Full text unavailable 25 
Study included pediatric samples (age ≤17), age not adjusted for or pediatric results reported 
separately 
22 
Study included males, sex not adjusted for or male results reported separately 47 
Study excluded due to small sample size (n<10) 3 
Study excluded due to race/ethnicity not adjusted for or results stratified by race/ethnicity 5 
Study excluded because sample included individuals with thyroid cancer, results not stratified 
by cancer status 
1 
Study excluded because no effect sizes/odds ratios given 3 
Study excluded because no positive predictive values/AUC given 15 
Study excluded because study did not address any of the key questions of the rapid evidence 
review 
225 
 
 
Table 27. List of studies providing ORs/effect sizes for genetic variants associated with 
hypothyroidism/TSH levels. 
First author, year of 
publication 
Type of study Study outcome Variants reported p-value 
Petrone, A.; 2001 candidate gene Hashimoto’s 
thyroiditis 
HLA region <0.05 
Terauchi, M.; 2003 candidate gene Hashimoto’s 
thyroiditis 
HLA region <0.01 
Brix, T.H.; 2005 candidate  Hashimoto’s 
thyroiditis 
X-inactivation n.s. 
Hansen, P.S.; 2007 candidate gene TSH levels TSHR 0.007 
Panicker, V.; 2008 linkage scan TSH levels 2q36, 4q32, 9q34 LOD 2.1-3.2 
Arnaud-Lopez, L.; 
2008 
GWAS TSH levels PDE8B 1.3x10-11 
Panicker, V.; 2008 candidate gene TSH levels DIO1 n.s. 
Panicker, V.; 2010 GWAS TSH levels CAPZB 3.2x10-8 
Volpato, C.B.; 2011 linkage, association TSH levels PDE10A LOD 2.66 
Denny, J.C.; 2011 GWAS,meta-analysis hypothyroidism FOXE1 3.96x10-9 
Eriksson, N.; 2012 GWAS hypothyroidism FOXE1, PTPN22, 
SH2B3, VAV3, HLA 
region 
2.4x10-19, 2.8x10-13, 
2.6x10-12, 7.5x10-10, 
1.3x10-8  
Rawal, R., 2012  meta-analysis TSH levels PDE8B, CAPZB, 
NR3C2, LOC440389 
2.79x10-27, 1.54x10-
8, 2.88x10-10, 
5.63x10-10 
Piacentini, S., 2013 candidate gene hypothyroidism GSTO2 0.009 
Porcu, E., 2013 meta-analysis TSH levels * * 
Data shown are the studies that provided odds ratios (ORs) or effect sizes and level of significance for an association 
between the variants reported and either hypothyroidism or serum thyroid stimulating hormone (TSH) levels. *Porcu 
et al. reported 26 independent associations with TSH. The associations and corresponding p-values can be found in 
Porcu E. et al., PLoS Genet 2013; 9(2):e1003266 doi: 10.1371/journal/pgen.1003266 Abbreviations: n.s.: not significant; 
TSH: thyroid stimulating hormone 
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Summary for rapid evidence review 
 This rapid review sought to identify analytic evidence that the inclusion of genetics in routine 
clinical care for common, complex disorders improves health outcomes. We generally followed the 
ACCE/EGAPP method for an evidence review with several key differences. Only one database was 
searched (Medline through PubMed) for pertinent articles and the breadth of the search was limited to 
articles with the clinically relevant patient population to allow for faster applicability in the medical 
setting. Two reviewers performed the abstract and full text reviews, though an additional reviewer was 
available as necessary. This review was completed in seven months over two academic semesters, with 
both reviewers working part-time on this project. Potential bias and the quality of evidence of the 
studies were not graded. Several potential analytic frameworks were considered for this rapid review: 
ACCE, Fryback-Thornbury, USPSTF framework for Screening, and the EGAPP framework. A 
combined ACCE/EGAPP structure was deemed the most appropriate framework to use with genetic 
studies and has been used successfully for several EGAPP projects, uses an analytic framework to 
visually address how the genetic test could lead to health outcomes, and incorporates key components 
of both the USPSTF and Fryback-Thornbury models. Consistent recommendations for laboratories to 
publish analytic validation studies of their genetic tests in peer-review journals have been ignored and 
most genetic studies do not provide the analytic evidence (analytic validity, clinical validity, clinical 
utility) that is needed to evaluate PM policies using current frameworks as described above. If these 
important data continue to be lacking, it may be necessary to consider alternate methods to evaluate 
PM initiatives. 
 Several studies have addressed the lack of appropriate data upon which to base 
recommendations for or against genetic testing for various health conditions. We found that the 
analytic evidence supporting genetic testing in asymptomatic women of childbearing age for 
hypothyroidism risk to be inadequate. Few of the articles that were full text reviewed addressed our 
key questions. Though our key questions were very specific and failed to identify studies that met the 
criteria for inclusion, broadening the queries would have undesired consequences due to identification 
of superfluous studies. Generalizing the population of interest would fail to meet the updated Wilson 
and Jungner screening criteria proposed by Andermann et al. for a targeted screening population (see 
Chapter I, Table 1). The five genetic variants of interest were selected based on their use by a DTC 
genetic testing company to provide risk of developing hypothyroidism to their clients (23&Me 2014a). 
We considered variants published in other studies as well, based on knowledge of other genetic 
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associations with hypothyroidism and serum TSH levels, but did not find adequate evidence of clinical 
validity or utility for any. 
 Using our review, we identified deficits in the knowledge base that future genetic studies 
should address. First, the lack of substantive evidence demonstrating analytic and clinical validity must 
be corrected. As our rapid review considered only articles cited within PubMed, it is possible that a 
more comprehensive search including other databases, manufacturer’s websites, and other grey 
literature would provide the sensitivity, specificity, and predictive values for these variants for 
hypothyroidism. However, our results are consistent with others that have documented the same 
challenges to obtaining this crucial information using more comprehensive approaches. Replication of 
genetic associations should be undertaken in large, independent cohorts to identify which variants may 
be false positives and which are robust disease associations; meta-analyses are another method. This is 
of particular importance as many of the reported disease associations are for variants with relatively 
small effect sizes and may not be the causal variant affecting the disease process. Though the PPV is 
one metric used to evaluate the clinical validity of a test, for genetic testing in common, complex 
diseases, the area under the receiver-operator characteristic curve (AUC) may be a better measurement.  
 Second, the clinical utility of genetic information in PM for common disorders is unclear and 
likely varies by disease. Comparing health outcomes using the current screening model to one that 
includes genetic information is a key part of demonstrating the utility of PM. For the general 
population, screening practices for hypothyroidism by measuring TSH levels can vary by physician. 
Though screening of high-risk pregnant women for hypothyroidism is advocated and recent studies 
have shown universal screening to be cost-effective, universal screening of remains contested. 
Additional studies with clearly stated and measureable health outcomes will improve researchers’ 
ability to determine the utility of PM. Quantitative measurements such as quality-adjusted life years 
(QALYs) or disability-adjusted life years (DALYs) may be of use in studies evaluating PM initiatives in 
large populations. The use of electronic health records (EHRs) may make obtaining the necessary 
clinical and outcomes data easier. Qualitative data, such as surveys of symptom severity or change in 
patient behavior, can further inform clinical utility studies.      
 Additionally, it is important to consider how generalizable the results from genetic studies are 
to populations of diverse ancestry, particularly when there are disease prevalence differences. These 
disease burden variations may occur from differences in environmental or behavioral exposures to risk 
factors, may arise through differences in risk allele frequencies across populations, or some 
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combination of these. Understanding the true population risk is an integral part of implementing PM in 
the clinical setting.  
 Despite these negative results, our rapid review methodology serves as an example of 
deploying an evidence review in an academic setting to systematically identify the essential data 
required to accurately assess the utility of including genetic data to improve health outcomes for 
common, complex diseases. We have highlighted the gaps in knowledge preventing researchers from 
adequately assessing the use of genetic information in the clinical setting for complex disorders. Future 
genetic studies that include analytic evidence will benefit outcomes research and help policymakers 
determine the use of genetic data for precision medicine in the clinical setting. Rapid reviews such as 
this one can be a valuable first-pass to establish the need for a more comprehensive evidence review 
prior to setting policy. 
Ethical, legal, and social issues 
Impact on health care system 
 If PM is to be implemented in the clinical setting for common, complex diseases, the impact on 
the health system should not be overlooked. Data management, access to data/privacy issues, 
integration with existing electronic health records (EHR) and physician decision-support mechanisms 
must be comprehensively investigated. These factors and the costs required to implement such a 
program should be carefully weighed and cost-benefit analyses performed if widespread adoption of 
such programs is to expand beyond a few academic medical centers. 
Data management 
 The amount of data generated by whole genome sequencing (WGS), whole exome sequencing 
(WES), and genotyping arrays with >2 million SNPs is substantial. This leads directly to two issues: the 
cost and infrastructure required for generating and maintaining the data, and the time and human 
capital needed to analyze and translate the data for clinical use. Though the technological cost of WES 
and WGS are decreasing, the cost of data storage has not declined as dramatically (Baker 2010). Each 
WES run yields several terabytes of raw sequence data and hundreds of GB of stored data and WGS 
will increase substantially the amount of stored data (Kho et al. 2013). Some medical centers are 
pursuing technologies such as cloud computing for managing data and data analysis; however, legal 
regulations such as HIPAA and others may restrict the use of cloud technologies for restricted and 
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personal health information (Fusaro et al. 2011; Kuo 2011; Schadt et al. 2010; Rosenthal et al. 2010). 
Similar to the declining cost of WES and WGS, the time required to obtain genetic data has also 
declined, with WES results in <24 hours and WGS results in a few days (Kho et al. 2013). Analysis of 
well-characterized variants is not difficult with databases that link genotype and phenotype; however, 
curation of novel variants is time consuming (Famiglietti et al. 2014). In addition, periodic re-
examination of the pathogenicity and function of genetic variants should take place, as demonstrated 
by Das et al. where variants previously described as pathogenic were reclassified as benign or of 
unknown significance, and variants previously classified as of unknown significance were upgraded to 
pathogenic (Das et al. 2014). Though the analysis of genetic data has become more automated, it is 
unclear to what extent the cost to analyze and translate the data into clinically meaningful information 
will decline; this is likely to vary substantially by disease and current knowledge of genetic variants.     
Data privacy 
 From the health system’s perspective, data security and privacy are not only ethically 
appropriate, but legally required (Juengst 2014). Controlling data access and ensuring data privacy are 
key issues that must be addressed for successful implementation of PM, given the sensitive health 
information contained in patients’ EMRs. Current identification of data breaches in EHRs occurs post-
event through random audits; new methods are being developed that can predict inappropriate access 
using historical data (Menon et al. 2014; Fabbri and Lefevre 2013). Maintaining patients’ genomic data 
outside of the EHR with controlled access to the data is one method of minimizing inappropriate access 
(Hazin et al. 2013). As patients gain access to their EHRs through patient portals, medical centers will 
need to create policies centered on educating patients of their responsibilities for privacy and security 
of their health care data (Hazin et al. 2013). A recent mandate (Swain and Patel 2014) that providers 
allow patients access to their laboratory records may serve as a test for medical centers to navigate data 
access and privacy requirements when patients play a key role in keeping those data secure. State or 
local laws may additional limitations on access to genetic data that surpass the requirements of HIPAA 
and dictate segregation of certain types of health data within EHRs or require additional levels of 
patient consent before genetic data can be disclosed (National Human Genome Research Institute 
2014a). Data security and controlled access will likely remain an integral facet to PM’s impact on the 
health system. 
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Integration with existing EHRs 
 Increased use of EHRs can play a substantial role in PM implementation through enhanced 
communication between patients and clinicians, physician decision-support mechanisms, PM cohort 
identification, exchange of health information between providers, and by providing the necessary data 
upon which clinical validity and utility of PM initiatives can be measured (Kohane 2011; Boland et al. 
2013; Goldspiel et al. 2014; Middleton et al. 2013; Payne et al. 2013). With the quantity of genomic data 
generated from WES, WGS, and genotyping arrays, not all data is likely to be inserted into the EHR. 
Maintaining genomic data in an off-site repository and including only the data that directly informs 
clinical care is one method to control the burden of data storage, but raises ethical and legal issues 
(Hazin et al. 2013). A segmented system in which only certain individuals have access to some of the 
data may pose a challenge to PM practices (Hazin et al. 2013). Determining which clinicians and 
ancillary health professionals have access to the genomic data and when they may access it, is an 
important facet to utilizing this information in the clinical setting.  
 Integrating genomic information and disease risk prediction into EHRs will be an essential 
component to PM for common, complex diseases and will require both accessible genomic data and 
physician decision support mechanisms (Hazin et al. 2013). Design and implementation of EHRs for 
this purpose should involve multiple stakeholders, including patient, physician, and informatics 
representatives (Hartzler et al. 2013); input from these perspectives may improve patient participation 
in healthcare choices and physician buy-in to PM initiatives. EHR platforms may require substantial 
modifications be made so they can be used for PM (Kho et al. 2013). Where genomic data will reside, 
how it will be accessed through bioinformatics pipelines, and when physician decision-support 
mechanisms will initiate are key questions for health systems to address. This will require a substantial 
level of automation for data to be updated routinely and quickly (Schneeweiss 2014).  Though adoption 
of EHR technologies have become more widespread following the Health Information Technology for 
Economic and Clinical Health (HITECH) Act (Ancker et al. 2013; Blumenthal 2011), technological and 
logistical issues relating to the management and analysis of genetic data in EHRs remain a barrier for 
the application of PM for common, complex diseases (Shoenbill et al. 2014). 
Physician decision support 
 Decision-support should be integrated into clinical care without adding to physician burden 
(Schneeweiss 2014). Alert fatigue, ignoring/overriding decision-support messages, remains a 
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considerable barrier to PM (Ancker et al. 2014; McCoy et al. 2014); however, successful examples of 
decision-support systems have emerged in pharmacogenetics (Goldspiel et al. 2014; Pulley et al. 2012; 
Laerum et al. 2014). More importantly, physicians must feel adequately prepared and comfortable 
integrating genetic testing into clinical practice (Gray et al. 2014; Hazin et al. 2013; Haga et al. 2012). 
Decision-support mechanisms with access to corroborating research may help to alleviate physician 
uncertainty and improve physician confidence integrating genetic data in routine clinical care. 
Economic costs 
 The economic costs involved in PM programs encompass several areas: diagnostic tests and 
equipment, personnel, computing infrastructure, the costs associated with false-negative and false-
positive test results, and the costs associated with risk-reducing interventions. These costs may be 
balanced or outweighed by improved health outcomes and decreased future health care costs resulting 
from the PM program.  It is currently unclear at what point implementation of PM is a cost-effective 
strategy (Phillips et al. 2014). Given the public health burden of common, complex diseases such as 
CVD and T2D, effective PM could improve health care outcomes while reducing health care 
expenditures.  Multiple methods exist for calculating the cost-effectiveness of a test; cost-utility analysis 
(CUA) is one method that integrates health outcomes using QALYs (Phillips et al. 2014). Current CUAs 
focus primarily on pharmaceuticals, though CUAs of PM tests for cancer and pharmacogenetics are 
becoming more common (Phillips et al. 2014).  
  
Impact on society: the patient perspective 
 Similar to the issues health systems face, the patient perspective should also be considered if 
PM programs are to be expanded for common, complex diseases. Privacy and data access issues of 
EHRs from the patient’s perspective must be addressed to allay fears of misuse. If PM is expanded as a 
screening mechanism to identify risk for common disorders, a significant portion of the population will 
be exposed to complex and abstract genetic concepts that may require patient education or counseling 
to understand. Public knowledge of genetics and genomics, fear of discrimination based on genetics, 
misinterpretation that genetic ancestry is a proxy for social constructs of race/ethnicity are challenges 
that must be addressed for public acceptance of PM initiatives for common diseases. 
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Data privacy/access 
 Patient-centric concern over privacy of their health records and control over data mirrors 
privacy issues from the health system perspective.  Patient concern over privacy and data access is 
considered a barrier to successful implementation of EHRs (Boonstra and Broekhuis 2010; Barrows, Jr. 
and Clayton 1996). These concerns include data access management to prevent discrimination or 
unconsented re-use of data for research or commercial purposes (Caine and Hanania 2013). These 
concerns were identified in a cross-sectional survey of health consumers in New York (Abramson et al. 
2014). These survey participants perceived that use of EHRs would not improve security or privacy 
(Abramson et al. 2014). A 2013 issue of JAMIA presented several papers with a socio-legal perspective 
on privacy with regard to EHRs (reviewed in (Malin, Emam, and O'Keefe 2013)). In general, patients 
have expressed desire to maintain some level of control over who may access their EHRs and for what 
purpose (Caine and Hanania 2013). Participants with highly sensitive data in their EHRs were less 
likely to grant access to the sensitive data. Participants were discriminating in their likelihood to share 
data; subjects indicated willingness to share a greater percent of their EHRs with primary care 
physicians, specialists, and emergency physicians and less willing to share with family, administration, 
researchers, or non-treating recipients (Caine and Hanania 2013). 
Health literacy  
 Overall health literacy, the ability of individuals to obtain, process, understand basic health 
information, and use that information to make appropriate health decisions is lacking for a significant 
proportion of the general public (Lea et al. 2011; Kutner et al. 2006). Health literacy contributes to 
health outcomes in that individuals with limited health literacy, for example, have increased incidence 
of chronic illness and decreased use of preventative care (Lea et al. 2011; Berkman et al. 2011). One facet 
of health literacy is genetics and genomics. Public awareness and understanding of genetics and 
genomics has improved over the past several years, though many misconceptions still abound 
(Christensen et al. 2010a). Mathematical illiteracy, or innumeracy, will make understanding true 
inherited risk of disease and population risk difficult, though the extent to which this impacts genetic-
based PM has not been evaluated (Lea et al. 2011; Syurina et al. 2011). Genomic health literacy requires 
understanding that for complex diseases, genetic and environmental factors contribute to disease risk 
and some competency in numeracy (Hurle et al. 2013). Health literacy and numeracy skills will play a 
significant role in successful PM; the average patient with an elementary understanding of genetic 
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inheritance may be unlikely to fully grasp the difference between the role genetic mutations play in 
Mendelian diseases with the role of genetic variation in conferring varying degrees of risk for complex 
traits without additional education. Christensen et al. determined that less than 50% of their survey 
population was able to correctly answer 7 out of 8 basic statements about genetics (Christensen et al. 
2010a). This held for black and white, male and female participants, though there were between group 
differences (Christensen et al. 2010a). The lack of genetic knowledge identified in Christensen et al. is 
consistent with earlier reports (Lanie et al. 2004; Emery, Kumar, and Smith 1998). Though public 
awareness of genetics has increased, it appears that genetic knowledge and understanding has not 
correspondingly improved. This deficit will impede implementation of PM for in the clinical setting if 
stakeholder support is lacking due to misinterpretations and lack of understanding. 
 A recent Health Information National Trends Survey (HINTS), a population-based, nationally 
representative survey of the civilian, non-institutionalized population in the United States, collected 
self-report questionnaires with questions relating to the genetic contribution to common, complex 
diseases, how disease risk is interpreted numerically, and awareness of direct to consumer genetic 
testing (2013). Analysis of the HINTS data showed participants largely expressed belief in 
multifactorial causes for common, complex diseases. About 10% of respondents believed the etiology of 
cancer, diabetes, heart disease, and hypertension to be mostly behavioral in nature, though one-fourth 
of the respondents believed obesity is caused by mostly behavioral factors (Waters, Muff, and 
Hamilton 2014). The results of this study are encouraging, in that the participants perceived common, 
complex diseases having both environmental and genetic causes; however, it is unclear if additional 
studies will come to the same conclusions or if belief in multifactorial causes of complex diseases is 
associated with risk-reducing behavior change (Waters, Muff, and Hamilton 2014).  
 Of particular concern is the penchant for persistent notions of genetic or biologic determinism.  
Biological determinism, the view that biological components are the causal factors of behavioral 
differences between people (Malott 2007), and genetic determinism, the idea that genes dictate health 
outcomes without any contribution from environment (Parrott et al. 2012) are key concepts that must 
be addressed to maximize potential risk-reducing behavior modification for PM. Numerous groups 
have attempted to quantify the extent of genetic deterministic beliefs (Lynch et al. 2008; Dambrun et al. 
2009; Parrott et al. 2004; Keller 2005). These scales have been criticized for mixing conceptual themes 
(Condit 2011), for example, genetic determinism and racial bias (Keller 2005; Lynch et al. 2008).  Genetic 
determinism has the potential to undermine PM initiatives if individuals believe behavioral change is 
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unlikely to improve their health condition or reduce risk of future illness (Shiloh, Rashuk-Rosenthal, 
and Benyamini 2002; Senior, Marteau, and Peters 1999; Nelkin and Lindee 1996).  Consistent with prior 
studies (Marteau and Weinman 2006; Michie et al. 2003; De Wit and Stroebe 2004), a recent review of 
the literature identified five factors  that determined whether or not a genetic test motivates behavioral 
change: characteristics of the target behavior, the patient’s perception of the severity of the disease, the 
amount of risk the genetic variant contributes to the disease, patient characteristics (e.g., demographic 
factors, socio-economic status, educational attainment, level of health literacy and numeracy), and how 
patients perceive the value of the genetic information compared to other data, such as family history or 
lab values (Condit 2011). Patients may rely on genetic determinism to support unhealthy behaviors, 
though this may be applied discriminately depending on the factors listed above (Condit 2011).  
 
Vulnerable populations 
 Given the complex interactions between ancestry and genetics, it is reasonable to acknowledge 
the concern that advances in genomics may make individuals and groups vulnerable or disadvantaged 
in new ways (McClellan et al. 2013). PM depends on the identification of genetic risk markers to 
classify patients into different risk groups. This classification process may leave some patients 
vulnerable if the risk categories in which they are placed are groups that historically have been 
discriminated against or if the risk groups are perceived as socially disadvantaged relative to others. 
Three types of vulnerabilities may result from the implementation of PM in the clinical setting: disease-
specific, genome-specific, or race/ethnicity-specific.   
 For some complex diseases, like T2D or asthma, the risk for vulnerability may be slight from the 
social perspective, when compared to other complex diseases like Alzheimer’s or autoimmune 
diseases. Individuals identified as “at risk” for stigmatizing diseases may require additional resources 
to reduce potential vulnerabilities in the PM setting. With PM utilizing genetics as a basis for assigning 
disease risk, individuals may be at risk of vulnerability if it becomes apparent that some genotypes 
(Table 23) consistently utilize more healthcare resources than others. This differs from increased 
resource utilization by individuals who are already sick, in that PM for common, complex diseases 
would target asymptomatic individuals who are clinically healthy at the time of screening. Rigorous 
safeguards to patient privacy and EHR data access may minimize harm to the patient. Even if genomic 
risk information is well protected, however, cultural beliefs about chronic, complex diseases impact the 
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patient’s ability to understand their disease risk and participant fully in their healthcare (Shaw et al. 
2009). Methods to assess how the patient perceives the severity and health risk of a disease, such as the 
explanatory model (Kleinman and Benson 2006) or the CSM (Marteau and Weinman 2006; McAndrew 
et al. 2008) may yield insight into ways in which vulnerabilities based on disease and disease risk can 
be minimized.   
 Vulnerable populations may result from the categorization of at-risk patients by race/ethnicity. 
This is a sensitive issue, as there are known differences in disease prevalence among ethnic groups that 
might naturally suggest candidates for risk group assignment and personalized medicine-driven 
interventions. Genetic researchers agree that labels such as “black” or “white” do not adequately 
convey the complexities involved in genetic ancestry and have developed sophisticated statistical 
methods to account for these complexities (Fujimura and Rajagopalan 2011; Fujimura, Duster, and 
Rajagopalan 2008), though some clinicians may be prone to using race/ethnicity as a proxy for genetic 
ancestry (Hunt, Truesdell, and Kreiner 2013). Individuals, who self-identify with a given 
race/ethnicity, are often genetically heterogeneous. For example, admixture in African Americans 
yields significant variation in the amount of European ancestry across individuals (Zakharia et al. 
2009).   This heterogeneity may influence an individual’s disease risk and should be taken into account 
when assigning individuals to a risk group based on sociocultural norms (e.g., European, African, 
white, black) (Fujimura, Duster, and Rajagopalan 2008; Fujimura and Rajagopalan 2011; Rajagopalan 
and Fujimura 2012). Though grouping individuals based on race/ethnicity allows geneticists to recruit 
diverse populations for health research, it is necessary to develop mechanisms that aid public 
understanding of how these terms are used by scientists, so that negative connotations associated with 
certain groups are not reinforced (Foster and Sharp 2002). Public understanding of genetic ancestry and 
potential conflation of genetic ancestry with complex social constructs of race/ethnicity remain a 
concern. Williams and Eberhardt developed a race conceptions scale (RCS) designed to quantify the 
idea that race is biologically based (Williams and Eberhardt 2008). The RCS has been correlated with 
Modern Racism Scale Scores, Attitudes Toward Blacks Scale, Social Dominance Orientation, and 
acceptance of racial disparities (Condit 2011). Similar to the way in which genetic determinism may be 
used to perpetuate some health behaviors or beliefs (Condit 2011), genetic ancestry may be 
misinterpreted to mean that health vulnerabilities are inherent to particular groups and could be 
dismissed as natural phenomena instead of being recognized as genuine health disparities (Isler et al. 
2013).  
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Summary 
Personalized medicine has risen in the public consciousness as medical centers advertise their 
ability to inform clinical care using a patient’s genetic information to improve outcomes and on-
demand genetic testing for health and ancestry gain popularity.  Until recently, adults could obtain an 
analysis of their DNA using direct-to-consumer genetic testing companies (Public Health Service Food 
and Drug Administration and Gutierrez 2013). These analyses included risk prediction for hundreds of 
common, complex diseases and traits, pharmacogenetic results, and disease carrier status (Public 
Health Service Food and Drug Administration and Gutierrez 2013).  However, integrating genetic 
information into clinical care for complex disease is challenging for a variety of scientific, ethical, and 
social issues.  
The very nature of complex diseases makes them challenging to understand disease risk on an 
individual level. Complex diseases result from a mixture of genetics and environmental influence, and 
the combination of these factors differ between diseases. Even when the entirety of genetic factors has 
been identified, risk prediction that includes genetics may perform poorly, if the environmental 
influence is significant. Due to incomplete penetrance, some individuals with a susceptible genotype 
may never develop the disease. Different variants may be responsible for disease development in some 
individuals, frustrating variant-phenotype associations, and phenotypic heterogeneity can play a role 
in recognition of at-risk individuals.  
A lack of clearly stated, measurable health outcomes makes determining the utility of 
personalized medicine challenging. In clinical care, quantitative outcomes could be measured in terms 
of morbidity and mortality, or through more nuanced measurements such as DALYs, QALYs, or 
HALEs. Patient/clinician perspectives or symptom severity are examples of more qualitative outcomes 
that may be assessed.  These valuable measurements will provide the foundation for clinical utility 
research in genetics. Though thousands of genetic variants have been associated with hundreds of 
clinical traits and diseases, few of them have been validated in the clinical setting. Additional studies 
should be performed to evaluate the clinical validity of variants that are likely to be included in risk 
models to identify at-risk populations or guide clinical care, as in pharmacogenetics. EHRs may 
facilitate this research by aiding risk model algorithm development, prescription information, and the 
ability to follow patients over the course of many years. Determining the clinical validity and utility of 
genetic variants for complex diseases could be accomplished through EGAPP, evidence-based practice 
centers, or translational scientists. The EGAPP working group has repeatedly determined there is 
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insufficient evidence at present to recommend genetic testing to improve health outcomes for several 
diseases; however, they have completed fewer than a dozen studies thus far, and the future may be 
more promising if the needed data become available. 
 Implementation of personalized medicine for complex disease is also complicated by ethical 
and social issues. The challenge of accurately identifying at-risk individuals without creating 
vulnerable populations needs to be addressed. For common, complex diseases such as diabetes or 
cardiovascular disease, the risk of stigmatization may be less than for other diseases, such as 
Alzheimer’s disease or autoimmune diseases. Certain racial/ethnic groups may be more likely to fall 
into a vulnerable classification due to historical discrimination; the targeting of specific groups for 
personalized medicine interventions or screenings may lead to increased vulnerability in those groups. 
Equitable access to screening and intervention should be based on genetic susceptibility and other risk 
factors for disease, not sociocultural labels.  
 How personalized medicine is implemented leads to ethical and social issues. Identification of 
the at-risk population for PM can take several forms and may depend upon the typical age of onset for 
a disease. A revised Wilson and Jungner screening criteria may be more appropriate for evaluating 
whether to pursue screening for a given disease using genomic information (Andermann et al. 2008). 
Vanderbilt’s PREDICT program demonstrates another method of identifying individuals for 
intervention; patients are identified as high-risk to start a particular drug therapy as calculated by a 
predictive algorithm, or as they come through the cardiac catheterization clinic (Pulley et al. 2012). For 
common, complex diseases, such as CVD, timing genetic testing for PM will depend on the value 
conferred by testing, the disease, its natural course, and the proposed intervention. Current 
implementation of precision medicine for cancer treatment or pharmacogenetics is targeted; non-
targeted approaches such as WGS, WES, and genome-wide genotyping arrays can provide additional 
data, though the utility of this information is unclear and raises other issues (Lawrence et al.2014).  For 
complex diseases with late-adulthood onset, such as age-related macular degeneration, identifying the 
at-risk patients in early adulthood or middle age may be the most appropriate time. For diseases that 
occur at earlier ages, such as CVD or T2D, it may be more advantageous to identify the at-risk 
population in childhood, perhaps maximizing the effects from the intervention, but raising a host of 
issues that are beyond the scope of this work (Erickson et al. 2014; Ross et al. 2013). These differences 
suggest that the decision to use PM for complex diseases will require thoughtful deliberation on a 
disease by disease and intervention by intervention basis. A new method of determining what diseases 
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are most appropriate for PM initiatives may be required and may rely on evidence-based medicine and 
cost-utility analyses. A three-pronged method that considers the potential utility, benefits, and harms is 
one method of identifying which diseases, which individuals, and when a precision medicine approach 
is best suited. Evidence supporting any precision medicine method should begin in multidisciplinary 
collaborations between social scientists, clinicians, and geneticists. Legal issues, which are outside the 
scope of this work, are numerous for precision medicine.  
Despite the recent cessation of risk prediction for complex diseases through a direct-to-
consumer genetic testing company, the public desire for useful health information and individualized 
treatment is unlikely to subside. Numerous medical centers have embraced precision medicine to 
inform cancer care and pharmacogenetics, though evidence that the practice has improved patient care 
or health outcomes is still emerging. Yet the role that precision medicine can play for common, 
complex disease has not been fully explored.  Numerous scientific, ethical, and social concerns will 
need to be addressed, and evidence that genetic information improves health outcomes through 
medical and lifestyle modifications must be determined.  
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CHAPTER VII 
CONCLUSION AND FUTURE DIRECTIONS 
VII. CONCLUSION AND FUTURE DIRECTIONS 
Conclusion  
 Personalized medicine, the use of genomic data to guide clinical decision making for an 
individual patient, currently takes a variety of forms. For numerous cancers, the result is cancer tumors 
being tested for specific genetic variants and measuring gene expression levels that may make the 
cancer more susceptible to a specific chemotherapy regimen. Genetic testing prior to the development 
of cancer for familial forms of breast cancer or colorectal cancer allows patients to modify risk 
behaviors or undergo prophylactic surgery or chemotherapy. Importantly, this may also be used to 
infer risk in related individuals, perhaps providing clinically useful information for entire families. 
Pharmacogenomic studies look to determine the correct dosing strategy and medication choice for 
patients to avoid adverse events and maximize therapeutic efficacy. For individuals who have 
previously been without a clear diagnosis, exome and/or whole genome sequencing may provide 
insight to the underlying biological mechanism responsible for their disorder and end the diagnostic 
odyssey. 
 Despite these successes, the promise of personalized medicine to revolutionize care for 
common, complex diseases has not materialized.  With the exception of Mendelian disorders, some 
cancers, and pharmacologic interactions, the prognostic capabilities of genetic tests to accurately gauge 
risk of disease development are low. This results from both an incomplete understanding of the 
biologic mechanisms responsible for disease development and progression, and a fragmented grasp of 
the role of environmental factors and interactions play in these disorders. Though cancer and adverse 
drug events contribute significantly toward the overall health picture of the nation, they are vastly 
overshadowed by the public health impact from complex diseases, like age-related macular 
degeneration, type 2 diabetes, and cardiovascular disease. Given the increasing population burden of 
these disorders, a personalized medicine approach to correctly identify which patients are at greatest 
risk prior to developing the disorder and then targeting interventions to those individuals in order to 
prevent, delay, or ameliorate the disorder, could result in substantially improved health outcomes. 
 127 
 
 This body of work sought to understand the role of genetic variation in complex traits 
associated with women’s health. Though women comprise a majority of the population in the United 
States, their specific health needs have been largely ignored until the past few decades. This disparity is 
mirrored in biomedical research in diverse populations. Differences in disease prevalence and severity 
between men and women or between individuals of European- and non-European ancestry for many 
complex traits have been documented. How gender, race/ethnicity, and the role of environmental 
interactions contribute to these differences is unclear. Nevertheless, that these differences exist suggests 
a potential role for personalized medicine approaches to health in women and diverse populations to 
improve health outcomes.  
 The role of the reproductive lifespan in women has been associated with various complex traits 
and diseases. Beginning with menarche during the pubertal period, until menopause, cyclic hormone 
patterns and the role of pregnancy impact a woman’s risk of developing certain cancers, osteoporosis, 
and cardiovascular disease. In addition, women are more at risk of most autoimmune disorders, and 
there are differences in autoimmune disease risk that varies by ethnicity. Despite the importance of 
these traits, their molecular basis and the biological mechanisms by which they play a role in disease 
development are not well understood. The importance of these traits, their association with disease, 
and gap in scientific evidence served as the impetus for studying these traits.  
 I began by assessing the role of genetic variation on age at menarche and age at natural 
menopause in African American women from the Population Architecture using Genomics and 
Epidemiology (PAGE) Study in the first of three case studies. Using the Metabochip, a genotyping 
array with a primary emphasis on fine-mapping GWAS-identified genomic regions associated with 
cardiovascular traits, I sought to generalize to our sample variants previously identified in European-
descent cohorts for these traits. Differences in the timing of these traits by race/ethnicity have been 
observed consistently and have yet to be fully explained. This was the first study to consider these 
traits in a large African American cohort at the time of publication, though others have followed. We 
were able to generalize only one previously identified SNP, rs1361108, for age at menarche, and two 
SNPs, rs897798 and rs9385399, for age at natural menopause, to our cohort. We failed to identify novel 
variants associated with age at menarche, after correcting for multiple tests; however, we observed 
three novel SNPs associated with age at natural menopause in this population. Our ability to generalize 
variants identified in European cohorts, including the LIN28B region, was compromised by 
Metabochip coverage of some genomic regions and its emphasis on genes involved in lipid metabolism 
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and cardiovascular traits. In addition, the sample size and minor allele frequency differences between 
our population and European populations likely impacted our ability to replicate known variants 
associated with these traits. Despite these limitations, our results demonstrated the ability to use the 
Metabochip to identify variants associated with reproductive lifespan traits in a diverse population.  
 As personalized medicine approaches rely substantially on the use of electronic health records 
(EHRs) to identify groups of patients for interventions, I developed an algorithm to extract age at 
menarche and age at menopause from the Vanderbilt University Medical Center biorepository, BioVU. 
My goal was to create an automated method of extracting these important data from EHRs; these data 
and this algorithm could subsequently be used by researchers who continue to study these traits and 
the genetic influences on their timing, as well as by clinicians who could use this information to 
identify individuals for clinical research cohorts or for targeted interventions using ages at these 
milestones as risk factors for cancers, cardiovascular diseases, or other complex traits. Despite known 
links between the timing of these events and complex diseases, these data are not consistently nor 
uniformly collected and placed in EHRs. To address this issue, we created a method using a 
combination of free text data mining for regular expressions and pattern matching, billing, and 
procedure codes to identify the age at these events in women and children (age>7) in BioVU. Our 
method captured these data successfully, with a positive predictive value of 94.0% for the age at 
menarche algorithm. In addition, we were able to discriminate between natural menopause and all-
cause menopause. 
 Our algorithm identified ages at these reproductive milestones that concur with national 
estimates. We identified several challenges to accurately extracting this information from BioVU that 
may be generalizable to other institutions using our method. First, in BioVU, specific ages and dates 
may be de-identified or date-shifted.  De-identification was observed in approximately half of our age 
at menarche and age at natural menopause results; it is possible that if these data were not de-
identified, our algorithm’s predictive abilities could change. In addition, the date-shifting that is done 
for privacy concerns meant that the actual timing of these events could have occurred within a one year 
window (six months forward or backward of the date), further compromising our ability to accurately 
identify these ages. Furthermore, both the de-identification and date shifting were applied 
inconsistently, sometimes within a single record. While our method prioritized an actual date/age over 
a de-identified or shifted age when reporting results, we found instances where the algorithm failed to 
find the exact date/age which decreased the predictive capability of our method. These challenges 
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frustrated our ability to obtain these data; however, our method has been recently used by another 
institution to extract the data from their biorepository/EHR for contribution to a meta-analysis for 
timing menarche and menopause in the PAGE Study (data not shown). It is hoped that data extraction 
methods, such as ours, may be used more frequently to provide researchers with necessary data for 
studies. 
 The second case study assessed the role of genetic variation in the development of endometrial 
cancer. Endometrial cancer (EC) is the most common invasive gynecologic cancer in the United States. 
Typically occurring in post-menopausal women, EC risks appear to vary by race/ethnicity. Multiple 
subtypes of EC complicate studies evaluating the genetic risk factors for disease. Endometrioid EC 
tends to be less aggressive than the clear cell or serous types of EC and is generally estrogen-
dependent. The molecular mechanisms for EC development are not fully understood; however, timing 
of menarche, menopause, and pregnancy, and parity are known to be associated with EC. Previous 
genetic studies have identified several genes implicated in EC, though results suffer from a lack of 
consistency. We performed a candidate-gene association study for EC using variants selected due to 
their association with a variety of cancers. Pleiotropic effects have been observed for other cancers; 
identifying cancer variants additionally linked to EC may result in better understanding of general 
cancer mechanisms. After quality control filters, our single-study sample size for this study was 
drastically reduced. Consequently, though our single-site results have been presented in Chapter IV, 
we contributed our results to a larger meta-analysis comprised of studies from two consortia: PAGE 
and the E2C2 (Epidemiology of Endometrial Cancer Consortium). The leading results from our 
analysis implicate SNPs previously associated with prostate and colorectal cancer. This is interesting, as 
the PAGE/E2C2 meta-analysis also observed significant associations for SNPs associated with prostate 
cancer, suggesting a potential shared mechanism for the development of both cancers. Given our small 
sample size, our single-site results should be interpreted with caution. 
 A genome-wide association study (GWAS) for thyroid stimulating hormone (TSH) levels was 
the last case study presented here. Unlike a candidate gene approach (Chapter IV), or a more targeted 
association study (Chapter II), this method generates hypotheses for additional studies, rather than 
testing specific hypotheses. Similar to the reproductive traits and endometrial cancer, the heritability of 
TSH levels is approximately 0.50, though genetic studies have failed to identify variants responsible for 
more than a few percent. And like reproductive traits and EC, sex and population differences have 
been observed in both mean TSH levels and prevalence of thyroid disease. Performed in the eMERGE 
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Network, this GWAS replicated known variants associated with TSH levels in European Americans, 
including the well-characterized PDE8B rs2046045; however, we were unable to generalize most 
associations to African Americans. Differences in minor allele frequencies between the European and 
African-descent populations may have impacted our statistical power to replicate in the African 
American population.  
 We also considered the role of interactions between genetic(SNPs) and environmental factors 
(body mass index (BMI)) in this case study. Obesity has been implicated in higher TSH levels and 
contribute to a change in an individual’s normal TSH level (Marzullo et al. 2010; De et al. 2007).  We 
identified two loci, NRG1 and NFIA, with BMIxSNP interactions in European Americans. Nominally 
significant, the NRG1 interaction is particularly interesting as it has been associated with thyroid cancer 
(Gudmundsson et al. 2009) and has been shown to regulate cell proliferation in an animal thyroid cell 
model (Breuleux 2007). Though interactions were identified for the African Americans, small sample 
sizes and low genotype counts per BMI category; comparisons across groups are therefore difficult. 
This study highlights the challenges in assessing genetic and environmental interactions in small 
samples.   
 Identifying the genetic variants associated with these women’s health-related traits lays the 
foundation for personalized medicine in a clinical setting; however, identification is merely the first 
step of many in translating this data into clinical practice for complex diseases. Though identification of 
genetic variants associated with a given trait may provide insight to the underlying biological 
mechanisms, these associations are rarely predictive for disease risk in an individual. The complexity in 
understanding the role of genetics in many common diseases, like cancer or hypothyroidism, results in 
part from the interactions of genes and environment, and is complicated by genetic heterogeneity and 
incomplete penetrance. Few genetic studies have considered the positive predictive value of the genetic 
associations for disease risk. Until recently, several companies provided disease risk for hundreds of 
common, complex diseases and traits, despite the lack of rigorously tested evidence that GWAS-
identified SNPs are substantially predictive of disease risk. It is not unlikely that physicians will 
encounter patients with this disease risk information in the near future, and be confronted with how to 
best manage preventative care based upon this genetic data. The EGAPP framework to evaluate genetic 
evidence for inclusion in clinical care was established in 2007 based off the earlier Analytic Validity, 
Clinical Validity, Clinical Utility, and Ethical, Legal, & Social Implications (ACCE) Project. EGAPP has 
performed numerous studies in the last seven years evaluating the evidence that genetic testing 
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improves health outcomes for several diseases. These studies have consistently found a lack of analytic 
evidence upon which to base their recommendations. This lack of evidence frustrates clinician’s 
abilities to determine when a personalized medicine approach may be effectively implemented. 
 To address the lack of data observed by the EGAPP working group and others, we developed a 
rapid evidence review procedure as a first-pass method that could be implemented in an academic 
medical center setting to evaluate the analytic evidence supporting the use of genetic data in the clinical 
setting to improve health outcomes for a complex disease and used hypothyroidism/serum TSH levels 
as the example. Systematic evidence reviews (SERs) are notoriously time consuming, often taking more 
than one year to complete, and costly, both economically and in terms of human capital. To address 
these issues, a streamlined approach to the SER was taken. As in a full SER, an overarching research 
question and supporting key questions were developed to identify the desired analytic evidence. One 
database was searched for the literature review (PubMed) and the abstract and full text reviews were 
performed by two individuals, with access to a third independent party as necessary. The REDCap 
database was used to capture and house the data for the review process; this tool has a web-based 
interface and allows for automatic export of the data to common statistical packages.    
 Though we identified hundreds of potential studies for the review, we found no studies that 
met our inclusion criteria. Importantly, we found studies lack important clinical validity data, such as 
positive predictive values or areas under receiver-operator characteristics curves. In addition, we found 
a lack of evidence that studies considered the clinical utility of knowing the genetic variants improved 
health outcomes. Finally, ethical, legal, and social issues were not addressed in the studies identified 
through our rapid review; though this may be a result of searching one database only or key questions 
that did not sufficiently address that topic. In general, our rapid review results concur with those 
performed for other diseases/traits and highlight the need for genetic studies to publish this key 
analytic data. 
 A lack of analytic evidence is not the only barrier to implementing personalized medicine for 
complex diseases. The health care system may not be adequately prepared to expand PM in this way 
due to data management challenges, data privacy issues, and complications arising from EHR 
integration and physician decision support mechanisms. Economic analyses on the costs to a health 
care system to implement PM are largely missing. Logistic issues with legal implications include the 
consequences of a patient changing their medical home, such as data and sample ownership. 
Institutions that develop highly predictive algorithms for certain complex diseases may feel protective 
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of their investment and be unwilling to share with other medical centers. Concerns around proprietary 
testing, analytic models, patents, and licensing will likely play a significant role as personalized 
medicine becomes more prevalent. The patient and public role in PM requires considering data privacy 
and access, health literacy, and vulnerable populations. Historic injustices to certain populations have 
led to distrust of the medical community and continue to inhibit participation in biomedical research. 
Unwillingness to share information with researchers presents an immediate challenge for PM 
implementation. Health outcomes research for PM initiatives will rely on a large number of individuals 
consenting that their data be included in analyses; if patients are less likely to allow sharing of their 
personal health information with researchers, necessary clinical utility and outcomes data may be 
difficult to obtain.  
 
Future Directions 
Genetic studies 
 Though the health of women and minorities has been significant focus of governmental 
agencies in the past several decades, health disparities still abound for many diseases. It is clear from 
the limitations described in the previous case studies that additional genetic research in women and 
minorities should remain a goal of researchers. The etiology of different disease trajectories for women 
and men for some diseases has yet to be fully explored. Self-defined or third-party observed labels of 
race/ethnicity may be insufficient to serve as proxies for genetic ancestry; known variation in percent 
African ancestry across African Americans should serve as an example of the complexities involved 
when assigning disease risk to an individual based on population-level data. However, this data may 
reflect socio-cultural data that genetic ancestry cannot.   
 Additional studies in large cohorts with diverse populations will improve our understanding of 
the genetic contribution to disease. Several studies, such as the Jackson Heart Study (Taylor, Jr. et al. 
2005) and the Southern Community Cohort (Signorello et al. 2005), focus their attention on 
understanding the underlying causes of health disparities for minorities in cancer and cardiovascular 
disease, and consortia like the PAGE Study have a considerable multi-ethnic component. Despite these 
and other studies, health disparities remain a significant challenge and it is unclear to what extent 
genetic ancestry, in combination with other genetic and environmental factors influences disease risk 
and highlights the need for additional large studies in these populations. This is much more easily said 
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than done, however. Past studies that led to mistrust of the medical and scientific community have had 
long-lasting effects on participation in research studies and clinical trials. While social scientists have 
identified methods to overcome this mistrust, minority participation in clinical trials is dismal, even 
where disease burden is higher in non-European descent individuals. Collaborations with social 
scientists and community leaders that lead to a better understanding of the barriers that exist to 
minority participation in biomedical studies may improve recruitment and retention.   
 Despite the hundreds of GWAS studies performed for dozens of diseases and complex traits, 
the vast majority of associations have failed to explain much of the variation observed. The “missing 
heritability” phenomenon has led to increased exploration of the role of interactions and rare variants, 
though there is little evidence that these studies will be more successful at explaining the heritability of 
a specific trait. Larger and larger samples sizes are required to uncover variants with smaller and 
smaller effect sizes. While the additive nature of variants likely plays a significant role in the “missing 
heritability,” for some diseases it is unlikely researchers will ever be able to amass enough samples to 
identify all causal variants. Prospective studies and nested case-control studies within prospective 
studies can reduce the effective sample size needed for some genetic studies; however, interaction 
analyses will likely be compromised by the number of samples for each possible interaction. Our lack 
of understanding of the biological mechanisms that lead to disease certainly plays a significant role in 
the failure to identify the responsible genetic variants. The ENCODE Project, which has identified 
regulatory regions of the genome, may lead to insight on the biologic relevance to disease of many 
intergenic or intronic GWAS associations. Whole exome (WES) and whole genome sequencing (WGS) 
may yield important clues about genetic contribution to disease. As the number of individuals who 
undergo WES/WGS increases, knowledge about allele frequencies across population will improve, 
leading to better understanding of which alleles are causal variants (and in which populations) and 
which are along for the ride. This again leads back to the need for increased participation in research by 
non-European populations. 
  
Role of research findings in clinical care 
Establishing an evidence base 
 Though genetic research to identify the basic biology underlying disease is necessary, this body 
of work has examined the role of genetic variation in disease from a context of personalized medicine. 
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Moving research findings into the clinical sphere is challenging and encompasses numerous 
disciplines. It is clear that from the studies performed in the past decade and the rapid review 
described herein, that the analytic evidence that genetic testing fails to improve health outcomes for 
common, complex diseases currently. I would like to emphasize that this does not suggest that genetic 
testing will never lead to improved outcomes, and certainly successes in cancer research and 
pharmacogenetics demonstrate the potential of PM approaches in the clinical setting.  I have outlined 
many of the challenges personalized medicine currently faces—they are by no means insurmountable. 
 The current lack of analytic evidence prevents researchers from demonstrating clinical validity 
and clinical utility. This can be addressed by a concerted effort from geneticists to publish the positive 
predictive value or AUC for their studies. It may be that neither the PPV nor the AUC is the most 
appropriate statistic to demonstrate clinical validity—PPV works best when the outcome is 
dichotomous and AUC implies the test captures all of the heritability. Any genetic test for a complex 
trait is unlikely to meet these criteria. Biostatisticians working alongside geneticists may be able to 
develop a new method that better describes the clinical validity of genetic variants. 
 How institutions prioritize which diseases may benefit from a PM approach is complicated. 
From an evidence-based perspective, those diseases for which the analytic evidence is complete and the 
disorder fulfills all/most of the updated Wilson and Jungner(Andermann) criteria may prove to be the 
easiest. Extensions to current PM initiatives in cancer and pharmacogenetics are a natural first step. 
Other disorders, for which there are well-documented interventions, such as cardiovascular disease 
and type 2 diabetes, may be alternative first steps. Prioritization based on the public health burden of 
the disease offers another method to determine which diseases could benefit from this approach.  
 The economic realities of biomedical research today cannot be overlooked. Economic studies 
considering the cost-effectiveness of various interventions or screening modalities, including genetic 
testing, are important and mostly absent from the literature. In light of limited financial resources, 
collaborations across institutions, the inclusion of non-academic medical centers in studies, 
partnerships with industry and non-academic entities (e.g., patient advocacy groups) with financial 
backing may provide opportunities for large-scale studies with reduced cost burden for any one 
institution. Additionally, data previously collected for other research studies or the information held in 
EHRs may alleviate the burden of researchers to recruit and test new participants. This leads directly to 
legal, ethical, and practical challenges which should be carefully considered. The role of patients and 
the public as research partners should not be underestimated. Examples of motivated patients who 
 135 
 
desire to become involved in biomedical research by contributing samples and financially may be seen 
in Patients Like Me, UBiome, and 23&Me’s research arm, 23&We. This approach led to recruitment of 
more than 3,000 individuals with Parkinson’s disease and the identification of two new variants 
associated with the disorder through 23&Me’s Parkinson’s Research Community(23&Me). How this 
method can be implemented in collaboration with a medical institution should be considered.  
Complex disease prevention and management 
 Personalized medicine requires a multidisciplinary approach—geneticists are experts in 
genetics, not behavioral psychology; roles for ethicists, psychologists, geneticists, epidemiologists, 
clinicians, and other professionals should be included. Patient motivation to change risk behaviors has 
been largely unsuccessful with regard to genetic testing, though BRCA1/2 testing has been shown to 
increase breast cancer screenings. Whether knowing disease risk based on genetics for other complex 
diseases will lead to heightened surveillance or reduction in risk behaviors, such as smoking, is unclear, 
and downstream consequences of these interventions are not likely to be known for many years. 
Tracking individual patients through the medical system would, in essence, become a prospective 
study, where health outcomes could be evaluated and nested case-control studies be performed. 
However, this calls into question additional ELSI and technical issues, such as how to manage patients 
who leave one medical home for another. Widespread collaborations across institutions nationally, or a 
single-payer health system could alleviate some of these problems, though thoughtful consideration of 
these suggestions is beyond the scope of this body of work.    
  
Summary 
 Our scientific understanding of the basis for many common, complex diseases and traits has 
improved in the past decades with advances in genomic studies. Despite these advances, real 
improvements to health outcomes remain generally unrealized and widespread health disparities 
continue. To address these issues, I have considered the role of genetic variation in the timing of the 
female reproductive lifespan, risk of endometrial cancer, and serum TSH levels in both European-
descent and African American populations, using candidate gene, large-scale association, and genome-
wide association studies. I developed a method to extract important reproductive lifespan data out of 
an EHR for use in research studies and suggest how that could be used in the clinical setting. I have 
identified variants associated with these traits, considered how prior published studies generalize to 
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more diverse populations, discovered potential gene-environment interactions. These studies have 
been undertaken in the context of personalized medicine—how genetic data can be used to inform 
clinical care. I have noted significant challenges facing implementation of personalized medicine for 
complex diseases and performed a rapid review that could serve as a template for others wishing to 
perform similar studies. Evaluation of the role of genetic variants as predictors of complex disease is 
developing; though the challenges are significant, it is likely they will be overcome in the future.
 137 
 
APPENDICES 
 138 
 
Appendix A: Comparison of SNPs in Elks et al. (2010) meta-analysis for AM to African American women in the PAGE Study.  
 
Locus Gene/ 
region 
Elks et al.  African American women from the PAGE Study 
SNP Chr Minor 
Allele 
MAF Beta P-value Best Proxy SNP 
from present 
study 
r2 in 
HapMap 
CEU/YRI 
Coded 
Allele 
CAF Beta (SE) P-value 
rs7759938 6 LIN28B C 0.32 0.12 5.4E-60 rs7759938 - A 0.46 -0.02(0.04) 0.61 
rs2090409 9 TMEM38B A 0.31 -0.09 2.2E-33 rs4452860 0.83/0.82 A 0.67 -0.03(0.04) 0.43 
rs1079866 7 INHBA G 0.15 0.08 5.5E-14 rs6947337 0.02/0.001 A 0.28 -0.07(0.04) 0.10 
rs466639 1 RXRG T 0.13 -0.08 1.3E-13 rs285482 0.36/0.05 A 0.55 -0.003(0.04) 0.93 
rs6438424 3 3q13.3 A 0.50 -0.05 1.4E-13 rs9283566 0.51/0.15 A 0.29 0.03(0.04) 0.47 
rs1398217 18 FUSSEL18 G 0.43 -0.05 2.3E-13 NA NA NA NA NA NA 
rs12617311 2 PLCL1 A 0.32 -0.06 6.0E-13 NA NA NA NA NA NA 
rs9635759 17 CA10 A 0.32 0.06 7.3E-13 NA NA NA NA NA NA 
rs6589964 11 BSX A 0.48 -0.05 1.9E-12 rs922252 0.24/0.16 A 0.40 0.03(0.04) 0.43 
rs10980926 9 ZNF483 A 0.36 0.05 4.2E-11 rs6477828 0.12/0.13 A 0.55 -0.01(0.04) 0.76 
rs17268785 2 CCDC85A G 0.17 0.06 9.7E-11 NA NA NA NA NA NA 
rs13187289 5 PHF15 G 0.20 0.06 1.9E-10 NA NA NA NA NA NA 
rs7642134 3 VGLL3 A 0.38 -0.05 3.5E-10 rs1825896 0.02/0.05 A 0.15 -0.04(0.05) 0.40 
rs17188434 2 NR4A2 C 0.07 -0.09 1.1E-09 NA NA NA NA NA NA 
rs2002675 3 TRA2B G 0.42 0.04 1.2E-09 NA NA NA NA NA NA 
rs7821178 8 PXMP3 A 0.34 -0.05 3.0E-09 NA NA NA NA NA NA 
rs1659127 16 MKL2 A 0.34 0.05 4.0E-09 rs1659127 - A 0.30 0.03(0.04) 0.46 
rs10423674 19 CRTC1 A 0.35 0.04 5.9E-09 rs757318 0.63/0.14 A 0.78 -0.03(0.04) 0.49 
rs10899489 11 GAB2 A 0.15 0.06 8.1E-09 rs7115850 0.96/0.58 C 0.58 -0.05(0.04) 0.23 
rs6575793 14 BEGAIN C 0.42 0.04 1.2E-08 NA NA NA NA NA NA 
rs4929923 11 TRIM66 T 0.36 0.04 1.2E-08 rs4929923 - A 0.46 0.07(0.04) 0.06 
rs6439371 3 TMEM108 G 0.34 0.04 1.3E-08 NA NA NA NA NA NA 
rs900145 11 ARNTL C 0.30 0.04 1.6E-08 rs900145 - A 0.47 -0.03(0.04) 0.41 
rs6762477 3 RBM6 G 0.44 0.05 1.6E-08 rs2240327 0.69/0.16 A 0.64 -0.06(0.04) 0.15 
rs2947411 2 TMEM18 A 0.17 0.05 1.7E-08 rs2947411 - A 0.23 -0.10(0.04) 0.02 
rs1361108 6 C6orf173 T 0.46 -0.04 1.7E-08 rs9385399 1.00/0.60 A 0.25 -0.12(0.04) 0.01 
rs1364063 16 NFAT5 C 0.43 0.04 1.8E-08 rs889398 0.93/0.42 A 0.28 -0.05(0.04) 0.25 
rs633715 1 SEC16B C 0.20 -0.05 2.1E-08 rs516636 1.00/0.92 A 0.11 0.04(0.06) 0.55 
rs4840086 6 PRDM13 G 0.42 -0.04 2.4E-08 NA NA NA NA NA NA 
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Locus Gene/ 
region 
Elks et al.  African American women from the PAGE Study 
SNP Chr Minor 
Allele 
MAF Beta P-value Best Proxy SNP 
from present 
study 
r2 in 
HapMap 
CEU/YRI 
Coded 
Allele 
CAF Beta (SE) P-value 
rs7617480 3 KLHDC8B A 0.22 0.05 2.8E-08 rs13096474 0.76/0.56 A 0.35 -0.05(0.04) 0.21 
rs9939609 16 FTO A 0.40 -0.04 3.1E-08 rs9939609 - A 0.48 0.003(0.04) 0.93 
rs852069 20 PCSK2 A 0.37 -0.04 3.3E-08 NA NA NA NA NA NA 
rs757647 5 KDM3B A 0.22 -0.05 5.4E-08 rs757647 - A 0.41 -0.06(0.04) 0.09 
rs9555810 13 C13orf16 G 0.28 0.04 5.6E-08 NA NA NA NA NA NA 
rs16938437 11 PHF21A T 0.09 -0.07 5.9E-08 rs16938437 - A 0.23 0.02(0.04) 0.63 
rs2687729 3 EEFSEC G 0.27 0.04 1.3E-07 rs2811415 0.17/0.83 A 0.29 0.05(0.04) 0.26 
rs1862471 19 OLFM2 G 0.47 0.04 1.5E-07 NA NA NA NA NA NA 
rs12472911 2 LRP1B C 0.20 0.05 1.5E-07 NA NA NA NA NA NA 
rs3914188 3 ECE2 G 0.27 -0.04 2.6E-07 NA NA NA NA NA NA 
rs2243803 18 SLC14A2 A 0.40 0.04 3.4E-07 NA NA NA NA NA NA 
rs3743266 15 RORA C 0.32 -0.04 8.0E-07 rs17270188 0.31/0.02 A 0.92 0.05(0.07) 0.47 
rs7359257 15 IQCH A 0.45 0.03 1.9E-06 rs7359257 - A 0.66 0.06(0.04) 0.15 
Comparison of previously reported SNPs associated with AM in European descent women to 4,159 African American women from the PAGE Study in a model minimally 
adjusted for study site and principal components (Model 1). Beta values from Elks et al. converted from weeks to years. Data presented are for the previously identified 
SNP. If the previously identified SNP was not directly genotyped in present study, data shown are for the best proxy SNP based on linkage disequilibrium from the 
International HapMap Project CEU panel. (NA) = no sufficient proxy available on the Metabochip. Abbreviations: single nucleotide polymorphism (SNP), age at menarche 
(AM), Population Architecture using Genomics and Epidemiology (PAGE), chromosome (Chr), minor allele frequency (MAF), coded allele frequency (CAF). 
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Appendix B. Comparison of SNPs in Stolk et al. meta-analysis for ANM to African American women in the PAGE Study.  
 
Locus Gene/ 
region 
Stolk et al.  African American women from the PAGE Study 
SNP Chr Minor 
Allele 
MAF Beta P-value Best Proxy SNP 
from present 
study 
r2 in 
HapMap 
CEU/YRI 
Coded 
allele 
CAF Beta (SE) P-value 
rs4246511 1 RHBDL2 T 0.27 0.24 9.08E-17 NA NA NA NA NA NA 
rs1635501 1 EXO1 C 0.48 -0.16 8.46E-10 rs1776133 0.91/0.23 A 0.70 -0.05(0.04) 0.17 
rs2303369 2 FNDC4 T 0.39 -0.18 2.25E-12 rs2303369 - A 0.36 -0.02(0.03) 0.48 
rs10183486 2 TLK1 T 0.37 -0.20 2.21E-14 rs4668368 0.86/0.62 A 0.65 0.03(0.03) 0.37 
rs7606918 2 METAP1D G 0.16 -0.23 2.89E-08 rs11681005 0.08/0.02 A 0.13 -0.06(0.05) 0.25 
rs4693089 4 HELQ G 0.49 0.23 2.38E-19 NA NA NA NA NA NA 
rs890835 5 RNF44 A 0.11 0.18 6.10E-06 NA NA NA NA NA NA 
rs365132 5 UIMC1 T 0.49 0.29 9.11E-32 NA NA NA NA NA NA 
rs2153157 6 SYCP2L A 0.49 0.17 7.76E-12 rs2153157 - A 0.70 0.03(0.04) 0.47 
rs1046089 6 PRRC2A A 0.35 -0.21 1.63E-16 rs9264532 0.08/0.05 A 0.65 0.02(0.03) 0.50 
rs2517388 8 ASH2L G 0.17 0.26 9.31E-15 rs4976896 0.003/0.000 A 0.78 0.01(0.04) 0.77 
rs12294104 11 MPPED2 T 0.17 0.23 1.46E-11 rs7951733 0.35/- A 0.99 0.11(0.13) 0.37 
rs2277339 12 PRIM1 G 0.10 -0.38 2.47E-19 rs12809466 0.01/0.04 A 0.88 0.02(0.05) 0.66 
rs3736830 13 KPNA3 G 0.16 -0.18 9.41E-08 NA NA NA NA NA NA 
rs4886238 13 TDRD3 A 0.33 0.17 9.53E-11 NA NA NA NA NA NA 
rs2307449 15 POLG G 0.41 -0.18 3.56E-13 rs12593363 0.91/0.12 A 0.74 0.01(0.04) 0.83 
rs10852344 16 GSPT1 C 0.42 0.17 1.01E-11 rs8053435 0.04/0.01 A 0.77 -0.01(0.04) 0.77 
rs11668344 19 TMEM150B G 0.36 -0.42 1.45E-59 NA NA NA NA NA NA 
rs12461110 19 NLRP11 A 0.36 -0.16 8.74E-10 rs302469 0.03/0.004 A 0.25 -0.05(0.04) 0.22 
rs16991615 20 MCM8 A 0.07 0.95 1.42E-73 rs16991615 - A 0.01 -0.17(0.15) 0.25 
Comparison of previously reported SNPs from Stolk et al. meta-analysis (Stolk et al.2012) associated with ANM in a combined cohort (discovery and replication) of 53,403 
European descent women to 1,860 PAGE Study African American women in a minimally adjusted for study site and principal components for ANM. MAF from Stolk et al. 
reported for discovery cohort, beta and p-values reported for combined discovery and replication cohorts (Stolk et al.2012). Data presented are for the previously identified 
SNP. If the previously identified SNP was not directly genotyped in present study, data shown are for the best proxy SNP based on linkage disequilibrium from the 
International HapMap Project CEU panel. (NA)= no sufficient proxy available on the Metabochip. Abbreviations: single nucleotide polymorphism (SNP), age at natural 
menopause (ANM), Population Architecture using Genomics and Epidemiology (PAGE), chromosome (Chr), minor allele frequency (MAF), coded allele frequency (CAF). 
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Appendix C. SNPs associated (p≤1x10-04) with AM in African American women from the PAGE Study.  
 
CHR 
 
SNP 
 
GENE 
 
GENE 
REGION 
 
CODED 
ALLELE 
 MODEL 1 MODEL 2 
CAF BETA SE P 
VALUE 
BETA SE P VALUE 
11 rs11604207 RSF1 upstream A 0.58 0.38 0.08 1.59E-06 0.38 0.08 1.82E-06 
17 rs59622946 HEXIM2 flanking A 0.01 1.01 0.23 1.14E-05 1.04 0.23 4.93E-06 
1 rs2753399 ZFYVE9 intronic A 0.08 0.31 0.07 1.16E-05 0.30 0.07 1.63E-05 
5 rs40602 MAST4 intronic A 0.57 0.16 0.04 1.26E-05 0.15 0.04 3.65E-05 
15 rs7181548 C15orf27 intronic A 0.58 -0.16 0.04 1.96E-05 -0.16 0.04 2.36E-05 
8 rs4922116 LPL downstream A 0.15 -0.22 0.05 2.18E-05 -0.21 0.05 3.10E-05 
8 rs1372339 LPL downstream A 0.84 0.21 0.05 2.19E-05 0.21 0.05 2.89E-05 
17 rs116523982 HEXIM2 flanking A 0.01 0.96 0.23 2.51E-05 0.99 0.23 1.11E-05 
17 rs3744412 HEXIM2 5’ UTR C 0.01 0.96 0.23 2.52E-05 1.00 0.23 1.12E-05 
3 rs11922097 PPP2R3A upstream A 0.55 0.16 0.04 2.55E-05 0.16 0.04 1.64E-05 
17 rs16939893 HEXIM2 intronic A 0.004 1.26 0.30 2.73E-05 1.29 0.30 1.46E-05 
6 rs73725617 PHACTR1 intronic A 0.99 -0.64 0.15 3.11E-05 -0.60 0.15 6.83E-05 
7 rs11979121 TFEC upstream A 0.98 -0.52 0.13 4.50E-05 -0.51 0.13 5.41E-05 
3 rs1320623 LSG1 intronic A 0.37 0.15 0.04 5.64E-05 0.15 0.04 5.56E-05 
12 rs61507607 CUX2 intronic A 0.43 0.15 0.04 5.85E-05 0.13 0.04 3.15E-04 
11 rs11224447 ARHGAP42 intronic A 0.07 0.30 0.07 6.11E-05 0.30 0.07 6.11E-05 
19 rs1273516 CYP4F22 downstream A 0.40 0.15 0.04 6.33E-05 0.15 0.04 6.29E-05 
6 rs9503555 IRF4 upstream A 0.78 0.18 0.04 6.83E-05 0.18 0.04 6.03E-05 
15 rs8032832 FAM174B upstream A 0.35 -0.15 0.04 7.26E-05 -0.16 0.04 3.70E-05 
5 rs17730451 C5orf41 3’ flanking A 0.05 0.34 0.09 7.53E-05 0.33  0.09 1.35E-04 
7 rs849326 JAZF1 upstream C 0.09 0.25 0.06 9.35E-05 0.24 0.06 1.07E-04 
Tests of association at p≤1x10-04 for Model 1 from individual SNP linear regressions adjusted for study site and principal components 
(Model 1) and study site, principal components, year of birth, and BMI (Model 2) in 4,159 African American women from the PAGE 
Study are shown.  For each significant test of association, the chromosome, rs number, nearest gene, location, coded allele, beta, 
standard error (SE), and p-value are given. Genes listed are nearest genes to the SNP as measured from the transcription start site for 
upstream SNPs or the transcription stop site for downstream SNPs. Abbreviations: single nucleotide polymorphism (SNP), age at 
menarche (AM), Population Architecture using Genomics and Epidemiology (PAGE), chromosome (CHR), coded allele frequency 
(CAF), standard error (SE). 
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Appendix D. SNP associations with ANM in African American women from the PAGE Study.  
 
CHR SNP GENE GENE REGION CODED 
ALLELE 
CAF BETA SE P 
VALUE 
19 rs189596789 LDLR upstream A 0.006 1.09 0.20 4.98E-08 
11 rs79972789 KCNQ1 intronic C 0.997 -1.76 0.34 1.90E-07 
5 rs181686584 COL4A3BP intronic A 0.002 2.35 0.46 2.85E-07 
6 rs114158228 CDKAL1 intronic A 9E-04 3.60 0.73 7.12E-07 
21 rs117876865 KCNE1 downstream A 9E-04 3.58 0.73 8.55E-07 
10 rs11195485 ADRA2A downstream A 0.002 2.89 0.59 9.63E-07 
11 rs11224401 ARHGAP42 intronic A 0.997 2.20 0.45 1.13E-06 
1 rs78937547 SEC16B downstream A 0.992 -1.97 0.41 1.89E-06 
17 rs75394140 KCNJ2 downstream A 0.002 -0.93 0.21 6.48E-06 
11 rs76988592 KCNJ1 downstream A 0.702 -0.93 0.21 7.24E-06 
3 rs114451007 PPARG intronic A 0.253 1.70 0.38 9.30E-06 
12 rs10846771 DHX37 downstream A 0.997 -0.16 0.04 9.43E-06 
11 rs12804247 CCDC81 upstream A 0.655 0.17 0.04 1.45E-05 
1 rs76571116 SEC16B downstream A 3E-04 -1.54 0.36 1.57E-05 
17 rs17634167 TTLL6 cds-synon. A 6E-04 -0.34 0.08 1.62E-05 
7 rs117382431 FKBP6 downstream A 0.999 4.38 1.03 2.17E-05 
6 rs76294174 LOC100130357 intronic C 3E-04 4.38 1.03 2.17E-05 
6 rs74918542 SCGN intronic A 0.999 -4.38 1.03 2.17E-05 
1 rs76078015 NOS1AP intronic A 9E-04 4.38 1.03 2.17E-05 
18 rs117454233 MC4R downstream A 0.999 -4.38 1.03 2.17E-05 
3 rs73025249 PPARG intronic A 9E-04 4.38 1.03 2.17E-05 
3 rs182857216 ETV5 intronic A 0.999 -4.38 1.03 2.17E-05 
3 rs73027210 PPARG intronic A 9E-04 4.38 1.03 2.17E-05 
9 rs75220302 CDKN2A downstream A 0.999 -4..38 1.03 2.18E-05 
9 rs74599268 CDKN2B upstream A 3E-04 4.38 1.03 2.18E-05 
9 rs3731245 CDKN2A intronic A 3E-04 4.38 1.03 2.18E-05 
9 rs76774391 CDKN2B upstream C 3E-04 4.38 1.03 2.18E-05 
2 rs117258126 IRS1 downstream A 3E-04 4.38 1.03 2.18E-05 
9 rs3808846 CDKN2B 5' flanking A 3E-04 4.38 1.03 2.18E-05 
9 rs77706751 CDKN2B upstream A 6E-04 4.38 1.03 2.18E-05 
9 rs3808845 CDKN2B 5' flanking A 3E-04 4.38 1.03 2.18E-05 
9 rs76810097 CDKN2B upstream A 3E-04 4.38 1.03 2.18E-05 
9 rs36228836 CDKN2A 5' flanking A 3E-04 4.38 1.03 2.18E-05 
9 rs75039118 ADAMTS13 intronic A 0.999 -4.38 1.03 2.19E-05 
18 rs75914913 MC4R downstream A 3E-04 4.38 1.03 2.19E-05 
11 rs190060931 BUD13 downstream A 0.999 -4.38 1.03 2.21E-05 
2 rs186397905 IRS1 downstream C 3E-04 4.38 1.03 2.21E-05 
16 rs9934222 JPH3 cds-synon. A 0.163 -0.19 0.04 2.28E-05 
15 rs72751410 MAP2K5 intronic A 0.998 -1.51 0.36 2.30E-05 
15 rs72747452 LOC100506686 intronic A 0.002 1.51 0.36 2.30E-05 
11 rs180751580 NUCB2 missense C 0.999 -4.36 1.03 2.30E-05 
3 rs186437034 SCN5A intronic A 0.999 -2.46 0.58 2.45E-05 
7 rs78912482 JAZF1 upstream A 0.012 0.64 0.15 3.04E-05 
1 rs116071515 SEC16B intronic A 0.002 1.88 0.45 3.06E-05 
6 rs1997770 OFCC1 downstream A 0.970 -0.41 0.10 3.55E-05 
7 rs118135044 DGKB upstream A 4E-04 4.22 1.02 3.73E-05 
11 rs74402657 ARFGAP2 intronic C 4E-04 2.93 0.72 3.96E-05 
1 rs117217277 SEC16B downstream A 0.999 -2.97 0.72 3.97E-05 
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CHR SNP GENE GENE REGION CODED 
ALLELE 
CAF BETA SE P 
VALUE 
1 rs116881786 SEC16B downstream A 0.999 -2.97 0.72 3.97E-05 
1 rs76471454 SEC16B downstream A 6E-04 2.97 0.72 3.97E-05 
1 rs79775735 SEC16B downstream A 6E-04 2.97 0.72 3.97E-05 
1 rs79468804 SEC16B downstream A 6E-04 2.97 0.72 3.97E-05 
1 rs74703854 SEC16B downstream A 0.999 -2.97 0.72 3.97E-05 
1 rs116923068 SEC16B downstream C 0.999 -2.97 0.72 3.97E-05 
1 rs117674205 SEC16B downstream C 0.999 -2.97 0.72 3.97E-05 
1 rs117260315 SEC16B downstream A 6E-04 2.97 0.72 3.97E-05 
1 rs76020919 SEC16B downstream A 6E-04 2.97 0.72 3.97E-05 
11 rs2306034 LRP4 UTR-3’ A 4E-04 2.94 0.72 3.99E-05 
2 rs189110944 IRS1 downstream A 4E-04 4.17 1.02 4.72E-05 
5 rs1976311 KCNN2 upstream C 0.996 -1.02 0.25 4.98E-05 
7 rs13245084 LOC100507421 intronic A 4E-04 4.14 1.02 5.07E-05 
6 rs115178932 LRRC16A intronic A 4E-04 4.14 1.02 5.07E-05 
1 rs77353590 SYF2 downstream A 0.009 0.74 0.18 5.42E-05 
2 rs111826230 APOB upstream A 0.984 -0.58 0.14 5.47E-05 
11 rs193030163 DDB2 upstream C 0.999 -4.11 1.02 5.57E-05 
11 rs114702513 KCNQ1 intronic A 0.996 -1.23 0.31 5.60E-05 
6 rs117124693 PHACTR1 intronic A 0.999 -4.11 1.02 5.62E-05 
6 rs181947983 SLC17A3 upstream A 4E-04 4.11 1.02 5.62E-05 
15 rs183951867 CHRNB4 upstream A 9E-04 4.11 1.02 5.62E-05 
9 rs191930498 CDKN2B upstream C 4E-04 4.10 1.02 5.83E-05 
17 rs192656758 CCT6B downstream A 4E-04 4.10 1.02 5.86E-05 
7 rs740259 JAZF1 5’ flanking A 4E-04 4.09 1.02 5.97E-05 
1 rs114389068 GPR153 cds-synon. A 0.005 0.93 0.23 6.07E-05 
11 rs185476610 KCNQ1 intronic A 0.999 -4.08 1.02 6.24E-05 
16 rs246192 NDRG4 intronic C 0.256 0.15 0.04 6.25E-05 
7 rs192457106 JAZF1 intronic A 0.999 -4.08 1.02 6.35E-05 
7 rs73702566 WBSCR22 intronic A 0.999 -4.08 1.02 6.35E-05 
6 rs187190790 TAP2D upstream A 0.999 -4.08 1.02 6.38E-05 
7 rs74984879 DGKB upstream C 0.999 -2.04 0.51 6.40E-05 
11 rs184056970 ARAP1 intronic A 4E-04 4.07 1.02 6.53E-05 
3 rs76909367 COLQ intronic A 4E-04 4.06 1.02 6.89E-05 
10 rs11187795 PLCE1 intronic A 4E-04 4.06 1.02 6.93E-05 
6 rs186129489 TFAP2D intronic A 4E-04 4.05 1.02 7.12E-05 
2 rs73923981 BRE intronic A 9E-04 4.05 1.02 7.32E-05 
15 rs180807356 ADAMTS7 upstream A 0.999 -4.04 1.02 7.52E-05 
5 rs10062135 NPR3 intronic A 0.009 0.73 0.19 7.85E-05 
12 rs17568045 C12orf42 intronic A 0.993 -0.86 0.22 8.11E-05 
1 rs116411856 WARS2 upstream A 0.003 1.32 0.34 8.16E-05 
1 rs78696400 LYPLAL1 downstream A 0.985 -0.58 0.15 8.96E-05 
15 rs74979292 C15orf39 upstream A 0.002 1.49 0.38 9.29E-05 
11 rs144204188 TRIM66 intronic A 0.002 2.79 0.72 9.39E-05 
1 rs78411379 TBX15 intronic A 0.999 -2.27 0.58 9.62E-05 
15 rs190893945 ADAMTSL3 intronic A 0.998 -1.76 0.45 9.67E-05 
9 rs12555547 CDKN2B upstream C 0.998 -2.30 0.59 9.69E-05 
2 rs10932320 C2orf67 intronic A 0.807 -0.17 0.04 9.93E-05 
Tests of association at p≤1x10-04 from individual SNP linear regressions adjusted for study site and principal 
components in 1,860 African American women from the PAGE Study are shown.  For each significant test of 
association, the chromosome, rs number, nearest gene, location, coded allele, beta, standard error, and p-value 
are given.  Genes listed are nearest genes to the SNP as measured from the transcription start site for upstream 
SNPs or the transcription stop site for downstream SNPs. Abbreviations: single nucleotide polymorphism 
(SNP), age at natural menopause (ANM), Population Architecture using Genomics and Epidemiology (PAGE), 
chromosome (CHR), coded allele frequency (CAF), standard error (SE). 
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Appendix E. Power calculations for AM analysis for women in the PAGE Study. 
 
 
Shown are power calculations for the age at menarche study of African American women in the PAGE 
Study calculated using QUANTO. Models were for 4,159 independent individuals and a continuous 
trait, gene-only hypothesis assuming an additive model of inheritance and a 3.1x10-7 two-sided 
significance level. Abbreviations: age at menarche, AM; Population Architecture using Genomics and 
Epidemiology, PAGE. 
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Appendix F. Power calculations for ANM analysis for African American women in the PAGE Study. 
 
Shown are power calculations for the age at natural menopause study of African American women in 
the PAGE Study calculated using QUANTO. Models were for 1,860 independent individuals and a 
continuous trait, gene-only hypothesis assuming an additive model of inheritance and a 3.1x10-7 two-
sided significance level. Abbreviations: age at natural menopause, ANM; Population Architecture 
using Genomics and Epidemiology, PAGE.  
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Appendix G. SNPs analyzed in endometrial cancer meta-analysis. 
SNP Chr Gene Cancer type GWAS  author GWAS 
year 
rs7538876 1 PADI4, PADI6, 
RCC2, ARHGEF10L 
Basal cell carcinoma Stacey SN 2008 
rs1866967 1 PTPRU Prostate cancer Tao S 2012 
rs903263 1 PRKACB Male breast cancer Orr N 2012 
rs11249433 1 intergenic Breast cancer Thomas G 2009 
rs4072037 1 MUC1 Esophageal & gastric cancer Abnet CC 2010 
rs2808630 1 CRP Lung cancer Amos CL 2008 
rs3790844 1 NR5A2 Pancreatic cancer Petersen GM 2010 
rs6687758 1 DUSP10 Colorectal cancer Houlston RS 2010 
rs801114 1 RHOU Basal cell carcinoma Stacey SN 2008 
rs1465618 2 THADA Prostate cancer Eeles RA 2009 
rs10490113 2 intergenic Breast cancer Murabito JM 2007 
rs721048 2 EHBP1 Prostate cancer Gudmundsson J 2008 
rs6545977 2 EHBP1 Prostate cancer Eeles RA 2009 
rs4254535 2 intergenic Lung cancer Broderick P 2009 
rs10187424 
2 
GGCX, VAMP8, 
VAMP5, RNF181 Prostate cancer Kote-Jarai Z 2011 
rs12615966 2 LOC284998 Pancreatic cancer Low SK 2010 
rs3789080 2 ACOXL Prostate cancer Tao S 2012 
rs12621278 2 ITGA6 Prostate cancer Eeles RA 2009 
rs16867225 2 CWC22 Prostate cancer Tao S 2012 
rs13398206 2 PLCL1 Prostate cancer Tao S 2012 
rs6435862 2 BARD1 Neuroblastoma (high-risk) Capasso M 2009 
rs13387042 2 intergenic Breast cancer Stacey SN 2007 
rs966423 2 DIRC3 Thyroid cancer Gudmundsson J 2012 
rs1656402 2 EIF4E2 Lung cancer Sato Y 2010 
rs11892031 2 UGT1A Bladder cancer Rothman N 2010 
rs7584330 2 intergenic Prostate cancer Kote-Jarai Z 2011 
rs2292884 2 MLPH Prostate cancer Schumacher FR 2011 
rs975334 3 CNTN4 Gallbladder cancer Cha PC 2012 
rs4973768 3 SLC4A7 Breast cancer Turnbull C 2010 
rs1530057 3 RBMS3 Lung cancer Broderick P 2009 
rs2660753 3 intergenic Prostate cancer Eeles RA 2008 
rs17023900 3 intergenic Prostate cancer Cheng I 2012 
rs17181170 3 LINC00506 Prostate cancer Eeles RA 2009 
rs10934853 3 EEFSEC Colorectal cancer Spain SL 2009 
rs6763931 3 ZBTB38 Prostate cancer Kote-Jarai Z 2011 
rs6788895 3 SIAH2 Breast cancer Elgazzar S 2012 
rs2665390 3 TIPARP Ovarian cancer Goode EL 2010 
rs10936599 3 MYNN Colorectal cancer Houlston RS 2010 
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SNP Chr Gene Cancer type GWAS  author GWAS 
year 
rs710521 3 TP63 Bladder cancer Kiemeney LA 2008 
rs7626795 3 IL1RAP Lung cancer Amos CI 2008 
rs4927850 3 TFRC Pancreatic cancer Wu C 2011 
rs735172 4 EVC Prostate cancer Tao S 2012 
rs12500426 4 PDLIM5 Prostate cancer Eeles RA 2009 
rs17021918 4 PDLIM5 Prostate cancer Eeles RA 2009 
rs1789924 
4 ADH1C 
Upper aerodigestive tract 
cancers McKay JD 2011 
rs971074 
4 ADH7 
Upper aerodigestive tract 
cancers McKay JD 2011 
rs7679673 4 TET2 Prostate cancer Eeles RA 2009 
rs9790517 4 TET2 Breast Cancer Michailidou K 2013 
rs10069690 5 TERT Breast cancer Haiman CA 2011 
rs2736100 5 TERT Testicular germ cell cancer Turnbull C 2010 
rs4635969 5 TERT Pancreatic cancer Diergaarde B 2010 
rs4975616 5 CLPTM1L Lung cancer Broderick P 2009 
rs402710 5 TERT, CLPTM1L Lung cancer McKay JD 2008 
rs401681 5 CLPTM1L Lung cancer Wang Y 2008 
rs12653946 5 intergenic Prostate cancer Takata R 2010 
rs6879627 5 LOC731559 Pancreatic cancer Low SK 2010 
rs2121875 5 FGF10 Prostate cancer Kote-Jarai Z 2011 
rs4415084 5 intergenic Breast cancer Fletcher O 2011 
rs7716600 5 MRPS30 Breast cancer Li J 2010 
rs981782 5 intergenic Breast cancer Easton DF 2007 
rs16886165 5 MAP3K1 Breast cancer Thomas G 2009 
rs889312 5 MAP3K1 Breast cancer Easton DF 2007 
rs10940579 5 ACTBL2 Prostate cancer Tao S 2012 
rs10052657 5 PDE4D Esophageal cancer Wu C 2011 
rs7717572 5 CD180 Prostate cancer Tao S 2012 
rs6869388 5 KIAA0825 Gallbladder cancer Cha PC 2012 
rs4624820 5 SPRY4 Testicular germ cell cancer Rapley EA 2009 
rs6556756 5 intergenic Breast cancer Murabito JM 2007 
rs9502893 6 FOXQ1 Pancreatic cancer Low SK 2010 
rs10456809 6 KIF13A Prostate cancer Tao S 2012 
rs2523395 6 LOC285830 Prostate cancer Tao S 2012 
rs130067 6 CCHCR1 Prostate cancer Kote-Jarai Z 2011 
rs3117582 6 BAT3,MSH5 Lung cancer Wang Y 2008 
rs1321311 6 CDKN1A Colorectal cancer Dunlop MG 2012 
rs10498792 6 PKHD1 Prostate cancer Murabito JM 2007 
rs763780 6 IL17F Pancreatic cancer Innocenti F 2011 
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SNP Chr Gene Cancer type GWAS  author GWAS 
year 
rs9363918 6 BAI3 Pancreatic cancer Wu C 2011 
rs17530068 6 FAM46A, C6orf37 Breast cancer Siddiq A 2012 
rs339331 6 GPRC6A,RFX6 Prostate cancer Takata R 2010 
rs2180341 6 ECHDC1,RNF146 Breast cancer Gold B 2008 
rs3757318 6 ESR1,C6orf97 Breast cancer Turnbull C 2010 
rs3734805 6 ESR1 Breast cancer Fletcher O 2011 
rs2046210 6 ESR1, C6orf97 Breast cancer Zheng W 2009 
rs651164 6 intergenic Prostate cancer Eeles RA 2009 
rs9364554 6 SLC22A3 Prostate cancer Eeles RA 2008 
rs7758229 6 SLC22A3 Colorectal cancer Cui R 2011 
rs3016539 6 PARK2 Pancreatic cancer Low SK 2010 
rs12155172 7 intergenic Prostate cancer Eeles RA 2009 
rs10486567 7 JAZF1 Prostate cancer Thomas G 2008 
rs7789197 7 INHBA Prostate cancer Tao S 2012 
rs10263639 7 intergenic Breast cancer Murabito JM 2007 
rs6465657 7 LMTK2 Prostate cancer Eeles RA 2008 
rs9649213 7 BAIAP2L1 Prostate cancer Tao S 2012 
rs1495741 8 NAT2 Bladder cancer Rothman N 2010 
rs1512268 8 NKX3.1 Prostate cancer Eeles RA 2009 
rs10503733 8 intergenic Prostate cancer Cheng I 2012 
rs7832232 8 RNF5P1 Pancreatic cancer Low SK 2010 
rs16892766 8 EIF3H Colorectal cancer Tomlinson IP 2008 
rs10088262 8 FAM91A1 Pancreatic cancer Low SK 2010 
rs1016343 8 intergenic Prostate cancer Eeles RA 2008 
rs13252298 8 intergenic Prostate cancer Schumacher FR 2011 
rs1456315 8 intergenic Prostate cancer Takata R 2010 
rs13254738 8 PRNCR1 Prostate cancer Cheng I 2012 
rs6983561 8 intergenic Prostate cancer Cheng I 2012 
rs10505483 8 intergenic Prostate cancer Cheng I 2012 
rs16902094 8 intergenic Prostate cancer Gudmundsson J 2009 
rs445114 8 intergenic Prostate cancer Gudmundsson J 2009 
rs13281615 8 intergenic Breast cancer Easton DF 2007 
rs1562430 8 intergenic Breast cancer Turnbull C 2010 
rs10505477 8 ORF DQ515897 Colorectal cancer Zanke BW 2007 
rs6983267 8 POU5F1B Lung cancer Spinola M 2007 
rs7014346 
8 
POU5FIP1, 
HsG57825, 
DQ515897 Colorectal cancer Tenesa A 2008 
rs4242382 8 intergenic Prostate cancer Thomas G 2008 
 149 
 
SNP Chr Gene Cancer type GWAS  author GWAS 
year 
rs7837688 8 intergenic Prostate cancer Takata R 2010 
rs9642880 8 MYC, BC042052 Bladder cancer Kiemeney LA 2008 
rs10088218 8 MYC,THEM75 Ovarian cancer Goode EL 2010 
rs2294008 8 PSCA Bladder cancer Wu X 2009 
rs7040024 9 DMRT1 Testicular cancer Kanetsky PA 2011 
rs755383 9 DMRT1 Testicular germ cell cancer Turnbull C 2010 
rs3814113 
9 
BNC2, LOC648570, 
CNTLN Ovarian cancer Song H 2009 
rs1412829 9 intergenic Glioma (high-grade) Wrensch M 2009 
rs1011970 9 CDKN2A,CDKN2B Breast cancer Turnbull C 2010 
rs11141915 9 DAPK1 Pancreatic cancer Kiyotani K 2012 
rs965513 9 FOXE1 Thyroid cancer Gudmundsson J 2009 
rs817826 9 RAD23B, KLF4 Prostate cancer Xu J 2012 
rs7847271 9 TNC Prostate cancer Tao S 2012 
rs505922 9 ABO Pancreatic cancer Amundadottir L 2009 
rs10795668 10 intergenic Colorectal cancer Tomlinson IP 2008 
rs3123078 10 intergenic Prostate cancer Eeles RA 2009 
rs10993994 10 MSMB Prostate cancer Thomas G 2008 
rs1926203 10 ACTA2 Lung cancer Broderick P 2009 
rs2274223 10 PLCE1 Esophageal cancer Wu C 2011 
rs3750817 10 FGFR2 Breast cancer Elgazzar S 2012 
rs2981579 10 FGFR2 Breast cancer Thomas G 2009 
rs1219648 10 FGFR2 Breast cancer Hunter DJ 2007 
rs2981582 10 FGFR2 Breast cancer Easton DF 2007 
rs10510102 10 FGFR2 Breast cancer Fletcher O 2011 
rs4962416 10 CTBP2 Prostate cancer Thomas G 2008 
rs3817198 11 LSP1 Breast cancer Easton DF 2007 
rs909116 11 LSP1 Breast cancer Turnbull C 2010 
rs7127900 
11 
IGF2, IGF2AS, INS, 
TH Prostate cancer Eeles RA 2009 
rs11228565 11 intergenic Prostate cancer Gudmundsson J 2009 
rs7931342 11 intergenic Prostate cancer Eeles RA 2008 
rs10896449 11 intergenic Prostate cancer Thomas G 2008 
rs7130881 11 intergenic Prostate cancer Eeles RA 2009 
rs614367 
11 
MYEOV,CCND1,OR
AOV1,FGF19,FGF4,F
GF3 Breast cancer Turnbull C 2010 
rs3802842 11 intergenic Colorectal cancer Tenesa A 2008 
rs11062040 12 DCP1B Pancreatic cancer Innocenti F 2011 
rs2900174 12 PRB2 Pancreatic cancer Innocenti F 2011 
rs2711721 12 AMIGO2 Prostate cancer Tao S 2012 
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SNP Chr Gene Cancer type GWAS  author GWAS 
year 
rs4489787 12 ANP32D Prostate cancer Tao S 2012 
rs10875943 12 PRPH Prostate cancer Kote-Jarai Z 2011 
rs11169552 12 DIP2B, ATF1 Colorectal cancer Houlston RS 2010 
rs902774 12 KRT8, EIF4B, TENC1 Prostate cancer Schumacher FR 2011 
rs1878022 12 CMKLR1 Prostate cancer FitzGerald LM 2011 
rs9600079 13 intergenic Prostate cancer Takata R 2010 
rs9543325 13 KLF5, KLF12 Pancreatic cancer Petersen GM 2010 
rs1886449 13 LOC730242 Pancreatic cancer Low SK 2010 
rs2039553 13 NDFIP2 Pancreatic cancer Low SK 2010 
rs16944141 13 MIR622 Prostate cancer Tao S 2012 
rs1926657 13 ABCC4 Breast cancer Murabito JM 2007 
rs17450420 13 SLC10A2 Esophageal cancer Wu C 2012 
rs1243647 14 RNASE9 Prostate cancer Tao S 2012 
rs944289 14 NKX2-1 Thyroid cancer Gudmundsson J 2009 
rs4444235 14 BMP4 Colorectal cancer Houlston RS 2008 
rs1314913 14 RAD51B Male breast cancer Orr N 2012 
rs3784099 14 RAD51L1 Breast cancer Shu XO 2012 
rs999737 14 RAD51L1 Breast cancer Thomas G 2009 
rs3850370 
14 
SKIIP, SNW1, 
ALKBH1, NRXN3 Lung cancer Hu L 2012 
rs4322600 14 GALC Breast cancer Chen F 2012 
rs2400997 14 MIR656 Prostate cancer Tao S 2012 
rs748404 15 TGM5 Lung cancer Broderick P 2009 
rs1876206 15 FBN1 Breast cancer Murabito JM 2007 
rs8034191 
15 
CHRNA3,CHRNA5, 
CHRNB4, PSMA4, 
LOC123688 Lung cancer Hung RJ 2008 
rs1051730 15 intergenic Lung cancer McKay JD 2008 
rs8042374 15 CHRNA3 Lung cancer Wang Y 2008 
rs9635542 16 PPL Lung cancer Wei S 2012 
rs8057939 16 C16orf78 Prostate cancer Tao S 2012 
rs3803662 16 TNRC9 Breast cancer Stacey SN 2007 
rs3112612 16 TOX3 Breast cancer Fletcher O 2011 
rs9929218 16 CDH1 Colorectal cancer Houlston RS 2008 
rs9934948 16 intergenic Breast cancer Shu XO 2012 
rs4924935 17 PRPSAP2 Pancreatic cancer Low SK 2010 
rs2257205 17 RNF43 Pancreatic cancer Low SK 2010 
rs16951095 18 LAMA1 Lung cancer Yoon KA 2010 
rs2847281 
18 PTPN2 
Esophageal cancer 
(squamous cell) Wu C 2012 
rs998124 18 MIR4319 Prostate cancer Tao S 2012 
 151 
 
SNP Chr Gene Cancer type GWAS  author GWAS 
year 
rs4939827 18 SMAD7 Colorectal cancer Broderick P 2007 
rs7504990 18 DCC Gallbladder cancer Cha PC 2012 
rs1978503 18 intergenic Breast cancer Murabito JM 2007 
rs8170 19 C19orf62,MERIT40 Ovarian cancer Bolton KL 2010 
rs2363956 19 ANKLE1 Ovarian cancer Bolton KL 2010 
rs8102137 19 CCNE1 Bladder cancer Rothman N 2010 
rs10411210 19 RHPN2 Colorectal cancer Houlston RS 2008 
rs8102476 19 intergenic Prostate cancer Gudmundsson J 2009 
rs2735839 19 KLK3 Prostate cancer Eeles RA 2008 
rs103294 19 intergenic Prostate cancer Xu J 2012 
rs961253 20 intergenic Colorectal cancer Houlston RS 2008 
rs4925386 20 LAMA5 Colorectal cancer Houlston RS 2010 
rs6010620 20 RTEL1 Glioma (high-grade) Wrensch M 2009 
rs4809324 20 RTEL1 Glioma (high-grade) Wrensch M 2009 
rs372883 21 BACH1 Pancreatic cancer Wu C 2011 
rs458685 21 GRIK1 Breast cancer Murabito JM 2007 
rs1209950 21 ETS2 Lung cancer Sato Y 2010 
rs9981861 21 DSCAM Breast cancer Li J 2010 
rs1547374 21 TFF1 Pancreatic cancer Wu C 2011 
rs5751168 22 ZNF280B Prostate cancer Tao S 2012 
rs6005451 22 MN1 Prostate cancer Tao S 2012 
rs738722 
22 CHEK2,HSCB 
Esophageal cancer and 
gastric cancer Abnet CC 2010 
rs2239815 
22 XBP1 
Esophageal cancer 
(squamous cell) Wu C 2012 
rs1014971 22 CBX6,APOBEC3A Bladder cancer Rothman N 2010 
rs9623117 22 TNRC6B Prostate cancer Sun J 2009 
rs5759167 22 intergenic Prostate cancer Eeles RA 2009 
rs5945572 
X 
NUDT10, NUDT11, 
LOC340602 Prostate cancer Gudmundsson J 2008 
Shown are SNPs associated with cancer in previous GWAS that were genotyped in EAGLE BioVU for association with 
endometrial cancer. Chromosome location, previous cancer association, first author and year of the first GWAS to 
publish an association of the SNP with cancer. Abbreviations: single nucleotide polymorphism (SNP), chromosome 
(Chr), genome-wide association study (GWAS). Adapted from Setiawan VW et al. 2014.  
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Appendix H. SNP associations with endometrial cancer in EAGLE BioVU. 
CHR SNP GENE A1 TEST NMISS OR SE P-value 
8 RS10086908 intergenic T ADD 92 8.059 0.8012 0.009196 
8 RS10090154 intergenic A ADD 92 3.555 0.7785 0.1033 
19 RS10411210 RHPN2 C ADD 92 4.339 1.278 0.251 
2 RS1045485 CASP8 G ADD 92 0.5402 0.6592 0.3503 
7 RS10486567 JAZF1 G ADD 92 1.025 0.6064 0.9671 
2 RS10490113 intergenic C ADD 92 0.207 1.048 0.1327 
8 RS10505477 ORF DQ515897 A ADD 92 0.2604 0.5934 0.02338 
15 RS1051730 intergenic A ADD 92 1.251 0.4745 0.6369 
12 RS10778826 PPFIA2 A ADD 92 4.407 0.6341 0.01933 
10 RS10795668 intergenic G ADD 92 2.54 0.666 0.1616 
11 RS10896449 intergenic G ADD 91 1.319 0.4948 0.5755 
10 RS10993994 MSMB T ADD 92 0.9444 0.5785 0.9212 
11 RS11228565 intergenic A ADD 92 0.9837 0.5761 0.9772 
1 RS11249433 intergenic C ADD 92 1.994 0.4832 0.1531 
16 RS11649338 intergenic C ADD 92 1.973 0.5418 0.2098 
17 RS11649743 HNF1B G ADD 92 2.847 0.8802 0.2346 
16 RS11861609 CDH13 C ADD 92 1.347 0.4561 0.5139 
7 RS12155172 intergenic A ADD 92 1.183 0.5354 0.7539 
11 RS12418451 RP11-554A11.8 A ADD 89 1.442 0.5311 0.4909 
4 RS12500426 PDLIM5 A ADD 92 1.842 0.5397 0.2576 
8 RS12543663 intergenic C ADD 92 0.4964 0.5742 0.2225 
2 RS12621278 ITGA6 A ADD 92 8.56E+07 7454 0.998 
8 RS13254738 PRNCR1 C ADD 89 0.8486 0.5218 0.7531 
8 RS13281615 intergenic T ADD 92 0.6143 0.5009 0.3307 
2 RS13387042 intergenic A ADD 92 0.4301 0.4724 0.07411 
11 RS1393350 TYR A ADD 92 1.458 0.5436 0.4878 
2 RS1465618 THADA T ADD 92 7.129 0.8207 0.01669 
8 RS1512268 intergenic T ADD 89 0.6309 0.5398 0.3935 
3 RS1530057 RBMS3 A ADD 92 0.6356 1.009 0.6534 
9 RS1571801 DAB2IP T ADD 92 1.6 0.4831 0.3308 
5 RS16891982 SLC45A2 G ADD 89 6.37E+08 1.01E+04 0.9984 
8 RS16892766 EIF3H C ADD 89 0.3024 1.234 0.3323 
8 RS16901979 intergenic A ADD 88 6.44E-09 1.05E+04 0.9986 
8 RS16902094 intergenic G ADD 91 1.218 0.6842 0.7732 
4 RS17021918 PDLIM5 C ADD 92 1.839 0.6172 0.3235 
15 RS1876206 FBN1 G ADD 89 0.4745 0.7257 0.3043 
10 RS1926203 ACTA2 T ADD 89 1.53 0.5566 0.4452 
13 RS1926657 ABCC4 T ADD 92 2.166 0.5809 0.1832 
18 RS1978503 intergenic G ADD 91 1.092 0.656 0.893 
6 RS2046210 ESR1, C6orf97 A ADD 91 2.623 0.6246 0.1227 
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CHR SNP GENE A1 TEST NMISS OR SE P-value 
17 RS2075555 COL1A1 T ADD 92 1.394 0.7214 0.6453 
22 RS2284063 PLA2G6 A ADD 92 1.028 0.5285 0.9584 
20 RS2296241 CYP24A1 G ADD 92 1.023 0.5002 0.9644 
19 RS25487 XRCC1 A ADD 92 1.009 0.5619 0.9876 
16 RS258322 CDK10 A ADD 92 0.9609 0.8933 0.9644 
3 RS2660753 intergenic T ADD 92 1.72 0.8109 0.5037 
19 RS266849 intergenic A ADD 91 0.7578 0.5888 0.6376 
2 RS2710647 EHBP1 C ADD 88 1.222 0.5054 0.6917 
19 RS2735839 KLK3 G ADD 92 0.6574 0.6681 0.5302 
5 RS2736100 TERT G ADD 88 1.843 0.502 0.2234 
8 RS2928679 intergenic A ADD 92 0.8392 0.4819 0.716 
10 RS2981578 FGFR2 G ADD 92 1.064 0.46 0.8935 
10 RS2981582 FGFR2 T ADD 92 0.8353 0.5096 0.724 
6 RS3131379 MSH5-SAPCD1 T ADD 90 1.191 0.718 0.8073 
5 RS31489 CLPTM1L C ADD 87 1.198 0.518 0.7275 
10 RS3750817 FGFR2 C ADD 92 1.302 0.4951 0.5943 
11 RS3802842 intergenic C ADD 92 0.8701 0.6396 0.8278 
16 RS3803662 TNRC9 T ADD 92 1.108 0.5643 0.8552 
9 RS3814113 BNC2, LOC648570, 
CNTLN 
T ADD 92 2.508 0.6238 0.1404 
11 RS3817198 LSP1 C ADD 92 1.548 0.5195 0.4003 
16 RS3863435 intergenic C ADD 92 1.119 0.4735 0.8122 
5 RS401681 CLPTM1L C ADD 92 1.739 0.537 0.3027 
5 RS402710 TERT, CLPTM1L C ADD 92 1.236 0.5136 0.6804 
2 RS4254535 intergenic C ADD 92 0.7048 0.6259 0.5761 
6 RS4324798 intergenic A ADD 88 0.9292 0.8394 0.9302 
5 RS4415084 intergenic T ADD 91 0.5186 0.5361 0.2206 
17 RS4430796 HNF1B G ADD 92 0.6604 0.5766 0.4718 
14 RS4444235 BMP4 C ADD 92 0.6297 0.5041 0.3588 
21 RS458685 GRIK1 C ADD 92 1.626 0.6899 0.4811 
4 RS4588 GC A ADD 89 0.643 0.5992 0.461 
9 RS4636294 intergenic A ADD 89 1.054 0.5592 0.9249 
15 RS4779584 intergenic T ADD 92 1.223 0.5631 0.7203 
16 RS4782780 CDH13 T ADD 92 1.105 0.4615 0.8292 
16 RS4785763 AFG3L1P A ADD 90 0.9574 0.5578 0.9378 
3 RS4857841 EEFSEC A ADD 92 0.7802 0.582 0.6698 
18 RS4939827 SMAD7 T ADD 92 0.9456 0.5161 0.9137 
8 RS4961199 intergenic A ADD 92 0.9528 0.6984 0.9449 
10 RS4962416 CTBP2 C ADD 92 2.734 0.6047 0.09627 
3 RS4973768 SLC4A7 T ADD 92 0.6317 0.5361 0.3916 
5 RS4975616 CLPTM1L A ADD 92 2.079 0.6011 0.2234 
22 RS5759167 intergenic G ADD 92 1.653 0.5844 0.3896 
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CHR SNP GENE A1 TEST NMISS OR SE P-value 
X RS5945572 NUDT10, NUDT11, 
LOC340602 
A ADD 92 0.5652 0.5983 0.3402 
X RS5945619 intergenic C ADD 89 0.5694 0.5963 0.345 
20 RS6068816 CYP24A1 T ADD 92 2.637 0.8508 0.2544 
8 RS620861 LOC101930033 G ADD 91 0.3639 0.5966 0.09016 
7 RS6465657 LMTK2 C ADD 92 0.6371 0.5054 0.3724 
17 RS6504950 STXBP4 G ADD 92 0.644 0.5058 0.3842 
5 RS6556756 intergenic G ADD 92 1.225 0.8238 0.8053 
8 RS6983267 POU5F1B G ADD 92 0.2593 0.5855 0.02115 
8 RS7000448 intergenic T ADD 92 0.4986 0.6317 0.2705 
8 RS7014346 POU5FIP1, 
HsG57825, DQ515897 
A ADD 92 0.4448 0.5552 0.1445 
9 RS7023329 MTAP A ADD 92 0.8699 0.5484 0.7994 
4 RS7041 GC T ADD 92 0.7994 0.4734 0.6363 
11 RS7117034 intergenic T ADD 92 0.9837 0.5761 0.9772 
9 RS719725 intergenic A ADD 92 1.083 0.5294 0.88 
12 RS731236 VDR C ADD 89 1.388 0.5071 0.5177 
15 RS748404 TGM5 T ADD 90 0.3624 0.5831 0.08175 
17 RS7501939 HNF1B C ADD 92 1.401 0.5466 0.5371 
3 RS7626795 IL1RAP G ADD 88 0.2351 1.158 0.2112 
4 RS7679673 TET2 C ADD 88 0.4859 0.5465 0.1866 
8 RS7837688 intergenic T ADD 92 3.555 0.7785 0.1033 
8 RS7841060 PRNCR1 G ADD 92 0.404 0.7368 0.2186 
15 RS8042374 CHRNA3 G ADD 90 0.8378 0.6759 0.7934 
19 RS8102476 intergenic C ADD 92 1.956 0.5504 0.2229 
5 RS889312 MAP3K1 C ADD 92 1.27 0.5024 0.634 
20 RS910873 PIGU A ADD 91 0.8671 0.9447 0.88 
6 RS9295740 intergenic A ADD 92 1.083 0.5632 0.8873 
15 RS931794 HYKK G ADD 92 1.525 0.4834 0.383 
6 RS9364554 SLC22A3 T ADD 92 1.691 0.5365 0.3275 
20 RS961253 intergenic A ADD 92 2.16 0.5243 0.1418 
22 RS9623117 TNRC6B C ADD 92 2.011 0.528 0.1857 
5 RS981782 intergenic T ADD 92 1.64 0.4911 0.3138 
16 RS9929218 CDH1 G ADD 92 1.2 0.5147 0.723 
14 RS999737 RAD51L1 C ADD 89 1.643 0.6949 0.475 
Data shown are SNP associations for EAGLE BioVU endometrial cancer analysis. Gene shown is the closest 
gene to the SNP. Abbreviations: chromosome (CHR), single nucleotide polymorphism (SNP), risk allele 
(A1), number of cases and controls used in each logistic regression (NMISS), odds ratio (OR), standard error 
(SE). 
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Shown are power calculations for the EAGLE BioVU endometrial cancer study calculated using QUANTO. (A) 206 cases, 11 
controls/case; (B) 20 cases, 8 controls/case. Models were for unmatched case-control, gene-only hypothesis assuming a log-additive 
model of inheritance and a 4.2x10-4 two-sided significance level.
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Appendix I. Power calculations for EAGLE BioVU endometrial cancer study.  
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Appendix J. eMERGE Network site contributions to TSH levels study. 
Site Primary Phenotype Total # 
Genotyped 
(n) 
TSH Levels 
European 
Americans (n) 
African 
Americans (n) 
Marshfield Clinic Cataracts 4,113 1,157 0 
Vanderbilt Cardiac Conductance 2,712 284 88 
Group Health Dementia 2,532 1,167 64 
Mayo Clinic Peripheral Artery Disease 3,043 1,881 10 
Northwestern Type 2 Diabetes 1,217 12 189 
Total  13,617 4,501 351 
Primary phenotypes reflects initial GWAS phenotype investigated at each site for the eMERGE Network. Total 
(n) genotyped are for each site’s primary phenotype GWAS. Euthyroid subjects for serum thyroid stimulating 
hormone (TSH) level analysis are a subset of the total number genotyped in eMERGE for the primary 
phenotypes. All sites contributed European Americans to the serum TSH level analysis; all sites except 
Marshfield Clinic contributed African Americans. Data shown are counts (n). 
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Appendix K. SNP associations for serum TSH levels in eMERGE study European Americans. 
CHR SNP GENE GENE 
REGION 
CODED 
ALLELE 
CAF BETA (SE) P-VALUE 
5 rs1382879 PDE8B intronic G 0.39 0.09 (0.01) 7.16E-18 
5 rs2046045 PDE8B intronic C 0.40 0.09 (0.01) 1.85E-17 
5 rs989758 PDE8B intronic T 0.36 0.08 (0.01) 1.33E-14 
5 rs9687206 PDE8B intronic G 0.43 0.08 (0.01) 5.52E-14 
5 rs12515498 PDE8B intronic C 0.26 0.07 (0.01) 3.27E-10 
5 rs6885813 PDE8B intronic A 0.25 0.06 (0.01) 4.05E-08 
5 rs1096752 PDE8B intronic A 0.45 -0.05 (0.01) 6.30E-07 
5 rs13361710 PDE8B intronic T 0.24 0.06 (0.01) 6.60E-07 
9 rs10759944 FOXE1 upstream A 0.33 -0.05 (0.01) 1.08E-06 
9 rs965513 FOXE1 upstream A 0.34 -0.05 (0.01) 1.09E-06 
9 rs925489 FOXE1 upstream C 0.34 -0.05 (0.01) 1.79E-06 
9 rs7850258 FOXE1 upstream A 0.33 -0.05 (0.01) 1.85E-06 
2 rs10496992 - intergenic G 0.38 0.05 (0.01) 2.22E-06 
2 rs1861628 IGFBP5 upstream T 0.27 -0.05 (0.01) 3.68E-06 
5 rs4348174 ITGA1 upstream C 0.40 0.05 (0.01) 3.97E-06 
9 rs657152 ABO intronic T 0.38 0.05 (0.01) 4.18E-06 
7 rs740083 VWC2 upstream A 0.24 -0.05 (0.01) 4.56E-06 
7 rs813379 CDK14 intronic G 0.06 -0.10 (0.02) 4.57E-06 
2 rs2712168 IGFBP5 upstream C 0.13 0.07 (0.01) 4.98E-06 
5 rs256438 THBS4 intronic C 0.36 0.05 (0.01) 5.53E-06 
18 rs4570936 - intergenic T 0.22 -0.05 (0.01) 5.73E-06 
2 rs6546537 AAK1 intronic C 0.28 -0.05 (0.01) 5.92E-06 
9 rs7855088 ANP32B upstream C 0.44 -0.05 (0.01) 6.23E-06 
9 rs925487 FOXE1 downstream G 0.37 -0.05 (0.01) 6.24E-06 
7 rs803174 CDK14 intronic G 0.06 -0.10 (0.02) 6.74E-06 
5 rs2438632 THBS4 downstream A 0.39 0.05 (0.01) 6.88E-06 
2 rs13020935 IGFBP5 upstream G 0.28 -0.05 (0.01) 7.02E-06 
5 rs12520862 PDE8B intronic T 0.14 0.06 (0.01) 7.48E-06 
9 rs10984103 FOXE1 downstream A 0.37 -0.05 (0.01) 7.81E-06 
9 rs907580 FOXE1 downstream A 0.27 -0.05 (0.01) 8.20E-06 
8 rs2466067 NRG1 intronic C 0.31 -0.05 (0.01) 8.42E-06 
9 rs7870926 ANP32B downstream G 0.50 -0.04 (0.01) 8.67E-06 
5 rs7341064 ITGA1 upstream C 0.40 0.04 (0.01) 1.03E-05 
8 rs4298457 NRG1 intronic G 0.27 -0.05 (0.01) 1.07E-05 
11 rs598599 MRE11A intronic A 0.28 0.05 (0.01) 1.09E-05 
4 rs4693596 COQ2 intronic C 0.38 -0.04 (0.01) 1.10E-05 
8 rs10954859 NRG1 intronic G 0.27 -0.05 (0.01) 1.12E-05 
5 rs404375 THBS4 intronic G 0.50 -0.04 (0.01) 1.26E-05 
6 rs2983525 PDE10A intronic C 0.27 -0.05 (0.01) 1.34E-05 
6 rs2983514 PDE10A intronic G 0.33 -0.05 (0.01) 1.36E-05 
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CHR SNP GENE GENE 
REGION 
CODED 
ALLELE 
CAF BETA (SE) P-VALUE 
1 rs3766122 SELP intronic C 0.05 -0.10 (0.02) 1.42E-05 
9 rs7866436 C9orf156 downstream G 0.37 -0.04 (0.01) 1.52E-05 
9 rs7024345 FOXE1 upstream A 0.27 -0.05 (0.01) 1.65E-05 
5 rs26367 FSTL4 intronic G 0.10 -0.07 (0.02) 1.65E-05 
5 rs10073636 HCN1 intronic T 0.43 0.04 (0.01) 1.73E-05 
9 rs13285674 ASTN2 upstream A 0.23 0.05 (0.01) 1.90E-05 
9 rs505922 ABO intronic C 0.36 0.04 (0.01) 1.94E-05 
5 rs7445986 ITGA1 upstream T 0.40 0.04 (0.01) 1.95E-05 
2 rs10204522 IGFBP5 upstream C 0.10 0.07 (0.02) 1.95E-05 
6 rs4054489 IBTK downstream T 0.18 -0.05 (0.01) 1.95E-05 
11 rs1055075 TTC12 downstream T 0.34 -0.04 (0.01) 1.96E-05 
4 rs4861534 DCTD downstream G 0.10 0.07 (0.02) 2.09E-05 
15 rs7168316 C15orf33 intronic T 0.23 -0.05 (0.01) 2.10E-05 
9 rs7848973 FOXE1 upstream A 0.40 -0.04 (0.01) 2.11E-05 
12 rs3136559 CD69 upstream A 0.28 0.05 (0.01) 2.13E-05 
2 rs6727435 AAK1 intronic A 0.27 -0.05 (0.01) 2.15E-05 
5 rs33613 FSTL4 intronic T 0.09 -0.07 (0.02) 2.35E-05 
15 rs12592277 C15orf33 intronic A 0.22 -0.05 (0.01) 2.35E-05 
8 rs2466062 NRG1 intronic G 0.30 -0.05 (0.01) 2.36E-05 
8 rs3898456 FAM135B intronic A 0.35 0.04 (0.01) 2.56E-05 
3 rs4402960 IGF2BP2 intronic T 0.30 -0.05 (0.01) 2.63E-05 
3 rs1470579 IGF2BP2 intronic C 0.31 -0.05 (0.01) 2.67E-05 
5 rs13354798 HCN1 intronic C 0.43 0.04 (0.01) 2.75E-05 
5 rs9686502 PDE8B intronic G 0.49 0.04 (0.01) 2.85E-05 
22 rs9606756 PDE8B intronic G 0.12 0.07 (0.02) 2.86E-05 
11 rs494442 KIRREL3 upstream T 0.40 -0.04 (0.01) 3.03E-05 
12 rs2695148 ANAPC5 upstream T 0.10 -0.07 (0.02) 3.11E-05 
1 rs17265852 NFIA intronic C 0.08 -0.07 (0.02) 3.16E-05 
5 rs6414906 HCN1 intronic C 0.43 0.04 (0.01) 3.51E-05 
16 rs3813583 WWOX downstream C 0.38 0.04 (0.01) 4.06E-05 
1 rs749378 GLIS1 downstream A 0.27 -0.05 (0.01) 4.09E-05 
5 rs6451801 HCN1 intronic A 0.43 0.04 (0.01) 4.10E-05 
5 rs13162651 HCN1 intronic C 0.43 0.04 (0.01) 4.11E-05 
6 rs12201217 CDKAL1 intronic T 0.38 -0.04 (0.01) 4.30E-05 
3 rs370234 VGLL4 upstream T 0.39 -0.04 (0.01) 4.32E-05 
12 rs1647253 ANAPC5 upstream A 0.10 -0.07 (0.02) 4.57E-05 
8 rs6989877 NRG1 downstream T 0.13 0.06 (0.01) 4.59E-05 
6 rs11963665 FAM46A upstream C 0.20 -0.05 (0.01) 4.63E-05 
5 rs6892290 HCN1 intronic G 0.43 0.04 (0.01) 4.76E-05 
1 rs6668505 PTAFR intronic T 0.06 -0.08 (0.02) 4.88E-05 
19 rs3745746 CABP5 missense C 0.39 -0.04 (0.01) 4.93E-05 
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CHR SNP GENE GENE 
REGION 
CODED 
ALLELE 
CAF BETA (SE) P-VALUE 
5 rs12521494 PDE8B intronic C 0.23 0.05 (0.01) 5.00E-05 
5 rs10064949 ITGA1 upstream C 0.43 0.04 (0.01) 5.07E-05 
2 rs1515259 - intergenic T 0.45 0.04 (0.01) 5.44E-05 
2 rs1012319 IGFBP5 upstream T 0.19 -0.05 (0.01) 5.47E-05 
6 rs2983500 PDE10A intronic T 0.11 -0.06 (0.02) 5.54E-05 
18 rs8096947 - intergenic A 0.19 -0.05 (0.01) 5.56E-05 
2 rs888186 IGFBP5 upstream C 0.10 -0.07 (0.02) 5.63E-05 
5 rs4703797 THBS4 intronic G 0.33 0.04 (0.01) 5.65E-05 
11 rs529126 MRE11A intronic A 0.26 0.04 (0.01) 5.65E-05 
1 rs11805172 SESN2 upstream G 0.07 -0.08 (0.02) 5.69E-05 
14 rs8009673 ARHGAP5 upstream A 0.15 0.06 (0.01) 5.83E-05 
11 rs1939422 C11orf87 upstream T 0.36 -0.04 (0.01) 5.94E-05 
2 rs1986415 AOX1 intronic A 0.12 0.06 (0.02) 6.05E-05 
8 rs2439300 NRG1 intronic A 0.27 -0.04 (0.01) 6.19E-05 
8 rs2943179 CNBD1 intronic T 0.22 0.05 (0.01) 6.31E-05 
15 rs8035662 MEGF11 intronic A 0.33 -0.04 (0.10) 6.37E-05 
11 rs877138 ANKK1 upstream G 0.35 -0.04 (0.01) 6.37E-05 
9 rs1443434 FOXE1 UTR-3’ G 0.40 -0.04 (0.01) 6.53E-05 
2 rs2381866 - intergenic C 0.44 0.04 (0.01) 6.68E-05 
2 rs888182 IGFBP5 upstream C 0.16 0.05 (0.01) 6.75E-05 
16 rs7184757 WWOX intronic C 0.09 -0.07 (0.02) 7.22E-05 
12 rs11172482 XRCC6BP1 downstream C 0.37 -0.04 (0.01) 7.29E-05 
7 rs39334 RELN intronic G 0.37 0.04 (0.01) 7.47E-05 
11 rs12278001 DDX10 downstream A 0.06 -0.08 (0.02) 7.53E-05 
5 rs12654213 HCN1 upstream G 0.43 0.04 (0.01) 7.69E-05 
1 rs10489909 NFIA intronic A 0.05 -0.09 (0.02) 7.81E-05 
7 rs13231383 TPK1 upstream A 0.25 0.04 (0.01) 8.19E-05 
5 rs2306344 PDE8B intronic A 0.31 -0.04 (0.01) 8.23E-05 
19 rs11666426 ZNF665 intronic C 0.41 0.04 (0.01) 8.30E-05 
1 rs12138950 CAPZB upstream C 0.15 -0.05 (0.01) 8.97E-05 
9 rs424829 STOM upstream A 0.29 0.04 (0.01) 9.02E-05 
15 rs11071858 MEGF11 intronic G 0.41 -0.04 (0.01) 9.33E-05 
11 rs12282135 OR52E2 upstream C 0.15 -0.05 (0.01) 9.47E-05 
1 rs11118832 DUSP10 intronic C 0.08 -0.07 (0.02) 9.52E-05 
1 rs630505 DENND2D intronic C 0.27 -0.04 (0.01) 9.58E-05 
2 rs16856529 IGFBP5 upstream C 0.15 0.05 (0.01) 9.80E-05 
12 rs1502816 XRCC6BP1 downstream C 0.38 -0.04 (0.01) 9.95E-05 
Tests of association using linear regression, adjusted for age, sex, principal component (PC1), and body mass index (BMI) 
were performed. Tests of association at p<1x10-4 are listed. Gene listed is the gene in closest proximity to the SNP. 
Coded allele frequency (CAF) is for the allele frequency in eMERGE European Americans in the serum TSH study 
(n=4,501). 
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Appendix L. SNP associations for serum TSH levels in eMERGE study African Americans. 
CHR SNP GENE GENE REGION CODED 
ALLELE 
CAF BETA (SE) P VALUE 
13 rs1409005 POU4F1-AS1 downstream T 0.20 0.25 (0.05) 5.02E-07 
1 rs2378497 DUSP10 upstream G 0.08 0.33 (0.07) 3.53E-06 
20 rs6062344 TCEA2 intronic T 0.40 0.18 (0.04) 4.06E-06 
16 rs270421 WWOX downstream C 0.28 0.19 (0.04) 7.75E-06 
7 rs2299116 CREB5 intronic A 0.17 0.25 (0.06) 8.16E-06 
2 rs6728613 MYT1L intronic A 0.24 0.20 (0.04) 1.14E-05 
10 rs6585018 PDCD4 near-5' G 0.17 -0.22 (0.05) 1.17E-05 
14 rs1013757 TTC6 downstream A 0.32 -0.19 (0.04) 1.33E-05 
2 rs4073401 MYT1L intronic T 0.24 0.19 (0.04) 1.33E-05 
14 rs12883861 LOC728755 downstream G 0.20 0.21 (0.05) 1.63E-05 
7 rs9784959 ABCA13 intronic A 0.30 -0.18 (0.04) 1.82E-05 
16 rs270422 WWOX downstream A 0.29 0.18 (0.04) 2.17E-05 
12 rs261875 BICD1 intronic C 0.32 0.18 (0.04) 2.24E-05 
7 rs274614 GRM3 intronic G 0.30 -0.18 (0.04) 2.36E-05 
3 rs11711934 DNAH1 intronic C 0.31 -0.17 (0.04) 2.45E-05 
2 rs12621889 KIAA1715 intronic T 0.06 0.36 (0.08) 2.68E-05 
2 rs12464144 KIAA1715 intronic A 0.06 0.36 (0.08) 2.68E-05 
18 rs10163845 NETO1 near-5' A 0.28 -0.18 (0.04) 2.74E-05 
19 rs12610504 ZNF536 downstream G 0.19 0.20 (0.05) 3.07E-05 
13 rs1274744 - intergenic C 0.42 -0.17 (0.04) 3.21E-05 
5 rs10060607 SLC36A3 intronic A 0.30 0.18 (0.04) 3.28E-05 
18 rs1824304 FAM59A intronic C 0.37 0.17 (0.04) 3.32E-05 
2 rs841452 HS6ST1 upstream C 0.37 0.17 (0.04) 3.52E-05 
7 rs11977108 ABCA13 intronic A 0.17 -0.21 (0.05) 3.70E-05 
3 rs4678798 ARPP21 intronic A 0.14 0.24 (0.06) 3.71E-05 
4 rs6851816 MLF1IP intronic T 0.50 0.16 (0.04) 3.83E-05 
22 rs133201 LRP5L 5'-UTR A 0.09 0.27 (0.06) 4.04E-05 
12 rs2593996 BICD1 intronic C 0.50 -0.16 (0.04) 4.09E-05 
19 rs1054713 KLK1 cds-synon T 0.26 0.19 (0.05) 4.16E-05 
19 rs12609319 ZNF536 downstream T 0.19 0.20 (0.05) 4.23E-05 
3 rs1918092 ARL8B,EDEM1  downstream C 0.09 0.30 (0.07) 4.90E-05 
12 rs2303478 ASCL4 downstream A 0.28 0.18 (0.04) 5.11E-05 
1 rs3738605 SZRD1 3'UTR A 0.12 0.24 (0.06) 5.12E-05 
19 rs2659099 MGC45922 near-5' T 0.29 0.18 (0.04) 5.13E-05 
3 rs4955261 CMTM8 upstream G 0.39 0.16 (0.04) 5.19E-05 
13 rs4772145 DOCK9 downstream T 0.43 0.15 (0.04) 5.23E-05 
2 rs13403407 C2orf43 intronic C 0.47 -0.16 (0.04) 5.31E-05 
3 rs1513476 ARPP21 intronic C 0.14 0.22 (0.05) 5.46E-05 
2 rs17032566 CAMKMT intronic T 0.07 -0.30 (0.07) 5.52E-05 
17 rs1105813 DNAH2 intronic T 0.43 0.16 (0.04) 5.61E-05 
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CHR SNP GENE GENE REGION CODED 
ALLELE 
CAF BETA (SE) P VALUE 
12 rs1563333 DYNLL1 intronic A 0.22 -0.19 (0.05) 5.64E-05 
10 rs1907356 C10orf11 intronic T 0.16 -0.21 (0.05) 5.71E-05 
10 rs11001788 C10orf11 intronic A 0.16 -0.21 (0.05) 5.71E-05 
2 rs12470895 LOC729164 ncRNA T 0.20 0.21 (0.05) 5.86E-05 
3 rs646929 CACNA2D3 intronic C 0.08 0.30 (0.07) 5.96E-05 
3 rs2335640 DNAH1 intronic C 0.30 -0.17 (0.04) 5.98E-05 
12 rs3742049 COQ5 missense T 0.25 0.18 (0.04) 6.08E-05 
3 rs17052068 DNAH1 intronic T 0.30 -0.16 (0.04) 6.46E-05 
1 rs2819757 RYR2 intronic C 0.18 0.22 (0.05) 6.49E-05 
2 rs10804139 PARD3B upstream A 0.38 -0.16 (0.04) 6.54E-05 
18 rs736218 FAM59A intronic C 0.38 0.16 (0.04) 6.66E-05 
9 rs10989120 MSANTD3-
TMEFF1 intronic A 0.39 -0.19 (0.05) 7.05E-05 
12 rs10744020 C12orf36 downstream C 0.23 0.16 (0.04) 7.05E-05 
19 rs2659103 KLK1 intronic T 0.25 0.19 (0.05) 7.29E-05 
1 rs10918914 XCL2 downstream G 0.17 0.22 (0.05) 7.39E-05 
12 rs261878 BICD1 intronic C 0.32 -0.16 (0.04) 7.42E-05 
15 rs12914266 SQRDL intronic A 0.29 0.17 (0.04) 7.58E-05 
7 rs6965055 C7orf10 intronic G 0.39 -0.16 (0.04) 7.65E-05 
7 rs7808606 C7orf10 intronic C 0.39 -0.15 (0.04) 7.66E-05 
14 rs17322359 PRKD1 upstream T 0.10 0.25 (0.06) 7.74E-05 
5 rs11949641 MSX2 downstream A 0.23 0.18 (0.05) 7.89E-05 
1 rs12120382 CHRM3 upstream C 0.09 0.29 (0.07) 7.96E-05 
2 rs6731363 LOC729164 ncRNA A 0.20 0.20 (0.05) 7.99E-05 
4 rs13144021 NR3C2 upstream G 0.14 0.23 (0.06) 8.00E-05 
18 rs877128 MC2R intronic A 0.25 0.18 (0.04) 8.10E-05 
10 rs7923004 BBIP1 intronic C 0.18 -0.20 (0.05) 8.19E-05 
8 rs6999969 XKR6 intronic C 0.42 -0.16 (0.04) 8.33E-05 
11 rs1027388 LRRC4C intronic A 0.28 -0.17 (0.04) 8.36E-05 
1 rs17011253 DUSP10 upstream- C 0.09 0.27 (0.07) 8.38E-05 
10 rs942077 RBM20 missense G 0.48 -0.15 (0.04) 8.47E-05 
4 rs4370216 - intergenic C 0.46 -0.15 (0.04) 8.55E-05 
4 rs2333727 HSFY2 upstream C 0.46 -0.15 (0.04) 8.55E-05 
7 rs1029357 SAMD9L 3'-UTR G 0.46 0.15 (0.04) 8.57E-05 
9 rs1332598 MSANTD3-
TMEFF1 intronic A 0.23 -0.19 (0.05) 8.69E-05 
5 rs6864667 SLC12A7 intronic G 0.47 0.15 (0.04) 8.98E-05 
12 rs4411338 CCND2 upstream C 0.29 0.16 (0.04) 9.05E-05 
19 rs171953 KLK1 downstream G 0.48 -0.15 (0.04) 9.07E-05 
19 GA035020 SSC5D intronic T 0.25 0.19 (0.05) 9.11E-05 
15 rs2040578 SV2B intronic G 0.29 0.17 (0.04) 9.13E-05 
17 rs1106826 DNAH2 intronic A 0.32 0.17 (0.04) 9.23E-05 
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CHR SNP GENE GENE REGION CODED 
ALLELE 
CAF BETA (SE) P VALUE 
20 rs6090040 TCEA2 intronic C 0.47 0.15 (0.04) 9.35E-05 
20 rs4408777 RGS19 intronic G 0.33 0.16 (0.04) 9.39E-05 
16 rs2521676 - intergenic G 0.39 0.16 (0.04) 9.73E-05 
1 rs16845412 - intergenic G 0.10 0.27 (0.07) 9.76E-05 
4 rs10518306 LOC285419 intronic A 0.06 0.35 (0.09) 9.78E-05 
8 rs10098991 - intergenic C 0.44 0.16 (0.04) 9.86E-05 
16 rs8059691 EMC8 intronic G 0.11 0.23 (0.06) 9.90E-05 
Tests of association using linear regression, adjusted for age, sex, principal component (PC1), and body mass 
index (BMI) were performed. Tests of association at p<1x10-4 are listed. Gene listed is the gene in closest 
proximity to the SNP. Coded allele frequency (CAF) is for the allele frequency in eMERGE African Americans in 
the serum TSH study (n=351). 
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Appendix M. Comparisons of reported associations with serum TSH levels in Europeans to eMERGE African Americans. 
Locus Prior Association Current Study 
SNP Chr Gene C
A 
CAF β (SE) P-value Ref. SNP/Best Proxy 
SNP 
r2 CA CAF β (SE) P-value 
rs10917469 1 CAPZB G 0.16 -0.16 (0.03) 3.2E-08 (Panicker et al.2010) rs12138950 1.00 C 0.24 -0.02 (0.05) 0.64 
rs10917477 1 CAPZB A 0.51 -0.06 (0.01) 1.54E-08 (Rawal et al.2012) rs6683419 0.62 G 0.49 0.01 (0.04) 0.85 
rs10799824 1 CAPZB A 0.16 -0.11 (0.01) 3.60E-21 (Porcu et al.2013) rs10799824 -- A 0.24 -0.03 (0.05) 0.58 
rs334699 1 NFIA A 0.05 -0.14 (0.02) 5.40E-12 (Porcu et al.2013) rs334713 1.00 A 0.17 -0.17 (0.05) 1.50E-03 
rs13015993 2 IGFBP5 A 0.74 0.08 (0.01) 3.24E-15 (Porcu et al.2013) rs13020935 1.00 G 0.48 -0.15 (0.04) 1.82E-04 
rs10028213 4 NR3C2 C 0.82 0.08 (0.01) 2.88E-10 (Rawal et al.2012) rs10519980 1.00 T 0.33 -0.07 (0.04) 0.11 
rs10032216 4 NR3C2 T 0.78 0.09 (0.01) 9.28E-16 (Porcu et al.2013) rs17025017 1.00 A 0.42 -0.07 (0.04) 0.08 
rs2046045 5 PDE8B T 0.62 -0.12 (0.01) 2.79E-27 
(Rawal et al.2012;Eriksson et 
al.2012;Medici et al.2011) 
rs2046045 -- A 0.28 -0.09 (0.04) 0.03 
rs6885099 5 PDE8B A 0.59 -0.14 (0.01) 1.95E-56 (Porcu et al.2013) rs2046045 1.00 A 0.28 -0.09 (0.04) 0.03 
rs4704397 5 PDE8B A 0.41* 0.21 1.64E-10 (Taylor et al.2011) rs2046045 0.94 A 0.28 -0.09 (0.04) 0.03 
rs753760 6 PDE10A C 0.69 0.10 (0.01) 1.21E-24 (Porcu et al.2013) rs2983514 0.93 G 0.38 -0.01 (0.04) 0.73 
rs9472138 6 VEGFA T 0.29 -0.08 (0.01) 6.72E-16 (Porcu et al.2013) rs9472138 -- T 0.19 -0.10 (0.05) 0.05 
rs11755845 6 VEGFA T 0.27 -0.07 (0.01) 1.68E-10 (Porcu et al.2013) rs11755845 -- T 0.14 -0.13 (0.05) 0.01 
rs9497965 6 SASH1 T 0.42 0.05 (0.01) 2.25E-08 (Porcu et al.2013) rs9377117 0.54 G 0.18 0.01 (0.06) 0.85 
rs7825175 8 NRG1 A 0.21 -0.07 (0.01) 2.94E-09 (Porcu et al.2013) rs7825175 -- A 0.13 -0.10 (0.06) 0.12 
rs657152 9 ABO A 0.34 0.06 (0.01) 4.11E-10 (Porcu et al.2013) rs657152 -- T 0.43 0.09 (0.04) 0.03 
rs1571583 9 GLIS3 A 0.25 0.06 (0.01) 2.55E-08 (Porcu et al.2013) rs1571583 -- T 0.22 0.01 (0.05) 0.79 
rs17723470 11 PRDM11 T 0.28 -0.07 (0.01) 8.83E-11 (Porcu et al.2013) rs17723470 -- T 0.11 -0.10 (0.06) 0.11 
rs1537424 14 MBIP T 0.61 -0.05 (0.01) 1.17E-08 (Porcu et al.2013) rs1537424 -- A 0.34 0.04 (0.04) 0.35 
rs11624776 14 ITPK1 A 0.66 -0.06 (0.01) 1.79E-09 (Porcu et al.2013) rs11624776 -- C 0.11 0.04 (0.07) 0.57 
rs10519227 15 FGF7 A 0.25 -0.07 (0.01) 1.02E-11 (Porcu et al.2013) rs7168316 1.00 T 0.12 -0.03 (0.06) 0.62 
rs17776563 15 MIR1179 A 0.32 -0.06 (0.01) 2.89E-10 (Porcu et al.2013) rs13329353 0.96 C 0.45 -0.07 (0.04) 0.09 
rs3813582 16 LOC44038
9/MAF 
T 0.67 0.08 (0.01) 8.45E-18 (Rawal et al.2012;Porcu et 
al.2013) 
rs17767383 1.00 A 0.25 -0.06 (0.05) 0.18 
rs9915657 17 SOX9 T 0.54 -0.06 (0.01) 7.53E-13 (Porcu et al.2013) rs9915657 -- T 0.49 -0.06 (0.04) 0.17 
rs4804416 19 INSR T 0.57 -0.06 (0.01) 3.16E-10 (Porcu et al.2013) rs4804416 -- G 0.26 0.01 (0.05) 0.81 
SNP rs number, chromosomal location, nearest gene/gene region, coded allele (CA), coded allele frequency (CAF), and association summary statistics (betas, 
standard errors, and p-values) are given for each previously reported association with TSH levels in European Americans. CAF highlighted with (*) represents the 
average CAF in the Taylor et al. study. For SNPs not directly genotyped in this study, the proxy in highest linkage disequilibrium in 1000 Genomes CEU samples was 
identified. Results of adjusted (age, sex, body mass index, and principal component 1) tests of association are given for each previously reported SNP or its proxy in 
this African American dataset (n=351). 
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Appendix N. Comparison of thyroid-related trait associations to eMERGE European Americans. 
Locus Prior Association Current Study 
SNP Chr Gene CA CAF OR P-value Ref. SNP/Best Proxy SNP r2 CA CAF β(SE) P-value 
Hypothyroidism 
rs6679677 1 PTPN22 A 0.09 1.36 2.80E-13 (Eriksson et al.2012) rs2476601 0.78 A 0.10 0.004 (0.02) 0.81 
rs2476601 1 PTPN22 A 0.09 1.36 3.9E-13 (Eriksson et al.2012) rs2476601 -- A 0.10 0.004 (0.02) 0.81 
rs4915076 1 VAV3 C 0.08 1.30 7.50E-10 (Eriksson et al.2012) rs4915076 -- C 0.09 0.03 (0.02) 0.06 
rs2517532 6 HLA A 0.40 0.86 1.30E-08 (Eriksson et al.2012) rs2517532 -- T 0.43 -0.01 (0.01) 0.27 
rs1064191 6 HCG22/C6orf15 T 0.46 0.87 2.2E-08 (Eriksson et al.2012) rs1064191 -- A 0.48 -0.002 (0.01) 0.83 
rs925487 9 FOXE1/C9orf156 C 0.37 0.86 4.1E-08 (Eriksson et al.2012) rs925487 -- G 0.37 -0.05 (0.01) 6.24E-06 
rs907580 9 FOXE1/C9orf156 T 0.26 0.84 1.2E-08 (Eriksson et al.2012) rs907580 -- A 0.27 -0.05 (0.01) 8.2E-06 
rs925489 9 KRT18P13,FOXE1 C 0.33 0.78 2.40E-19 (Eriksson et al.2012) rs925489 -- C 0.34 -0.05 (0.01) 1.79E-06 
rs1877432 9 KRT18P13,FOXE1 A 0.40 1.16 4.40E-09 (Eriksson et al.2012) rs1877432 -- A 0.40 0.02 (0.01) 0.03 
rs7024345 9 KRT18P13,FOXE1 A 0.26 0.84 1E-08 (Eriksson et al.2012) rs7024345 -- A 0.27 -0.05 (0.01) 1.65E-05 
rs7848973 9 KRT18P13,FOXE1 A 0.40 0.84 7.10E-11 (Eriksson et al.2012) rs7848973 -- A 0.40 -0.04 (0.01) 2.11E-05 
rs11065987 12 LOC100101246 BRAP G 0.45 1.18 1.70E-10 (Eriksson et al.2012) rs11065987 -- G 0.44 0.006 (0.01) 0.53 
rs17696736 12 NAA25 G 0.46 1.18 2.80E-10 (Eriksson et al.2012) rs17696736 -- G 0.45 0.003 (0.01) 0.75 
rs11066320 12 PTPN11 A 0.45 1.17 3.50E-09 (Eriksson et al.2012) rs11066320 -- A 0.45 0.002 (0.01) 0.82 
rs3184504 12 SH2B3 C 0.50 0.84 2.60E-12 (Eriksson et al.2012) rs3184504 -- T 0.50 0.007 (0.01) 0.50 
rs11066188 12 C12orf51 A 0.44 1.18 4.1E-10 (Eriksson et al.2012) rs11066188 -- A 0.43 0.007 (0.01) 0.46 
rs653178 12 ATXN2 T 0.50 0.84 5.0E-12 (Eriksson et al.2012) rs653178 -- G 0.50 0.006 (0.01) 0.51 
Grave’s Disease/Autoimmune Thyroid Disease 
rs3761959 1 FCRL3 A 0.40 1.23 1.50E-13 (Chu et al.2011) rs3761959 -- A 0.44 -0.006 (0.01) 0.53 
rs1024161 2 CTLA4 T 0.69 1.3 2.34E-17 (Chu et al.2011) rs1024161 -- T 0.41 0.01 (0.01) 0.15 
rs6832151 4 RHOH,CHRNA9 G 0.35 1.24 1.08E-13 (Chu et al.2011) rs6832151 -- G 0.28 0.01 (0.01) 0.24 
rs9355610 6 RNASET2 G 0.47 1.19 6.85E-10 (Chu et al.2011) rs9355610 -- A 0.33 -0.008 (0.01) 0.46 
rs4947296 6 MUC21,C6orf15 C 0.14 1.77 3.51E-51 (Chu et al.2011) NA NA NA NA NA NA 
rs2281388 6 HLA-DPB1 T 0.32 1.64 1.5E-65 (Chu et al.2011) NA NA NA NA NA NA 
rs6457617 6 HLA-DR-DQ T 0.45 1.4 7.38E-33 (Chu et al.2011) rs6457617 -- T 0.50 0.01 (0.01) 0.14 
rs6903608 6 HLA-DR-DQ C 0.38 1.34 5.12E-24 (Chu et al.2011) rs6903608 -- C 0.31 -0.02 (0.01) 0.13 
rs965513 9 FOXE1 A 0.34 1.75 1.70E-27 (Eriksson et al.2012) rs965513 -- A 0.34 -0.05 (0.01) 1.09E-06 
rs12101261 14 TSHR T 0.64 1.35 6.64E-24 (Chu et al.2011) rs12101261 -- T 0.36 0.002 (0.01) 0.87 
Thyroid Cancer 
rs966423 2 DIRC3 C  1.34 1.30E-09 (Gudmundsson et al.2012) rs966423 -- C 0.42 -0.02 (0.01) 0.13 
rs2439302 8 NRG1 G  1.36 2.00E-09 (Gudmundsson et al.2012) rs7005606 1.00 G 0.46 -0.02 (0.01) 0.02 
rs944289 14 NKX2-1/TTF1 T 0.57 1.37 2.0E-09 
(Gudmundsson et 
al.2012;Gudmundsson et al.2009) 
rs944289 -- C 0.43 0.02 (0.01) 0.01 
rs116909374 14 MBIP T  2.09 4.60E-11 (Gudmundsson et al.2012) rs2553571 0.13 T 0.22 -0.005 (0.01) 0.68 
SNP rs number, chromosomal location, nearest gene/gene region, coded allele (CA), coded allele frequency (CAF), and association summary statistics (odds ratio (OR) and p-values) are given 
for each previously reported association with thyroid-related traits in European Americans. For SNPs not directly genotyped in this study, the proxy in highest linkage disequilibrium in 1000 
Genomes CEU samples was identified. Results of adjusted (age, sex, body mass index, and principal component 1) tests of association are given for each SNP in this European American dataset. 
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Appendix O. Comparison of thyroid-related trait associations to eMERGE African Americans. 
Locus Prior Association Current Study 
SNP Chr Gene CA CAF OR P-value Ref. SNP/Best Proxy SNP r2 CA CAF Β (SE) P-value 
Hypothyroidism 
rs6679677 1 PHTF1, RSBN1 A 0.09 1.36 2.80E-13 (Eriksson et al.2012) rs1217413 0.60 G 0.05 0.08 (0.10) 0.43 
rs2476601 1 PTPN22 A 0.09 1.36 3.9E-13 (Eriksson et al.2012) rs1217413 0.56 G 0.05 0.08 (0.10) 0.43 
rs4915076 1 VAV3 C 0.08 1.3 8.00E-10 (Eriksson et al.2012) rs4915076 -- C 0.05 -0.03 (0.08) 0.72 
rs2517532 6 LOC729792 HCG22 A 0.40 0.86 1.3E-08 (Eriksson et al.2012) rs2517532 -- T 0.34 -0.02 (0.04) 0.59 
rs1064191 6 HCG22/C6orf15 T 0.46 0.87 2.2E-08 (Eriksson et al.2012) rs1064191 -- A 0.46 -0.04 (0.04) 0.36 
rs925487 9 FOXE1/C9orf156 C 0.37 0.86 4.1E-08 (Eriksson et al.2012) rs925487 -- G 0.25 -0.04 (0.05) 0.41 
rs907580 9 FOXE1/C9orf156 T 0.26 0.84 1.2E-08 (Eriksson et al.2012) rs907580 -- A 0.07 0.04 (0.08) 0.64 
rs925489 9 KRT18P13,FOXE1 C 0.33 0.78 2.40E-19 (Eriksson et al.2012) rs925489 -- C 0.21 -0.03 (0.05) 0.53 
rs1877432 9 KRT18P13,FOXE1 A 0.40 1.16 4.40E-09 (Eriksson et al.2012) rs1877432 -- A 0.34 0.11 (0.04) 9.73E-03 
rs7024345 9 KRT18P13,FOXE1 A 0.26 0.84 1E-08 (Eriksson et al.2012) rs7024345 -- A 0.07 0.03 (0.08) 0.69 
rs7848973 9 KRT18P13,FOXE1 A 0.40 0.84 7.10E-11 (Eriksson et al.2012) rs7848973 -- A 0.23 -0.09 (0.04) 0.06 
rs11065987 12 LOC100101246 BRAP G 0.45 1.18 1.70E-10 (Eriksson et al.2012) rs11065987 -- G 0.08 0.12 (0.08) 0.13 
rs17696736 12 NAA25 G 0.46 1.18 2.80E-10 (Eriksson et al.2012) rs17696736 -- G 0.09 0.11 (0.08) 0.16 
rs11066320 12 PTPN11 A 0.45 1.17 3.50E-09 (Eriksson et al.2012) rs11066320 -- A 0.08 0.08 (0.08) 0.31 
rs3184504 12 SH2B3 C 0.50 0.84 2.60E-12 (Eriksson et al.2012) rs3184504 -- T 0.10 0.09 (0.07) 0.20 
rs11066188 12 C12orf51 A 0.44 1.18 4.1E-10 (Eriksson et al.2012) rs11066188 -- A 0.08 0.12 (0.08) 0.12 
rs653178 12 ATXN2 T 0.50 0.84 5.0E-12 (Eriksson et al.2012) rs653178 -- G 0.10 0.09 (0.07) 0.20 
Grave’s Disease/Autoimmune Thyroid Disease 
rs3761959 1 FCRL3 A 0.40 1.23 1.50E-13 (Chu et al.2011) rs3761959 -- G 0.39 0.03 (0.04) 0.45 
rs1024161 2 CTLA4 T 0.69 1.3 2.34E-17 (Chu et al.2011) rs1024161 -- C 0.48 -0.06 (0.09) 0.13 
rs6832151 4 RHOH,CHRNA9 G 0.35 1.24 1.08E-13 (Chu et al.2011) rs6832151 -- G 0.31 -0.10 (0.04) 0.01 
rs9355610 6 RNASET2 G 0.47 1.19 6.85E-10 (Chu et al.2011) rs9355610 -- A 0.39 -0.03 (0.04) 0.47 
rs4947296 6 MUC21,C6orf15 C 0.14 1.77 3.51E-51 (Chu et al.2011) NA NA NA NA NA NA 
rs2281388 6 HLA-DPB1 T 0.32 1.64 1.5E-65 (Chu et al.2011) NA NA NA NA NA NA 
rs6457617 6 HLA-DR-DQ T 0.45 1.4 7.38E-33 (Chu et al.2011) rs6457617 -- T 0.48 0.02 (0.04) 0.63 
rs6903608 6 HLA-DR-DQ C 0.38 1.34 5.12E-24 (Chu et al.2011) rs6903608 -- C 0.38 0.02 (0.04) 0.61 
rs965513 9 FOXE1 A 0.34 1.75 1.70E-27 (Eriksson et al.2012) rs965513 -- A 0.17 -0.03 (0.05) 0.50 
rs12101261 14 TSHR T 0.64 1.35 6.64E-24 (Chu et al.2011) rs12101261 -- T 0.39 -0.01 (0.04) 0.82 
Thyroid Cancer 
rs966423 2 DIRC3 C  1.34 1.30E-09 (Gudmundsson et al.2012) rs966423 -- T 0.23 0.03 (0.05) 0.47 
rs2439302 8 NRG1 G  1.36 2.00E-09 (Gudmundsson et al.2012) rs4733130 1.00 C 0.23 -0.06 (0.05) 0.25 
rs944289 14 NKX2-1/TTF1 T 0.57 1.37 2E-09 
(Gudmundsson et al.2012; 
Gudmundsson et al.2009) 
rs1169151 0.93 A 0.23 0.03 (0.05) 0.57 
rs116909374 14 MBIP T  2.09 4.60E-11 (Gudmundsson et al.2012) NA NA NA NA NA NA 
SNP rs number, chromosomal location, nearest gene/gene region, coded allele (CA), coded allele frequency (CAF), and association summary statistics (odds ratio (OR) and p-values) are given 
for each previously reported association with thyroid-related traits in European Americans. For SNPs not directly genotyped in this study, the proxy in highest linkage disequilibrium in 1000 
Genomes CEU samples was identified. Results of adjusted (age, sex, body mass index, and principal component 1) tests of association are given for each SNP in this African American dataset. 
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Appendix P. Comparison of SNP associations in regression models with and without BMI 
covariates for serum TSH levels in eMERGE study European Americans. 
SNP P BMI BETA BMI  P NO BMI BETA NO BMI 
rs1382879 7.16E-18 0.09  2.16E-15 0.08 
rs2046045 1.85E-17 0.09  2.07E-15 0.08 
rs989758 1.33E-14 0.08  1.10E-12 0.07 
rs9687206 5.52E-14 0.08  4.98E-11 0.06 
rs12515498 3.27E-10 0.07  3.18E-09 0.06 
rs6885813 4.05E-08 0.06  1.41E-07 0.06 
rs1096752 6.30E-07 -0.05  7.48E-06 -0.04 
rs13361710 6.60E-07 0.06  2.20E-06 0.05 
rs10759944 1.08E-06 -0.05  1.33E-06 -0.05 
rs965513 1.09E-06 -0.05  1.40E-06 -0.05 
rs925489 1.79E-06 -0.05  2.52E-06 -0.05 
rs7850258 1.85E-06 -0.05  2.87E-06 -0.05 
rs10496992 2.22E-06 0.05  1.61E-05 0.04 
rs1861628 3.68E-06 -0.05  2.15E-05 -0.04 
rs4348174 3.97E-06 0.05  1.13E-05 0.04 
rs657152 4.18E-06 0.05  1.06E-07 0.05 
rs740083 4.56E-06 -0.05  1.37E-05 -0.05 
rs813379 4.57E-06 -0.10  2.66E-06 -0.10 
rs2712168 4.98E-06 0.07  2.05E-05 0.06 
rs256438 5.53E-06 0.05  1.81E-05 0.04 
rs4570936 5.73E-06 -0.05  2.32E-07 -0.06 
rs6546537 5.92E-06 -0.05  2.92E-05 -0.04 
rs7855088 6.23E-06 -0.05  2.37E-05 -0.04 
rs925487 6.24E-06 -0.05  6.99E-06 -0.04 
rs803174 6.74E-06 -0.10  3.38E-06 -0.09 
rs2438632 6.88E-06 0.05  1.01E-05 0.04 
rs13020935 7.02E-06 -0.05  3.45E-05 -0.04 
rs12520862 7.48E-06 0.06  9.36E-05 0.05 
rs10984103 7.81E-06 -0.05  7.69E-06 -0.04 
rs907580 8.20E-06 -0.05  6.14E-06 -0.05 
rs2466067 8.42E-06 -0.05  5.86E-07 -0.05 
rs7870926 8.67E-06 -0.04  1.47E-05 -0.04 
rs7341064 1.03E-05 0.04  2.18E-05 0.04 
rs4298457 1.07E-05 -0.05  1.05E-06 -0.05 
rs598599 1.09E-05 0.05  8.83E-05 0.04 
rs4693596 1.10E-05 -0.04  1.05E-04 -0.04 
rs10954859 1.12E-05 -0.05  1.21E-06 -0.05 
rs404375 1.26E-05 -0.04  2.38E-05 -0.04 
rs2983525 1.34E-05 -0.05  1.04E-06 -0.05 
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SNP P BMI BETA BMI  P NO BMI BETA NO BMI 
rs2983514 1.36E-05 -0.05  6.45E-07 -0.05 
rs3766122 1.42E-05 -0.10  7.20E-04 -0.07 
rs7866436 1.52E-05 -0.04  1.55E-05 -0.04 
rs7024345 1.65E-05 -0.05  1.41E-05 -0.05 
rs26367 1.65E-05 -0.07  2.05E-05 -0.07 
rs10073636 1.73E-05 0.04  1.35E-04 0.04 
rs13285674 1.90E-05 0.05  1.86E-05 0.05 
rs505922 1.94E-05 0.04  3.55E-07 0.05 
rs7445986 1.95E-05 0.04  5.84E-05 0.04 
rs10204522 1.95E-05 0.07  3.89E-05 0.07 
rs4054489 1.95E-05 -0.05  7.09E-05 -0.05 
rs1055075 1.96E-05 -0.04  1.44E-05 -0.04 
rs4861534 2.09E-05 0.07  2.15E-05 0.06 
rs7168316 2.10E-05 -0.05  2.55E-05 -0.05 
rs7848973 2.11E-05 -0.04  2.22E-05 -0.04 
rs3136559 2.13E-05 0.05  8.51E-04 0.03 
rs6727435 2.15E-05 -0.05  9.24E-05 -0.04 
rs33613 2.35E-05 -0.07  2.68E-05 -0.07 
rs12592277 2.35E-05 -0.05  2.39E-05 -0.05 
rs2466062 2.36E-05 -0.05  1.50E-06 -0.05 
rs3898456 2.56E-05 0.04  9.80E-05 0.04 
rs4402960 2.63E-05 -0.05  1.03E-05 -0.04 
rs1470579 2.67E-05 -0.05  8.35E-06 -0.04 
rs13354798 2.75E-05 0.04  1.91E-04 0.03 
rs9686502 2.85E-05 0.04  3.83E-04 0.03 
rs9606756 2.86E-05 0.07  1.27E-04 0.06 
rs494442 3.03E-05 -0.04  1.76E-04 -0.04 
rs2695148 3.11E-05 -0.07  9.14E-05 -0.06 
rs17265852 3.16E-05 -0.07  3.34E-05 -0.07 
rs6414906 3.51E-05 0.04  1.81E-04 0.04 
rs3813583 4.06E-05 0.04  5.94E-06 0.04 
rs749378 4.09E-05 -0.05  1.03E-04 -0.04 
rs6451801 4.10E-05 0.04  2.27E-04 0.03 
rs13162651 4.11E-05 0.04  2.14E-04 0.03 
rs12201217 4.30E-05 -0.04  1.86E-05 -0.04 
rs370234 4.32E-05 -0.04  6.80E-05 -0.04 
rs1647253 4.57E-05 -0.07  1.23E-04 -0.06 
rs6989877 4.59E-05 0.06  3.06E-06 0.06 
rs11963665 4.63E-05 -0.05  2.73E-04 -0.04 
rs6892290 4.76E-05 0.04  2.41E-04 0.03 
rs6668505 4.88E-05 -0.08  1.85E-04 -0.07 
rs3745746 4.93E-05 -0.04  8.12E-05 -0.04 
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SNP P BMI BETA BMI  P NO BMI BETA NO BMI 
rs12521494 5.00E-05 0.05  1.05E-03 0.04 
rs10064949 5.07E-05 0.04  7.77E-05 0.04 
rs1515259 5.44E-05 0.04  3.21E-04 0.03 
rs1012319 5.47E-05 -0.05  1.04E-04 -0.05 
rs2983500 5.54E-05 -0.06  4.80E-06 -0.07 
rs8096947 5.56E-05 -0.05  9.39E-06 -0.05 
rs888186 5.63E-05 -0.07  2.03E-04 -0.06 
rs4703797 5.65E-05 0.04  7.77E-05 0.04 
rs529126 5.65E-05 0.04  1.85E-04 0.04 
rs11805172 5.69E-05 -0.08  2.09E-04 -0.07 
rs8009673 5.83E-05 0.06  3.14E-05 0.05 
rs1939422 5.94E-05 -0.04  2.35E-04 -0.04 
rs1986415 6.05E-05 0.06  1.56E-04 0.05 
rs2439300 6.19E-05 -0.04  1.91E-05 -0.04 
rs2943179 6.31E-05 0.05  4.18E-05 0.05 
rs8035662 6.37E-05 -0.04  2.98E-04 -0.03 
rs877138 6.37E-05 -0.04  4.11E-05 -0.04 
rs1443434 6.53E-05 -0.04  5.97E-05 -0.04 
rs2381866 6.68E-05 0.04  9.97E-05 0.04 
rs888182 6.75E-05 0.05  3.55E-05 0.05 
rs7184757 7.22E-05 -0.07  6.70E-05 -0.07 
rs11172482 7.29E-05 -0.04  1.11E-04 -0.04 
rs39334 7.47E-05 0.04  2.38E-04 0.04 
rs12278001 7.53E-05 -0.08  8.24E-05 -0.08 
rs12654213 7.69E-05 0.04  3.64E-04 0.03 
rs10489909 7.81E-05 -0.09  8.43E-04 -0.07 
rs13231383 8.19E-05 0.04  1.71E-04 0.04 
rs2306344 8.23E-05 -0.04  6.54E-05 -0.04 
rs11666426 8.30E-05 0.04  8.65E-05 0.04 
rs12138950 8.97E-05 -0.05  1.29E-04 -0.05 
rs424829 9.02E-05 0.04  3.39E-04 0.04 
rs11071858 9.33E-05 -0.04  4.40E-04 -0.03 
rs12282135 9.47E-05 -0.05  2.44E-04 -0.05 
rs11118832 9.52E-05 -0.07  1.71E-04 -0.07 
rs630505 9.58E-05 -0.04  1.38E-04 -0.04 
rs16856529 9.80E-05 0.05  5.90E-05 0.05 
rs1502816 9.95E-05 -0.04  1.32E-04 -0.04 
 For each SNP, p-values and betas are given for models that include or exclude 
body mass index (BMI) as a covariate. All models are linear regressions 
assuming an additive genetic model adjusted for age, sex, and principal 
component 1 in this European American dataset (n=4,501). 
 169 
 
Appendix Q. Comparison of SNP associations in regression models with and without BMI 
covariates for serum TSH levels in eMERGE African Americans. 
SNP P BMI BETA BMI P NO BMI BETA NO BMI 
rs1409005 5.02E-07 0.25 2.60E-05 0.17 
rs2378497 3.53E-06 0.33 4.76E-03 0.16 
rs6062344 4.06E-06 0.18 3.64E-03 0.09 
rs270421 7.75E-06 0.19 3.08E-03 0.10 
rs2299116 8.16E-06 0.25 6.13E-05 0.18 
rs6728613 1.14E-05 0.20 7.95E-03 0.10 
rs6585018 1.17E-05 -0.22 2.58E-04 -0.14 
rs1013757 1.33E-05 -0.19 7.32E-04 -0.12 
rs4073401 1.33E-05 0.19 8.28E-03 0.09 
rs12883861 1.63E-05 0.21 2.22E-04 0.14 
rs9784959 1.82E-05 -0.18 1.63E-05 -0.15 
rs270422 2.17E-05 0.18 0.01 0.09 
rs261875 2.24E-05 0.18 3.56E-05 0.14 
rs274614 2.36E-05 -0.18 0.03 -0.08 
rs11711934 2.45E-05 -0.17 1.41E-03 -0.11 
rs12621889 2.68E-05 0.36 0.01 0.16 
rs12464144 2.68E-05 0.36 0.01 0.16 
rs10163845 2.74E-05 -0.18 0.04 -0.07 
rs12610504 3.07E-05 0.20 2.44E-03 0.12 
rs1274744 3.21E-05 -0.17 1.98E-03 -0.10 
rs10060607 3.28E-05 0.18 8.25E-05 0.13 
rs1824304 3.32E-05 0.17 9.22E-04 0.11 
rs841452 3.52E-05 0.17 1.96E-03 0.10 
rs11977108 3.70E-05 -0.21 6.20E-04 -0.14 
rs4678798 3.71E-05 0.24 8E-05 0.18 
rs6851816 3.83E-05 0.16 6.50E-04 0.10 
rs133201 4.04E-05 0.27 0.05 0.11 
rs2593996 4.09E-05 -0.16 5.52E-05 -0.13 
rs1054713 4.16E-05 0.19 9.71E-03 0.10 
rs12609319 4.23E-05 0.20 2.76E-03 0.12 
rs1918092 4.90E-05 0.30 4.47E-04 0.20 
rs2303478 5.11E-05 0.18 0.02 0.08 
rs3738605 5.12E-05 0.24 6.33E-03 0.13 
rs2659099 5.13E-05 0.18 6.38E-03 0.10 
rs4955261 5.19E-05 0.16 3.77E-04 0.11 
rs4772145 5.23E-05 0.15 0.03 0.07 
rs13403407 5.31E-05 -0.16 4.40E-03 -0.09 
rs1513476 5.46E-05 0.22 1.17E-04 0.17 
rs17032566 5.52E-05 -0.30 1.45E-03 -0.19 
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SNP P BMI BETA BMI P NO BMI BETA NO BMI 
rs1105813 5.61E-05 0.16 1.07E-03 0.10 
rs1563333 5.64E-05 -0.19 2.06E-03 -0.11 
rs1907356 5.71E-05 -0.21 2.26E-04 -0.15 
rs11001788 5.71E-05 -0.21 2.26E-04 -0.15 
rs12470895 5.86E-05 0.21 1.46E-03 0.13 
rs646929 5.96E-05 0.30 7.19E-04 0.19 
rs2335640 5.98E-05 -0.17 3.31E-03 -0.10 
rs3742049 6.08E-05 0.18 3.31E-03 0.11 
rs17052068 6.46E-05 -0.16 1.96E-03 -0.10 
rs2819757 6.49E-05 0.22 3.77E-03 0.13 
rs10804139 6.54E-05 -0.16 8.86E-04 -0.11 
rs736218 6.66E-05 0.16 2.02E-03 0.10 
rs10989120 7.05E-05 -0.19 0.11 -0.06 
rs10744020 7.05E-05 0.16 1.97E-03 0.10 
rs2659103 7.29E-05 0.19 0.01 0.10 
rs10918914 7.39E-05 0.22 1.29E-04 0.16 
rs261878 7.42E-05 -0.16 7.12E-05 -0.13 
rs12914266 7.58E-05 0.17 1.16E-03 0.11 
rs6965055 7.65E-05 -0.16 1.34E-03 -0.10 
rs7808606 7.66E-05 -0.15 9.37E-04 -0.10 
rs17322359 7.74E-05 0.25 4.05E-03 0.15 
rs11949641 7.89E-05 0.18 2.12E-03 0.11 
rs12120382 7.96E-05 0.29 8.34E-04 0.20 
rs6731363 7.99E-05 0.20 1.77E-03 0.13 
rs13144021 8.00E-05 0.23 1.06E-03 0.15 
rs877128 8.10E-05 0.18 2.34E-03 0.11 
rs7923004 8.19E-05 -0.20 1.03E-03 -0.13 
rs6999969 8.33E-05 -0.16 7.19E-03 -0.09 
rs1027388 8.36E-05 -0.17 2E-03 -0.11 
rs17011253 8.38E-05 0.27 0.03 0.12 
rs942077 8.47E-05 -0.15 1.58E-04 -0.12 
rs4370216 8.55E-05 -0.15 1.8E-03 -0.10 
rs2333727 8.55E-05 -0.15 1.8E-03 -0.10 
rs1029357 8.57E-05 0.15 1.05E-03 0.10 
rs1332598 8.69E-05 -0.19 0.11 -0.06 
rs6864667 8.98E-05 0.15 2.21E-03 0.09 
rs4411338 9.05E-05 0.16 0.02 0.08 
rs171953 9.07E-05 -0.15 0.03 -0.07 
GA035020 9.11E-05 0.19 0.01 0.10 
rs2040578 9.13E-05 0.17 2.72E-04 0.13 
rs1106826 9.23E-05 0.17 0.01 0.08 
rs6090040 9.35E-05 0.15 0.02 0.08 
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SNP P BMI BETA BMI P NO BMI BETA NO BMI 
rs4408777 9.39E-05 0.16 0.07 0.06 
rs2521676 9.73E-05 0.16 8.4E-04 0.11 
rs16845412 9.76E-05 0.27 6.14E-03 0.15 
rs10518306 9.78E-05 0.35 4.33E-03 0.19 
rs10098991 9.86E-05 0.16 0.08 0.06 
rs8059691 9.90E-05 0.23 0.01 0.11 
For each SNP, p-values and betas are given for models that include or exclude body 
mass index (BMI) as a covariate. All models are linear regressions assuming an 
additive genetic model adjusted for age, sex, and principal component 1 in this 
African American dataset (n=351). 
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Interaction analyses were performed using the SNPs with p<1x10-4 significance levels in the model adjusted for age, sex, principal 
component 1 (PC1), and body mass index (BMI) in a model stratified for race/ethnicity and by normal/overweight BMI (normal: BMI 18-
24.9; overweight: BMI 25+). We considered a SNPxBMI interaction significant at a threshold of p<0.05. Shown are p-values from Wilcoxon 
rank-sum tests comparing median TSH values between BMI categories at each genotype. 
 
Appendix R. Body mass index as a modifier of serum TSH levels genetic associations in eMERGE African Americans.  
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Appendix S. Power calculations for replication/generalization in eMERGE TSH levels study. 
Locus Prior Association    
SNP Chr Gene CA CAF β P-value Ref. CAF 
EA 
Power 
EA 
n=4501 
CAF 
AA 
Power 
AA 
n=351 
rs10917469 1 CAPZB G 0.16 -0.16 3.2E-08 
 
(Panicker et al.2010) 0.15 1.00 0.24 0.53 
rs10917477 1 CAPZB A 0.51 -0.06 1.54E-08 (Rawal et al.2012) 0.48 0.74* 0.49 0.14* 
rs10799824 1 CAPZB A 0.16 -0.11 3.60E-21 (Porcu et al.2013) 0.15 0.97* 0.24 0.41 
rs334699 1 NFIA A 0.05 -0.14 5.40E-12 (Porcu et al.2013) 0.08 0.93* 0.17 0.49 
rs13015993 2 IGFBP5 A 0.74 0.08 3.24E-15 (Porcu et al.2013) 0.27 0.95 0.48 0.31 
rs10028213 4 NR3C2 C 0.82 0.08 2.88E-10 (Rawal et al.2012) 0.18 0.88 0.33 0.28 
rs10032216 4 NR3C2 T 0.78 0.09 9.28E-16 (Porcu et al.2013) 0.19 0.95 0.42 0.37 
rs2046045 5 PDE8B T 0.62 -0.12 2.79E-27 (Rawal et al.2012;Eriksson 
et al.2012;Medici et al.2011) 
0.40 1.00 0.28 0.51 
rs6885099 5 PDE8B A 0.59 -0.14 1.95E-56 (Porcu et al.2013) 0.40 1.00 0.28 0.64 
rs4704397 5 PDE8B A 0.40* 0.21 1.64E-10 (Taylor et al.2011) 0.39 1.00* 0.28 0.92* 
rs753760 6 PDE10A C 0.69 0.10 1.21E-24 (Porcu et al.2013) 0.33 1.00* 0.38 0.41* 
rs9472138 6 VEGFA T 0.29 -0.08 6.72E-16 (Porcu et al.2013) 0.28 0.96 0.19 0.21 
rs11755845 6 VEGFA T 0.27 -0.07 1.68E-10 (Porcu et al.2013) 0.24 0.86 0.14 0.15 
rs9497965 6 SASH1 T 0.42 0.05 2.25E-08 (Porcu et al.2013) 0.30 0.41* 0.18 0.08* 
rs7825175 8 NRG1 A 0.21 -0.07 2.94E-09 (Porcu et al.2013) 0.31 0.33* 0.13 0.14 
rs657152 9 ABO A 0.34 0.06 4.11E-10 (Porcu et al.2013) 0.38 0.84 0.43 0.19 
rs1571583 9 GLIS3 A 0.25 0.06 2.55E-08 (Porcu et al.2013) 0.25 0.76 0.22 0.15 
rs17723470 11 PRDM11 T 0.28 -0.07 8.83E-11 (Porcu et al.2013) 0.29 0.87* 0.11 0.13 
rs1537424 14 MBIP T 0.61 -0.05 1.17E-08 (Porcu et al.2013) 0.43 0.71 0.34 0.14 
rs11624776 14 ITPK1 A 0.66 -0.06 1.79E-09 (Porcu et al.2013) 0.22 0.29* 0.11 0.11 
rs10519227 15 FGF7 A 0.25 -0.07 1.02E-11 (Porcu et al.2013) 0.23 0.85 0.12 0.13 
rs17776563 15 MIR1179 A 0.32 -0.06 2.89E-10 (Porcu et al.2013) 0.35 0.75* 0.45 0.18* 
rs3813582 16 LOC4403
89/MAF 
T 0.67 0.08 8.45E-18 (Rawal et al.2012;Porcu et 
al.2013) 
0.31 0.97 0.25 0.25 
rs9915657 17 SOX9 T 0.54 -0.06 7.53E-13 (Porcu et al.2013) 0.46 0.86 0.49 0.20 
rs4804416 19 INSR T 0.57 -0.06 3.16E-10 (Porcu et al.2013) 0.44 0.86 0.26 0.16 
Power calculations for replication/generalization of SNPs previously associated with serum TSH levels to eMERGE euthyroid 
European Americans (EA) and African Americans (AA). SNP rs number, chromosomal location, nearest gene/gene region, coded 
allele (CA), coded allele frequency (CAF), and association summary statistics (betas and p-values) are given for each previously 
reported association with serum TSH levels in European Americans. Starred (*) CAF represents mean CAF from Taylor et al. Power 
was calculated for each race/ethnicity using Quanto assuming the previously reported effect size, an additive genetic model, a 
liberal significance threshold of p<0.05,the eMERGE minor allele frequencies, and the eMERGE sample sizes. Power calculations 
labeled with an asterisk indicate proxy SNPs listed in Table 20 (European Americans) and Appendix M (African Americans) as 
described in the Chapter V. 
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Appendix T. 2x2 table for calculating the PPV of a hypothetical rare disorder. 
Variant Disease (+) (-) Total 
 (+) 99 199 298 
(-) 1 19,701 19,702 
Total 100 19,900 20,000 
PPV=99/298=33% 
Data shown are for calculating the positive predictive value (PPV) of a 
hypothetical rare disorder with a population n=20,000, disease 
prevalence = 0.5%, and tests sensitivity and specificity of 99%. 
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Appendix U. 2x2 table for calculating the PPV of a hypothetical common disorder. 
Variant Disease (+) (-) Total 
 (+) 822 72 894 
(-) 8 9,098 9,106 
Total 830 9,170 10,000 
PPV=822/894=92% 
Data shown are for calculating the positive predictive value (PPV) of a 
hypothetical common disorder with a population n=10,000, disease 
prevalence = 8.3%, and tests sensitivity and specificity of 99%. 
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